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DEDICATION
To my dogs
A faithful friend is the medicine of life. 
(Ecclesiasticus vi, 16)
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AUC area under the time v plasma concentration curve
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ABBREVIATIONS (contd)
RIA radioimmunoassay
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s.d. standard deviation
[SDIG] serum digoxin concentration
[SPAR] serum paracetamol concentration
tl/2 elimination half-life
UCr urinary creatinine (mg)
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CABG coronary artery bypass graft
CCF congestive cardiac failure
COAD chronic obstructive airways disease
CVA cerebrovascular accident




IDDM insulin dependent diabetes mellitus
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LVF left ventricular failure
MI myocardial infarction
MND motor neurone disease
MS multiple sclerosis
NG neoplastic growth
NIDDM non-insulin dependent diabetes mellitus




SOB shortness of breath
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TIA transient ischaemic attack
TURP trans-urethral resection of the prostate
UC - ulcerative colitis
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ABSTRACT
1 "The elderly" do not form a single homogeneous group, and 
those to whom medication is most commonly prescribed were 
identified as forming at least two separate groups: those 
who are active & able to live independently in the 
community, and those who are infirm & immobile, requiring 
help with activities of daily living. Definitions were 
constructed to enable these groups to be readily 
differentiated without laboratory investigations, using a 
combination of social & functional criteria. Terms "fit" 
& "frail" were used to describe these two populations.
2 Creatinine clearance was measured in 245 elderly people. 
In addition to those subjects who were defined as fit or 
frail, a third group of healthy elderly people were . 
recruited from the Research Institute for the Care of the 
Elderly volunteer panel & categorised as "very fit". CCr, 
UCr & SCr were significantly different between females & 
males. No significant difference was found between the 
CCr of age-matched very fit & fit subjects, although both 
groups exhibited the normal reduction in CCr known to 
occur with increasing chronological age. Frail subjects 
had significantly lower CCr than their age-matched very 
fit & fit counterparts, suggesting that frailty imposes 
an additional decrement on CCr in old age.
3 CCr calculated from the usual 24h urine collection was 
found to be accurately & reliably predicted when urine 
collections of about 8h were instead employed. Time of 
day over which the collection was carried out appeared to 
have little effect on prediction accuracy, although an 
overnight urine collection is probably the simplest &
vii
most convenient to carry out. Neither diuretic use, 
magnitude of measured CCr nor frailty influenced the 
accuracy of CCr prediction.
4 CCr was predicted using serum creatinine concentration in 
conjunction with a variety of equations available for the 
purpose. Accuracy of prediction was greatest when 
equations were employed which incorporated patients age & 
bodyweight, but in all cases this method was found to be 
less reliable than those using reduced urine collection 
times. Accuracy of CCr prediction by equation was not 
influenced by diuretic use, although those subjects with 
the lowest CCr, who were mostly frail, tended to have CCr 
overpredicted.
5 Elimination t^^2 and serum & renal clearance of frusemide 
were measured and compared between groups of fit & frail 
elderly subjects. Those subjects taking Frusemide BP 
tablets cleared FRU less efficiently than those taking 
Frumil tablets. No significant difference was found 
between the mean % dose recovered in urine of the fit & 
frail groups. FRU tended to be increased & FRU 
clearances reduced in the frail groups. CCr was also 
significantly lower in the frail groups. When fit & 
frail subjects taking Frumil were age-matched, the rate 
of FRU excretion remained slightly reduced in the frail 
group. While CCr appears to be more important than 
frailty in the determination of the rate of FRU 
elimination, frailty is associated with a reduced CCr 
below that expected from age alone.
6 Paracetamol was selected as a model drug to compare the 
efficiency of hepatic drug clearance between fit & frail
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elderly subjects. The frail group had a significantly 
increased elimination reduced serum clearance &
reduced recovery of urinary PAR + metabolites. The frail 
group was significantly older, and so fit & frail 
subjects were age-matched and again compared? similar 
trends remained. While impaired absorption in frail 
subjects could explain the reduced clearances observed in 
this group, the increased tl/2 could not be accounted for 
in this way. These results suggest that hepatic drug 
clearance is impaired in frail subjects.
7 Serum & renal clearance of digoxin were compared between 
groups of fit & frail subjects, all of whom had been 
regularly taking DIG for a variety of cardiovascular 
conditions, and were known to be in steady-state. 
Clearance was found to be significantly reduced in frail 
subjects who also had a reduced CCr, while % dose 
recovered in urine over 24h was similar between both 
groups. When fit & frail subjects were matched for CCr 
this trend was lost. These results suggest that the 
additional reduction in CCr associated with frailty, 
rather than frailty per se, may impair the efficiency of 
DIG elimination in the frail elderly.
8 Results from this thesis suggest that when drugs are 
prescribed for frail elderly patients, dosage levels 
should take into account the additional decrement in 
renal & hepatic drug clearance which appears to be 
associated with this state. If frail elderly patients 
received reduced dosages compared to their fit counter­
parts, the excess of dose-related adverse drug reactions 
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At present about 20% of the British population are aged 60 
years or over and demographic trends indicate a continual 
expansion in the proportion of elderly people in developed 
countries in the foreseeable future (1,2). This increase is 
predicted to be steepest in the very elderly age group, and 
while the UK already has 2 million people aged over 80, 12% 
of the population will be over 75 by the year 2020 (3,4). 
Disability increases with age and over 40% of retired 
people are limited in their activities by chronic ill 
health, with this figure increasing sharply for the very 
elderly (5). The proportion of those who are housebound 
increases from 1% of the population in the age group 65-69 
to over 20% after 85 (6,1).
From these statistics it is not surprising that the elderly 
are the major consumers of prescribed medication, and 
figures from the British Pharmaceutical Industry for 1985 
indicate that they account for 35-40% of drug expenditure 
(3,7). Adverse drug reactions are known to be two to three 
times more likely in the elderly age group due to their 
increased drug consumption and altered drug response.
In recognition of these patterns of drug use & misuse 
licensing authorities have now set down requirements for 
studies to be conducted on new drugs in old age. As 
FI Caird commented "For new drugs likely to be a risk for 
the elderly there are stringent requirements for testing in 
old age, and close monitoring. Thus what has for years been 
immoral & unethical has suddenly become compulsory” (8).
21.1 PHYSIOLOGICAL & PHARMACOKINETIC CHANGES OF OLD AGE
Various physiological changes associated with the normal 
ageing process are implicated in the excess of adverse drug 
reactions occurring in old age. The main changes seen even 
in the absence of specific pathology are listed below
i) decreased gastric acid secretion & reduced GX motility
ii) altered body composition
iii) decreased plasma albumin concentration
iv) decreased liver mass & hepatic blood flow
v) decreased renal blood flow, GFR & tubular secretion
These physiological changes can influence pharmacokinetic 
profiles via alterations in drug handling during absorption 
distribution, metabolism and/or excretion as given below.
Drug Absorption
Changes in function of the gastrointestinal tract in old 
age include a reduction in gut surface area, a decrease in 
gastric parietal cells leading to reduced gastric acid 
secretion (to elevate luminal pH), and impaired splanchnic 
blood flow, gastric motility & gastric emptying (9,10).
Most drugs in clinical use are absorbed via passive 
diffusion and neither rate nor extent of absorption appears 
to be significantly delayed following these age-related 
changes (11). Studies comparing the rate & extent of 
absorption of paracetamol, sulphamethizole, phenylbutazone, 
lorazepam & aspirin have shown no difference between groups 
of young & elderly subjects (12,13,14). However, active 
transport mechanisms appear not to function as well in the 
elderly and the absorption of some vitamins & minerals such 
as iron, calcium & thiamine may be impaired (15,16).
3Distribution
Body composition changes with age when the proportion of 
lean body mass and body water declines and adipose tissue 
increases (9). Studies relating muscle mass to age have 
shown a 30% reduction by the age of 80, and this figure is 
further increased by ill health & immobility (17). While 
this trend is seen in both sexes, elderly males tend to 
retain a greater proportion of muscle : adipose tissue than 
their female counterparts of similar age & weight (17).
The degree of plasma protein binding also determines drug 
distribution. Many basic drugs have a high affinity for ox­
acid glycoprotein whose concentration tends to increase in 
old age (18). Binding of basic drugs such as propranolol 
may thus increase in the elderly but this change is not 
considered clinically relevant. Acidic drugs have a higher 
affinity for plasma albumin whose concentration declines in 
old age (18). While this decrease is small in the healthy 
elderly, differences are more pronounced in the presence of 
chronic disease and also malnutrition, thought to affect up 
to 12% of those aged over 80 (19). Thus binding of acidic 
drugs is reduced in old age but again clinical relevance is 
usually not significant. However, when an increase in free 
fraction occurs in conjunction with pharmacokinetic changes 
greater clinical significance may be assumed.
Hepatic Metabolism
Metabolism by the liver is, for the majority of drugs, the 
rate-limiting factor in their duration of action, and many 
studies have been conducted in an attempt to determine 
whether the efficiency of hepatic metabolism is compromised 
in the elderly. Hepatocytes carry out a range of reactions
4which contribute to the removal of drugs, traditionally 
termed Phase I & Phase II biotransformations. Phase I 
reactions include oxidation, reduction & hydrolysis which 
render drugs more polar. Phase II reactions involve 
conjugation of the drug or its Phase I metabolite(s) to a 
larger endogenous substituent such as glucuronide, sulphate 
or acetate to give a much more polar compound, facilitating 
excretion into urine. Whilst no clear pattern has arisen 
from studies into age-related changes in drug metabolism, 
two general trends have emerged :-
i) drugs undergoing hepatic microsomal oxidation (Phase I) 
are likely to be more slowly metabolised in the elderly 
(eg. diazepam) whilst those that are conjugated (Phase II) 
are usually not influenced by age (eg. lorazepam),
ii) drugs with high hepatic clearances & extraction ratios, 
which undergo extensive first-pass metabolism during oral 
dosing, may show substantially increased bioavailability in 
old age (20).
These trends associated with hepatic senescence could be 
due to either a decrease in number or activity of enzymes 
responsible for biotransformation, or a reduction in rate 
of drug delivery to the liver (impaired hepatic blood flow)
Hepatic blood flow, rather than microsomal-enzyme activity, 
is the major determinant of total clearance of many 
commonly used drugs that are collectively termed "flow 
limited" or "highly extracted" drugs (eg. chlormethiazole). 
Studies have shown conclusively that apparent hepatic blood 
flow declines with age, by about 35% in those over 65 years 
compared to those under 40 years, even after allowing for 
changes in body weight (21). Furthermore, liver perfusion 
(liver blood flow per unit of liver volume) has also been
5found to fall by about 11%. The relevance of this is that 
drugs which are readily metabolized by the liver will 
exhibit an increased bioavailability after oral dosing 
since the degree of first-pass metabolism is reduced.
Other drugs undergo "capacity limited" metabolism when the 
hepatic extraction ratio is low (eg antipyrine,imipramine). 
Studies have failed to show a correspondence between 
activity or affinity of specific Phase I enzymes & 
chronological age in humans (19,20,21,22). However, using 
ultrasound it has been shown unequivocally that liver 
volume is negatively correlated with age, when expressed in 
absolute terms or in relation to body weight, and a 28% 
fall in liver volume has been noted in those over 65 years 
when compared to those aged less than 40 (21).
Thus changes in liver size may be the major factor 
determining decreased elimination of capacity-limited drugs 
with age, and any changes in enzyme activity are secondary 
to this, at least in the healthy elderly (21).
To date, the consensus of opinion is thus : liver size & 
blood flow declines with increasing age, and the reduced 
elimination of both capacity-limited & flow-limited drugs 
seen in the elderly is likely to be due to these 
morphological and physiological changes. These changes may 
at least in part explain the excess of dose-related adverse 
drug reactions in old age. Unfortunately there is no easy 
way of assessing the efficiency of an individuals hepatic 
drug clearance before initiating treatment with hepatically 
metabolised drugs. This emphasises the need for research 
into the change in hepatic function in old age.
6Renal Excretion
The best documented alteration in pharmacokinetics with age 
is the reduction in rate of renal drug elimination.
Between the fourth & eighth decades of life human kidneys 
lose approximately a fifth of their weight from a variety 
of morphological changes (23). Beginning in mid life, renal 
blood flow decreases progressively from about 600ml/min at 
age 40 to 300ml/min at age 85 (24). Similarly a normal GFR 
of 120ml/min at age 40 declines to about 60ml/min at age 85 
and this closely correlates with a decline in creatinine 
clearance (25). Tubular mass declines in a comparable way 
to renal blood flow & GFR, and both tubular secretion & 
reabsorption are impaired in old age (24). Essentially, 
ageing produces impaired homoeostatic flexibility, with the 
kidneys less able to conserve water and salts, and also 
less able to handle a water or solute load (26,27).
For any drug whose clearance is accomplished entirely or 
partially by renal excretion of the parent drug, rate of 
elimination will decline in proportion to the inevitable 
reduction in GFR and tubular secretion observed in old age. 
Thus accumulation of the parent drug or renally excreted 
metabolites may occur if drug dosages are not altered 
appropriately when prescribing for elderly people. 
Fortunately renal function may be estimated by a variety of 
methods to facilitate the accurate calculation of drug 
dosage levels when renally cleared drugs with a narrow 
therapeutic window are prescribed. The accuracy with which 
renal function may be predicted has itself been subject to 
extensive research since errors in prediction could lead to 
inappropriate therapy.
71.2 WHO ARE THE FRAIL ELDERLY?
Even in the absence of discernable disease there is a 
substantial heterogeneity in the physiological abilities of 
old people. Some remain independent until well into their 
ninth decade, exhibiting little loss of function even at
this advanced age, while others require full care soon
after retirement. It is possible that lifestyle rather 
than the intrinsic ageing process underlies much of the age 
change in physiological processes. To date few studies 
have attempted to identify physiological and biochemical 
differences between those elderly who are generally fit and 
active and those who are almost entirely dependent on 
others in the absence of acute physical illness. Most
research into drug handling in old age has concentrated on
groups of "fit individuals", frequently ill defined, and 
implicit extrapolations have subsequently been made for 
frail patients (28). The fit elderly are undoubtedly an 
easier group to study since they are able to give valid 
informed consent, and are free from disease and subsequent 
medications which may confound the effect of old age per 
se. Conversely, their less fit counterparts are frequently 
unable to give informed consent, posing a range of ethical 
dilemmas before the trial outset; in addition, they will 
almost without exception be receiving medications which may 
interfere with the studies.
The first attempt to standardize the selection of subjects 
for studies into the effects of ageing was made when a 
working party was set up within the framework of the 
European Community EURAGE Concerted Action Programme on 
Ageing. The resulting document, "The Senieur Protocol", 
was published in 1984 to establish strict admission
8criteria for studies on immunogerontology in man, based on 
clinical information and biochemical data, and setting 
limits for pharmacological interference (29). The aim was 
to contribute to the dissection of the influence of disease 
versus ageing on the immune system. However, the exclusion 
criteria set down to select healthy participants is extreme 
and impracticable for the purposes of the present set of 
investigations.
An alternative operational definition has been proposed by 
a second group in an attempt to dissociate biological and 
chronological age and the terms "fit" & "frail” have been 
coined for this purpose (28); their definitions are below 
The fit elderly are individuals, over 65 years of age, 
living independently at home or in sheltered accommodation. 
They are freely ambulant and without significant hepatic, 
renal, cardiac, respiratory or metabolic disorder on either 
clinical examination or laboratory investigation. They do 
not receive regular prescribed medication.
The frail elderly are individuals, over 65 years of age, 
dependent on others for activities of daily living, and 
often in institutional care. They are not independently 
mobile; whilst they do not have overt cardiac, respiratory, 
hepatic, renal or metabolic disease minor abnormalities may 
be revealed on laboratory investigation. They may require 
regular prescribed drug therapy. Conditions contributing 
to frailty commonly include Alzheimer's disease, multi­
infarct cerebro-vascular disease, Parkinsonism, 
osteoporosis, osteoarthritis, and healed fracture events.
Although the distinction proposed is based primarily on 
social and functional criteria it is paralleled by 
psychological and physiological differences. Using these
9definitions differences in hepatic function between the fit 
& frail elderly has undergone investigation. While the fit 
elderly exhibit the normal biological reduction in liver 
volume & blood flow associated with old age the frail 
elderly appear to possess an additional decrement in 
hepatic function to further reduce hepatic drug metabolism, 
which may be due to a reduction in the specific activity of 
some hepatic enzymes (19,20,22,30). While the fit elderly 
similarly undergo a reduction in renal function as a normal 
consequence of ageing, it has yet to be determined whether 
an additional decrement is imposed upon the frail elderly 
to further reduce drug clearance beyond that expected. The 
frail elderly also appear to have reduced mental function, 
reduced total body potassium, alterations in electrolytes, 
and a reduced serum albumin is apparently common (28).
Distinction between apparently different groups of elderly 
people is obviously important in the field of 
gerontological research and geriatric practice. However, 
the definitions above appear to exclude the majority of 
elderly people who are usually cared for by General 
Practitioners, who have the appearance of '•fitness11 whilst 
taking regular medications for well controlled chronic 
conditions. It seems important that the differences 
between these elderly subjects and their less fit 
counterparts, who have similar chronic conditions but are 
nevertheless considerably more infirm, be examined. 
Therefore, the main aim of this thesis was to successfully 
identify, define and compare these groups of elderly 
people, in terms of renal function and hepatic & renal drug 
clearance.
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1.3 CREATININE CLEARANCE STUDIES IN ELDERLY PEOPLE 
For drugs whose clearance is accomplished entirely or 
partially by renal excretion of the intact drug, total 
clearance will predictably decline in approximate 
proportion to the reduced GFR. It is therefore desirable 
to know the GFR of a patient before such drugs are 
prescribed to prevent accumulation, particularly when the 
therapeutic window is narrow.
Creatine occurs almost exclusively in muscle where it 
serves to guarantee the continuous supply of energy 
necessary to perform work. The breakdown of creatine 
liberates energy and creatinine is the final metabolic 
product of this process. Creatinine is released into the 
bloodstream at an almost constant rate in a person not 
taking severe exercise and in the absence of active muscle 
damage, and subsequently renally excreted mainly by 
glomerular filtration, although a variable amount is 
actively secreted by the renal tubules (31,32).
For some time it has been recognized that knowledge of 
renal function would be advantageous in order to assess the 
degree of renal damage in certain disease states, to 
measure changes in renal function over time, and to aid 
prescribing of drugs. For GFR to be accurately measured 
the ideal substance should be metabolically inert and 
excreted exclusively by glomerular filtration, ie. neither 
reabsorbed nor secreted by renal tubules. In 1926 it was 
suggested that since creatinine is produced at a constant 
rate, and excretion is mainly via glomerular filtration, 
measurement of endogenous creatinine clearance (CCr) would 
provide a good estimate for GFR (33). This could be 
practically carried out by collecting urine for 24 hours
11
and comparing the quantity of creatinine excreted in urine 
with the concentration of creatinine in serum. Since the 
rate of urine production would be known, creatinine 
clearance could then be calculated as for any other 
clearance value, to give an estimate of GFR.
Since this time many studies have been carried out to 
compare CCr with GFR measured by other more specific 
methods. Serum creatinine concentration (SCr) has also 
been suggested to provide a good estimate of renal function 
with the advantage that it is easier to obtain (34,35). 
However, the decline in muscle mass & lean body mass in old 
age is often overlooked, and since SCr levels depend upon 
creatinine turnover as well as renal function, the reduced 
renal function in the elderly usually does not give a 
meaningful elevation in SCr (36). To many it appeared that 
the most helpful & easily obtained result would be if SCr 
was measured and then used to predict CCr by use of a 
mathematical formula. Various formulae have subsequently 
been produced, the earliest in 1959 (37), and to date 12 
equations & 4 nomograms exist. Further studies have 
attempted to determine which, if any, formula most 
accurately predicts CCr in healthy individuals and in those 
with specific disease states. One problem addressed in 
this thesis is whether these formulae predict CCr equally 
well in both fit & frail elderly subjects. Accuracy of CCr 
prediction using formulae is also compared with that using 
a urine collection of less than 24 hours duration. If CCr 
can be accurately predicted, prescribing of drugs which are 
renally cleared may thus be made safer in this age group 
who are at greatest risk of adverse drug reactions.
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1.4 DRUG STUDIES IN ELDERLY PEOPLE
A number of studies have been conducted to determine which 
groups of drugs the elderly are most frequently prescribed, 
and of those, which are associated with the highest 
incidence of adverse reactions. The most recently 
published study to examine drug use in patients admitted to 
hospital found that out of all the principal drug groups 
prescribed, diuretics were the most commonly prescribed 
drug, identified in over 40% of admissions (38). Also 
significant in patients' drug regimes were hypnotics & 
anticonvulsants (25%), analgesics & antipyretics (25%) and 
digitalis alkaloids (16%). For this population, adverse 
drug reactions were identified in 10% of subjects taking 
medication, and drug classes most frequently implicated 
were antidysrhythmics, antihypertensives, NSAIDS, diuretics 
and digitalis alkaloids.
The aim of this thesis was to examine the efficiency of 
drug elimination in elderly people and to determine whether 
frail subjects exhibited an altered pattern of excretion 
when compared to their fit counterparts. This would be 
most relevant if the drugs which were most commonly 
prescribed and frequently implicated with an excess of 
adverse drug reactions were investigated. When drug usage 
in the Bath area was examined, both in the community and 
hospitals, frusemide, either alone or in combination with 
amiloride, was the diuretic most frequently prescribed. 
Frusemide is eliminated mainly via renal excretion, and so 
it seemed appropriate to choose a second drug which is 
hepatically cleared to compare the two modes of drug 
clearance. Paracetamol was found to be the most commonly 
used drug known to be solely hepatically cleared. The
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excess morbidity & mortality associated with digoxin use 
has been well documented for many years, and this seemed to 
be a suitable third drug for close investigation.
Therefore, in addition to the studies relating to 
measurement & prediction of CCr in fit & frail elderly 
people, this thesis was extended to investigate the 
efficiency of excretion/metabolism of three "model" drugs, 
that is, frusemide & digoxin which undergo mainly renal 
excretion, and paracetamol whose elimination is 
accomplished via hepatic metabolism.
1.4.1 FRUSEMIDE
The elderly receive a disproportionate number of drugs on 
prescription, and diuretics are one of the most common 
classes prescribed - it has been estimated that one third 
of people aged over 65 take a diuretic (39,40,41). By 
definition a diuretic induces a diuresis of water & solutes 
with the loss of sodium essential for the anti-oedema 
effect. However, sodium loss is inevitably accompanied by 
loss of other ions, and this is a potentially serious side- 
effect (42). Modern diuretics have revolutionized the 
treatment of oedema, and removal of fluid from peritoneal & 
pleural cavities by aspiration, or from the limbs by the 
insertion of tubes, is now rarely practised (43). Although 
these agents are invaluable in the control of hypertension, 
congestive cardiac failure & other oedematous conditions, 
widespread use of diuretics is often questionable, and some 
older persons undoubtedly receive diuretics inappropriately 
to reduce gravitational ankle oedema (39). Thus the risk- 
benefit ratio should always be considered before initiating 
diuretic therapy, and their prescription should be 
regularly reviewed during chronic therapy (42).
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Mode of Action and Therapeutic Uses
Frusemide (furosemide, FRU) is a member of the group of 
••loop” or "high-ceiling" diuretics - the others are 
bumetanide, piretanide & ethacrynic acid. All have a rapid 
onset of action, cause a brisk diuresis and have a short 
duration of action (32). FRU is a "loop" diuretic since it 
appears to inhibit specific enzymes concerned with pumping 
chloride ions (and therefore NaCl) across lining cells of 
the ascending limb of the loop of Henle. The site of 
action is reached intraluminally after the drug has been 
excreted by the proximal tubules. Potassium secretion into 
the distal convoluted tubule is increased because of the 
exchange of potassium for sodium, under the influence of 
aldosterone and increased intraluminal sodium, and this 
leads to increased potassium loss. In addition to the 
effects on ions, FRU increases blood flow through the renal 
medulla. This tends to reduce efficiency of the counter- 
current multiplier system in the loop, since this depends 
on a hypertonic medulla, resulting in less reabsorption of 
water from the collecting tubules (32,42,44). In addition, 
FRU is also thought to cause systemic venous dilatation and 
hence a reduction in cardiac pre-load. This property is 
utilized in the treatment of acute pulmonary oedema, where 
i.v. FRU will reduce pulmonary venous pressure and vascular 
congestion within a few minutes, well before it has an 
appreciable diuretic effect (44).
FRU is used to treat a number of conditions including acute 
pulmonary oedema, acute & chronic renal failure, 
hypertension, and peripheral oedema associated with cardiac 
failure, hepatic disease, nephrotic syndrome, and drug use 
(eg carbenoxolone). FRU is prescribed at a daily dose of
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20 to 160mg as a diuretic. In chronic renal insufficiency 
doses may vary from 250 to 2000mg a day (45,46).
Interactions and Toxicity
FRU diminishes the excretion of lithium whose dose should 
be halved. Hypokalaemia potentiates the effects of cardiac 
glycosides and diminishes the effects of anti-arrhythmic 
drugs such as procainamide & quinidine. The nephrotoxic & 
ototoxic effects of aminoglycoside antibiotics are 
potentiated by FRU. Drugs which promote sodium reabsorption 
eg. oestrogen, can antagonize the effect of FRU. Drugs 
which promote potassium excretion, eg. corticosteroids, may 
act additively with FRU to produce serious hypokalaemia. 
Non-steroidal anti-inflammatory drugs, in particular 
indomethacin, can interact with FRU, probably via their 
action on renal prostaglandins, inhibiting the diuretic 
effect of FRU. FRU in combination with a potassium-sparing 
diuretic such as amiloride, can cause hyperkalaemia when 
given concomitantly with an ACE-inhibitor (32,44,47).
The most common side-effect associated with FRU therapy is 
fluid & electrolyte imbalance and hypotension. Other side- 
effects are relatively uncommon and include allergy, 
nausea, diarrhoea, blurred vision, skin rashes, tinnitus & 
deafness. FRU may provoke hyperuricaemia, and less 
frequently, hyperglycaemia. FRU therapy in the elderly is 
particularly likely to provoke hypokalaemia, and 
malnutrition increases this risk. In elderly women 
incontinence may be exacerbated by loop diuretics, and 
elderly men with benign hypertrophy of the prostate may 
suffer from acute retention of urine following a large 





FRU is incompletely but fairly rapidly absorbed from the 
gastrointestinal tract, with a bioavailability of around 
61% (48). Following absorption, FRU is extensively bound 
to the plasma protein albumin, with the usual percentual 
binding of 97.7% decreasing in renal impairment, advanced 
illness and old age (49,50,51,52). Peak plasma 
concentrations occur about 60 minutes after oral ingestion, 
and although the extent of FRU absorption may be reduced in 
severe cardiac failure (53,54), age does not appear to 
influence FRU absorption (55). Effects of an oral dose are 
seen within an hour of administration, and last for 4-6h. 
When given i.v. FRU takes effect after 5 minutes, with a 
duration of action of around 2h (47).
Metabolism and Excretion
FRU has a biphasic half-life, the terminal phase 
representing elimination, which has a half-life of about 90 
minutes (53,56,57,58). Elimination is prolonged in renal 
impairment, acute pulmonary oedema & congestive heart 
failure and also in old age (57,58,59,60,61,62). FRU is 
mainly excreted unchanged in the urine, with active tubular 
secretion, via the nonspecific organic acid pathway 
excreting bound FRU, and glomerular filtration eliminating 
free drug (48). Metabolism to FRU-glucuronide appears to 
occur, and CSA (4-chloro-5-sulphamoyl-anthranilic-acid) may 
be another metabolite although this is controversial (58,60 
62). FRU is also excreted into the bile (53,61). Non-renal 
excretion is thought to become more important when renal 
function is compromised (59,60).
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1.4.2 PARACETAMOL
Acetanilide was first introduced into medicine in 1886 as 
an antipyretic but was found to increase methaemoglobin 
(32). The search for safer alternatives led to the 
development of phenacetin & paracetamol, derivatives of 
acetanilide. Phenacetin was initially very popular until 
it was found to possess nephrotoxic properties - this led 
to a subsequent decline in usage (63). From this point on 
the use of PAR increased and it is now widely used for many 
minor complaints.
Mode of Action & Therapeutic Uses
Paracetamol (acetaminophen, PAR) is a moderately water & 
lipid soluble weak organic acid with a pKa of 9.5 which is 
largely unionised over the physiological range of pH (64). 
It has antipyretic & analgesic actions similar to aspirin 
but only a weak anti-inflammatory action (65). Its mode of 
action may be similar to that of aspirin and dependent on 
inhibition of prostaglandin synthesis (66). PAR is used to 
treat a variety of conditions including mild pain, headache 
dysmenorrhoea & pyrexia. It is invariably taken orally, in 
an adult dose of 500-1000mg every 6-8h (max 4g/24h). It is 
often used in combination with other analgesics eg codeine.
Interactions and Toxicity
PAR interacts with phenytoin & phenobarbitone which 
increase its metabolism, probably through enzyme induction 
(67,68). PAR metabolism is also increased by desipramine 
(69) and reduced by chloramphenicol (70).
Adverse affects are rarely seen with therapeutic doses - 
skin rashes & haematological reactions have been noted 
(71). Liver damage resulting in jaundice, and kidney
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damage may follow chronic use of PAR (66,72). In overdose 
however, paracetamol can be extremely toxic with only 7g 
causing acute centrilobar hepatic necrosis, and 15g causing 
death (47). The mechanism of hepatic toxicity involves a 
highly reactive metabolite which is usually inactivated by 
conjugation with hepatic glutathione. Hepatic glutathione 
is rapidly used up by toxic doses of PAR, and when stores 
are reduced to less than 30% of normal, excess metabolite 
is free to combine with cell constituents to cause damage 
(73). There are no clinical manifestations of poisoning 
and maximum abnormalities of liver function tests can be 
delayed for 3 days? the plasma PAR concentration is 
therefore often used as a guide to prognosis. Exogenous 
glutathione does not enter cells readily but precursors 
such as methionine and N-acetyl cysteine can penetrate to 
combine with the intermediate and avert hepatic toxicity if 
administered sufficiently early (32).
PARACETAMOL DISPOSITION 
Absorption and Distribution
Paracetamol absorption is negligible from the stomach but 
rapid from the small intestine? peak plasma concentrations 
occur 30-120 minutes after ingestion of solid dose 
formulations (12). Absorption rate is influenced by gastric 
emptying rate which is increased by posture & drugs such as 
metoclopramide, and reduced by food and drugs such as 
morphine & loperamide? extent of absorption is unchanged. 
Age does not appear to affect the rate or amount of PAR 
absorbed (12,13,74). PAR undergoes dose-dependent first- 
pass metabolism with 90% bioavailability for a lg dose, and 
distributes throughout most tissues & fluids except CSF & 
fat, with no protein binding at a therapeutic dose (64).
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Metabolism and Elimination
PAR is extensively metabolised with only 2-5% of a 
therapeutic dose appearing unchanged in urine - the major 
metabolites are sulphate & glucuronide conjugates. A minor 
fraction is converted by cytochrome P-450-dependent hepatic 
mixed function oxidase to a highly reactive intermediate, 
usually inactivated by further conjugation with glutathione 
which is metabolised into PAR cysteine & PAR mercapturic 
acid. In healthy subjects approximately 85-95% of a lg 
dose appears in urine within 24h? about 4% as unchanged 
PAR, 55% as glucuronide, 30% as sulphate, 4% as cysteine & 
4% as mercapturic acid conjugates (75). These proportions 
may change in old age? the percentage of PAR glucuronide 
may increase and the percentage of PAR cysteine decrease 
with increasing age (76).
PAR is filtered at the glomerulus with subsequent extensive 
reabsorption, while PAR conjugate clearances suggest active 
renal tubular secretion (77). Plasma PAR concentration-time 
curves are multiexponential with a short half-time for the 
initial distribution phase (about 3-19 minutes). The 
elimination phase undergoes first order kinetics from 2-12h 
post-dose, with a half-life in the range of 1.9-2.5h (78). 
Total body clearance is about 5ml/kg/min in healthy young 
volunteers but may be reduced in old age (13,74,79,80,81).
1.4.3 DIGOXIN
Digitalis has been in clinical use for many centuries with 
the first description of its therapeutic effect in cardiac 
oedema published by William Withering in 1785. The active 
components of digitalis are collectively termed "cardiac 
glycosides”, and all share an aglycone ring wherein the 
pharmacologic activity resides, combined with one to four
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sugar molecules that modify the pharmacokinetic properties 
(42,44). All have characteristic electrophysiological & 
inotropic effects on the heart (82), but isolation of the 
individual components has led to production of standardized 
formulations. By far the most commonly prescribed 
glycoside used in the UK is digoxin, although digitoxin is 
occasionally used as an alternative. All subjects in the 
"Digoxin Study” were prescribed digoxin and so the scope of 
this thesis is limited to discussion of digoxin alone.
Mode of Action and Therapeutic Uses
Digoxin (DIG) is a polar compound consisting of a steroid 
nucleus with an OH side group (44), and its two main 
pharmacological properties utilized in therapeutics are
(i) the production of complex electrophysiological changes 
in cardiac conducting tissue to slow heart rate (negative 
chronotropic effect).
(ii) the ability to increase force & velocity of myocardial 
contraction (positive inotropic effect).
These two properties lend themselves to the use of DIG in 
the treatment of supraventricular tachyarrhythmias and CCF. 
In atrial tachycardias (in particular atrial fibrillation) 
DIG is singularly effective in reducing heart rate to 
improve ventricular filling, and this property remains 
beneficial until heart rate falls below 60bpm. In cardiac 
failure the principal therapeutic action is the positive 
inotropic effect on the myocardium. The desirability of 
this is controversial, particularly long term, since the 
benefit of reducing heart size and thus reducing oxygen 
demand is offset by an increase in work load and associated 
oxygen demand of the failing heart in the face of
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myocardial disease (42,82,83,84,85,86). Thus DIG is no 
longer the drug of choice for patients with heart failure 
in sinus rhythm (45,47).
Cardiac glycosides inhibit the ATPase responsible for the 
sodium pump. Their electrophysiological effects are 
thought to be due to changes in transroembrane potential 
brought about directly by that inhibition. The effect on 
cardiac muscle is probably due to changes in intracellular 
free calcium secondary to changes in intracellular sodium 
concentrations brought about by that inhibition (44).
DIG has a narrow therapeutic window, and the daily dosage 
is therefore variable and dependent on a number of factors. 
When renal function is normal, the recommended maintenance 
dose is 0.25-0.5mg or 5mcg/kg daily reduced to 0.125-0.25mg 
or 2mcg/kg daily in old age & renal insufficiency (44,87).
Interactions and Toxicity
A number of drugs have been shown to affect DIG pharmaco­
kinetics and these are summarized in Table 1.4.1 (82,88); 
Interactions of clinical importance are given in bold type.
Table 1.4.1 Agents affecting DIGOXIN pharmacokinetics 
Alteration Agents
Decreased absorption charcoal, antacids, dietary fibre,
neomycin, cytotoxic agents, kaolin, 
metoclopramide, sulphasalazine
Increased absorption antibiotics (inhibits gut flora)
anticholinergics (propantheline)
Inhibition of renal quinidine, quinine, verapamil
tubular secretion spironolactone, trimethoprim,
triamterene
Decreased Vd quinidine
Increased [SDIG] amiodarone,aspirin, diltiazem,
(mechanisms unknown) indomethacin, nifedipine,
flecainide, nicardipine
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In addition to these pharmacokinetic interactions, other 
drugs may give rise to pharmacodynamic interactions. 
Hypokalaemia is associated with an increased myocardial 
sensitivity to DIG (89), which may be induced by a variety 
of drugs eg. corticosteroids, potassium wasting diuretics, 
acetazolamide and carbenoxolone (45,46). Myocardial 
responsiveness may also be enhanced by other electrolyte 
disturbances eg. hyperkalaemia, hypercalcaemia and 
hypomagnesaemia, also hypoxia & acidosis (88).
Disease states known to affect response to DIG are given in 
Table 1.4.2 (42,82). Although old age is not especially 
associated with increased myocardial sensitivity, DIG 
elimination rate is reduced due to the inevitable decline 
in renal function (90,91,92). In addition, DIG Vd is 
reduced in old age and changes in body composition also 
influence DIG distribution to increase [SDIG] (9,10,93).
Table 1.4.2 Effect of disease state on response to DIG
Disease State Altered Response
Renal disease decreased DIG elimination & Vd
CCF decreased DIG elimination
increased Vd in oedematous patient
Hyperthyroidism reduced myocardial sensitivity
increased renal elimination & Vd
Hypothyroidism enhanced myocardial sensitivity
reduced renal elimination & Vd
Gastrointestinal decreased absorption, vomiting
disease & diarrhoea may reduce [K ]
Muscle wasting disease reduced binding to skeletal muscle
Pulmonary disease increased myocardial sensitivity
during hypoxia & acidosis
Acute MI increased myocardial sensitivity
Hepatic disease no significant changes
Diabetes insipidus no significant changes
obesity no significant changes
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Although knowledge of [SDIG] is generally thought to be 
useful in the diagnoses of both DIG toxicity & sub-maximal 
therapy, interpretation depends not only on the absolute 
level but also on the clinical status of the subject, since 
presence of factors known to influence myocardial response 
affect the clinical outcome. This is discussed in chapter 6
Toxicity is dose related, but the threshold at which signs 
first appear varies greatly between individuals (89,94). 
Symptoms of DIG toxicity fall into five categories as given 
in Table 1.4.3 (42,46,85,93). Moreover, the less serious 
manifestations of toxicity do not serve as a reliable 
warning of cardiotoxicity which is potentially fatal (93).
Table 1.4.3 Clinical features of digoxin toxicity
System Signs & Symptoms
Gastrointestinal anorexia, nausea, vomiting,
diarrhoea salivation
Neurological malaise, fatigue, confusion,
facial pain, insomnia, depression, 
vertigo, hallucinations, 
dizziness, coloured and hazy 
vision (green or yellow haloes), 
transient psychosis, sweating
Cardiological palpitations, arrhythmias, syncope
bradycardia, heart block
Blood high SDIG level with low potassium
Miscellaneous gynaecomastia, skin reactions
DIGOXIN DISPOSITION 
Absorption and Distribution
Limited absorption takes place from the stomach and the 
majority is passively absorbed from the proximal part of 
the small intestine (95,96) with peak plasma concentrations 
seen between 45 & 105 minutes after ingestion of a solid 
dose formulation (82,91). Factors which influence the rate
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of absorption have little effect on the total amount 
absorbed, but those which influence the extent of DIG 
absorption determine [SDIG] at all times (97), as discussed 
in chapter 6.
Following ingestion, 60-70% of the administered dose is 
available for systemic circulation in most subjects, 
although this figure can vary, sometimes due to disease, 
gut flora or tablet formulation (44,47,82,91,98,99,100,101) 
DIG is widely distributed and so Vd is large (61/kg), but 
may be reduced in old age & renal insufficiency and 
increased in hyperthyroidism (82,91,93,98,102,103,104,105, 
106). The largest proportion of circulating DIG is taken up 
by skeletal muscle, with the liver, heart, brain & kidneys 
also binding smaller amounts (107). DIG is 20% bound to 
plasma proteins but the large Vd makes any interaction at 
the site of binding clinically unimportant (47,92,98). DIG 
does not bind to adipose tissue and dosage calculations are 
more reliable if based on lean body mass rather than actual 
bodyweight for obese subjects (108,109).
Metabolism and Elimination
Although DIG is usually reported to be excreted unchanged 
in urine, evidence suggests that metabolism may at times be 
extensive. A number of metabolites have been detected in 
urine, particularly after chronic dosing, when detection is 
facilitated by their long elimination half-life (97,98,110, 
111). The degree of metabolism varies between subjects, is 
independent of renal function, and possibly under pharmaco- 
genetic control (110,112).
In most subjects however, renal excretion of unchanged DIG 
by passive glomerular filtration & active tubular secretion 
is the most important route of elimination (82,92,98).
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Approximately one third of the dose absorbed may be 
excreted by nonrenal routes eg secretion into bile (82). 
Following i.v. administration, DIG pharmacokinetics may be 
described by a two- or three-compartment model, although 
steady state kinetics after multiple dosing may be 
sufficiently described by a one-compartment model (44,92,93 
105,113). Distribution is complete 6h after ingestion, and 
blood sampling for [SDIG] estimation should be carried out 
after this time (114). Elimination half-life is variable 
and related to renal function (91,93,104); estimates of 
mean t ^ 2 have varied eg. 37h in healthy young subjects,
70h in nontoxic elderly people, 79h in those with renal 
impairment, and the highest values for DIG t-|y2 have been 
reported as 118h in elderly people with symptoms of 
toxicity, and 189h in a subject with renal insufficiency 
(91,93,98,102,104). Total body clearance has also been 
found to decline in old age & renal impairment (91,98,104). 
Due to the long attainment of steady-state commonly
takes in excess of a week if a fixed daily dose of DIG is 
administered (44). In emergencies a therapeutic [SDIG] 
level may be obtained more quickly by administration of a 
loading dose, eg. 15mcg/kg in divided doses over 12h (44, 
45). However, this is often associated with an increased 
incidence of gastrointestinal side effects and slower 
digitalisation is preferable in most non urgent cases (47).
1.5 SCOPE OF THE THESIS
To even the most casual observer a substantial 
heterogeneity in the abilities of old people can be seen to 
exist, although in the past many studies have considered 
"the elderly" to form a single homogeneous group. Whilst
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age-related changes in renal & hepatic function have been 
extensively investigated, most studies have used "fit" 
elderly subjects, often ill defined, and the results 
extrapolated to encompass the entire elderly population. 
However, recent research has suggested that hepatic & renal 
function, and consequently drug clearance, may differ 
between those who are fit & active and those who are frail 
& immobile (28).
Many elderly people living in the community have an 
appearance of "fitness" whilst having a well controlled 
chronic disease which requires medication but causes little 
interference with activities of daily living. Conversely, 
those elderly people frequently found in nursing homes or 
long-stay hospital wards have an appearance of "frailty", 
seeming less well than their active counterparts despite 
being of similar age and having comparable diagnoses. In 
addition, those in care tend to be prescribed more drugs 
and be more severely restricted in their mobility and 
ability to carry out activities of daily living. Attempts 
have been made to define particular sub-groups of old 
people but none appear to encompass the majority.
Therefore, the aim of this thesis was primarily to identify 
and define distinct groups of elderly people who together 
form the majority of the aged in the community and in care? 
the two resulting groups were termed "fit" and "frail".
Elderly people consume a disproportionate quantity of drugs 
and both groups studied were frequent users of prescribed 
medication. It is often desirable to know a patients renal 
function before renally excreted drugs are prescribed but 
CCr is often difficult to accurately measure in elderly 
patients, particularly when confused or incontinent.
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CCr was measured in both fit & frail groups and compared to 
determine whether renal function differed significantly 
between the groups when matched for sex, age & weight.
The estimation of CCr from a single SCr and use of a 
mathematical equation has been offered as an alternative, 
with results readily obtained from minimal effort. Since 
renally excreted drugs are commonly prescribed to both fit 
& frail elderly people, the accuracy with which CCr is 
estimated in these groups was examined, using a variety of 
equations and timed urine collections of less than 24 hours 
duration.
Following this, the efficiency of renal clearance of 
frusemide and digoxin was examined and compared between 
groups. Unfortunately, hepatic function cannot be measured 
as readily as renal function and so comparable studies 
could not be conducted to determine whether differences in 
hepatic function existed between the two groups of elderly 
people. Therefore, paracetamol was chosen as a model drug 
and the efficiency of its hepatic clearance measured and 
compared between the fit & frail groups.
To summarise, the aim of this work was to identify, define 
and compare groups of fit & frail elderly people in terms 
of renal function, and hepatic and renal drug clearance. 
Since frail elderly patients seem to exhibit an excess of 
adverse drug reactions when compared to their fit 
counterparts, increased understanding of the differences in 
efficiency of drug clearance between fit & frail elderly 
people may reduce the incidence of drug-related morbidity & 






i) Frusemide tablets BP 40mg (non-proprietary brands, 
supplied by patients own Pharmacy on prescription)
ii) Frumil tablets (frusemide 40mg, amiloride HC1 5mg, 
Rorer Pharmaceuticals, Eastbourne, Sussex. Various 
lots supplied by patients Pharmacist on prescription)
iii) Lanoxin tablets (62.5, 125 or 250micrograms Digoxin BP 
Wellcome Medical Division, Crewe, Cheshire. Various 
lots supplied by patients Pharmacist on prescription)
iv) Paracetamol tablets BP 500mg (Sterwin Medicines, 
Guildford. Lot 1EF539, supplied by Pharmacy Dept,
St. Martin's Hospital, Bath.)
Analytes
i) Creatinine 10.0mmol/l in 0.1M HC1, C4H2N30 mw=113 
(BDH Chemicals Ltd., Poole. Lot 7778120H)
ii) Creatinine 0.088, 0.265 & 0.883mmol/l in 0.02M HC1 
(Sigma Chemical Company. Lot 128F-6149)
iii) Frusemide BP (furosemide) C^H^jCl^OgS mw=330.8 
(Sigma Chemical Company. Lot 26F-0636)
iv) Paracetamol BP (4-acetominophenol, acetaminophen) 
CH^CONHCgH^OH mw=151 (Pharmacy, University of Bath)
Solvents
i) acetonitrile (methyl cyanide) HPLC grade CH3CN mw=41 
(Fisons, Loughborough)
ii) isopropanol HPLC grade (CH3)2CHOH mw=60 (Fisons)
iii) methanol HPLC grade CH3OH mw=32 (Fisons)
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Kits
i) Coat-A-Count Digoxin containing digoxin antibody-
125coated tubes, [ I] digoxin & calibrators 0-8 ng/ml 
(Diagnostic Products Corp., USA. Lot TKDI1 365 & 387).
Other Chemicals
i) acetic acid AR grade CH3C00H mw=60.1 (Fisons)
ii) beta-glucuronidase enzyme from Helix pomatia. 
activity: 440000 beta-glucuronidase, 15000 sulphatase 
units/g solid (Sigma. Lot 88F-7325)
iii) orthophosphoric acid 88% AR H3P04 mw=98 (Fisons)
iv) potassium dihydrogen orthophosphate KH2P04 mw=136 
(Fisons)
v) sodium acetate HPLC grade CH3COONa mw=136.1 (Fisons)
vi) sodium hydroxide AR grade NaOH mw=40 (BDH)
2.2 HUMAN VOLUNTEERS
Studies were carried out in accordance with the Declaration 
of Helsinki (Venice revision 1983) and studies received 
approval from the Bath District Research Ethical Committee. 
Before participation in a study, approval was given by the 
subjects Consultant Geriatrician or General Practitioner. 
Volunteers gave informed consent (verbal witnessed or 
written) and were free to withdraw from the study at any 
time without explanation. Subjects of both sexes aged 
between 64 & 100 years were recruited from
a) Wards 1, 2, 3, 4, 21 & 22 of St. Martins Hospital, Bath.
b) Patients registered with General Practitioners at
St. Mark's Road Surgery, Widcombe, Bath.
c) Subjects on the volunteer panel of the Research 
Institute for the Care of the Elderly, St. Martins 
Hospital, Bath.
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Exclusion criteria were as below :-
a) inability to give informed consent
b) incontinence
c) an acute episode of illness
d) co-medication with drugs interacting with the study drug
Records were made of the following :-
a) date of birth and age to nearest year
b) height & weight (surface area calculated from this)
c) all drugs currently being taken (prescribed or over-the- 
counter), the dose & frequency.
d) diagnoses and blood results if available
e) approximate amount of meat consumed during the study
The mobility of each subject was assessed during the study 
using a mobility rating scale devised for the studies 
(appendix A2). From their independence, mobility & ability 
to carry out activities of daily living, each subject was 
also categorized as fit or frail according to the 
definitions used during these studies (appendix Al).
2.2.1 Administration of drugs
Drugs were administered orally under supervision, taken 
with a glass of water, in the upright position. Drugs were 
given in the morning after a light breakfast eaten at least 
one hour previously, unless otherwise stated. Urine was 
voided immediately prior to dosing when the time was noted.
2.2.2 Treatment & storage of biological samples
Samples were processed as soon as possible after collection 
Urine was collected into a plastic jug or bottle for 
continent subjects, or into a catheter bag for catheterised 
patients, and saved in sealed plastic bottles labelled with
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the subjects name and time of voiding. Urine volume was 
measured and, when required, grouped into aliquots each 
spanning about 6-8h, before freezing. Blood was taken 
using plain Vacutainer tubes, labelled, and left to clot 
for one hour before being spun at 2000rpm for 15m. Serum 
was then collected & frozen. Frusemide-containing samples 
were wrapped in silver foil and processed in subdued light. 
Samples were stored at -20°C prior to analysis; serum in 
2x5ml or 2x1.5ml plain glass tubes and urine in 2x20ml or 
2x1.5ml aliquots. Samples were defrosted once just before 
use, and used within their stability period? 6 months for 
creatinine, 2 months for FRU & DIG, 6 weeks for PAR.
2 . 3 INSTRUMENTATION
During periods pf analytical work balances were checked 
monthly, and pipettes weekly, for accuracy and constancy.
2.3.1 Radioimmunoassay
Radioactivity was measured using a LKB Wallac 1275 Gamma
Counter (Pharmacia Ltd, Milton Keynes). The counter was
125set to the appropriate isotope ( I) and counts measured 
over 60s. Equipment was operated at ambient temperature.
2.3.2 Analysis of Digoxin
DIG was assayed using a commercially available RIA kit. 
Serum DIG was analysed as per the data sheet (appendix B1). 
Although the diagnostic kit was intended for use with serum 
the method was validated using urine diluted with water, 
and thus the same method was employed to measure urinary 
DIG. Calibrators supplied were used to construct 
calibration curves. Urine was diluted 1 in 10 or 1 in 20 
to ensure that readings fell within the calibration range.
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Quantitation of Digoxin in serum & urine
The mean net count for each calibration tube and patient
sample were calculated as below :-
net counts = mean count - mean NSB count 
The binding for each concentration was then found as a 
percent of maximum binding (MB), with the nonspecific 
binding (NSB) corrected counts of the A tubes taken as 100% 
percent bound = (net counts / net MB counts) x 100 
Using logit-log paper percent bound was plotted against 
concentration for each of the calibrators to form a line. 
Digoxin concentrations for the unknowns were then estimated 
from the line by interpolation.
2.3.3 High Performance Liquid Chromatography
HPLC is a technique used to separate components of a 
chemical mixture. Components are initially dissolved in 
liquid solvent and forced to flow through a chromatographic 
column at a stable pressure of normally between 1000-3000 
psi. Following application onto the column, the mixture is 
resolved into its components which are separately eluted & 
selectively detected using a uv monitor. This technique is 
therefore amenable to the separation of compounds which 
occur naturally as a mixture eg. biological fluids. The 
specificity of the system is such that components can be 
quantified to a high precision.
Mobile phase was pumped at a constant flow rate by a CM4000 
pump (Laboratory Data Control, (LDC), Stone, Staffs), which 
provides a pulseless flow using dual-reciprocating pistons. 
Samples were either injected onto the column using a Promis 
II autosampler (LDC) or via a rheodyne valve (model 7125), 
fitted with a 20ul or lOOul loop. Detection was by a
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SM4000 variable uv wavelength detector (LDC) and signals 
were recorded & plotted by a Cl10 (LDC) printer/integrater. 
Mobile phase was made up using high purity salts (HPLC 
grade) and double distilled deionised (DDDI) water. After 
adjustment to the required pH, mobile phase was filtered 
through a 0.45um membrane filter (Millipore), and before 
use degassed by purging with helium for 10m. The columns 
(15cm or 25cm x 4.5mm internal diameter) were constructed 
from stainless steel tubing, and packed with reversed phase 
micro-particle (5um) silica (Hypersil ODS, Shandon Ltd., 
Cheshire). Equipment was operated at ambient temperature 
and all samples were run in duplicate.
No internal standards were employed as sample preparation 
in all cases was by simple dilution. Calibration curves 
were constructed for each drug in urine & serum 
appropriately diluted, and the correlation coefficient r, 
gradient m, & intercept c, were calculated by linear least- 
squares regression. For linearity to be assumed over the 
chosen range r was required to be near to unity (r > 0.980)
2.3.4 Analysis of creatinine
Creatinine was assayed in urine (U) & serum (S) by HPLC 





Flow rate lml/m 
Chart speed 5mm/m
Column RP Hypersil 5um ODS 25cm x 4.5mm i.d. (LDC)
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Mobile Phase
urine 12% CH3CN : 88% 0.05M CH3COONa (6.80g/l) to pH 6.5 
serum 0.2% CH3CN : 99.8% 0.05M CH3C00Na to pH 7.5
Using the above conditions the retention time was 2.4 & 3.2 
minutes for creatinine in human urine & serum respectively, 
and typical chromatograms are given in Fig. 2.3.1
Sample Treatment
(i) Urine Analysis
100U1 or 50ul U + 900U1 (U/10) or 950ul (U/20) DDDI
I mix, lOOul U/10 or U/20 + 200ul CH3CN + 800ul DDDI
W mix, centrifuge for 10m at 13000rpm
20ul taken for HPLC analysis
(ii) Serum Analysis
lOOul serum + 200ul CH3CN + 500ul DDDI water 
I lOOul water or lOOul 0.088 mmol/1 Cr 
y mix, centrifuge for 20m at 13000rpm 
20ul taken for HPLC analysis
Calculation of Serum Creatinine Concentration 
Linearity over the expected range of creatinine in serum 
was verified. Due to the wide interindividual variation in 
SCr, [SCr] was determined by "spikeing" samples with 
creatinine, and comparing the mean peak height of duplicate 
samples before and after "spikeing”. The concentration of 
creatinine in each sample was determined by the equation 
overleaf
pH adjustment by glacial acetic acid
Stock Solutions Working Solutions
0.088 mmol/1 creatinine 







Typical chromatograms of CREATININE in









i— i— i— i— r
0 1 2 3 0 1 2 3 4
MINUTES MINUTES
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® -  y2 -  Yi
where y1 = mean unspiked peak height
y2 = mean spiked peak height
m = gradient of line (linear from standard curve)
then x = y^/m where x is unknown SCr in unspiked sample
Standard Curve
The calibration curve was constructed from 0-40ug/ml and 
was linear over this range for peak height & area (r=0.998) 
The coefficient of variation was i) 0.8% at lug/ml (n=10)
ii) 0.7% at 40ug/ml (n=10)
2.3.5 Analysis of frusemide
Frusemide (FRU) was assayed in urine & serum by HPLC using 






Column RP Hypersil 5um ODS 15cmx4.5mm i.d. (Jones)
Mobile Phase
53% methanol : 47% 0.02M KH2P04 (2.72g/l) to pH 3.0 
pH adjustment by orthophosphoric acid
Analyses were carried out in subdued light. Using the 
above conditions the retention time was 3.48m for FRU in 
urine & serum; typical chromatograms are given in Fig 2.3.2
Stock Solution Working Solutions
(a) lmg/ml FRU in methanol (a) diluted 1/10 & 1/100 with
H2 °
Fig. 2.3.2
Typical chromatograms of FRUSEMIDE
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The following were added to an eppendorf tube :
(1) Urine Analysis
50ul urine + 950ul DDDI water 
mix, centrifuge for 10m at 13000rpm 




500ul serum + 500ul CH3CN
mix, centrifuge for 20m at 13000rpm
20ul taken for HPLC analysis
Standard Curve
A calibration curve was constructed from 0 - 2 . 0  ug/ml and 
was linear over this range for peak height & area (r=0.990) 
The coefficient of variation was i) 3.1% at 0.lug/ml (n=10)
ii) 2.3% at 2.0ug/ral (n=10)
2.3.6 Analysis of paracetamol
Paracetamol was assayed in human urine (U) & serum (S) by







Column RP Hypersil 5 ODS 15cm x 4.5mm i.d. (Jones)
Nobile Phase
urine 5% isopropanol : 95% 0.08M KH2P04 (10.9g/l) to pH 3.0
serum 3% isopropanol : 97% 0.08H KH2P04 to pH 3.0
pH adjustment by orthophosphoric acid
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Using the above conditions the retention time was 4.68 &
3.28 minutes respectively for PAR in human urine & serum,
and typical chromatograms are given in Fig. 2.3.3.
Stock Solution Working Solutions
(a) lmg/ml PAR in methanol (a) diluted 1/10 & 1/100 with
»2°
Sample Treatment
The following were added to an eppendorf tube 
i) Urine Analysis
lOOul urine + 900ul DDDI water (U/10)
I Mix, lOOul U/10 + 200ul CH3CN + 900ul DDDI water 
y Mix, centrifuge for 10m at 13000rpm 
lOOul taken for HPLC analysis
ii) Urine Analysis of Paracetamol Glucuronide & Sulphate 
Paracetamol glucuronide & sulphate conjugates were 
assayed as PAR following enzymatic hydrolysis (at 37°C 
for 24h) by sulphatase and beta-glucuronidase.
iii) Serum Analysis
lOOul serum + 200ul CH3CN + 900ul DDDI water 
X  Mix, centrifuge for 20m at 13000rpm 
20ul taken for HPLC analysis
Standard Curve
The calibration curve was constructed from 0 - 1 5  ug/ml and
was linear over the range for peak height & area (r=0.990)
The coefficient of variation was i) 3.2% at 0.2ug/ml (n=10)
ii) 0.7% at lOug/ml (n=10)
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Fig. 2.3.3
Typical chromatograms of PARACETAMOL in
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2.4 STATISTICAL EVALUATION & TREATMENT OF RESULTS 
Statistics
Statistical analyses were performed using the computer 
package "Minitab" version Release 7.
Results were expressed as means & standard deviations 
(s.d.). Upper & lower quartiles (Q3 & Ql) and medians were 
also quoted in particular instances.
Statistical difference between two means was determined 
using the Mann-Whitney U test with statistical significance 
occurring at a probability of p<0.05 (5%).
Correlations between parameters were determined using 
Pearsons correlation coefficient for normally distributed 
samples, or when n > 50, or Spearmans coefficient of rank 
correlation for non-normally distributed samples and when 
n < 50. Due to the large number of correlations performed 
within each data set (eg. 15 columns x 14 rows) it was 
highly likely that Type II errors (ie. null hypothesis 
falsely accepted) would occur by chance. To reduce this 
probability statistical significance was taken to occur at 
p<0•01 (1%) for Pearsons & Spearmans correlations.
Calculations
Elimination half-life, t]y2f was calculated from the plot
of log [drug] v time, where kel is the elimination rate
constant from m = -kel then tl/2 = 0.693
2.303 kel
Serum clearance, Cls = dose x fraction absorbed
AUC
- AUC is the area under the [serum] v time curve
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Renal clearance, Clr = dose recovered in urine
[drug]
- [drug] is the concentration of drug in serum at the 
mid-time point for the urine collection.
Creatinine clearance, CCr *■ UCr x v x 100
SCr x 1440
- UCr is the urinary creatinine concentration (mg/lOOml)
- v is the urine flow rate (ml/24 hours)
- SCr is the serum creatinine concentration (mg/ml)
Body surface area, SA ■ AQ .Hal.Wa2
- AQ is 0.0235
- H is the height in cm, al is 0.42246
- W is the weight in kg, a2 is 0.51456
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CHAPTER THREE 
CREATININE CLEARANCE IN ELDERLY PEOPLE
3.1 INTRODUCTION
For drugs whose elimination is accomplished entirely or 
partly by renal excretion, total clearance will decline in 
proportion to the inevitable reduction in GFR occurring in 
old age. It is often desirable to know a patients' GFR 
before such drugs are prescribed to prevent accumulation, 
particularly when the therapeutic window is narrow. In 
clinical practice renal function is often estimated by 
measurement of creatinine clearance (CCr), involving the 
assay of creatinine in serum & a 24h urine sample. 
Alternatively, specially derived formulae may be utilized 
to predict CCr from serum creatinine alone, with the 
advantage of speed & convenience. Few studies have 
addressed the question of whether these "short-cut" methods 
are valid in the elderly, when inaccuracy of prediction may 
lead to inappropriate drug therapy. In this study CCr was 
measured in an heterogeneous group of old people and 
compared with the predicted CCr obtained from SCr and use 
of equations. In addition CCr was calculated from urine 
collections of about 8h, carried out at various times of 
day, and their accuracy to predict 24h CCr compared. The 
influence of mobility & frailty on CCr and its prediction 
were also investigated.
3.2 PROCEDURE
Very fit, fit & frail people, as defined in appendix Al, 
aged 60 years and over were invited to take part in the 
study. Exclusion criteria are given in 2.2. Subjects were
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recruited specifically for the CCr study from patients in 
St. Martins hospital, from General Practice, and from the 
Research Institute volunteer panel. In addition, subjects 
taking part in the Frusemide, Paracetamol & Digoxin studies 
(chapters 4, 5 & 6) were included in the present study 
since 24h urine collections were also necessary, providing 
the opportunity to maximize the use of collected material. 
Each subject was provided in advance with an information 
sheet (appendix Cl, standard or enlarged type) and given 
the opportunity to question Dr L Parker (GP trainee) or 
myself about the study prior to its commencement. On the 
morning of the study subjects emptied their bladder, noted 
the time, and from then on collected all urine for 24h, 
either in a single vessel or in a separate container per 
specimen, labelled with the time of voiding. When the 
latter method was employed the separate samples were later 
combined into 3 aliquots, each of approximately 8h, the 
final aliquot spanning the time spent in bed overnight. On 
completion of the urine collection, blood was taken in the 
morning after an overnight fast or meat-free breakfast. 
Forms given in appendix C2 (urine in aliquots) & C3 (single 
24h urine collection) were completed during the study. 
Samples were assayed for creatinine as per 2.3.4.
During the study subjects were questioned about their daily 
activities and mobility, and were categorized as very fit, 
fit or frail and had their mobility scored according to the 
mobility rating devised for the study (appendix A1 & A2). 
Current medication was noted and subjects were weighed and 
had their height measured where possible. Drugs taken & 
demographic details are given in appendices C4,D3,E3,F3.
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Correlations were determined using Pearsons correlation 
with significance levels being taken at p<0.01 for reasons 
outlined in 2.4. Groups (males v females and fit v frail) 
were compared using the Mann-Whitney test with significance 
levels being taken at p<0.05.
3.3 RESULTS OF CREATININE CLEARANCE STUDIES 
245 subjects (146F) successfully participated in the study 
to compare measured with predicted CCr, 194 (116F) of whom 
collected urine in aliquots enabling CCr from 24h & 8h 
urine collections to be compared. 115 subjects (71F) took 
part in the CCr study only, 34 (21F) also took part in the 
frusemide study, 49 (30F) in the paracetamol study & 47 
(24F) in the digoxin study. For the CCr study 35 (21F) 
subjects were very fit, 113 (70F) fit & 97 (55F) frail.
The 11 equations & 1 nomogram used to predict CCr from SCr 
are given in Fig. 3.1.
Comparison of Hales and Females
Data from males & females were compared with results given 
in appendix C6 & Figs 3.2 to 3.4. No significant difference 
was seen between sexes for age, M.Sc, urine vol or CCr/SA 
but the groups differed in every other respect. The males 
weighed significantly more, had a greater SA & excreted 
more UCr. Minimum, maximum & mean SCr values were also 
greater in the male group, likewise CCr although CCr/SA was 
similar between groups. These results suggest that males 
produce and excrete more creatinine, probably due to their 
increased weight & muscle mass, giving rise to disparate 
values for UCr, SCr & CCr. Because of these differences 
data from males & females were analysed separately.
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Females
Individual results for all 24h urine collections are given 
in appendices C5, D5, E5 & F5. Results from the entire 
female group are summarized in appendix C7 and correlations 
between parameters are given in appendix C8.
Age ranged from 60-100y (77±8? mean±s.d.) and significantly 
correlated with M.Sc, weight, urine vol, UCr & CCr.
Mobility score ranged from 1-5 and significantly correlated 
with urine volume, UCr, SCr & CCr.
UCr ranged from 240-2441mg (823+313) and correlated with 
age, M.Sc, weight, urine volume & CCr. SCr varied from 
0.34-4.32mg/100ml (1.39±0.69), correlating with M.Sc & CCr. 
CCr ranged from 7-141ml/min (48.7+24.1), correlating with 
age, M.Sc, urine volume, UCr & SCr. Similar correlations 
were seen for CCr/SA.
116 female urine collections were stored as aliquots 
enabling CCr from collections of less than 24h to be 
calculated. The 24h collection was divided into a morning 
collection (CCram), afternoon/evening collection (CCrpm), 
and overnight collection (CCrn), each varying in length 
according to the pattern of urine excretion exhibited by 
the subject. In all cases CCrn was calculated from urine 
produced during the time spent in bed overnight. Collection 
periods ranged from 2.42-11.OOh for CCram, 2.08-l4.75h for 
CCrpm, and 4.25-18.OOh for CCrn for females & males. 
Differences between 24h CCr & CCr from reduced collections 
was determined for each subject ie CCr - CCram = dCCram? a 
negative value would result if predicted CCr>measured CCr. 
CCr from reduced collection times were also expressed as 
%24h CCr ie. CCr/CCram x 100 = %CCram; a value less than 
100 would result when predicted CCr > measured CCr.
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CCram, CCrpm & CCrn are given in appendix C7 with the 
correlation coefficient between each reduced collection & 
24h CCr and the equation of the resulting line. Plots of 
measured v predicted CCr for each of the three reduced 
urine collections are given in Figs. 3.3.1 to 3.3.3.
For the 116 females with CCr calculated from reduced urine 
collection times, 24h CCr varied from 7-141ml/min (49+26). 
CCram varied between l-160ml/min (51±30) dCCram varied from 
“57-36ml/min (“2.0+13.3) and %CCram from 5-263% (103+32). 
The correlation coefficient between CCr & CCram was 0.901? 
the line had a gradient of 1.05 and y intercept of ”0.45. 
CCrpm varied between 2-156ml/min (52±32) dCCrpm ranged from 
“80-39ml/min (~3.3±15.3) while %CCrpm varied from 20-332% 
(107±40). The correlation coefficient between CCr & CCrpm 
was 0.877, the gradient was 1.06 and the intercept 0.37. 
CCrn varied from 6-153ml/min (46±26), dCCrn ranged from 
“41-42 ml/min (2.4+10.3) and %CCrn from 27-241% (96±25).
The correlation coefficient between CCr & CCrn was 0.922, 
the gradient was 0.93 and the intercept 1.21.
CCr, CCr/SA or CCr/70kg were calculated using 11 equations 
& 1 nomogram numbered El to El2 and where applicable female 
modifications are expressed as ExF. Formulae & authors are 
given in Fig. 3.1. Results are given in appendix C7 with 
the correlation coefficient and equation of the regression 
line between measured & predicted CCr for each formulae. 
Measured v predicted CCr were plotted and are given in 
Figs. 3.3.4 to 3.3.23.
The “ideal” formula, when plotted against measured CCr, 
would have a correlation coefficient of 1, a gradient of 1 
and an intercept of 0. No formula exhibited these
characteristics and so the 5 "best fit" formulae were 
selected for further investigation. Female modifications 
in all except one case did not increase the accuracy of 
prediction of CCr, and so 4 formulae chosen were common 
with those suggested for males. Equations selected were 
El, E4, E9, E10 & E11F. Plots of measured CCr v %CCr for 
the reduced urine collections and 5 best fit equations are 
given in Figs. 3.3.24 to 3.3.31.
Males
Individual results for all 24h urine collections are given 
in appendices C5, D5, E5 & F5 and results from the male 
group are summarized in appendix C9. Correlations between
parameters are given in appendix CIO.
Age ranged from 60-97y (76+8) and significantly correlated 
with M.Sc, SA, urine vol, UCr & CCr.
Mobility score ranged from 1-5, correlating with age, 
weight, SA, urine volume, UCr, SCr & CCr.
UCr ranged from 302-2624mg (1192±433), correlating with 
age, M.Sc, weight, SA, urine volume & CCr. SCr varied from 
0.55-6.71mg/100ml (1.67+1.01), correlating with CCr & M.Sc. 
CCr ranged from 10-193ml/min (61±30) & CCr/SA from 10-164 
ml/min/1.73m2 (56+26). Both correlated with age, M.Sc, 
weight, SA, urine volume, UCr & SCr.
78 male urine collections were stored as aliquots enabling
CCr from collections of less than 24h to be calculated, and 
results are shown in appendix C9.
For these subjects 24h CCr ranged from 10-193ml/min (60+31) 
CCram varied from 6-195ml/min (68+41) with dCCram ranging 
from -87-17ml/min (-8±22) & %CCram from 30-350% (112±49). 
The correlation coefficient between CCr & CCram was 0.846,
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the gradient was 1.11 and a y intercept 1.6.
CCrpm varied between 9-209ml/min (63+37) dCCrpm from -75-29 
ml/min (-4+14), %CCrpm from 37-274% (105±30). The 
correlation coefficient was 0.925, the gradient 1.09 & the 
intercept -1.5.
CCrn ranged from 3-186ml/min (54±30), dCCrn from -43-50 
ml/min (6+14), %CCrn from 7-149% (92+22). The correlation 
coefficient was 0.905, the gradient 0.87 and intercept 1.8. 
Plots of measured v predicted CCr for each of the reduced 
urine collections are given in Figs. 3.4.1 to 3.4.3.
CCr, CCr/SA or CCr/70kg were calculated from SCr using 11 
equations & 1 nomogram as in Fig. 3.1. Results are given 
in appendix C9 with the correlation coefficient & equation 
of the line between measured & predicted CCr for each 
formulae. Measured v predicted CCr were plotted and given 
in Figs. 3.4.4 to 3.4.15.
No formula was "ideal" and so the 5 best fit formula were 
selected - these were El, E4, E9, E10 & Ell. Plots of 
measured CCr v %CCr for each reduced urine collection & the 
5 best fit equations are given in Figs. 3.4.16 to 3.4.23.
3.3.1 Influence of Diuretics on CCr Prediction 
Females
Females were divided into groups according to whether or 
not they took diuretics and results are shown in appendix 
Cll. The 60 females who took diuretics during the study 
were older and less mobile than the 86 who did not. CCr 
tended to be lower in those taking diuretics but this was 
not significant. CCram, CCrpm & CCrn were reduced for 
those taking diuretics, but this was only significant for 
CCrpm (p<0.02). dCCrn tended to be greater in those who
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did not take diuretics (p<0.05), but dCCram & dCCrpm were 
unchanged. The accuracy of CCr prediction using 5 selected 
formulae did not appear to be affected by diuretics.
Males
Males were divided into two groups according to whether or 
not diuretics were taken and results are shown in appendix 
C12. The 36 males who took diuretics during the study 
tended to be older and less mobile (p<0.002) than the 63 
males who did not. CCr tended to be reduced in those 
taking diuretics, with a small difference seen when CCr/SA 
was compared (p<0.05). CCram, CCrpm & CCrn tended to be 
reduced in the group taking diuretics but this was not 
significant. The difference between 24h & 8h CCr was not 
influenced by diuretic taking. The accuracy of CCr 
prediction using the 5 selected formulae was not altered 
significantly when diuretics were taken.
3.3.2 Measured CCr vs Predicted CCr 
Females
When measured v predicted CCr were plotted for the 5 best 
fit formulae the accuracy of prediction was seen to alter 
with magnitude of the measured CCr. If the "ideal" line of 
measured = predicted CCr was drawn, the point of 
interception between the two lines occurred between 40 & 
50ml/min. Below this point there was a tendency to over­
estimate CCr, above this point CCr tended to be under­
estimated with the greatest discrepancies seen for extreme
values of measured CCr. Subsequently, females were divided
into groups of CCr > 50ml/min & CCr < 50ml/min and
compared. Results are given in appendix Cl3.
Those with CCr < 50ml/min were older, less mobile, excreted
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less UCr but had a greater SCr. The accuracy of CCr 
prediction for urine collections less than 24h was not 
compromised by a reduced CCr, with no statistical 
difference seen between absolute or percent differences for 
CCram, CCrpm or CCrn. However, when CCr was predicted using 
the formulae a significant difference was seen between both 
the absolute & percent differences of the predicted CCr.
CCr tended to be overestimated when measured CCr < 50ml/min 
and underestimated when measured CCr > 50ml/min.
Males
When measured v predicted CCr was plotted for the males, a 
similar pattern was seen, with the accuracy of prediction 
changing with the measured CCr. The intercept between the 
lines measured v predicted CCr and measured ** predicted CCr 
occurred between 30 & 40ml/min. Although a lower intercept 
was seen between measured & predicted CCr than for the 
female group, males were still divided into groups of 
CCr > 50ml/min & CCr < 50ml/min since it is below this 
point that renal dysfunction starts to become important in 
drug dosage calculations (45). Groups were compared with 
results given in appendix C14.
Those with CCr < 50ral/min were older, less mobile, excreted 
less UCr & had a higher SCr. CCram & CCrpm remained 
comparable to 24h CCr for both groups, but CCrn tended to 
overestimate CCr when CCr was < 50ml/min. When CCr 
predicted by the formulae were examined a significant 
difference was seen between both the absolute and percent 
difference of the predicted CCr. CCr tended to be over­
estimated when measured CCr < 50ml/min and underestimated 
when CCr > 50ml/min.
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3.3.3 Influence of Frailty on CCr prediction 
Females
Females were divided into two groups of all fit (very fit + 
fit) & frail subjects and compared with results in appendix 
C15. The frail group was 6.4y older, less mobile, excreted 
less UCr (934mg v 639mg), had a greater SCr (1.24mg/dl v 
1.63mg/dl) & lower CCr (57ml/min v 36ml/min). The accuracy 
of CCr prediction was not compromised for urine collections 
of less than 24h in this group. However, when CCr was 
predicted using the equations both the absolute & percent 
differences were significantly different between fit & 
frail groups. CCr tended to be overestimated in the frail 
group who had a low measured CCr, and underestimated in the 
fit group where the greatest measured CCr values were seen. 
The frail group was significantly older than the fit group 
and it was not possible to determine whether frailty or 
increased age was the more important determinant of the 
reduced CCr seen in the frail group. Very fit, fit & frail 
female subjects were therefore age matched and compared 
with results in appendix C16,C17,C18.
When age matched, no statistical differences were seen 
between the very fit & fit female groups in terms of M.Sc, 
weight, SA, urine volume, UCr, SCr or CCr. CCrpm & CCrn 
closely predicted 24h CCr but CCram overestimated 24h CCr 
for the fit group when compared to the very fit group. For 
each of the serial collections, the regression coefficient 
was not less than 0.919 and the gradient of the measured v 
predicted line closely approached unity. The accuracy of 
CCr prediction using equations was not significantly 
different between very fit & fit groups, but the variation 
in accuracy of prediction was wide. The regression
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coefficient varied between 0.889-0.565, and those with the 
greatest CCr tended to have CCr underpredicted.
When age matched fit & frail female groups were compared, 
frail subjects were less mobile with a significantly lower 
urine volume, UCr & CCr. There was no difference between 
groups for weight, SA or SCr. The accuracy of prediction of 
CCr for urine collections less than 24h was not compromised 
in the frail group and there was a good correlation between 
measured & predicted CCr. However, the accuracy of CCr 
prediction using equations differed significantly between 
groups. CCr tended to be underpredicted in the fit group 
who had the greater measured CCr, and overpredicted in the 
frail group. The correlation between measured & predicted 
CCr was less good than for the serial 8h urine collections.
When age matched very fit & frail female groups were 
compared frailty was associated with a reduced M.Sc, urine 
output, UCr & CCr, although both groups were similar in 
weight. Accuracy of CCr prediction was comparable between 
the groups for urine collections less than 24h when the 
correlation between measured & predicted CCr was good. 
However, the accuracy of CCr prediction using the formulae 
differed between groups, with the very fit group showing a 
strong tendency towards underprediction & the frail group 
exhibiting a strong tendency towards overprediction.
Males
Males were divided into two groups of all fit & frail 
subjects and compared; results are given in appendix C19. 
The frail group was on average 6.5y older, less mobile, had 
a lower urine output, excreted less UCr (1371mg v 950mg), 
had a greater SCr (1.42mg/dl v 2.00mg/dl) and lower CCr
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(73ml/min v 44ml/min). The accuracy of CCr prediction for 
urine collections less than 24h was not compromised for
CCram or CCrn although CCrpm tended to overestimate CCr in
the fit group (p<0.05). However, accuracy of CCr prediction 
using the 5 best eguations varied significantly between 
groups. CCr tended to be underpredicted in both groups but 
the degree of underprediction was greater in the fit group 
who had the greater measured CCr. The frail group was older 
than the fit group, and in order to separate out the 
influence of frailty against increased age, very fit, fit & 
frail males were age matched and compared, with the results
given in appendices C20, C21 & C22.
No statistical differences were seen between age matched 
very fit & fit male groups for M.Sc, weight, SA, urine vol, 
SCr or CCr, although UCr excretion was lower in the fit 
group. Accuracy of CCr prediction from reduced urine 
collections was not significantly different between groups, 
although CCrpm was the least accurate. CCr predicted from 
equations tended to be less than the measured CCr for both 
groups, with the discrepancy between measured & predicted 
CCr significantly greater for the very fit group.
When age matched fit & frail male groups were compared 
frail subjects were significantly less mobile, had a lower 
weight & SA, excreted less UCr, with a lower CCr. Both 
CCrpm & CCrn accurately predicted CCr for both groups but 
CCram tended to underpredict CCr in the frail group 
(p<0•05)• Using the equations CCr tended to be 
underpredicted in both groups, with the degree of 
underprediction greater in the fit group.
When age matched very fit & frail male groups were compared
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a similar pattern was seen, although most differences 
failed to reach significance with only 7 subjects in each 
group. The frail group was significantly less mobile, 
weighed less & excreted less UCr than their very fit 
counterparts, and CCr tended to be reduced in the frail 
group (76+16ml/min fit, 58±29ml/min frail). The accuracy 
of CCr prediction using both reduced urine collections and 
equations was not significantly different between groups 
although CCr tended to be underpredicted most in the very 
fit group who had the greater measured CCr.
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Fig. 3.1
EQUATIONS FOR THE PREDICTION OF CREATININE CLEARANCE 
age - years SCr - mg/lOOml weight - kg
EQUATION 1 - COCKCROFT & GAULT, 1976 - (118)
MALES (El)
CCr (ml/min) = (140 - age) (weight)
72 x SCr
FEMALES (E1F)
CCr males x 0.85
EQUATION 2 - JELLIFFE, 1971 - (119)
MALES (E2) 0
CCr (ral/min/1.73m ) = 100 - 12
SCr
FEMALES (E2F) 0
CCr (ml/min/1.73m ) = 80 - 7
SCr
EQUATION 3 - JELLIFFE, 1973 - (120) 
MALES (E3) 0
CCr (ml/min/1.73m ) = 98 - 0.8(aqe-20)
gCr
FEMALES (E3F)
CCr males x 0.9
EQUATION 4 - JELLIFFE & JELLIFFE, 1972 - (121)
MALES (E4)
step 1 E = weight (29.3 - 0.203 age)
step 2 R =1.035 - (0.0037 x  SCr)
step 3 E __ = ESS x  R = EF corr
step 4 CCr (ml/min) = E
SCr x 1 4 .4
FEMALES (E4F)
step 1 E = weight (25.1 - 0.175 age) then as for malesSo
EQUATION 5 - EDWARDS & WHYTE, 1959 - (37) 
(E5)




EQUATION 6 - WAGNER, 1971 - (122) 
MALES (E6)
CCr (ml/min) = 1.96 - 1.19 (log SCr) 
FEMALES (E6F)
CCr (ml/min) = 1.85 - 1.18 (log SCr)
EQUATION 7 - ROWE, 1976 - (123)
(E7) 2
CCr (ml/min/1.73m ) = 165.57 - 0.80(age)
EQUATION 8 - ROWE, 1976 - (124)
(E8)
CCr (ml/min/1.73m2) = 133 - 0.64 (age)
EQUATION 9 - MAWER, 1976 - (125)
MALES (E9)
step 1 Q = weight (29.3 - (0.203 x age))
Step 2 Q__ = Q (1 - (0.003 scr))cr corr cr
step 3 CCr (ml/min) = Qcr
14.4 x SCr
FEMALES (E9F)
Qcr = QCr males x 0,8
EQUATION 10 - HULL, 1981 - (126) 
MALES (E10)
CCr (ml/min/70kq) = (145 - aqe) - 3
SCr
FEMALES (E10F)
CCr (ml/min/70kg) = CCr male x 0.85
EQUATION 11 - GATES, 1985 - (127)
MALES (Ell) - -
CCr (ml/min) =89.4 (SCr“1,z)+(55-age) [0.005(89.4) (SCr*"1,1) ]
FEMALES (Ell) - - , -
CCr (ml/min) =60 (SCr“-L*‘L) + (56-age) [0.005(60) (SCr“J"-L) ]
















Fig. 3.2 Distribution of UCr in Fit & Frail 58
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Fig. 3.3 Distribution of SCr in Fit & Frail
Female and Male Elderly Subjects
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Distribution of CCr/SA in Fit & Frail
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CCrpm = 1.06CCr + 0.37 
r = 0.877 
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El 0.70CCr +11.6 
0.826 
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E1F = 0.60CCr +9.9 
r = 0.826 
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E2F = 0.95CCr/SA +13.6 
r = 0.779 








































E3 = 0.67CCr/SA +10.6 
r = 0.844 
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**60 ** E3F = 0.61CCr/SA +9.6 
r = 0.844 
n = 146 
p < 0.001** *23*
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E4F = 0.67CCr +11.1 
r = 0.826 





































E5 = l.UCCr/SA +22.5 
r = 0.779 
























•H * * * E6 = 1.29CCr + 16.1 
r = 0.696 
n = 146 
P < 0.001
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** 2*32*2^3344** E6F l.OlCCr +8.8 
0.774 


























































E7 = 0.07CCr/SA + 100 
r = 0.293 
n = 146 
p < 0.001
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E8 = 0.06CCr/SA +80.6 
r = 0.293 







































Fig. 3.3.17 Predicted v Measured CCr using E9
for Female Subjects
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Fig. 3.3.20 Predicted v Measured CCr using E10F 
for Female Subjects
160
*2, E10F = 0.64CCr/70kg + 11.0 
r = 0.858 
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* E12 = 0.57CCr +13.2 
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Fig. 3.3.27 Measured 24h CCr v % Predicted CCr 

















Fig. 3.3.28 Measured 24h CCr v % Predicted CCr
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Fig. 3.3.29 Measured 24h CCr v % Predicted CCr 
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Fig. 3.3.30 Measured 24h CCr v % Predicted CCr
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Fig. 3.3.31 Measured 24h CCr v % Predicted CCr 
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1.52CCrpm = 1.09CCr 



















































































El = 0.64CCr +8.2 
r = 0.862 
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E7 = 0. UCCr/SA + 98.6 













































































*2 E10 = 0.68CCr/70kg +8.0 




















































Ell = 0.67CCr + 15.9 
r = 0.694 
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Fig. 3.4.19 Measured 24h CCr v % Predicted CCr 
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Fig. 3.4.20 Measured 24h CCr v % Predicted CCr
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Fig. 3.4.21 Measured 24h CCr v % Predicted CCr 
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Fig. 3.4.22 Measured 24h CCr v % Predicted CCr
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Creatinine clearance was measured and predicted, using 11 
equations, one nomogram, and urine collections of less than 
24h* in a heterogeneous group of elderly people. The 
influence Of immobility & frailty on 24h CCr and the 
accuracy of its prediction were investigated.
3.5.1 Creatinine Clearance in Elderly People 
Comparison of Male & Female Results
Elderly males studied were matched in terms of age & M.Sc 
with their female counterparts but they Weighed more, had a 
greater SA, and significantly higher mean values for SCr, 
UCr & CCr. When CCr was normalized to 1.73m SA the 
difference in CCr was no longer significant. This suggests 
that part of the difference observed may be due to the 
inequality in weight between the sexes. One longitudinal 
study of people of working age found UCr excretion to be 
33% greater in males, although the difference was reduced 
when expressed per kg bodyweight. While SCr was also found 
to be elevated by 21% in the males, CCr was only modestly 
increased, by about 8% when expressed per kg bodyweight 
(129). Others found SCr to be significantly higher in 
healthy males than females even when differences in body 
surface area were taken into account (130). Another study 
investigating renal function in 70 & 75 year olds found no 
sex difference with respect to GFR (131). A fourth study 
also reported little difference in normalized CCr between 
elderly males & females (132). Young males usually have a 
greater proportion of muscle per kg bodyweight than females 
although this may not necessarily be so in old age when the 
proportion of muscle to adipose tissue declines (108,132). 
Creatinine levels in serum & urine are strongly influenced
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by total muscle mass (31,129,133,134), and even If the 
muscles fat ratio is similar in elderly males & females, 
males in this study weighed on average 10kg more than 
females and it is likely that their total muscle mass was 
greater. This may explain the difference in UCr & SCr 
observed between sexes.
Equations to predict CCr, often in ml/min, utilize SCr & 
weight, both of which were significantly different between 
sexes. Moreover, some include a "female correction factor” 
to take into account the difference in muscle mass between 
sexes. One aim of this study was to determine if CCr was 
more accurately predicted for females in the presence of 
this factor, and so was more appropriate to analyse male & 
female data separately and then compare results.
Females
Females studied ranged in age from 60-100y and increasing 
age was associated with a reduction in mobility. This was 
accompanied by a reduction in UCr excretion, probably due 
to the decline in muscle mass associated with a sedentary 
existence, suggesting that the mobility rating scale gave a 
reasonable measure of activity. While no correlation was 
seen between age & SCr, CCr declined with increasing age. 
This trend has been extensively reported as an inevitable 
consequence of ageing, occurring even in the absence of 
active renal disease (123,128,131,135,136). Longitudinal 
studies have suggested that CCr declines from the age of 30 
onwards with an acceleration in rate after age 50 (23,123), 
although considerable interindividual overlap occurs.
In the present study CCr/SA ranged from 8-167ml/min/1.73m2 
(52+26) with most subjects having a measured CCr below that 
quoted for a "normal” female of 80-100rol/min/1.73m2? those
92
who were immobile and very elderly generally had the lowest 
values. Other studies have reported similar CCr values for 
elderly people. Mixed sex groups of elderly people, with 
mean ages of 75 & 88y, had CCr of 60 & 47ml/min (136,137), 
while CCr was found to be 57±18 & 77+23 ml/min in groups of 
females with mean ages of 76 & 83y (132). 19 elderly infirm 
females (79±6y), had a mean CCr of 51+16ml/min but this 
value was calculated from two 8h urine collections and all 
subjects had chronic indwelling urethral catheters (87).
SCr was mainly within normal limits despite some subjects 
having a lower than normal CCr. This will be discussed in 
more detail later in the chapter. UCr varied greatly 
within the female group from 240-2441mg (823+313). While 
some data at the lower end of the range could have resulted 
from incomplete urine collections, steps were taken to 
ensure that these were discarded. Other studies have 
reported UCr excretion to be 1173mg/24h/1.73m2 & 785mg/24h 
in groups with mean ages of 67 & 75y (26,136) & 746mg/24h 
in patients (63±16y) with rheumatoid arthritis (138).
Males
Age of the male group ranged from 60-97y and increased age 
was again associated with reduced mobility; both old age & 
immobility were associated with a decline in UCr. As for 
the females, increasing age was associated with reduced 
renal function as measured by CCr, which ranged from 10-164 
ml/min/1.73m2 (56+26). Other studies found CCr to be 110 & 
97ml/min/1.73m in healthy males between 65-74 & 75-84y 
respectively (54) which is higher than the present results. 
UCr Varied considerably between males from 302-2624mg/24h 
(1192+433), and these values are in accordance with others 
reported. Groups of fit elderly males aged between 65-74y
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& 75-84y excreted 1409±25mg & 1259±45mg of UCr in 24h (123) 
3*5*2 Influence of Diuretics on CCr
The elderly are known to take a disproportionate quantity 
of drugs, and diuretics are one of the most commonly 
prescribed classes* The 36 females & 60 males taking 
diuretics during the study were compared with subjects who 
were not, to determine whether diuretic use was associated 
with a change in CCr. For both sexes a small reduction in 
CCr was seen for those taking diuretics but this was not 
significant. Those taking diuretics were older and 
significantly less mobile which may explain the slight 
trend in CCr observed. Overall, diuretics do not appear to 
influence CCr and it was therefore not necessary to treat 
those taking diuretics separately.
3*5*3 Influence of Frailty on CCr
The elderly are not a homogeneous group but possess a range 
of physical abilities. The least able are usually found in 
care differing from their fit counterparts in the community 
by their limited mobility and altered body composition & 
posture. It is possible that these factors associated with 
infirmity may influence renal blood flow and hence renal 
function. In this study females & males were divided up 
into groups of fit & frail subjects and compared. For both 
sexes the frail group was significantly older than the fit 
group and the way in which frailty contributed to CCr could 
not be determined. Very fit, fit & frail subjects were 
therefore age matched & compared in an attempt to eliminate 
the effect of increasing age on CCr.
For both sexes UCr, SCr, CCr & CCr/SA was not statistically 
different between very fit & fit groups, suggesting that
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chronic but well controlled non-renal conditions are not 
generally associated with loss of renal function.
Subsequent studies in this thesis have compared drug 
excretion in fit & frail groups and similar results would 
probably have been obtained if very fit instead of fit 
subjects had been used. When either very fit or fit groups 
were compared with their frail age-matched counterparts, a 
similar trend was seen for both sexes. The frail group was 
significantly less mobile than the fit since information on 
mobility was used to categorize subjects. UCr was 
significantly lower in the frail groups, probably due to a 
reduced muscle mass resulting from severely restricted 
mobility. Urine volume was also reduced in frailty although 
this was only significant for the females. It is possible 
that the frail group more often had incomplete urine 
collections, although most frail subjects were in care and 
urine collections were therefore supervised. Elderly 
subjects in general are at risk of dehydration and those in 
care particularly so (24,139), and this may explain the 
reduced urinary output in the frail group, likely to be a 
real observation.
CCr & CCr/SA were significantly lower in the frail groups, 
but no statistical difference was seen for SCr between 
groups although frailty appeared to be associated with an 
increased SCr. A SCr value is dependent on both the rate of 
production & excretion of creatinine, and weight tended to 
be reduced in the frail groups. In addition, frail subjects 
are more likely to have muscle atrophy as a result of 
restricted mobility & chronic illness, and UCr was seen to 
be significantly reduced in this group. Thus the reduction 
in CCr associated with frailty would not necessarily be
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reflected in a raised SCr. Another group of sick elderly 
people, mean age 80y, had a GFR of 41ml/min when measured
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by the single shot Cr-EDTA method. Although the authors 
concluded that GFR was reduced in sick elderly people 
compared to their fit counterparts no parallel trial was 
carried out in the fit elderly, and results were compared 
with those reported by other groups who had measured GFR by 
other means (135).
3.6 PREDICTION OF CREATININE CLEARANCE 
In clinical practice GFR may be estimated by measuring 
endogenous creatinine clearance. While the accuracy with 
which CCr predicts GFR is subject to debate CCr measurement 
nevertheless remains in clinical usage as it is relatively 
easy and inexpensive to carry out compared to other methods
ci a Qivt
available such as Cr-EDTA, Tc-DTPA or inulin clearance 
(31,33,36,134). To determine CCr a timed 24h urine 
collection is required together with a single blood sample. 
Concentration of creatinine in urine & serum are then 
measured, and since the volume of urine passed in 24h is 
known, a clearance value can be calculated for creatinine. 
One of the main criticisms of this method of GFR estimation 
is that an accurately timed 24h urine collection is at best 
difficult to achieve and at worst impossible in, for 
example, a confused, incontinent elderly patient. Besides 
this difficulty there is the obvious delay in obtaining a 
result, a particular drawback when GFR needs to be known 
before certain drugs can be prescribed. Since analyses of 
both urine & serum are required the cost of the test is 
increased and additional errors are introduced, in addition 
to those inherent in timing & collecting urine (140).
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Within-subject variation in UCr excretion may be wide even 
in healthy people where the coefficient of variation has 
been found to be around 13%, even when urine is collected 
under strictly controlled conditions (141,142). Such 
variation is therefore likely to be due to true day-to-day 
alterations in creatinine production & excretion rather 
than methodological inaccuracies.
Studies have shown that not all creatinine is excreted via 
glomerular filtration, with some eliminated via tubular 
secretion? this route is thought to become more important 
in chronic renal failure, although proteinuria does not 
appear to exert a significant effect on the degree of 
secretion (123,143,144,145,146,147). Thus CCr may over­
estimate GFR, although a good correlation has been observed 
between CCr & GFR as measured by inulin clearance where 
some of the likely causes of variation (eg diet & activity) 
do not exist (148).
It has been suggested that more information is gained from 
knowledge of SCr alone (34,35). This has the advantage of 
speed & convenience, with a reduction in cost. However,
SCr is usually assayed using a modification of the Jaffe 
reaction which has been shown to be non-specific for 
creatinine. Other substances able to react with the active 
moiety include protein, glucose, ascorbic acid, keto-acids, 
pyruvate, acetone, bilirubin & cepha antibiotics (35,149, 
150). "Total chromagen” (creatinine + non-creatinine 
chromagens) rather than creatinine alone is measured, and 
this is an obvious source of inaccuracy when a SCr value is 
relied upon. In the present study SCr & UCr were measured 
using HPLC in order to eliminate this source of analytical 
error, since this method has been shown to be more specific
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(115,151,152,153).
A postprandial rise in SCr & UCr has been reported after a 
cooked meat-containing meal, which can give a falsely 
elevated SCr level, although CCr is not influenced by 
dietary factors (153,154,156). In this study blood was 
taken in the morning following the 24h urine collection in 
all subjects, following an overnight fast or a meat-free 
breakfast. Most subjects were asked about their meat intake 
but few consumed quantities near to the 225g or more of 
lean meat used in other studies.
A further criticism of the use of SCr alone to estimate 
renal function is that the normal range quoted is much 
wider than the variation in SCr observed for an individual, 
even when analytical errors are taken into account (157,158 
159). Since SCr is related to GFR in a reciprocal fashion, 
when renal function is normal or only mildly impaired small 
changes in SCr represent large changes in GFR (35,36,134). 
This can be a particular problem in the frail elderly and 
in specific conditions such as rheumatic disease, paralysis 
and burns where the disease process and physical inactivity 
leads to a reduced muscle mass and lowered creatinine 
production (31,123,131,136,138,160,161,162,163). Abnormal 
body compositions may therefore produce a normal SCr in the 
presence of renal impairment and an over-estimation of CCr 
when the classical equations are employed.
One solution to this problem would be to develop more 
reference ranges for SCr for a variety of body weights & 
ages (35,134,158,163). A reduction in urine collection time 
would offer an advantage over the traditional 24h urine 
collection, particularly for those groups of patients where 
SCr is difficult to interpret (36). Alternatively, a better
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method for predicting CCr from SCr would enable more easily 
interpreted results to be obtained from SCr without the 
inherent difficulties associated with a urine collection.
3.6.1 Prediction of CCr From Reduced Urine Collections 
Few studies have evaluated the accuracy of using a reduced 
urine collection interval to estimate 24h CCr despite the 
fact that the difficulties inherent in carrying out a 24h 
urine collection are well known. Studies investigating the 
change in urine output with time of day in healthy young 
subjects have found a reduction overnight (26,164). However 
this pattern is reversed in elderly subjects who excrete a 
higher proportion of water, sodium, potassium & solute 
output at night irrespective of fluid intake during the 
evening (26,165). Frail elderly females resident in 
hospital were nursed supine in bed for 3 days or upright in 
chairs for an 8h period each day for 3 days and their urine 
output examined (166). All exhibited a complete absence of 
"morning tide" of water & electrolytes regardless of 
position. The first day of total bedrest was associated 
with a large diuresis, and patients nursed in chairs also 
produced a large nocturnal urine output when returned to 
bed. After a 3 day period of bedrest the first session of 
nursing in chairs was characterized by oliguria. The 
authors concluded that changes in posture were important 
determinants of urinary output patterns, and may account 
for the frequent nocturia seen in elderly subjects.
Another study investigated urine output in healthy males 
during normal activity & rest in the antiorthostatic 
position (167). While diuresis was enhanced in the 
antiorthostatic position, SCr & CCr did not appear to 
change with position. Conversely, two other studies found
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an increase in both diuresis & CCr in healthy males & 
patients with fluid-retaining states in the supine position 
compared to when sitting upright (168,169).
Those who have measured the circadian variation in CCr or 
GFR have found a small but pronounced reduction in CCr 
occurring during the night in healthy young subjects (156, 
164,170). This pattern remains when subjects are fasted to 
eliminate any dietary effect, and is also seen in paralysed 
patients and is therefore unlikely to be due to changes in 
muscle activity. CCr has been observed to change little 
during a 2h period of normal activity compared to that 
during 2h of immobilization in healthy males (171) although 
a period of unusually heavy exercise may give rise to an 
increased UCr & SCr (134,142). However, strict control of 
diet & activity is reported to have little influence on the 
within subject variation in UCr (142).
In this study urine was collected in aliquots in 76 males & 
116 females to determine whether urine collections of less 
than 24h could be used to accurately predict 24h CCr.
Urine was collected over time periods of 4-12h to represent 
morning, afternoon/evening and night urine collections. 
Since urine was passed as usual collection periods varied 
in length although the night collection always represented 
that urine passed during the hours spent in bed overnight. 
For both male & female groups CCram, CCrpm & CCrn, when 
plotted against 24h CCr had a high correlation coefficient, 
a gradient near to unity and a y intercept close to 0 
(appendix C7). CCram & CCrpm overestimated CCr by a mean 
figure of between 2-8 ml/min while CCrn underestimated CCr 
by about 5-10ml/min. The small reduction in CCr observed 
overnight is in agreement with other studies following the
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diurnal variation in CCr. Other comparisons of CCr from 
urine collections less than 24h with traditional 24h CCr 
have generally chosen shorter time periods over which to 
collect urine. One study compared CCr from a lh collection 
with a 24h collection in healthy young males and found good 
correlations between them (172). A second compared CCr 
calculated from urine collections of 2, 4 & 24h with GFR 
measured using " mTc-DTPA (147). GFR was overestimated by 
all urine collection methods with the 2h collection seen to 
be least accurate. Patients with CCr < 50ml/min were more 
likely to have CCr overestimated than those with CCr > 50 
ml/min. No similar studies have been carried out in elderly 
people. A very short urine collection would not be 
practical in the elderly who more frequently suffer from 
incomplete bladder emptying, difficulty in micturition and 
dehydration. The accurate timing required would also pose 
problems on a busy ward. Although water loading to increase 
urine flow was used to facilitate a one hour urine 
collection, results were less accurate (172), and problems 
would be experienced in the elderly. One study saw CCr 
increased in healthy young & elderly males following water 
loading, with the elderly group appearing less able to 
efficiently excrete excess water (27).
The accuracy of CCr prediction using urine collection 
periods less than 24h was compared between those with CCr > 
50ml/min & those with CCr < 50ml/min. For both females & 
males the correlation between measured & predicted CCr 
remained good and was not compromised at the extremes of 
24h CCr. Diuretic use did not appear to influence accuracy 
of CCr prediction for any of the collection periods.
Males & females were divided up into groups of very fit,
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fit & frail age matched subjects and CCr prediction 
compared. While frailty was strongly associated with a 
reduction in 24h CCr, predictability was not generally 
compromised in any group. For each group CCrn remained 
slightly less than 24h CCr while CCram and less so CCrpm 
were slightly greater than 24h CCr.
3.6.2 Prediction of CCr from SCr and Equations 
From as far back as 1959 groups of workers have attempted 
to devise either an equation or nomogram to accurately 
predict CCr from SCr. Early equations consisted of a 
simple mathematical relationship between SCr & CCr but 
their validity was found to be limited. The reduction in 
CCr with increasing age and the relationship of SCr to 
bodyweight or lean body mass led to the development of more 
complex equations and to date 12 equations & 4 nomograms 
exist for use in adults (31,118,119,120,121,123,125,126,128 
133,135,173,174,175,176,177,178). A further variety of 
studies have been carried out to evaluate the use of these 
formulae in healthy young & elderly subjects and in 
patients with a variety of conditions.
In the present study the accuracy of CCr prediction using a 
variety of formulae was assessed in a heterogeneous group 
of elderly people. A 24h urine collection was successfully 
completed by 146 females & 99 males aged between 60-100y, 
and used to calculate CCr. Each individuals SCr was then 
used to predict CCr using 11 equations (El-Ell) and 1 
nomogram (E12), and the absolute & percent differences 
between measured & predicted CCr were determined.
When predicted v measured CCr was plotted for each equation 
and both sexes a large variation in accuracy between 
equations was seen; those which relied upon a simple
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relationship between SCr & CCr without the incorporation of 
age or weight factors were the least accurate. Although 
these equations are the most easy to use and remember, they 
have little place in the clinical practice due to their 
poor predictability, and so they were not used any further 
in the statistical analyses. Those equations found to 
predict CCr best were similar for both sexes and were El 
(Cockcroft & Gault), E4 (Jelliffe & Jelliffe), E9 (Mawer), 
E10 (Hull) & Ell (Gates).
In only one case (Ell) did the "female correction factor” 
enhance predictability for females and the other selected 
equations were used in the same form for both sexes. While 
few studies have investigated the usefulness of the female 
correction factor, those studies that have are divided in 
opinion. Two studies have found the use of a correction 
factor to be unnecessary in elderly females (137,179), 
although in the former study the sample size was small. 
Others studies found a correction factor of 0.9 & 0.84 more 
appropriate when El & E3 were used (180,181). Body 
composition is known to change in old age, with the 
proportion of fat to muscle increasing and body water 
decreasing (108,182). Thus in the elderly it is possible 
that males & females differ little in respect to muscle:fat 
proportions particularly when muscle atrophy is present. 
Accuracy of CCr prediction was similar for the 5 best fit 
equations for both sexes. Correlation coefficients for 
predicted v measured CCr ranged from 0.716-0.858 & 0.694- 
0.862, gradients from 0.70-0.78 & 0.64-0.71, and intercepts 
from 11.6-13.1 & 8.0-15.9 for females & males respectively. 
Mean predicted CCr agreed well with mean measured CCr for 
each equation, but the accuracy of prediction was not
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constant across the spectrum of measured CCr. When 
predicted v measured CCr was plotted those with the lowest 
measured CCr tended towards overprediction, and those with 
the highest CCr tended towards underprediction. This 
pattern was most pronounced for the females.
Out of the 5 best fit equations E10 & Ell were the least 
accurate and most variable for both sexes. The most 
accurate and least variable equations were El & E4 for the 
females and E4 & E9 for the males.
Using the 5 ”best fit” equations subjects were divided into 
groups of those with a CCr > 50ml/min & those with a CCr < 
50 ml/min. For both sexes the error of prediction was seen 
to alter between groups. Those with measured CCr > 50ml/min 
tended to have CCr underestimated by the equations, while 
those with a measured CCr < 50ml/min tended to have CCr 
overestimated, and the change in prediction accuracy 
between the two groups was significant in all cases.
The line of measured v predicted CCr for the females was 
shifted to the left of that for males with the degree of 
overprediction greater and underprediction lower for the 
females. The use of a female correction factor would have 
improved the position of the female line with respect to 
the male line, although the correlation coefficient would 
not be improved. It seems likely that a correction factor 
of 0.95 would be more appropriate, if thought necessary, in 
this group, since 0.90 or 0.85 reduced the accuracy of 
prediction considerably.
Using a similar technique the accuracy of CCr prediction 
for females & males taking diuretics was compared to those 
who did not and appeared to be independent of diuretic use. 
The accuracy of CCr prediction in very fit, fit & frail age
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matched groups of males & females were then compared. For 
the females, very fit & fit groups had comparable measured 
CCr and while CCr tended to be underpredicted the degree of 
underprediction was similar between groups. The very fit 
males tended to have a greater measured CCr than the fit 
group, and consequently the degree of underprediction was 
significantly greater in the very fit group. Frailty was 
associated with a significantly reduced measured CCr for 
both sexes when compared with their age matched fitter 
counterparts. For the females, the frail group had the 
lowest measured CCr & exhibited consistently overpredicted 
CCr using the selected equations. For the males, very fit, 
fit & frail groups all tended to have CCr underpredicted, 
although the degree of underprediction was lowest in the 
frail group who had the lowest measured CCr.
Other studies have compared the accuracy of CCr prediction
using a variety of equations on selected groups of
subjects. Most have investigated CCr prediction in healthy
people with a range of ages and found a good correlation
between measured & predicted CCr (118,119,128,174,176,177,
180,181,183,184,185). El predicted GFR measured by 99mTc- 
51DTPA or Cr-EDTA at least as accurately as 24h CCr m  two 
studies although only 35 patients carried out 24h urine 
collections in the former study (147,185). Two groups 
investigated CCr prediction in elderly people (88 & 70y) 
and found good correlations between measured & predicted 
CCr using El (132,137). Another group found E12 to best 
predict CCr for elderly people (72y) with measured CCr of 
between 25-89 ml/min (186). However, debilitated elderly 
females resident in nursing homes were found to have CCr 
overpredicted using El & E3, although urine collections of
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8h were used to calculate a 24h CCr without validation 
(87). These subjects were also chronically catheterised, 
which may have adverse effects on renal function.
Several studies have examined CCr prediction in patients 
with renal impairment and found differing results, although 
in all cases renal function was stable; only E4 & E9 may be 
used when renal function is changing. CCr was predicted 
accurately in a group of Chinese patients with renal 
impairment using El (177). Another study found CCr 
predicted more accurately using E9 & E10 than El & E3 in 
patients with renal dysfunction (126). A further study 
concluded that E2 best predicted CCr if patients had a 
SCr > 1.5mg/dl, while CCr of those with SCr < 1.5mg/dl was 
best predicted using E2 (178).
Accuracy of CCr prediction appears to breakdown for 
patients with hepatic dysfunction using E1,E3,E9 & E10 
(126). Others have found CCr poorly predicted in gross RVF 
and low cardiac output states using E12 and CCF using E1,E3 
& E9 (187). Males with extensive burns have been found to 
have CCr overpredicted using E2 & E3, with El & E12 giving 
better results although the tendency towards overprediction 
remained when measured CCr < 60ml/min (188). This study 
also found that the use of lean body mass in place of 
actual bodyweight did not improve accuracy of prediction. 
CCr overprediction has also been found for both paraplegics 
& tetraplegics using El, with the authors recommending a 
correction factor of 0.8 for paraplegics & 0.6 for 
tetraplegics (160). Patients with rheumatoid arthritis also 
had CCr overpredicted by 20ml/min using El & E12 (138).
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3.7 CONCLUSIONS
CCr was measured & predicted for a range of elderly people, 
and those who were frail had a reduced renal function when 
compared to their fit counterparts if age-sex matched.
Urine collections of less than 24h predicted CCr better 
than any equation or nomogram studied, for both males & 
females. Predictability of CCr from a reduced urine 
collection was not influenced by the magnitude of measured 
CCr, or compromised in frailty. Those taking diuretics had 
CCr predicted equally well as those who were not. CCrpm & 
CCrn were the most accurate and least variable, with CCrpm 
tending to overpredict CCr slightly and CCrn tending to 
underpredict CCr.
Given that CCr tends to overpredict GFR, it would seem most 
appropriate to employ an overnight urine collection to 
estimate CCr and GFR. This could simply be carried out if 
urine passed before going to bed was discarded, and the 
time noted. All urine passed overnight would then be 
collected, up until and including that passed on getting 
up, when the time would again be noted. Blood for SCr 
determination could then be taken, and the two specimens 
sent together for analysis.
Of the 11 equations & 1 nomogram studied none predicted CCr 
as accurately as reduced urine collections. The variability 
was greater, and the predictability varied with magnitude 
of measured CCr. Those with the lowest measured CCr tended 
to have CCr overpredicted by the greatest degree. Frailty 
is associated with a reduced CCr and it is on this 
population that the formulae are most often applied, and 
who are at greatest risk of adverse drug reactions.
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The literature suggests that the greatest inaccuracies in 
CCr prediction occur in subjects suffering from conditions 
which produce an abnormal body composition. Therefore 
weight loss & muscle atrophy commonly seen with frailty 
would be likely to cause inaccuracies in CCr prediction, 
and results from the present study confirm this.
Data from this study suggests that use of urine collections 
less than 24h, particularly when carried out overnight, 
predicts CCr more accurately than any of the existing 
equations or nomograms. The accuracy of CCr prediction 
using a reduced urine collection is valid for both fit & 
frail elderly people, even in the presence of renal 
impairment, and immobility and diuretic use do not appear 
to affect the results.
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CHAPTER FOUR 
FRUSEMIDE EXCRETION IN ELDERLY PEOPLE
4.1 INTRODUCTION
It has been estimated that one in three elderly people 
regularly take diuretics. Currently one of the most widely 
prescribed diuretic formulation is co-amilofruse (frusemide 
40mg + amiloride 5mg? 39). Frusemide excretion in man has 
been the subject of a number of studies which have used 
both healthy volunteers and patients with particular 
diagnoses. However, there appears to have been little work 
carried out specifically in elderly patients with multiple 
pathology with associated immobility and data compared with 
those of similar age whose lifestyle is not restricted by 
chronic disease. In this study frusemide (FRU) excretion 
was studied in elderly people taking FRU chronically, who 
were either "fit" (well controlled chronic illness, mobile 
& living independently) or "frail" (similar diagnoses but 
immobile & lack of independence) in an attempt to determine 
the influence of immobility and frailty on FRU elimination.
4.2 PROCEDURE
Fit & frail elderly people aged over 64y were invited to 
take part in the study. All were non-acutely ill and had 
been regularly taking FRU as frusemide (FS) or Frumil (FM) 
tablets, for chronic illness of cardiovascular origin, for 
a minimum of one month. Exclusion criteria are given in 
2.2. Each subject was provided with an information sheet 
(appendix Dl, standard or enlarged type) and given the 
opportunity to question Dr L Parker (GP trainee) or myself 
about the study prior to its commencement.
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On the morning of the study subjects were asked to empty 
their bladder and then take their usual FRU tablet with a 
glass of water, in the upright position. FRU dose varied 
according to individual prescriptions which were not 
altered for the study. Tablets were taken after a light 
breakfast of toast or cereal then food & drink was avoided 
for the next hour, after which time both were taken freely.
During the study subjects were questioned about their day- 
to-day activities & mobility. They were categorized as fit 
or frail and had their mobility scored according to the 
mobility rating devised for the study (Appendix Al, A2).
The form given in appendix D2 was completed during the 
study when co-medication was noted and subjects were 
weighed & measured. Demographic details & drugs taken are 
given in Appendix D3.
5-10ml of blood was taken at 2,4,8 & 24h & urine collected 
for 24h after dosing. FRU is light sensitive so all samples 
were collected and stored in lightproof containers. FRU 
was measured in all samples, UCr in all urine samples, and 
SCr in serum at 24h. Urine samples collected over 24h were 
assayed in 3 aliquots each of about 8h, with the final 
aliquot spanning the time spent in bed overnight. Methods 
of analysis for creatinine & FRU are given in 2.3.4 & 2.3.5
Elimination AUC, apparent serum clearance (Cls),
Cls/kg, renal clearance (Clr), Clr/kg, Clr from 0-6h (Clr 
0-6), and CCr were calculated as per 2.4.
Correlations were determined using Spearmans correlation 
with significance levels taken as p<0.01 to reduce the 
chance of Type II error. Groups were compared using the 
Mann-Whitney test when significance levels were p<0.05.
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4.3 RESULTS OF PHARMACOKINETIC PARAMETERS 
35 subject (22F) successfully completed the study? results 
from Individuals for FRU & creatinine measurements are 
given in appendices D4 & D5, and summarized in appendix D6.
4.3.1 Fmmil v Frusemide
Data from FM & FS groups were compared using the Mann- 
Whitney test with results given in appendix D7. A 
significant difference was seen for elimination t1/2 which 
ranged from 0.82-11.90h (4.49±2.85) for FM & 1.36-20.17h 
(9.83+5.55) for FS (p<0.01). Clearances were not 
significantly different between groups although the FS 
group consistently had a greater variability & s.d. No 
other statistical differences were seen. However, the above 
differences in kinetic parameters were considered important 
enough for the FS & FM groups to be treated separately.
4.3.2 Females v Males
Data were divided into male & female groups for both those 
taking FM & FS and compared using the Mann-Whitney test 
with results given in appendices D8 & D9.
The FM group comprised of 16 females & 9 males. UCr was 
significantly greater in the male group (1279±252mg M, 776± 
258mg F?p<0.001) as was SA (p<0.02) & weight (p<0.03). No 
other significant differences were seen.
6 females & 4 males took FS. When the sexes were compared 
no significant differences were seen.
From these results it seemed most appropriate for FM & FS 
groups to be of mixed sex since no significant differences 
were seen between sexes in terms of FRU clearance
4.3.2 Subjects Taking Frumil
25 of the 35 participants in the study took either 1 or 2
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FM tablets and a summary of results & correlations from 
this FM group are given in appendices D7 & D8.
Age ranged from 65-100y (80±9), correlating with urine 
volume (p<0.001). Mobility score ranged from 1-4 and 
correlated with CCr (p<0.01).
Elimination showed a wide interindividual variation of
0.82-11.90h (4.49+2.8) correlating with no other parameter. 
Apparent serum clearance, Cls, exhibited an 18 fold range 
from 16-279ml/min (116±69), correlating with Clr (p<0.001). 
Cls/kg showed a narrower interpatient range of 0.31-4.36 
ml/min/kg (1.72±0.99). Renal clearance, Clr, was also 
highly variable with a range of 10-197ml/min (81.8+54.5), 
correlating with %Du (p<0.01); Cls & Cls/kg (p<0.001).
While Clr/kg was less variable, Clr 0-6h was more so (range 
7-520ml/min? 170±131).
Dose of FRU ranged from 40-80mg and did not correlate with 
any other parameter. Urine volume/24h varied between 472- 
2761ml (1515+564). Percent dose in urine, %Du, ranged from 
8.3-69.1% (36.2+16.2), correlating only with Clr.
UCr ranged from 365-1524mg and correlated with CCr/SA, 
urine vol & weight (p<0.01); CCr & SA (p<0.001). SCr varied 
from 1.00-4.19mg/100ml (1.86+0.84), correlating with CCr. 
CCr varied from 9-77ml/min (41.8+19.8) and correlated with 
M.Sc, SCr & urine volume (p<0.01)? UCr (p<0.001). CCr/SA 
ranged from ll-67ml/min/1.73m2.
4.3.4 Subjects taking Frusemide
10 subjects studied took FS at a dose varying from 40 to 
120mg. A summary of results & correlations are given in 
appendices D12 & D13.
For this group age ranged from 67-89y (77±9). Elimination 
ti/2 var*ed widely from 1.36-20.17h (9.83±5.55). Cls varied
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from 14-422ml/min (114±139) & Clr from ll-289ml/min (79±91) 
Numbers were limited in the FS group, and so while many 
trends seen were similar to the FM group, few reached 
significance. Significant correlations similar to the FM 
group were: Clr v Cls & Cls/kg. Correlations reaching 
significance in the FS group but not in the FM group were : 
urine volume v Cls (p<0.01); & tjy2 v Clr (p<0.01).
4.4 COMPARISON OF PARAMETERS FOR FIT V FRAIL GROUPS 
Since pharmacokinetic parameters did not appear to be 
affected by sex, groups studied were of males + females. 
Proportionally more frail than fit subjects were found to 
be taking FS. Since tjy2 was increased & Cls tended to be 
reduced in those taking FS, data from subjects taking FS & 
FM were analysed separately.
4.4.1 Subjects Taking Frumil
Results from fit (n=14) & frail (n=ll) subjects taking FM 
are given in appendix D14 and Figs. 4.4.1 to 4.4.6.
The frail group were on average 8y older than the fit group 
who were significantly more mobile. FRU dose differed 
between groups - all fit & 6 frail subjects took 40mg FRU,
5 frail subjects took 80mg of FRU.
No significant difference was seen between groups for t ^ 2 
(4.00+3•33h fit, 5.12+2.06h fr), although it tended to be 
lower in the fit group who exhibited the greater range.
CCr & CCr/SA were significantly greater in the fit than 
frail group (CCr: 51±18ml/min fit, 30±17ml/min fr.?p<0.02). 
Urine volume also tended to be greater in fit subjects 
although %Du was comparable between fit & frail groups.
Cls & Clr were consistently greater in the fit subjects 
taking FM, even when corrected for bodyweight, but this was
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not statistically significant.
Fit & frail groups were similar for UCr, SCr, weight & SA.
4.4.2 Subjects taking Frusemide
Results from fit (n=3) & frail (n=7) subjects taking FS are 
given in appendix D15. Both groups were similar in age 
(72±6y fit, 80±9y fr) but fit subjects were significantly 
more mobile. All fit & 4 frail subjects took 40mg FRU, 2 
frail subjects took 80mg & 1 took 120mg.
The fit group taking FS tended to have a lower tjy2 but 
this was not significant (4.00±3.33h fit, 5.12±2.06h fr). 
Cls & Cls/kg were again reduced in the frail group as were 
Clr, Clr/kg & Clr 0-6h, but none of these observations 
reached statistical significance. Groups were similar for 
urine volume, %Du, UCr, SCr, CCr, weight & SA.
4.4.3 Age-Matched Group taking Frumil
The inequality in age between fit & frail groups for those 
taking FM meant that the effects of frailty & age could not 
be separated. It was not possible to age-sex match subjects 
and so sub-groups were formed of the 8 oldest fit & 7 
youngest frail subjects. Results are given in appendix D16. 
Despite the equalization in age between groups, fit 
subjects remained significantly more mobile than frail 
subjects. Elimination t ^ 2 was found to be significantly 
greater in the frail group (3.69±3.53h fit, 5.09±1.68h fr.? 
p<0.05). However, while clearances again tended to be 
reduced in the frail group significance was not reached.
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In this study the elimination of FRU was investigated in 
elderly people chronically taking FS or FM, with varying 
degrees of immobility & frailty. FRU excretion was followed 
to determine whether immobility or frailty appeared to 
influence the efficiency of elimination.
4.5.1 Frusemide Kinetics
17 fit & 18 frail subjects with mobility scores ranging 
from 1 to 4 took part in the study. 25 were taking FM, and 
of those 14 were fit. FRU kinetics were followed from 
3-24h post-dose and over this period underwent first-order 
kinetics, with log serum [FRU] v time yielding a linear 
plot. This agrees with other studies where FRU 
disappearance has been described by an open two compartment 
model, with the biexponential decline in serum [FRU] 
resolving into 2 first-order disposition constants (53,56, 
57,58). The first phase predominantly describes 
distribution and has a half-life approximating to 10m, with 
peak serum concentrations occurring about 60 minutes after 
oral dosing (53,60,189). The longer second phase 
corresponds to drug elimination whose tjy2 is estimated to 
be 50-70 minutes in controls (48).
Only the elimination phase was followed in the present 
study, since this involved fewer blood samples being taken. 
Sampling times were therefore chosen such that distribution 
would be complete and peak plasma concentration passed 
before sampling. Analysis of results showed that blood 
sampling times were not optimal and would have been more 
consistent had samples been taken earlier and closer 
together. An improved scheme for sampling would have been
2.3.4.5 & 6h post-dose. Correlation coefficient of log
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serum [FRU] v time, used to calculate t±/2 > varied between 
0.997-0.821 (0.942+0.05? mean+s.d.) and in a few cases 
had to be calculated from 2 time points. An initial pilot 
study would have been advantageous.
No statistical difference was seen between sexes for t1^2 
or Cl, for FS or FM. This agrees with other studies which 
have found that FRU excretion is not influenced by sex (56, 
58,62). The groups discussed were therefore of mixed sex.
4.5.2 Elimination Half-life
Elimination t^y2 was determined in all but one subject 
taking FS (F49F) whose case will be discussed later. The 
range in tjy2 for the remaining subjects was wide, from 
0.82 - 11.90h (4.49+2.85) for the group taking FM & 1.36 - 
20.17h (9.83+5.55) for those taking FS.
Means & ranges are greater than those reported from 
investigations of FRU excretion in young healthy 
individuals where mean tjy2 has been estimated as 52±15, 
36±5, 51+4 & 70+16 minutes when FRU was assayed by HPLC (61 
190,191,192). Earlier work on FRU disposition involving 
paper chromatography, spectrofluorometry or radiolabelling 
are thought to have been less specific? using these methods 
mean t^y2 estimates have ranged from 26-72 minutes (48).
Studies of FRU elimination in particular disease states 
have found a wider variation in mean t^/2 ' patients with 
uraemia were found to have a 3 fold prolongation in tjy2 
compared to controls (51+4m controls, 156+25m uraemics; 
p<0.05) although in the same study (59) patients with 
nephrotic syndrome were found to have a similar tjy2 to 
controls (54+6m). Another study compared FRU t1^2 in those 
suffering from renal failure with controls - averaged
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0.79h in controls & ranged from 1.15-24.58h in patients
(61). While the longest t^^s were found in those with
advanced renal disease, 2 patients with CCr of 8 & 6ml/min
had ti/2 s of 1-42 & 1.55h, comparable with controls.
Investigations into FRU disposition in patients with acute
pulmonary oedema found that elimination t1 varied widely1/ z
from 127-1190m and presence of acute MI or differences in 
the severity of pulmonary oedema did not correlate with 
variations in (58)* Patients with heart failure were
also found to have an increased elimination tjy2 compared 
to normals (60). Patients with decompensated heart failure 
not previously treated with FRU had a mean tjy2 of 92m 
while those with cardiac decompensation under long term FRU 
treatment had a mean t1^2 of 134m.
Studies of FRU disposition in old age have concluded that 
increased age appears to prolong elimination t^^2, although 
to what extent is uncertain. When FRU was administered to 
healthy "elderly" volunteers (age 64±4y), mean t1^2 was 102 
±33m (62-149m), compared to 70±20m seen in healthy young 
volunteers (57). A second study (62) used elderly patients 
(70-93y) already on FRU long term for chronic disease, and 
found tjy2 to range from 59-317m.
Elimination t ^ 2 obtained in the present study are greater 
than those seen in healthy young & elderly volunteers, but 
agree with those obtained in patients suffering from 
cardiovascular disease or chronic renal impairment. All 
subjects used in the present study were already taking FRU 
for treatment of a specific disease state, that is, no 
"healthy" volunteers were used. The fit & frail 
definitions are relative terms, and fit subjects were far 
less disabled by their illness than frail subjects.
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FRU t1/2 has been reported as increasing in old age,
although the degree by which it changes is not certain (57,
62). The present study aimed to determine whether frailty
or immobility influenced FRU elimination and so the age
range of subjects studied was relatively narrow. Absence
of correlation between t^y2 & age for those taking FM is
not contrary to previous studies since the majority of
subjects were aged between 70-86y. Mean t1/0 was 4.31±3.73hl / z
for those aged 70-78y & 4.40±2.02h for those aged 80-86y. 
Only 6 subjects taking FM were outside the age ranges. 
Similarity of mean tjy2 between the cohorts explains the 
lack of correlation seen between age & t1^2 i-n the FM group 
For subjects taking FS, a tendency towards a correlation 
between age & t^y2 was seen. For those aged 67-69y tjy2 
was 5.30+2.64h & for those aged 81-89y the mean was 15.49+ 
4.72h? 2 subjects were outside these ranges, aged 78 & 89y. 
The difference in t1^2 between cohorts gives rise to the 
trend towards a correlation between age & t^y2 despite the 
small age range and limited numbers used. However, all 
subjects aged 81-89y were frail while of those aged 67-69y 
2 were fit & 2 frail. The correlation between age & 
may have arisen due to the loss of fitness associated with 
an increase in age, rather than age per se.
No correlations were seen between t^^2 & SCr, CCr or CCr/SA 
FRU is highly protein bound (approximately 98%) and so 
elimination is mainly via active secretion into the kidney 
tubule lumen via the non-specific organic acid secretory 
pathway (194), since only free drug can be excreted by 
glomerular filtration (48). Both GFR & tubular secretion 
are known to decline with age although controversy exists 
over whether the rates are linked. The reduction in GFR
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with age, even in the absence of significant pathology, is 
now well documented (123,136) and observed in this study 
for all participating subjects (age v CCr? p<0.02).
Less is known about the decline in tubular function with 
age, since it is much more difficult to measure. Tubular 
mass has been show to decline with age but the loss of 
tubular function is not a homogeneous process and not 
associated with a commensurate contraction of kidney mass. 
The question of whether the nephron degenerates as a unit 
is unresolved. One study (195) concluded that a significant 
correlation between dimensions of the glomerulus & proximal 
tubules in young subjects was lost as the kidney aged. 
Hypertrophy of tubules in nephrons with normal or even 
absent glomeruli was observed. Conversely, other workers 
who examined 100 kidneys from subjects who died suddenly 
showed that after the fourth decade the volume of glomeruli 
& tubules diminished at the same rate (196). Since the 
majority of FRU is excreted by tubular secretion, tjy2 
would not necessarily correlate with CCr if proximal 
tubules & glomeruli degenerated at differing rates.
A plot of CCr v tjy2 shows that for those taking FM or FS 
in this study, subjects with compromised renal function can 
have a prolonged or normal t ^ 2 compared to those of a 
similar age with good renal function. Some studies have 
shown a direct correlation to exist between CCr & t^^2 (58) 
while others have not (59,61). The variation in tjy2 may be 
explained by differences in rate of tubular & glomerular 
degeneration which may occur in old age & renal impairment. 
In renal failure endogenous anions may accumulate which can 
compete with anionic drugs for the active anion secretory 
pathway (59). Variations in concentrations of endogenous
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anions may influence the amount of FRU excreted by the 
tubules. Alternatively, the diversity of t^/2 could be due 
to differences in nonrenal clearance (61), discussed 
presently.
Differences could also be due to changes in Vd or body 
composition between individuals. Elimination tjy2 a 
hybrid quantity, depending on both clearance & Vd. Since 
ti/2 inversely proportional to Cl, any change in Cl is 
only reflected in an increased t^/2 if Vd is not 
significantly altered in those being compared. Age is 
known to be associated with alterations in body 
composition, which in turn affect Vd (9). A decline in 
lean body mass & increase in adipose-tissue in relation to 
total body mass is generally seen in old age (10,108,197), 
and variations in their proportions between subjects could 
influence Vd and hence t^/2 in this study. Weight & SA did 
not correlate with t^/2 for FM or FS, and these are known 
to influence Vd, but do not reflect body composition.
The apparent Vd of an extensively protein-bound drug may be 
influenced by changes in the extent of binding to plasma 
proteins (9,18). Studies have consistently shown an age- 
related decline in albumin, which appears to be the only 
plasma protein with which FRU binds (52). The reduction in 
albumin may be large when elderly subjects are poorly 
nourished, have advanced or chronic illness or are severely 
debilitated (49). Studies have shown the percentual binding 
of FRU to albumin to be slightly but significantly reduced 
in serum from elderly patients than in serum from controls 
(96.5+0.7% v 97.7+0.3%) with a positive correlation between 
protein binding and albumin concentration (50). Decreased 
binding has also been found in acute renal failure (51,52),
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nephrotic syndrome & ureamia (59) and in anephric patients 
(56). The age & disease-related changes in the free 
fraction of FRU could influence Vd to complicate 
interpretation of the differences in elimination t^y2 
observed between subjects.
One frail subject (F49F) taking FS had only one measurable 
serum [FRU], at 1.92h, with a low recovery of FRU in urine 
(8.6%). The subject was obese (84kg), oedematous, had a 
CCr of 55ml/min and was not taking any other drugs 
concomitantly which were known to influence FRU absorption 
or elimination. Although it is possible that the daily 
dose of FRU was not taken, and that FRU detected was from a 
late dose the previous day, this is unlikely since the 
patient was hospitalized. These observations suggest that 
either reduced absorption or increased metabolism were 
occurring. Although no other person had only one detectable 
serum [FRU], a wide variation in t1^2 was seen between 
subjects which cannot be accounted for by changes in CCr as 
discussed above.
Age per se has not been reported as influencing drug 
absorption except in a very few specific cases. Early work 
carried out on kinetics in the elderly found absorption of 
sulphamethizole, phenylbutazone & paracetamol unchanged 
(13). Later reports agreed with this finding, including 
one where absorption of FRU was investigated and found to 
be only very slightly decreased in old age (55). However, 
reports with regards to FRU absorption in disease states 
have varied, and it is thought that reduced absorption may 
in certain cases be responsible for "diuretic resistance". 
This term has been used to describe cases where even large 
doses of oral diuretic have evoked a very small response
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(43). One case was reported of a patient with ideopathic 
oedema who exhibited a change in FRU bioavailability 
according to the degree of oedema - it varied from 75% in 
the oedema-free to only 17% in the oedematous state.
Kinetic parameters were similar in both states and response 
to i.v. FRU was unchanged (198). It was proposed that the 
changes were due to reduced absorption from the 
gastrointestinal tract which was affected by oedema.
Another group reported erratic and incomplete absorption of 
FRU in CHF (199). Patients with severe CHF were given oral 
& i.v. doses of FRU & AUC ratios compared. Average 
absorption was 61%, consistent with previous reports (48), 
but varied widely from patient to patient (31-79%).
Kinetics were again comparable between patients. Another 
study reported no difference in FRU bioavailability between 
patients with CCF & controls, although again the 
interindividual variation was wide but the within subject 
variation was low (200). Other studies have reported FRU 
bioavailability to vary from 34-80% in heart failure (48) 
with a decrease also seen in patients with uraemia or 
nephrotic syndrome. Reports have also suggested than FRU 
is ineffective orally when CCr is less than 3ml/min thought 
to again be due to impaired absorption from the GI tract 
since i.v. FRU remains effective (43,201). Conflicting 
results were obtained by another group of workers 
investigating FRU absorption in decompensated heart failure 
(54). Each subject served as their own control, with FRU 
absorption compared before and after cardiac compensation. 
While lag time & time to peak serum concentrations 
decreased by 57% & 27%, and peak serum [FRU] increased by 
27%, no significant changes occurred for absorption or
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elimination AUC or absorPti°n of D-xylose, when the
two states were compared. This suggests a qualitative but 
not quantitative, alteration in FRU absorption in 
decompensated heart failure. This was thought to be a 
contributing factor to diuretic resistance seen in some 
patients.
There have also been reports of malabsorption of FRU by 
phenytoin, which can reduce absorption by 50%, with a 
corresponding reduction in Cmax but unchanged clearances. 
The mechanism for malabsorption is not clear (202).
It is possible that reduced FRU absorption could account 
for a low serum [FRU] & %Du in subjects such as F49F but no 
reports have found an associated change in kinetics. This 
would imply that even if reduced absorption occurred in 
some cases it could not account for the variation in tjL/2*
Mobility score was not correlated with suggesting that
mobility is unlikely to be an important determinant of FRU 
excretion rate. From these results it would appear that 
while age & probably clinical condition may influence FRU 
elimination no direct correlations exist which can be
used to predict t1^2 for a particular subject. Other 
factors are important and will be discussed in 4.5.3.
Subjects taking FS were found to have a significantly 
greater t^y2 than those FM - when all t^^s were ranked, 
subjects taking FS were responsible for 5 out of 6 highest 
results. It seems that either the presence of amiloride in 
FM influences FRU disposition, or those subjects prescribed 
FS are in some way different from those prescribed FM. 
Considering the 10 subjects taking FS, more were frail 
(n=7) than fit (n=3). They tended to pass less urine than
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the FM group despite the dose of FRU being greater for some 
FS individuals. Fluid intake was not measured in either 
group. While no significant differences were seen between 
clearances of the groups, inspection of data showed that 
the lower quartile was consistently lower, and s.d. 
greater, in the FS group for Cls, Cls/kg & Clr. FM & FS 
groups were similar in age, mobility, UCr, SCr, CCr & 
CCr/SA.
Two frail subjects (F14GPF & F51F) taking FS were also 
taking spironolactone but their 11/2S not appear to
differ from those only taking FS. Other workers have 
reported a lack of pharmacokinetic interaction between 
spironolactone and FRU, although a trend towards a higher 
clearance and lower 2 for FRU was seen (203)? if 
spironolactone influenced FRU excretion it would have been 
in the opposite direction to that observed between FS & FM 
groups. With only two subjects taking spironolactone a 
definitive statement cannot be made but there appears to be 
no need to exclude them from the FS data.
Two fit subjects (F05GPF & M17GPF) taking FM were also 
taking a non steroidal anti-inflammatory drug (NSAID) 
concomitantly. An interaction has been reported to occur 
between indomethacin & FRU, probably due to inhibition of 
prostaglandin synthesis (42,43), resulting in a loss of 
response to FRU and possible reduction in FRU renal 
clearance. The two subjects taking a NSAID had relatively 
high tjy2s but M17GPF had a low CCr. If an interaction had 
occurred in these subjects, the effect would be an 
increased t.jy2. Since those taking FM have a significantly 
lower tjy2 the use of a NSAID by two subjects in the FM 
cannot explain the result. Amiloride is a potassium
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sparing diuretic seldom used alone, but frequently 
administered in combination with thiazide or loop diuretics 
to attenuate their potassium wasting effects. It is a 
basic drug eliminated by filtration and active secretion 
via the nonspecific organic base secretory pathway of the 
proximal tubule. A study of amiloride disposition in the 
elderly has shown that age appears to reduce clearance and 
increase probably due to a reduced GFR observed in
old age (204).
No studies have compared FRU disposition when alone and in 
combination with amiloride, and so the possibility of a 
pharmacokinetic interaction between FRU & amiloride during 
absorption, distribution or elimination cannot be ruled 
out. Amiloride is unlikely to influence FRU absorption 
since it is not related to any drug known to do so.
Albumin has high capacity but low affinity binding for most 
cationic drugs, with a low capacity but high affinity for 
acidic drugs. There are no reports of amiloride binding to 
albumin making this mode of interaction also unlikely.
FRU is secreted by the organic acid pathway while amiloride 
is secreted by the organic base pathway, so no competition 
would be likely at that site.
It is difficult to explain the difference observed between 
FM & FS groups on the basis of a pharmacokinetic 
interaction, although the possibility remains. A more 
likely explanation may be the preponderance of LVF observed 
in the FS group when compared to those taking FM. This 
difference in pathology between the groups may account for 
the reduced efficiency of elimination in the FS group.
From these results it seems likely that there is a 
difference between those taking FS & FM despite comparable
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kidney function & mobility, and thus more appropriate to 
treat the groups separately than to combine data.
4.5.3 Apparent Serum Clearance of Frusemide 
To determine a drugs total body clearance i.v. 
administration is necessary. This was not possible and so 
oral FRU was given and apparent (relative) serum clearance 
(Cls) was calculated. FRU is rapidly but incompletely 
absorbed from the gastro-intestinal tract, with 50-70% of 
an oral dose being available for systemic circulation (48, 
53,193,199,205). A figure of 50% of the dose administered 
was used to calculate Cls in this study, it being assumed 
that absorption was similar for all individuals studied. 
Studies have shown that while age does not appear to 
significantly alter FRU absorption (55,62), bioavailability 
of FRU may be altered in some disease states as discussed 
in 4.5.2. All subjects studied were elderly and clinically 
stable and whilst the percentage of dose recovered in urine 
varied between subjects, no significant difference was seen 
between fit & frail groups. These results suggest that the 
assumption is reasonable, although it could only be proven 
with comparative i.v. and oral studies.
Using a figure of 50% systemic bioavailability, Cls ranged 
from 16-279ml/min (116±69) in the FM & 14-422ml/min (115± 
139) in the FS group. Cls/kg ranged from 0.31-4.36ml/min/kg 
(1.72+0.99) in the FM & 0.23-6.59ml/min/kg (1.90±2.09) in 
the FS group. Other workers have calculated Cls following
i.v. FRU and obtained different values according to the 
method of analysis. When HPLC has been employed, Cls in 
young healthy volunteers has been estimated at 194±35, 
170+19, 219±49 & 170±19ml/min (56,57,61), 2.18±0.12 & 2.54+ 
0.96ml/min/kg (59,206). Studies of FRU excretion in old age
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have calculated Cls to be 129+1lml/min in healthy elderly 
subjects (64+4y) & 73+27 ml/min in elderly patients with 
cardiovascular disease on long term FRU therapy (57,62).
Cls has been reported to be 86+16ml/min in patients with 
cardiac decompensation previously untreated with FRU & 69+ 
22ml/min in patients with cardiac decompensation under long 
term FRU therapy (60). Cls in renal failure has also been 
investigated, and estimated to be 66±19ml/min in anephric 
patients, 2.96+0.51 & 2.54+0.96ml/min/kg & 80+29ml/min in 
those with nephrotic syndrome (56,59,61,206). Patients with 
uraemia have been reported to have Cls of 0.62+0.1ml/min/kg 
(59). Estimates of Cls in the present study are lower than 
those seen in healthy young volunteers, but are comparable 
with those for elderly and chronically ill subjects. There 
is a wide interpatient variation however, with a very high 
Cls being seen in a few individuals.
For subjects taking FM or FS, Cls correlated with CCr & 
CCr/SA in agreement with findings from other studies (58,59
61). While renal function appears to be a determinant of 
FRU Cl, it is not the only one, since a few subjects with 
low CCr had a high Cls. GFR is known to decline with age 
and this could lead to the reduction in Cls observed in 
those studies carried out in elderly subjects. The 
importance of renal function in FRU excretion would also 
explain the reduction in Cls seen in patients with 
nephrotic syndrome or uraemia. Reasons for the 
interindividual variations seen will be discussed in 4.5.4.
4.5.4 Renal Clearance of Frusemide
Clr in the present study was calculated to be 82±55ml/min 
(1.24+0.85ml/min/kg) for subjects taking FM and 79+91ml/min
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(1.37+1.40ml/min/kg) for those taking FS. This agrees with 
other groups investigating FRU Clr in elderly & chronically 
ill patients. A mean Clr of 75+9ml/min was found for 
healthy elderly (57), 40+18ml/min for chronically ill 
elderly (62), 1.18±0.29 & 1.31+0.59ml/min/kg in patients 
with nephrotic syndrome (59,206), & 0.06+0.01ml/min/kg in 
uraemics (59). FRU Clr is generally agreed to be reduced 
in old age & chronic illness compared to healthy young 
volunteers.
There was a tendency for Clr to be correlated with CCr in 
both the FM & FS groups. This has been observed in other 
studies (62,48) but not all (58,59). Where a correlation 
has been found, it is thought to be due to the role renal 
function plays in FRU excretion in urine, when tubular 
secretion decreases with GFR. However, this correlation is 
not seen in all studies, suggesting that other routes of 
elimination besides renal excretion are possible.
In severe renal impairment accumulation of endogenous 
anions may inhibit active anion transport and thus reduce 
Clr of drugs such as FRU (59).
When renal clearance is subtracted from total body 
clearance the product represents that FRU cleared by 
nonrenal routes. In this study nonrenal clearance, Clnr, 
could not be calculated since oral administration only 
enabled Cls to be estimated, but Cls & Clr were correlated. 
Studies have found Clnr to approximate to 42% of Cls in 
healthy elderly (57) and 47% in the chronically ill elderly 
on long term FRU (62). In uraemia Clnr was reduced by 41% 
of that seen in normals but in nephrotic syndrome it tended 
to increase (59), as confirmed in a second study (206). 
Controversy exists about nonrenal routes of FRU excretion.
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Radiolabelling studies have detected FRU in bile which may 
be one route of elimination, increasing when renal function 
is impaired (53,61). It has been suggested that FRU is 
metabolized to FRU-glucuronide & 4-chlor-5-sulphamoyl- 
anthranilic-acid (58,60,62). The glucuronide conjugate has 
been detected in urine of patients administered FRU, with 
elderly appearing to excrete less than young volunteers (57
62). The amount of glucuronide excreted has been reported 
to vary from 0.7mg/24h in subjects not previously treated 
with FRU, to 7mg/24h in subjects given FRU for a minimum of 
6 months, when a 40mg dose is given i.v. (60). This has 
given rise to the idea that chronic FRU therapy may induce 
glucuronidation, to enable t1^2 to be normal despite a 
reduced CCr. With the advent of HPLC, while FRU- 
glucuronide has been detected, CSA has not. Any remaining 
FRU not excreted renally, secreted into bile or metabolized 
to FRU-glucuronide may be metabolized by another route but 
evidence is lacking.
It is possible that the degree of nonrenal elimination may 
have varied between subjects in the present study. 
Elimination not correlate with CCr suggesting that
filtration alone is not responsible for FRU excretion. If 
tubular secretion declines at a similar rate to GFR, the 
lack of correlation suggests that extrarenal elimination is 
taking place. The wide interindividual variation in both 
ti/2 and clearance also suggests that nonrenal excretion 
may be occurring, to differing degrees in those studied. 
Subjects on long term FRU may have developed an enhanced 
glucuronidation pathway which could give rise to a near 
normal t^/2 in some with low CCr. Clearance is calculated 
assuming 50% bioavailability but reports indicate that this
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may change with clinical condition, and this could explain 
the variation in Cl. Elimination t1^2 is not calculated 
using dose absorbed and yet a wide variation is also seen 
with this parameter. It seems likely that extrarenal 
metabolism has occurred in some subjects studied.
4.5.5 Urine Volume & Frusemide Dose
Urine volume passed over 24h ranged from 472-2761ml (1515+ 
564) for subjects taking FM & 656-3217ml (1450+819) for 
those taking FS. Volumes were lower than would be expected 
following a potent diuretic, suggesting that some subjects 
were fluid-depleted. Urine volume was not related to FRU 
dose for either group, whilst urine volume correlated with 
Cls for subjects taking FS.
4.5.6 Frusemide Recovery in Urine
All fit subjects taking FM took 40mg FRU & frail subjects 
took 40 or 80mg FRU. Of those taking FS, all fit subjects 
took 40mg & frail subjects took 40,80 or 120mg FRU. The 
absolute amount of FRU in urine could not be compared & so 
percent of dose recovered in urine was calculated (%Du). 
Means & ranges of %Du were similar for both groups - 
subjects taking FM excreted from 8-69% (36+16) & those 
taking FS excreted 9-65% (33+15).
Elderly patients have been reported as excreting 22-55% of 
an oral dose in urine as FRU & FRU-glucuronide, with 
recovery increasing to 51-84% after i.v. injection (62). 
Urinary recovery of an oral dose was reported to drop to 
1.4% & 0.7% in patients with CCr of 3ml/min (61).
One subject taking FS & 5 taking FM excreted more than 50% 
of dose administered. This suggests that in some cases in 
excess of 50% of the dose is absorbed although this figure
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was used in clearance calculations.
The wide interpatient range of %Du suggests that either 
absorption is not comparable or nonrenal excretion differs 
between subjects. FRU metabolites were not assayed and so 
it is not possible to say from the data which is the most 
likely. Studies report a change in both absorption and 
nonrenal excretion in certain disease states.
It is possible that urine was not collected accurately for 
24h, and this gave the wide variation in %Du, but this 
would only account for those subjects excreting lower than 
expected amounts. The urine collection could have been 
carried out for longer than 24h but this would have 
involved the omission of at least one dose of FRU which 
would not have been acceptable to many of the participants. 
A collection period in excess of 24h would also have caused 
more inconvenience for those subjects who were mobile, and 
while this possibility was examined it was not felt to be 
practicable particularly in the community.
Subjects with the shortest did not excrete
significantly more of the dose, also suggesting that a 
longer collection period would not have increased recovery. 
%Du was related to CCr for both groups but this 
relationship failed to reach significance. FRU excretion 
is only partially dependent on GFR as previously discussed, 
and this route of elimination appears to become less 
important with a decline in renal function. This could 
explain the weak correlation seen.
4.6 FRUSEMIDE KINETICS IN FIT & FRAIL ELDERLY PEOPLE
4.6.1 Comparison of Age
14 fit & 11 frail subjects took FM. Age was significantly
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different between groups, with the fit being on average 8y 
younger than the frail. This arose from a scarcity of 
•'young" immobile volunteers - only 2 subjects below 80y 
were frail. It would have been possible to recruit more 
immobile subjects if the study been extended to more than 
one general practice. At the time this was not possible 
but this method was later used in the digoxin study where 
recruitment was difficult. A sub-group was formed of FM 
subjects in the age range 76-86y in an attempt to separate 
the influence of age and frailty on parameters measured. 
This will be discussed in 4.6.8
3 fit & 7 frail subjects took FS and age was not 
significantly different between groups.
4.6.2 Mobility Score
Mobility score was significantly different between fit & 
frail groups as expected since fit & frail definitions 
included information on mobility. For those taking FM 
there was little overlap of scores between groups - 1 fit & 
5 frail subjects had a mobility score of 3. No overlap was 
seen for the FS group - all fit subjects had a score of 1.
4.6.3 Comparison of Elimination Half-lives
For those subjects taking FM, no significant difference was 
found for t1^2 between fit & frail groups despite the age 
difference, although the trend was towards a reduced t^^2 
in fit subjects (4.00±3.33h fit, 5.12±2.06h fr). The range 
of tjy2 was greater in the fit group with 3 subjects 
(F05GPF, M08GPF & M10GPF) having t ^ s  of 9.13, 11.90 &
7•56h. These subjects all had mobility scores of 1, and 
CCr of 55, 29 & 77ml/min respectively. The high tjy2 & 
reduced CCr of M08GPF were probably linked, but the CCr of
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the other 2 subjects were normal for their age and cannot 
explain the - M10GPF had the highest CCr of the entire
group. None were on drugs known to interact with FRU 
disposition. This would suggest that neither age or CCr 
can be used to predict FRU t^y2 in the elderly. Fitness 
and clinical condition may be important, but all 3 subjects 
were highly mobile at the time of the study. However, 22 
months after the study, both M08GPF & M10GPF were deceased, 
although the cause of death was not known. Unfortunately, 
overall mortality rates in fit & frail groups were not 
known. Subjects were categorized as fit or frail according 
to a combination of factors detectable by eye. No 
biochemical or haematological tests were carried out since 
this was thought to be more relevant and applicable to the 
situation faced by the prescriber. Had blood tests been 
carried out it is possible that undiagnosed pathology may 
have been detected in those subjects now deceased which may 
have led to them being categorized as frail rather than 
fit. If fit & frail definitions included results from 
blood tests the usefulness would be limited, particularly 
in general practice.
For those taking FS, 3 were fit & 7 frail. Fit subjects 
had a smaller range, a lower mean t ^ 2 and smaller s.d. 
than frail subjects but these observations failed to reach 
significance. One fit subject (F22GPF) recruited from 
general practice had subsequently died. Again the 
disparity between t1^2 & CCr can be seen - one fit subject 
with a CCr of 45ml/min had a t1^2 of 9.33h and another with 
a CCr of 50ml/min had a t^^2 of 1.36h. Other factors 
besides CCr and mobility appear to be important in the 
determination of tjy2.
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As previously discussed, elimination t ^ 2 is a hybrid 
function of both Cl & Vd. Groups were matched for weight & 
SA but body composition & hence Vd may have differed 
between fit & frail subjects. However, the assumption that 
absorption is comparable for all subjects, made for Cl 
calculation, may not be correct. Differences seen between 
the fit & frail for t1^2 is therefore important since 
is calculated without the inclusion of % dose absorbed.
4.6.4 Comparison of Apparent Serum Clearance 
For those taking FM, Cls ranged from 47-273ml/min (130+64) 
for fit & 16-279ml/min (98±64) for frail subjects (p<0.2). 
Although the ranges are similar for both groups there is a 
trend towards an increased Cls in the fit group.
The fit had a significantly greater CCr than the frail 
group (p<0.02). If Cls v CCr is plotted for fit & frail a 
relationship between them can be seen with a few notable 
exceptions. One frail subject (F47F) had a CCr of 33ml/min 
but a Cls of 278ml/min. This subject is separate from the 
rest of the frail group but the reason for this is not 
clear. The category she was placed in was correct 
considering her clinical condition.
Results indicate that other factors besides CCr and fitness 
category appear to influence Cls. It is possible that the 
assumption made about absorption in the calculation of Cls 
may not be correct, and that differences in absorption may 
have given rise to the differences in Cls.
For the FS group Cls of fit varied from 39-422ml/min (187+ 
206) & 14-263ml/min (78±96) for frail subjects (p<0.4).
The results show that fit subjects tended to have greater 
Cls, but there were only 3 subjects in that group, and the
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s.d. was wide. However, one frail subject with a CCr of 
28ml/min had a Cls of 263ml/min which emphasises the 
difficulty in determining what factors influence FRU Cls. 
When Cls was expressed per kg bodyweight the differences 
between fit and frail groups observed remained the same.
4.6.5 Comparison of Renal Clearance
For those taking FM, Clr ranged from 22-197ml/min (85±55) 
in fit & 10-176ml/min (78+57) in frail subjects (p<0.7).
The fit group had higher minimum, maximum, Q1 and mean 
values for Cls, but Q3 and median were greater for the 
frail group. While CCr correlated with Cls for the FM 
group, this was not the case for Clr. Subjects with a low 
CCr had some of the highest Clr values. A similar pattern 
was seen for Clr/kg when the fit and frail groups were 
compared•
CCr had been calculated over 24h and also over 3 time 
periods each approximating to 6-8h. The CCr 0-6h was 
compared with the Clr 0-6h and with a few exceptions the 
pattern seemed to be more predictable, and the correlation 
was significant when all those taking FM were considered 
(p<0•01). CCr 0-6h appears to be a more reliable predictor 
of FRU Clr, but other factors are also important.
For the FS group, Clr ranged from 24-289ml/min (124±144) 
for the fit & ll-109ml/min (52±40) for the frail group.
Clr was higher for the fit group but there were only 3 
subjects in that group. When CCr 0-6h was plotted against 
Clr 0-6h a relationship was seen but was not significant.
4.6.6 Comparison of Urine Volume & % Dose Excreted in Urine 
For the FM group, urine volume ranged from 928-2761ml (1727 
±567) for the fit & 472-1880ml (1245±449) for the frail
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group (p<0.06). Volumes were low suggesting that some 
subjects were fluid depleted. One fit subject and 2 frail 
subjects passed volumes less than 1000ml but these subjects 
did not excrete the lowest % dose in urine, suggesting that 
urine collections were accurate. Frail subjects tended to 
pass lower volumes despite being administered on average a 
greater dose of FRU. However, measurement of fluid intake 
was not attempted in either group, although this may have 
provided some useful information on accuracy of urine 
collection.
%Du ranged from 12-61% (34±15) for the fit & 8-69% (39±17) 
for the frail group, with the similarity in %Du suggesting 
a comparable accuracy of urine collection between groups. 
However, there was no correlation between FRU dose & urine 
volume. The dose response curve for FRU is not linear and 
there is a ceiling response - if the dose of FRU is doubled 
the diuresis would not necessarily also double (48).
It is possible that subjects with a low urine output poorly 
absorbed the FRU or suffered circulatory fluid depletion 
which could contribute to a reduced urine output. Elderly 
patients have an impaired capacity to reabsorb water, 
manifested by a reduction in maximum concentrating ability 
(24,207), and this can readily lead to dehydration, both 
from lack of water and sodium. Diuretic use can upset the 
normal physiological state and hospital routine may 
compound this problem (40,139). This can lead to fluid 
depletion which may account for the reduced urine volumes.
For the FS group, urine volume ranged from 1093-1458ml 
(1245±190) for the fit & 656-3217ml (1553±1010) for the 
frail group. %Du varied from 29-34% (32+2) in the fit &
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9-65% (33+19) in the frail. There appears to be little 
difference between the fit & frail groups taking FS in 
terms of response to, or excretion of FRU in urine.
4.6.7 Age-Matched Subjects Taking Frumil
Subjects taking FM aged between 76-86y were selected to 
form fit & frail subgroups, to enable the influences of age 
& frailty to be separated, and appendix D16 gives the 
results. When fit (n=8) & frail (n=7) groups no longer 
differed in age, mobility score remained significantly 
different. UCr, SCr, CCr, weight, SA, %Du & urine volume 
were similar between groups.
Both Cls & Clr tended to be lower in the frail group, but 
this was not significant, and this trend disappeared when 
Cl was normalized for bodyweight. However, elimination 
ti/2 was significantly higher in the frail group, with the 
mean value differing by 1.4h.
4.7 CONCLUSIONS
The elimination of FRU was followed in fit & frail elderly 
people with chronic illness of cardiovascular origin, with 
the aim of determining whether mobility & “fitness” 
influenced FRU excretion. FRU had to be administered 
orally, and blood samples were not taken at optimum time 
intervals. These limitations meant that data was 
interpreted with caution.
Elimination t1/2 was calculated by estimating the gradient 
of time v log serum [FRU] plot. Blood sampling was not 
optimal with the correlation coefficient of the line 
varying? in a few cases t1^2 was calculated from two time 
points. Elimination a hybrid quantity, depending
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on both clearance and Vd. Vd is in turn influenced by 
weight, body composition, and plasma-protein binding, all 
of which can change in old age & chronic disability. There 
are inherent errors in the accuracy of FRU analysis by 
HPLC, although the coefficient of variation was low (3.1% 
at 0.lug/ml, 2.3% at 2.0ug/ml), and further difficulties 
were experienced in the collection & assay of a light- 
sensitive compound. In order to calculate apparent 
clearance it was assumed that absorption was comparable for 
all subjects studied. However, a review of the literature 
showed that the assumption may be invalid in some cases. 
Furthermore, groups of subjects were small and 
heterogeneous. Because of flaws in this study comparisons 
made should be considered orientating & qualitative rather 
than definitive & quantitative.
All participants were regularly taking FRU for a variety of 
cardiovascular problems. None were "healthy” volunteers 
and the terms "fit” and "frail” were therefore used 
relatively in this study, according to the definitions 
given in appendix Al. The lifestyle of fit individuals 
appeared to be relatively unaffected by the presence of 
chronic disease and all were able to live independently in 
the community. On the other hand frail subjects experienced 
some degree of disablement through chronic illness, and 
although none were acutely ill, all were unable to live 
independently, requiring assistance with activities of 
daily living. Those classified as frail were also likely 
to have more significant pathology, and be taking more 
drugs. The definitions did not require biochemical or 
haematological tests to be carried out since this was 
thought to best represent the situation usually faced by
140
the prescriber. Had a battery of tests been run it is 
possible that some fit subjects may have been recategorized 
as frail. This would have had the effect of increasing 
numbers in the frail group but the trends observed would 
have most likely remained the same.
Subjects taking FS appeared to eliminate FRU less 
efficiently than those taking FM. While there was no 
statistical difference between subjects taking FS & FM with 
respect to CCr or mobility score, those subjects taking FS 
were more likely to be frail. The decision to prescribe FS 
rather than FM may have been made on the basis of diagnosis 
(more subjects taking FS had LVF), or results from 
biochemical tests obtained by the physician. Since there 
appeared to be a difference between those taking FM & FS 
the groups were kept separate rather than combined which 
had been the original intention. Despite the reduced 
numbers seen in FS and FM, both exhibited similar patterns.
Since the calculation of t ^ 2 in some cases involved the 
use of only two time points, and estimation of clearance 
necessitated the use of an unsubstantiated assumption, 
the findings from both will be combined to form a general 
statement.
Although significance was rarely reached, there appeared to 
be a trend towards a decreased elimination rate of FRU in 
frail subjects compared to their fit counterparts, and this 
trend remained when FM subjects were age-matched. While 
CCr tended to be related to clearance, t1y2 was not* it 
known that FRU is eliminated at least partially via the 
kidney? the minor fraction of free drug being excreted by 
glomerular filtration and the bound drug excreted via
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secretion by proximal tubules (48). Studies have failed to 
show conclusively whether degeneration of tubules and 
glomeruli occurs at similar rates during the aging process 
(23). If rates are comparable, then the lack of correlation 
between elimination rate & CCr, remarkable in a few cases, 
suggests that either tubular secretion is inhibited or 
other excretory mechanisms are also responsible for the 
removal of FRU from the body.
In severe renal impairment, particularly with uraemia, 
endogenous anions may accumulate and compete with anionic 
drugs for secretion via the proximal tubule. If this 
occurred in some subjects it could account for those cases 
where Clr is especially low. Competition can occur to 
differing degrees, but this would not explain the 
apparently high Cls seen in some subjects with a low CCr.
Absorption of FRU following administration of a solid dose 
formulation is not complete (48), but even if systemic 
bioavailability approximated to 50% of the dose 
administered, recovery of unchanged FRU in urine was often 
substantially lower. Studies using i.v. administration 
have also showed a urinary recovery less than 100% (57,60). 
This suggests the existence of alternative pathways by 
which FRU may be eliminated, with the relative importance 
varying between individuals. Since the advent of HPLC, 
frusemide glucuronide, a metabolite of FRU, has been 
detected in urine (57,62), while the more controversial CSA 
has not. While it is not known whether other metabolic 
pathways exist, studies have shown that FRU may also be 
secreted into bile and excreted in the faeces (53,61).
In the present study only unchanged FRU in urine was 
assayed, and it is not possible to comment on whether
142
alternative metabolic pathways were responsible for the 
excretion of part of the FRU administered. However, those 
individuals with a low CCr who also had a low FRU may
have eliminated FRU via other mechanisms besides renal 
clearance of unchanged FRU.
Frail subjects appeared to have consistently increased 
tjy2s and reduced clearances compared to fit subjects, 
although this was only significant when subjects taking FM 
were age-matched. Frail subjects had a significantly lower 
CCr and this could be the explanation for the difference. 
Other studies have noted that while renal clearance is 
reduced in elderly compared to young volunteers the 
proportion of FRU cleared nonrenally is unchanged (57). If 
in the present study fit subjects excreted more FRU renally 
due to an increased GFR and accompanying increased tubular 
secretion, with both groups excreting similar quantities of 
FRU via nonrenal mechanisms this could explain the results. 
Fit & frail groups differed in many ways. The frail were 
much less mobile than the fit, spending more time sitting 
and supine. The difference in posture between the groups 
could explain the changes in FRU kinetics, since marked 
circulatory and plasma volume changes occur in the upright 
compared to the supine position (208). Benzylpenicillin, 
also eliminated via the nonspecific organic acid secretory 
pathway, has been shown to have an increased renal 
clearance but reduced first-order rate constant for 
metabolism when patients were subject to bedrest as opposed 
to normal activity. The authors concluded that bed rest 
per se could bring about pronounced changes in the 
distribution, metabolism and excretion of drugs relative to 
values obtained in ambulatory subjects (41,209). It was
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thought that these changes, which have also been seen 
following physical exercise, could be due to an increased 
metabolic rate seen in active subjects.
Changes ih posture may influence CCr, although evidence has 
been inconclusive. One study observed no change in CCr 
when subjects were rested in the antiorthostatic position 
compared to when they underwent ordinary ambulatory 
activities (167). However, a considerable increase in 
diuresis and sodium excretion was observed in the 
antiorthostatic position. When FRU was orally administered 
a summation of the effects of diuretic and antiorthostatic 
position was seen, thought to be due to different 
mechanisms of action. Another study found an increase in 
CCr, diuresis & natriuresis in the supine compared to a 
sitting position for "normals” and patients with 
hypoalbuminaemic states (168). CCr increased further when 
the subject was placed in the head down tilt position. 
Patients with cirrhosis and ascites given bumetanide i.v. 
have been found to have an increased GFR, and enhanced 
diuretic and natriuretic response when supine than when in 
the upright position (210). However, the kinetics of 
bumetanide in the different positions were not 
investigated.
In the present study frail patients, who were more likely 
to be inactive and spend longer in the supine position, had 
a lower CCr and reduced elimination of FRU. This suggests 
that the differences observed are not mainly due to 
differences in posture, although they may attenuate the 
effect of old age & frailty. To determine the effect of 
posture, a study could to be carried out with each subject 
acting as their own control and FRU administered on two
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occasions with subjects either upright or supine. Frail 
subjects were less "well" than fit subjects although all 
were suffering from cardiovascular disease. Prolonged 
inactivity is known to cause gradual deterioration of 
cardiovascular function, and frail subjects may have a 
reduced cardiac output, stroke volume and renal plasma flow 
(57). These difference in clinical status between the two 
groups may have influenced FRU elimination.
To conclude, fit elderly people appeared to handle an oral 
dose of FRU more efficiently than their frail counterparts. 
Age appears to be associated with a decline in FRU 
elimination and this is partly related to the inevitable 
decline in kidney function seen with increasing age. In a 
few individuals impaired renal function, and hence reduced 
CCr, seemed to have little bearing on FRU elimination which 
was more efficient than would be expected. It would seem 
likely that FRU is eliminated by nonrenal routes, which may 
be enhanced in some individuals with poor renal function. 
The qualitative differences observed between fit and frail 
elderly people may in part be due to the inevitable 
differences in activity, posture and blood flow. More work 
needs to be done to investigate the probable routes of FRU 
metabolism in order to determine the cause of differences 
observed in this study.
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CHAPTER FIVE 
PARACETAMOL METABOLISM IN ELDERLY PEOPLE
5.1 INTRODUCTION
Paracetamol (PAR) is a commonly used mild analgesic whose 
elimination is accomplished by hepatic metabolism. A 
number of studies have been performed to investigate PAR 
disposition in both young & elderly healthy volunteers but 
little work has been done in the chronically ill, disabled 
elderly. In this study an acute dose of PAR (lg) was given 
to elderly people who were either "fit" (well & living 
independently in the community) or "frail” (having chronic 
illness, immobility & loss of independence). PAR excretion 
was followed to determine the influence of immobility & 
frailty.
5.2 PROCEDURE
Fit & frail elderly people aged over 64y were invited to 
take part in the study. Exclusion criteria are given in 
2.2. Agreement of the volunteers' GP or Geriatrician was 
received before proceeding with the study. Each subject 
was provided in advance with an information sheet (appendix 
FI, standard or enlarged type) and able to question myself 
or Dr L Parker (trainee GP) prior to commencement of the 
study. Subjects avoided taking any PAR-containing 
preparation from the night before the study start.
On the morning of the study subjects ate a light breakfast 
of toast or cereal and an hour later emptied their bladder 
and took 2 x 500mg PAR tablets with a glass of water, 
either standing or sitting upright. Food was avoided for 
at least an hour after dosing, and thereafter taken freely.
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During the study subjects were questioned about their day- 
to-day activities & mobility, categorized as fit or frail, 
and had their mobility scored according the mobility scale 
devised for the study (appendices A1 & A2). The form given 
in appendix F2 was filled in during the study when subjects 
were weighed & measured and any medications taken were 
noted. Demographic details, diagnoses & drugs taken are 
given in appendix F3.
5-10ml of blood was taken at 0,3,4,6 & 12h and all urine 
collected for 24 hours after dosing. PAR was measured in 
all samples, UCr in all urine samples, and SCr in serum at 
time 0. Urine samples collected over 24h were assayed in 3 
aliquots each as near to 8 hours as possible with the final 
aliquot spanning the hours spent overnight in bed. 
Analytical methods for PAR & creatinine are given in 2.3.3,
For patients prescribed PAR regularly or "as required", 
further doses were omitted for 12h after the lg test dose 
until the last blood sample was taken. After this time PAR 
was avoided wherever possible until completion of the 
study. If any patient required PAR after 12h then urine 
was voided before PAR was taken, to provide a final urine 
specimen for UPAR analysis. The urine collection continued 
for measurement of UCr excretion only.
PAR elimination half-life ' AUC * apparent clearance
(Cl) were calculated as per 2.4. From the urine data free 
urinary paracetamol (UPAR), PAR glucuronide + sulphate 
conjugates (UPARG+S), and total UPAR (free PAR + UPARG+S) 
were determined. SCr & UCr were measured to calculate CCr.
Correlations between parameters were determined using
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Spearmans coefficient of rank correlation with significance 
levels taken to occur at p<0.01. Groups of fit & frail 
subjects and males & females were compared using the Mann- 
Whitney U test, with significance occurring at p<0.05.
5.3 RESULTS OF PHARMACOKINETIC PARAMETERS 
5.3.1 All Subjects
56 subjects successfully participated in the study (34F & 
22M). One patient (F37P) was later found to be taking 
phenytoin, known to interact with PAR metabolism, and so 
these results were excluded from statistical analyses (67, 
211). Individual results are given in appendices F4 & F5. 
Results & correlations from the entire group (males + 
females) are summarized in appendices F6 & F7.
Age ranged from 64-97y (80+8; mean±s.d.) and was not 
related to M.Sc or t1^2 but correlated with Cl, total UPAR, 
UCr, CCr & CCr/SA (p<0.01).
Mobility score correlated with CCr (p<0.01)? UPARG+S, total 
UPAR & UCr (p<0.001).
PAR elimination t^^2 correlated with Cl & Cl/kg (p<0.01).
A large inter-individual range was seen for Cl (5.3-38.71/h 
a multiple of 7.3), which correlated with age, t1/2, CCr & 
CCr/SA (p<0.01); urine volume, UCr, SA & weight (p<0.001). 
However, Cl/kg exhibited a smaller range (0.12-0.591/h/kg? 
a multiple of 4.8) and only correlated with t-jy2 (p<0.01). 
Urine volume correlated with age, UPARG+S, total UPAR, CCr 
& weight (p<0.01); Cl, UCr & SA (p<0.001).
Free UPAR showed no correlations. Between 0 (none detected) 
& 101.5mg of free UPAR (30.5±21.3), and 289.2-1192.lmg of 
total UPAR (715.1+185.3mg) were recovered in urine over 24h 
Of this an average of 680.8+184.8mg PAR equivalents (187.7-
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1109.8mg) were as PAR glucuronide + sulphate. UPARG+S & 
total UPAR correlated with M.Sc & UCr (p<0.001)? urine 
volume, age & CCr (p<0.01).
SCr ranged from 0.50-3.78mg/100ml (1.38+0.66), correlating 
with CCr/SA & CCr (p<0.001). CCr varied from 10-105ml/min 
(48+25) and CCr/SA from ll-115ml/min/l.73m2 (51±24). Both 
correlated with age, M.Sc, Cl, UPARG+S, total UPAR (p<0.01) 
UCr, SCr, weight & SA (p<0.001).
5.3.2 Female Subjects
Results & correlations from all female subjects are given 
in appendices F8 & F9. The females were not well matched 
with respect to age & mobility, with no females below the 
age of 80 years having a mobility score of 3 or less. This 
gave a correlation between age & mobility score (p<0.01). 
Many of the relationships previously seen in 5.2.1 failed 
to reach significance when only the females were considered 
but the trends remained noticeable and formed a similar 
pattern to the entire group. Significant correlations 
were: age v M.Sc & urine vol (p<0.01); M.Sc v UCr, UPARG+S 
& total UPAR (p<0.01)? t^ / 2  v Cl (p<0.01); Cl V tjy2' urine 
vol, UCr & CCr (p<0.01), weight & SA (p<0.001)? UPARG+S v 
M.Sc & total UPAR (p<0.01)? Total UPAR v M.Sc, urine vol & 
UPARG+S (p<0.01); SCr v CCr (p<0.001)? CCr v Cl, weight &
SA (p<0.01), UCr & SCr (p<0.001)
5.3.3 Male Subjects
Results & correlations from all male subjects are given in 
appendices F10 & Fll. Males were well matched with respect 
to age & mobility score which were not correlated. Age & 
SCr were correlated (p<0.01), a relationship not seen with 
the females or the entire group. Overall, the male group
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exhibited a similar pattern of correlations as the entire 
group, but the reduction in numbers caused most trends to 
only approach significance. Significant correlations were:- 
age v SCr (pcO.Ol); M.Sc v UPARG+S, total UPAR & UCr 
(p<0.01)? Total UPAR & UPARG+S v M.Sc (p<0.01), UCr 
(p<0.001); UCr v M.Sc, UPARG+S, total UPAR, CCr, weight &
SA (p<0.01)? SCr v CCr (p<0.01); CCr v UCr & SCr (p<0.01).
5.3.4 Comparison of Male and Female Results
Results from females & males were compared using the Mann-
Whitney test and the results are given in appendix FI2.
The pattern of correlations seen for females & males were 
similar with few exceptions. The males were better matched 
for age & mobility, with mobility scores evenly spanning 
the range of ages. Thus the correlation of age v mobility 
score seen for the female group was not reproduced for the 
males. The mean age was lower for the males (78+8y M, 82+8y 
F) but this difference was not significant. Mobility scores 
were similar.
The male group had a significantly greater t1^2 (3.32+1.15h 
M, 2.80+0.69h F? p<0.04) but they exhibited a wider range 
and hence standard deviation. A significant difference 
also existed between [SPAR] at 3 & 4h post-dose reflecting 
the difference in t^^2 between sexes.
SCr was significantly increased for the males (1.65±0.78 M, 
1.20+0.50mg/dl F?p<0.02) likewise UCr (970+504mg M, 696+252 
mg F?p<0.05).
The male group had a significantly greater weight (66+14kg 
M, 58±15kg F?p<0.04) & SA.
Cl, Cl/kg, urine vol, free UPAR, UPARG+S, total UPAR, CCr & 
CCr/SA were not significantly different between sexes.
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5.4 COMPARISON OF PARAMETERS FOR FIT V FRAIL GROUPS
5.4.1 All Subjects
Subjects were divided into fit & frail groups according to 
the definitions given in appendix A1 and compared. Results 
for the entire group (females + males) are given in 
appendix F13 and Figs. 5.4.1 to 5.4.6.
There was a 6 year age difference between fit & frail 
groups (75±8y fit, 84±7y fr.?p<0.01), largely due to the 
lack of immobile females under 80y.
From the serum PAR data significant differences were seen 
between groups for t1^2 (2.67±0.46h fit, 3.38±1.16 fr; 
p<0.005), Cl (18±7ml/min fit, 14±5ml/min fr?p<0.02) &
Cl/kg (p<0.05). [SPAR] at 3h & 4h were not significantly 
different.
From the UPAR data no difference between fit & frail groups 
was found for free UPAR excretion, but UPARG+S & total UPAR 
were significantly greater for the fit group (p<0.002).
This was reflected in the difference in excretion rate of 
total UPAR from 0-7 & 0-15h post-dose (p<0.01). Fit 
subjects passed significantly more urine during the 24h 
collection period (1392±551ml fit, 1037±465ml fr?p<0.02). 
SCr was similar for both groups (1.28+0.41mg/dl fit, 1.50± 
0.85 mg/dl fr), while UCr & CCr were significantly greater 
for the fit group (p<0.002 & p<0.05). The difference in 
CCr/SA approached significance (p<0.06) but [UCr] did not. 
Weight & SA were comparable between groups.
5.4.2 Female Subjects
Fit & frail female groups were compared and the results are 
given in appendix FI4. The females were poorly matched in 
terms of age, with an 8y difference between the mean age of 
the fit & frail groups (78+9y fit, 86+5y fr.?p<0.01).
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The frail females had a significantly increased elimination 
ti/2 (2.59+0.35h fit, 3.04±0.91h fr?p<0.05), although no 
statistical difference was seen between fit & frail females 
for Cl (17±8ml/min fit, 14±5ml/min fr), Cl/kg or [SPAR] at 
3h or 4h.
While there was no difference between free UPAR excretion 
for the two groups, frail females excreted significantly 
less UPARG+S & total UPAR (p<0.02).
UCr excretion was significantly greater in the fit group 
(789+231mg fit, 556±221mg fr?p<0.02).
There was no difference in urine volume, [UCr], SCr, CCr or 
CCr/SA between the fit & frail groups who were matched in 
terms of bodyweight & SA.
5.4.3 Hale Subjects
Fit & frail groups of male subjects were compared and the 
results are given in appendix F15. The two groups were 
well matched for age (76+8y fit, 80+9y fr).
From the serum PAR data was 9reater frail group
(2.79+0.59h fit, 3.85+1.34h fr?p<0.02), who also showed a 
significant reduction in both Cl & Cl/kg (Cl: 21+5ml/min 
fit, 14+5ml/min fr?p<0.01). [SPAR] at 3 & 4h were also 
significantly lower for the fit males (p<0.02).
From the UPAR data there was no difference between the 
groups for free UPAR, but the frail males excreted 
significantly less UPARG+S (p<0.02) & total UPAR (p<0.04), 
with the rate of total UPAR excretion at 0-7h & 0-15h post­
dose significantly lower in this group (p<0.02 & p<0.005). 
Urine volume & UCr excretion were significantly lower in 
the frail group (p<0.03).
There was no difference between groups for [UCr], SCr, CCr, 
CCr/SA, weight & SA.
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5.4.4 Age-Sex Hatched Pairs
Some of the differences seen between the fit & frail groups 
could be confounded by their disparity in ages and so 32 
subjects were age-sex matched to within one year to give 16 
pairs. Results & correlations from these groups are given 
in appendices F16, F17 & F18.
With equalization of mean ages, the increased tjy2 in the 
frail group remained (2.69±0.52h fit, 3.52±1.37h fr;p<0.02) 
Cl & Cl/kg both tended to be reduced in the frail group 
(Cl: 17±5ml/min fit, 14+6ml/min fr) but neither reached 
statistical significance (p<0.07).
Free UPAR excretion was similar between groups while 
UPARG+S & total UPAR were again significantly reduced in 
the frail group.
Urine volume, UCr, SCr, CCr, CCr/SA, weight & SA did not 
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In this study a therapeutic dose of PAR was given orally to 
55 elderly people with varying degrees of immobility and 
frailty. Their mobility was scored from 1 (most mobile) to 
5 using a rating scale devised for the study, according to 
their activity in general and during the study. Subjects 
were also categorized as fit or frail. The excretion of PAR 
was followed with serum PAR data allowing elimination 
AUC, apparent Cl & Cl/kg to be calculated. Urine PAR data 
enabled free UPAR, UPARG+S and total UPAR to be determined. 
SA, SCr, CCr and CCr/SA were also calculated.
5.5.2 Paracetamol Kinetics
29 fit (18F) & 26 frail (15F) elderly people took part in 
the study, with mobility scores ranging from 1 to 5. PAR 
kinetics from 3-12h after dosing were followed and appeared 
to undergo first-order kinetics, with log [SPAR] v time 
yielding a linear plot. This agrees with other studies of 
PAR pharmacokinetics (64). The sampling times chosen were 
past the peak [SPAR] and the maximal [SPAR] had been 
reached in every subject before the 4h sample. PAR 
absorption from a solid dose formulation is reported to 
give peak [SPAR] around 0.79h postdose in young volunteers 
(12) and 0.74h in elderly subjects (13), with distribution 
complete at 1-1.5h (212). Sampling times in the present 
study anticipated both the absorption and distribution 
phases to be well passed. The correlation coefficient of 
log [SPAR] v time approximated to unity in all cases 
(r>0.947), enabling accurate estimation of t^y2, AUC & Cl.
There was a significant difference between the females &
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males for t1 ,^2 and [SPAR] at 3 & 4h, and so for these the 
sexes will be discussed separately. No differences were 
seen for other pharmacokinetic parameters and so the sexes 
will be combined, and only the entire group discussed.
5.5.3 Elimination Half-life
A circadian variation in the rate of PAR elimination has 
been reported with t-jy2 being reduced by 15% when given at 
6am compared to 2pm (213). PAR was therefore administered 
at a similar time of day for all subjects, between 0730 & 
1050. The mean elimination for the female group was
2•80+0.69h (range 1.96-6.09h), and for males 3.32±1.15h 
(1.97-7.33h). The ranges, similar for both sexes, spanned 
an almost fourfold range. The mean t1^2 are higher than 
those quoted in other texts but within the ranges cited. 
Reports of elimination t1^2 have varied, ranging from 
1.9-3.3h in young subjects (mean age 29y? 79) and 1.9-4.3h 
(79), 1.43-3.45h (80) & 1.9-4.3h (12) for elderly subjects 
with mean ages of 70, 77 & 71y respectively.
The group in the present study were older (80.3±8.3y) than 
elderly groups in other studies, who have used only healthy 
volunteers. The markedly raised t.jy2 se©n here in a few 
individuals suggests that the physical condition of the 
subject may influence the rate of PAR elimination. 
Elimination t ^ 2 was not related to age for either sex, 
even when subjects were grouped into ten year cohorts, and 
the mean t^^2 for each group compared. This study aimed to 
determine changes in PAR kinetics with mobility and frailty 
in old age, so the age range examined was narrower than in 
other studies where young and elderly groups have been 
compared. Comparisons of PAR tjy2 in young and elderly 
volunteers are inconclusive, with different authors stating
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both that age increases PAR tjy2 (80,13) and does not 
affect PAR t^^2 (79).
The female group had a significantly lower t1^2 (p<0.04) 
and [SPAR] at 3 & 4h than the male group, while Cl & Cl/kg 
were not statistically different. The males were on 
average 8kg (14%) heavier than the females with a 12% 
greater SA. Drug distribution is known to be influenced by 
body composition & weight, and PAR has been shown to 
distribute into excess bodyweight over ideal bodyweight by 
a factor of 0.44 (108). This suggests an incomplete 
distribution of the non-lipophilic drug into body fat. 
References report a decline in PAR Vd with age, when a 
higher proportion of bodyweight comprises of fat, with 
elderly females having a lower Vd than elderly males (79, 
80). Since Cl = (Vd x 0.693)/t1^2 it is possible that a 
reduction in both Vd & fci/2 cou^^ produce no change in Cl. 
It therefore seems likely that inequality in weight & body 
composition between sexes may be an important factor in the 
explanation of the reduced tjy2 seen in the female group. 
Furthermore, the amount of UCr excretion was significantly 
greater in the male group although [UCr] was comparable, 
emphasizing the difference in body composition (especially 
muscle mass) between the sexes.
Elimination t ^ 2 is influenced by both Cl & Vd, with Vd 
being related to body weight and composition. Cl, which is 
independent of Vd is therefore a preferable pharmacokinetic 
parameter to use when comparisons are being carried out, 
particularly when weight & SA are not closely matched 
between groups (9). Sex differences have not been noted by 
other groups (12,79,80) and since Cl & Cl/kg were not 
statistically different for males & females, the disparity
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in would appear to be for the above reasons.
Elimination t ^ 2 was correlated with Cl & Cl/kg, and since 
tjy2 is mathematically related to Cl this correlation is to 
be expected. However, t^y2 was not correlated with other 
parameters measured.
5.5.4 Apparent Clearance
In order to calculate apparent Cl it was assumed that PAR 
absorption was complete and did not differ between groups. 
PAR is known to be readily absorbed from the small 
intestine, and is thought to undergo first-pass metabolism 
in the liver, with a bioavailability of about 90% for a lg 
dose (146). From the data collected it could not be shown 
unequivocally that bioavailability was comparable for all 
subjects studied and so the apparent (relative) clearance 
was calculated, using the dose administered rather than 
that reaching the circulation.
From the literature neither age nor renal impairment 
appears to significantly influence the extent of PAR 
absorption although the rate may vary (9,12,13,74,212). PAR 
is absorbed from the small intestine and absorption rate is 
therefore related to the rate of gastric emptying (64). 
Absorption is slowed if gastric emptying is delayed by 
food, posture or certain drugs, and increased by drugs such 
as metoclopramide, but the total amount absorbed is not 
affected.
In the present study factors known to affect the rate of 
PAR absorption were standardized in order to maximize 
absorption without disruption to the volunteers normal 
routine. All subjects were allowed only a light breakfast 
at least one hour before the start of the study, and 
abstained from further food for at least an hour after PAR
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administration. Tablets were administered either with the 
patient sitting upright or standing, although posture 
during the study varied. Only subjects F26 & M35 were 
taking drugs known to affect gastric emptying (both oral 
S/R morphine sulphate, appendix F3).
Previous studies have shown PAR Cl, when administered 
orally or iv, to be reduced in old age, but the magnitude 
with which Cl has varied with age has been inconclusive 
(13,74,79,80,81). In the present study mean Ci for the
- 1
entire group was 16.3±6.41/h (range 5.3-38.7), and Cl/kg
(
0.27-0.101/h/kg (0.12-0.59). These values are similar to 
those reported in other studies where oral PAR was 
administered to elderly people. A mean-Cl of 
0.25+0.081/h/kg was calculated using data from~28 healthy 
elderly volunteers with a mean age of 77 years (80). 
Individual Cl values were highly variable spanning a 
sevenfold range and Cl/kg an almost fivefold range.
The excretion of PAR conjugates would be expected to be 
positively linked to the rate of PAR elimination, since PAR 
glucuronide and sulphate form the majority of metabolised 
PAR. Cl correlated with CCr & CCr/SA, but not with SCr. 
Although unchanged PAR is hepatically metabolised, its 
metabolites are renally excreted. Therefore if Cl is 
related to conjugate formation, and their rate of excretion 
is related to renal function, then a correlation between 
PAR Cl & renal function is likely to result. Since SCr is 
a less satisfactory measure of renal function than CCr, 
particularly in cases of muscle wasting, this may explain 
why SCr does not appear to be correlated with Cl while CCr 
is. Cl/kg was not correlated with any of the parameters
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suggesting that the correlations for Cl were at least in 
part due the way in which weight was related to the other 
parameters.
5.5.5 Free Paracetamol in Urine
Between 0-10% (31+21mg) of the dose administered appeared 
in urine as free PAR. This agrees with other reports where 
it is cited that unchanged PAR forms approximately 2-5% of 
PAR excreted in the urine (64). Free UPAR was not affected 
by any other parameter examined. Excretion of free UPAR is 
via glomerular filtration although subsequent extensive 
passive tubular reabsorption occurs (212), thought to be 
primarily dependent on urine flow rate. These results 
suggest that passive tubular reabsorption is not 
disproportionately affected by age or mobility.
5.5.6 Paracetamol Glucuronide & Sulphate Excretion in Urine 
Recovery of total UPAR averaged 715±185mg with PAR 
glucuronide & sulphate forming between 118-1110mg (681±185; 
68%) of the total. As a proportion of all PAR excreted, 
approximately 55% is in the form of UPARG & 30% as UPARS 
(214). Results from the present study are within this 
range.
UPARG+S elimination was correlated with mobility score & 
CCr. Polar conjugates are excreted primarily by active 
tubular secretion and so it would be expected that their 
elimination is strongly influenced by CCr as the results 
show. This agrees with others examining PAR dispositon in 
patients with renal failure (212). Their study showed that 
while excretion of free UPAR differed little between normal 
subjects and patients with renal failure, elimination of 
PAR conjugates was increasingly impaired with a decline in
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renal function.
CCr is documented as declining in old age (123) and this 
correlation is seen in this study. This most likely 
explains the correlation of UPARG+S & age. The correlation 
of mobility score with CCr may explain the relationship 
between UPARG+S excretion & mobility score but it is 
possible that conjugate excretion is affected by mobility.
5.5.7 Total Urinary Paracetamol
Correlations for total UPAR are similar to those for 
UPARG+S, since total UPAR = free UPAR + UPARG+S. UPAR 
conjugates form a greater proportion of total UPAR excreted 
than free UPAR, so the similarity in correlations is to be 
expected.
5.6 PARACETAMOL KINETICS IN FIT & FRAIL ELDERLY PEOPLE
5.6.1 Sex Difference
Fit & frail groups were further divided into male & female 
groups, and trends seen were similar between them. 
Therefore, fit & frail groups are of mixed sex except where 
specific differences were seen - these are discussed under 
each heading where applicable.
5.6.2 Comparison of Age
Results from 29 fit & 26 frail elderly were used in this 
study. Fit subjects were on average 6y younger than their 
frail counterparts (77±8y fit, 84±7y fr.?p<0.01), largely 
due to the scarcity of frail females below the age of 80y. 
Fit & frail males were matched with respect to age (p<0.3). 
32 subjects were age-sex matched to enable the influence of 




The two groups differed significantly in their mean 
mobility scores as would be expected, since the mobility of 
the subject was taken into consideration when they were 
categorized as fit or frail. Fit subjects had a mean 
mobility score of 1.5+0.7 & frail subjects a mean score of 
3.7+0.7. There was some overlap between groups with respect 
to mobility score, with 3 fit and 11 frail people having a 
score of 3. This is due to the definitions used taking 
into account not only mobility but also clinical condition 
of the subject. The remaining fit elderly scored 1 (n=18) 
or 2 (n=8), and the frail elderly 4 (n=ll) or 5 (n=4).
5.6.4 Comparison of Elimination Half-lifes
Mean PAR elimination t^/2 was 2.67+0.46h (1.96-3.60) for 
the fit group compared to 3.38±1.16h (2.20-7.33) for the 
frail group, and this difference was highly significant 
(p<0.003). While there was some overlap between groups, a 
distinct difference could be seen, with a wider variation 
in t1^2 for the frail group (Fig. 5.4.1).
Elimination t^y2 is affected by Vd & Cl, and it is possible 
that the difference could be explained by changes in Cl or 
Vd occurring with increasing frailty. Weight & SA were 
similar between groups suggesting that Vd was also 
comparable. It is worthy of note that the significant 
difference in t ^ 2 remained when groups were further 
divided into females & males or age-sex matched pairs, 
suggesting that a difference in Vd is unlikely to be 
responsible for this result.
5.6.5 Comparison of Apparent Clearance
The true Cl could not be calculated since PAR was given
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orally necessitating instead the calculation of apparent 
Cl. While fit & frail groups were matched for weight & SA, 
a significant difference was observed between mean Cl 
(p<0•02), with the difference in Cl/kg approaching 
significance (p<0.06). The frail group showed an overall 
reduction in Cl & Cl/kg which approximated to 77% & 83% of 
those of the fit group, although a degree of overlap was 
seen (Fig. 5.4.2). This suggests that frailty may be an 
important influence on PAR clearance, but not the sole 
determinant. On considering the entire group the effect of 
age could not be excluded, due to an age difference of 6y 
between groups. For this reason groups were subdivided to 
give two smaller age-sex matched groups and the results are 
discussed in 5.6.9.
The influence of diet on conjugation reactions in man has 
been examined (215). It has been found that PAR Cl undergos 
a 17% increase following a diet high in cruciferous 
vegetables for 10 days, with an 8% increase in recovery of 
PARG in urine 24h post-dose. This may explain the 
differences observed since individuals in the community may 
well consume a diet different both in content and calories 
than those in institutions.
5.6.6 Comparison of Free Paracetamol in Urine 
The absolute amounts of free UPAR did not differ between 
fit and frail groups, with the ranges and mean values being 
comparable (Fig. 5.4.3). No correlations were seen between 
mobility, age, Cl or CCr and free UPAR and this finding 
would suggest that frailty does not influence free UPAR 
excretion either. Unchanged UPAR is eliminated by 
glomerular filtration with extensive passive reabsorption,
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and these findings suggest that this method of elimination 
does not exhibit a reduction in capacity with frailty.
5.6.7 Paracetamol Glucuronide & Sulphate Conjugate in Urine 
The amount of conjugated PAR excreted was significantly 
reduced in the frail elderly, with the mean UPARG+S 
approximating to 80% of that for the fit elderly. Again 
there was overlap between the ranges for the groups (323- 
1109mg fit, 188-896mg fr.) but the frail group occupied a 
distinctly lower range (Fig. 5.4.5).
This implies that either less conjugate was formed, leading 
to the reduction in Cl & t1y2 observed in the frail group, 
or else the conjugates were formed at a similar rate but 
not as efficiently excreted. In the latter case conjugates 
could accumulate particularly if active tubular excretion 
was reduced in frailty. This cannot be concluded from this 
study, since the passage of the conjugates in blood was not 
followed. CCr was significantly different between groups, 
with the frail group showing an overall reduction in CCr 
(p<0.04). This again would suggest that the conjugates 
could accumulate, particularly if the patient was on long­
term, regular therapy.
When the sexes are separately considered, CCr is comparable 
for fit & frail groups, while the amount of PARG+S excreted 
remained significantly less in the frail groups. This 
would indicate that less conjugate was formed, rather than 
it accumulating due to a reduced CCr.
5.6.8 Comparison of Total Paracetamol Excreted in Urine 
There was a significant difference between the absolute 
quantities of free plus conjugated UPAR (total UPAR) 
excreted in the urine, with the frail group excreting on
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average 80% of that excreted by the fit group (782±184mg 
fit, 623±148mg fr? p<0.002). This can be explained by 
observing excretion of free UPAR & UPARG+S. No difference 
in free UPAR excretion was seen between fit & frail groups, 
while the elimination of UPARG+S differed significantly.
The sum of these components gives total UPAR, and PAR 
conjugate in urine exceeds that of the free PAR. The 
contribution of UPARG+S is therefore greater, leading to 
the observed significance, reduced compared with UPARG+S 
alone.
The rate of total UPAR excretion from 0-7h & 0-15h postdose 
was found to be significantly lower for the frail group. 
From these results it is not possible to determine whether 
a reduction in the formation of conjugates or their 
accumulation is responsible for their reduced elimination 
rate.
It would seem likely, given the differences in t1^2 & Cl 
between the fit & frail groups, that formation of 
conjugates is reduced in frailty. From this study it is not 
possible to determine whether glucuronide or sulphate 
formation, or both, are reduced. The lower CCr seen in the 
frail group suggest that PAR conjugates could accumulate in 
the body, contributing to the reduced recovery in frailty. 
The result is that PAR is cleared less efficiently in the 
frail person, with sustained levels of both PAR and its 
conjugates, although the effects of increased levels of PAR 
and PAR conjugates are not known.
5.6.9 Comparisons Between Age-Sex Matched Groups.
Because the differences observed between fit & frail groups 
could be exaggerated by the difference in mean ages, a
166
subgroup was formed using an age-sex matching technique. 
Pairs of individuals of the same sex were formed having a 
similar age + 1 year. Mobility scores between individuals 
in a pair were as diverse as possible. 16 age-sex matched 
pairs resulted who formed fit & frail groups. Differences 
between these groups were again examined (appendix F18).
Mean elimination t^y2 remained significantly shorter in the 
fit group despite the reduction in numbers (p<0.03), and 
the range of values was narrower in the fit group (1.97 - 
3.60h) than the frail group (2.20-7.33h). Both Cl & Cl/kg 
were lower in the frail group but this trend failed to 
reach significance (p<0.07). Free UPAR excretion was 
unchanged between groups, but UPARG+S & total UPAR 
excretion were reduced significantly in the frail group, 
who also had a significantly lower rate of total UPAR 
elimination over 0-15h postdose (p<0.03). CCr, SCr, urine 
volume, UCr, weight & SA were similar between groups.
5.6.10 Relevance of Tobacco and Alcohol Consumption
6 fit & 3 frail subjects smoked tobacco, although only one 
from each group smoked in excess of 10 cigarettes per day. 
B°th fcl/2 * Cl values for smokers were distributed evenly 
throughout the ranges, suggesting that smoking was not 
likely to be responsible for the differences observed 
although the numbers involved are too small for a 
definitive statement. Moderate smoking (about 10/day) has 
been reported as having little effect on PAR metabolism, 
while heavy smoking (about 40/day) appears to induce 
conjugation with glucuronic acid, but not sulphates (163).
1 fit & 2 frail subjects admitted to excess consumption of 
alcohol (>14 units/week F, >21 units/week M). With only 3
167
participants known to drink alcohol in excess the 
importance of this cannot be determined from this study.
5.7 CONCLUSIONS
In this study lg of PAR was given to 55 elderly people with 
varying degrees of immobility & frailty. PAR in serum was 
followed from 3-12h post-dose, and a 24h urine collection 
was carried out. Various pharmacokinetic parameters were 
calculated from the serum data, and PAR & PAR conjugate 
excretion in urine was measured.
Mobility score appeared to be associated with an increase 
in t1y2 and a reduction in Cl, although these correlations 
were only of borderline significance. However, an increase 
in mobility score was strongly correlated with a reduction 
in excretion of both UPARG+S & total UPAR, while the 
Elimination of free UPAR did not change significantly. 
Frailty was consistently associated with an increase in 
tjy2 and reduction in Cl & Cl/kg? the change in 
remained significant when individual sexes were considered, 
while the difference in Cl approached significance. In all 
cases free UPAR did not appear to be affected by frailty 
while UPARG+S & total UPAR were significantly reduced.
These observations could be the result of a number of 
differences between fit & frail elderly.
A difference in absorption of PAR seems to be an unlikely 
explanation for the differences between the fit & frail 
groups. Authors have found that absorption rate is 
affected by factors such as age, posture, gastric emptying 
rate & diet, but there are no reports of an age-related 
reduction in the extent of drug absorption via passive
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diffusion (9,12,13,74,212,214). Although increased PAR 
absorption with frailty could explain the elevated [SPAR] 
at 3 & 4h, the increased tjy2 & reduced Cl could not be 
accounted for by a change in absorption since PAR kinetics 
are independent of dose. Furthermore, the reduced recovery 
of total UPAR also indicates that increased PAR absorption 
in the frail group is unlikely.
Dietary intake could differ between those who are frail & 
institutionalized and those who are fit & self-caring in 
the community. PAR metabolism is known to be increased in 
subjects eating a diet high in cruciferous vegetables, when 
it seems that induction of the glucuronidation pathway by 
certain indoles occurs (215). Diets consumed by the fit & 
frail groups were not standardized, but many elderly 
people, even those who are relatively mobile, often appear 
to consume a diet lacking in fresh vegetables for economic 
reasons (49).
Each subject took the PAR tablets in the upright position, 
either sitting or standing. This was the only attempt made 
to standardize posture during the study. The frail group 
were much less mobile than the fit group, and tended to 
spend longer in bed and more time semi-recumbent or supine. 
It has been noted that bed rest per se can bring about 
pronounced changes in distribution, metabolism & excretion 
of drugs relative to values obtained in ambulatory subjects 
(209). One study followed serum levels & urinary excretion 
of i.m. benzylpenicillin in subjects when in bed and 
subsequently when ambulatory (41). The fraction of the dose 
excreted unchanged and the renal clearance of the drug were 
significantly increased, and the first-order rate constant
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was significantly decreased during bed rest. This was 
thought to be due to an increased "metabolic rate” in 
ambulatory subjects or marked plasma circulatory volume 
differences found in upright and recumbent subjects (208).
It is possible that PAR metabolism may also be influenced 
by the above factors. However, prolonged bed rest can 
cause a deterioration in cardiovascular function which is 
associated with a decrease in plasma volume, and many of 
the frail subjects had been immobile for some time. It is 
not possible to say whether a difference in posture could 
at least in part account for the changes in PAR metabolism 
seen in frail subjects, but it can certainly not be 
discounted.
Associated with the differences in posture seen between the 
two groups of elderly subjects is the obvious variation in 
physical activity. The fit group were generally more active 
than the frail group who had a very restricted pattern of 
activity. Studies have investigated the effect of both 
acute & chronic exercise on drug disposition. One examined 
the effect of chronic exercise in a group of young people 
using each subject as their own control (216). It was found 
that as fitness improved, as measured by an increase in 
maximal oxygen uptake, so the hepatic metabolism of model 
drugs antipyrine & aminopyrine also increased. It is not 
known whether the enhanced hepatic metabolism was 
accompanied by changes in other liver enzymes. This result 
has been reproduced in other studies suggesting that 
chronic exercise which increases physical fitness is 
accompanied by accelerated hepatic biotransformation of low 
clearance drugs.
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Studies on the effect of chronic exercise on the metabolism 
of high clearance drugs however, have been inconclusive 
(216).
The effect of acute physical exercise on liver blood flow 
has been studied using indocyanine green (ICG) which has a 
high hepatic extraction ratio. ICG t^y2 is prolonged by 
vigorous physical exercise and the greater the degree of 
exercise the greater the prolongation in tjy2 (217)- Using 
this method a 60% reduction in liver blood flow during 
exercise has been estimated. A second acute exercise study 
involved the use of propranolol, another high clearance 
drug (218). During exercise ICG Cl was significantly 
reduced but propranolol exhibited a reduced tjy2 & AUC.
This result was unexpected since the ICG Cl indicated a 
reduction in liver blood flow, and so a rise in propranolol 
ti/2 was also anticipated. The explanation offered for 
this was that the absorption of the drug may have been 
affected, although other studies have not shown this to be 
likely. The reduction in liver blood flow seen with 
vigorous exercise could have resulted in a lower 
bioavailability of propranolol, explaining the reduced AUC. 
Exercise could have also increased the Cl of the drug but 
this seems to be contrary to a reduced liver blood flow.
The study concluded that other factors besides exercise may 
have influenced propranolol Cl on the study day. Low 
clearance drugs, such as antipyrine, with capacity limited 
hepatic elimination do not appear to undergo a change in 
metabolism with acute exercise.
No studies have been carried out on the effect of acute or 
chronic exercise on the kinetics of PAR, a low clearance 
drug exhibiting capacity limited metabolism. Studies on
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the metabolic effects of chronic exercise are more likely 
to be relevant to this study than those on acute exercise. 
The frail elderly were not as physically fit or active as 
their fit counterparts. Since metabolism of other drugs 
with a low hepatic extraction ratio appears to be 
stimulated by an increase in physical activity, it is 
possible that the same could be true for PAR. Although the 
actual activity of each subject was not studied the 
mobility scale and the fit & frail definitions included an 
assessment of each subjects activity. It would seem likely 
that the increased activity seen in the fit subjects may 
increase their general "metabolic rate” and stimulate liver 
blood flow thereby enhancing PAR metabolism.
During hepatic senescence liver histology appears to alter 
little. There is a rise in the average cell size in people 
over 60 years and an increase in the number of cells with 
large nuclei, but the significance of this is not clear 
(30). It is now well documented that both liver size and 
blood flow decline with age as discussed in 1.1 (9,21,30, 
81,219,220).
In the present study age & t1y2 were not correlated while a 
negative correlation was found between age & Cl, even over 
the small range of ages studied. When fit & frail groups 
were compared t^y2 & Cl were significantly different, 
suggesting that other factors besides age difference were 
important in the determination of PAR metabolism. When 
subjects were subdivided to give two age-sex matched 
groups, the significant difference between remai-nec*
while the difference in Cl approached significance.
This agrees with another study where PAR Cl was found to be 
greatest in young people compared with healthy elderly
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people, with those elderly people who were frail having the 
lowest PAR Cl (81). When PAR Cl was expressed per unit 
volume of liver, no difference was found between fit young 
& elderly people but there was a significant difference 
between the fit & frail elderly.
While we were not able to measure liver volume in the 
present study, it would seem likely that a similar case 
would be found if we had. That is, that the reduction in 
liver volume in old age is partly responsible for the 
decline in Cl seen for many drugs with increasing age, but 
an additional factor, such as the general health of the 
subject, adds an additional decrement to the hepatic 
clearance of a drug.
It is possible that the frail elderly may have reduced 
liver perfusion resulting in increased drug 
bioavailability. Following first-pass metabolism 
approximately 90% of an oral dose of PAR is found in the 
circulation. Any changes in bioavailability would have to 
be extreme before changes were seen in the order of this 
study, although any changes occurring as a result of 
frailty may be more important for drugs with a much lower 
bioavailabi1ity.
It is possible that the enzyme systems responsible for 
conjugation reactions have a lower activity or affinity for 
substrate, to explain the results observed. A reduction in 
conjugation would produce sustained [SPAR] levels and less 
conjugate excretion into urine, as this study found. From 
the literature it would appear that enzyme systems may be 
variably affected by age & frailty. Frailty rather than 
age has been shown to influence plasma levels of the enzyme 
aspirin esterase, found to be significantly lower in a
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group of frail hospitalized elderly patients compared with 
healthy elderly & young volunteers (221). Conversely an in 
vitro study failed to detect an age associated decline in 
microsomal mono-oxygenase activity or affinity in man 
(222). The effect of frailty on this system was not been 
determined in vitro.
Acetanilide Cl has been found to be similar in fit & frail 
elderly but significantly lower than in young subjects. 
However, when Cl was expressed per unit volume of liver no 
difference in Cl was found, suggesting that a decline in 
liver size was responsible for the reduced Cl seen in old 
age (220).
The present study only compared PAR Cl in fit & frail 
elderly people and so a definitive statement on the 
importance of age cannot be made. It would appear that 
frailty does have an effect on PAR metabolism, and it is 
possible that liver volume and/or blood flow could be 
reduced in the frail elderly compared to their fit 
counterparts.
Glucuronide & sulphate conjugates were not assayed 
separately in urine or in serum and so the influence of 
frailty upon conjugate formation cannot be commented on. 
Frail subjects excreted significantly less UPARG+S & total 
UPAR, suggesting that their formation may be impaired. It 
is possible that the reduction in CCr seen in the entire 
group when comparing fit & frail subjects was responsible 
for this. When CCr was comparable, for single sex & age- 
sex matched groups, the increase in and reduction in
Cl remained. As previously discussed, patients with renal 
impairment have been found to excrete less PAR conjugate 
although it appears to be formed at a similar rate than
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those with normal kidney function, leading to accumulation 
of conjugate in the body (212). In a study where PAR 
conjugates were quantified, glucuronide, but not sulphate 
conjugate formation was impaired in frail subjects compared 
to fit subjects of a similar age (81). This could offer an 
explanation to the results observed in the present study, 
since a sustained [SPAR], increased t^y2, reduced clearance 
and recovery of UPARG+S would fit with this hypothesis.
In summary, PAR elimination t^y2 was increased and apparent 
clearance reduced in subjects who were frail & immobile 
compared with their fit, mobile counterparts of similar 
age. Various hypotheses could explain these findings.
It is possible that PAR absorption was altered in the frail 
group but from the literature this seems unlikely.
Diet may have varied between fit & frail groups, and it is 
known that certain foods, and chemicals contained in them, 
can induce metabolic pathways. A diet containing more 
fresh vegetables consumed by the fit group could explain 
the findings.
A difference in activity & posture between the two 
populations could also afford an explanation, with 
differences in plasma & circulatory volumes, and changes in 
liver perfusion, causing the inequality in PAR metabolism 
observed.
Liver size & blood flow are known to be reduced in old age, 
and they may be reduced further in frailty. Any reduction 
in liver volume could reduce the metabolism of a 
hepatically cleared drug with a low extraction ratio. 
Enzymes responsible for conjugation reactions in the liver 
could have a reduced activity or affinity in frailty 
explaining both the reduction in elimination and the lower
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recovery of PAR conjugates in urine.
Although none of these explanations can be proven from the 
present study, it is highly probable that more than one 
factor is important. Changes in activity & posture may 
well be important, perhaps in some way influencing the 
activity of the conjugating enzymes, which appear to reduce 
PAR conjugation reactions.
The effect of sustained PAR levels in the body is not 
known, nor the accumulation of PAR conjugates which is 
likely to occur when renal function is reduced. However, 
it would seem reasonable that PAR is prescribed with 
caution in the very old, frail elderly person.
Further work needs to be carried out to determine whether a 




DIGOXIN EXCRETION IN ELDERLY PEOPLE
6.1 INTRODUCTION
Digoxin has been used in therapeutics for over two hundred 
years but its use is still associated with increased 
mortality & morbidity. Digoxin has a narrow therapeutic 
index (0.8-2.0ng/ml) and it is desirable to know which 
factors most influence the rate of elimination in order to 
prevent toxicity. For this reason digoxin (DIG) disposition 
has been extensively researched, with studies using both 
healthy volunteers & patients. While many studies have 
used elderly subjects, none have compared DIG excretion in 
those with varying degrees of immobility & ill health.
In this study DIG excretion was investigated in elderly 
people who were either "fit” (mobile, controlled chronic 
illness, living independently) or "frail" (immobile, poorly 
controlled chronic illnesses, loss of independence) in an 
attempt to determine whether frailty & immobility affected 
the efficiency of DIG elimination.
6.2 PROCEDURE
Fit & frail elderly people aged over 64y were invited to 
take part in the study. All were chronically ill, mostly 
with AF or CCF, and had been regularly taking the same dose 
of DIG for a minimum of 3 weeks. Exclusion criteria are 
given in 2.2. Each subject was given an information sheet 
(appendix El, standard or enlarged type) and had the 
opportunity to question myself or Dr L Parker (GP trainee) 
about the study prior to its commencement.
On the morning of the study subjects emptied their bladder
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and took their usual DIG tablet with a glass of water, in 
the upright position. DIG dose varied according to 
individual prescriptions which were not altered for the 
study. All tablets were manufactured by Wellcome (Lanoxin), 
but were from different batches as dispensed by the 
patients' own Pharmacist. Tablets were generally taken 
after a light breakfast of toast or cereal, with food and 
drink being freely taken thereafter.
During the study subjects were questioned about their day- 
to-day activity & mobility, categorized as fit or frail and 
had their mobility scored according to the mobility rating 
used in the study (appendix Al, A2). The form given in 
appendix E2 was completed during the study when subjects 
were weighed & measured and had their co-medication noted. 
Demographic details & drugs are given in appendix E3.
The ideal sampling time for DIG has been calculated to be 
llh post-dose, when [SDIG] best estimates DIG concentration 
at "steady-state” (114). 5-10ml of blood was therefore
taken at 11 & 24h and urine collected for 24h after dosing. 
DIG was assayed in serum at llh & all urine samples, UCr in 
all urine samples, SCr in serum at 24h. Urine collected 
over 24h was assayed in 3 aliquots each as near to 8h as 
possible, the final aliquot spanning the hours spent in bed 
overnight. Analytical methods are given in chapter 2.
About 5 days later a second blood sample was taken llh 
post-dosing. [SDIG] on the two occasions were compared to 
ensure that subjects were in steady state ([SDIG] samples 
did not differ by > 15%), and the mean value used in 
subsequent calculations.
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Total body clearance & renal clearance were calculated and
2
expressed per kg bodyweight & 1.73m SA as below:-
Total body clearance = dose x fraction absorbed
Clt (ml/min) [SDIG] x dosing interval
where fraction absorbed was 67%
Renal clearance = DIG recovered in urine/24h
Clr (ml/min) [SDIG]
Non-renal clearance = Clt - Clr
Clnr (ml/min)
UCr, SCr & CCr were also determined for each subject. 
Compliance
On initiation of therapy, steady state is only reached when 
5 half-lives have elapsed, that is for DIG about 8 days in
healthy subjects, if a set dosage is administered each day.
If a loading dose is given, steady state is reached sooner 
(44). The therapeutic range is only valid if steady state 
has been reached and sampling is at least 6h post-dose when 
absorption & distribution are complete (114). If compliance 
is poor the relationship between dose, [SDIG] & therapeutic 
range does not hold, and a low [SDIG] could be indicative 
of underdigitalisation or failure to comply. All 
participants when asked "how frequently do you take your 
heart tablet?”, gave the reply "every day”, but compliance 
of all subjects could not be assumed. This is a continual 
problem when steady state kinetics are investigated, 
particularly when ambulant subjects are used who take 
medications unsupervised.
49 subjects (26F) successfully completed the study of whom 
25 were frail. Results were considered statistically for 
the entire group (F + M) and for separate sexes.
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Correlations were determined using Spearmans Correlation 
Coefficient and significance levels taken to occur when 
p<0.01. Fit & frail groups, and males & females, were 
compared using the Mann-Whitney U test with significance 
taken to occur at p<0.05.
6.3 RESULTS OF PHARMACOKINETIC PARAMETERS
6.3.1 Female Subjects Taking Digoxin
Results from individuals are given in Appendices E4 & E5, 
with results & correlations from the female group 
summarized in appendices E6 & E7.
Age ranged from 73-96y (82±6y? mean±s.d.) and correlated 
with no other parameter studied. Mobility score ranged 
from 1-5 (2.8+1.4), correlating with Clt & Clt/kg (p<0.01). 
DIG dose was 0.0625, 0.125 or 0.25mg daily (0.135±0.07) and 
correlated with [SDIG] (p<0.01) & UDIG (p<0.001).
Urine volume/24h varied from 490-2059ml (1133±461), while 
DIG in urine in 24h, UDIG, varied from 19.4-165.9ug (57+33) 
correlating with only with DIG dose (p<0.001). Percent 
dose recovered in urine in 24h, %Du, varied from 19.0-82.8% 
(45+19) correlating with Clr, Clr/kg, Clnr & Clnr/kg.
Serum DIG concentration [SDIG], ranged from 0.14-3.OOng/ml 
(0.91+0.72) and correlated with dose (p<0.01); Clt, Clt/kg, 
Clr & Clr/kg (p<0.001).
Total body clearance Clt, varied from 19-224ml/min (95±54) 
for females, & Clt/kg from 0.40-4.47ml/min/kg and both 
correlated with MSc, SCr & CCr (p<0.01)? [SDIG], Clr,
Clr/kg & Clnr (p<0.001).
Renal clearance Clr, varied from 10-171ml/min (66±47) and 
Clr/kg from 0.18-3.30ml/min/kg (1.23+0.88). Both correlated 
with SCr, CCr & %Du (p<0.01); [SDIG], Clt & SCr.
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SCr ranged from 0.34-2.69mg/dl (1.09+0.66) correlating with 
CCr, Clt, Clt/kg, Clr & Clr/kg (p<0.01). CCr varied from 
9-141ml/min (63±32), and CCr/SA from ll-167ml/min/l.73m2 
(70+38). CCr correlated with SCr, Clt, Clt/kg & Clr/kg 
(p<0.01) & Clr (p<0.001).
Weight varied from 35-76kg (53.9+10.1) and did not 
correlate with any parameter measured.
6.3.2 Male Subjects Taking Digoxin
23 subjects studied were male and results & correlations 
from this group given in appendices E8 & E9. Males were 
less old than females - male age varied from 66-89y (78+6) 
while mobility score varied from 1-4. Age correlated with 
dose & UDIG (p<0.01). Mobility score correlated with CCr 
(p<0.01). Correlations of age v Clt & Clr seen in the 
female tended towards significance for the males.
DIG dose was 0.0625, 0.125 or 0.25mg daily (0.152±0.07) and 
correlated with UDIG (p<0.001) as for the females, in 
addition with age & Clt. Urine volume/24h was greater for 
males than females, varying from 492-3742ml (1603±784).
UDIG & [UDIG] were similar for both sexes, UDIG varying 
from 23-164ug (69+34) and correlating with dose and also 
age, CCr & Clr. %Du was also comparable, ranging from 
25.0-84.9% (47.7+16.4) for males correlating with Clnr & 
Clnr/kg (p<0.001).
[SDIG] ranged from 0.26-1.70ng/ml (0.65+0.36), correlating 
with Clt/kg & Clr/kg (p<0.01) as for the females.
Clt ranged from 34-264ml/min (128±69) & Clt/kg from 0.55- 
3.46ml/min/kg (1.58+0.9), correlating with dose, CCr, 
[SDIG], Clnr & Clnr/kg (p<0.01); Clr & Clr/kg (p<0.001). 
These relationships are similar to those seen for the 
female group.
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Clr varied from 27-194ml/min (85+45) and Clr/kg from 0.42- 
2.28ml/min/kg (1.17+0.55), correlating with UDIG & [SDIG] 
(p<0.01); CCr, Clt & Clt/kg (p<0.001), in a pattern similar 
to that for the females.
SCr ranged from 0.55-2.37mg/dl (1.13+0.42) and correlated 
with no other parameter. CCr ranged from 29-193ml/min (82+ 
33) and CCr/SA from 37-164ml/min/l.73m2, correlating with 
MSc, UDIG & Clt (p<0.01) and Clr (p<0.001).
Weight varied from 41-96kg (71.6±12.4) for the male group.
6.3.3 Comparison of Female & Male Results
Results from female & male groups were compared using the
Mann-Whitney Test and results are given in appendix E10.
Males were younger than females (78+6y M, 82+6y F) and this
difference approached significance, but the groups had
similar mobility scores. DIG dose prescribed was similar
for male & female groups, with UDIG, %Du & [SDIG] being
comparable between groups, although urine volume was
greater in the male group (1603±784 M, 1133+461 F?p<0.02).
UCr excretion was also significantly greater for the male
group (1273±484mg M, 816±475mg F;p<0.001), with the
difference in [UCr] tending towards significance between
groups. SCr was similar between groups (1.13+0.42 M, 1.09±
0.66 F) but CCr was greater for the males (82+33 M, 63+32 F
p<0.03) while CCr/SA was not significantly different.
Clt, Clr & Clnr were not significantly different between
2sexes even when expressed per kg or 1.73m SA.
These results suggest that the male & female groups studied 
did not differ in their ability to eliminate DIG. Results 
were therefore combined and correlations re-examined, with 
results given in appendices Ell & E12. A similar pattern 
of correlations were seen when the results were combined
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and these will subsequently be discussed.
6.4 COMPARISON OF PARAMETERS FOR FIT V FRAIL GROUPS
6.4.1 All Subjects
Subjects were divided into fit or frail groups according to 
definitions given in appendix A1 and compared, with results 
given for the entire group in appendix E13, and Figs. 6.4.1 
to 6.4.8.
Of the 49 subjects participating in the study, 25 were 
frail. Fit & frail groups were matched for age & DIG dose, 
but were significantly different in terms of mobility 
score. The fit passed a significantly greater urine volume 
than the frail group (1517±520 fit, 1216±780 fr.?p<0.01), 
and also weighed significantly more (p<0.05), with a 
greater SA (p<0.05).
DIG dose & [SDIG] were not significantly different between 
groups although the frail group exhibited a greater mean 
SDIG level and levels also tended to be higher when those 
taking similar dosages were compared (Figs. 6.4.1-6.4.3). 
UDIG, [UDIG] and %Du were not significantly different 
between fit & frail groups (%Du: 46+6 fit, 47+19 fr).
Total clearance was significantly greater for the fit group 
(133+67 fit, 89+52 fr.;p<0.02) and this difference remained 
when Clt was expressed per kg bodyweight or normalized to 
1.73m2 SA.
Renal clearance also tended to be greater in the fit group 
(86+43 fit, 65+48 fr.?p<0.06) but this trend became less 
distinct for Clr/kg (p<0.2) & Clr/SA (p<0.2), although 
minimum, maximum, Q1 & Q3, median & mean values remained 
consistently lower in the frail group.
Clnr was not significantly different between groups.
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UCr was significantly greater in the fit group (1170+371 
fit, 915+625 fr.;p<0.02) but [UCr] was not. SCr did not 
differ significantly between groups but frail subjects 
showed a greater range (0.55+1.66mg/dl fit, 0.34+2.69mg/dl 
fr). CCr & CCr/SA were both significantly greater for the 
fit group (CCr/SA: 83±24 fit, 63+37 fr.?p<0.002).
6.4.2 Female Subjects
26 female subjects participated in the study and 14 were 
frail. Results from this group are shown in appendix E14. 
Fit & frail groups of female subjects were matched for age 
(81+5y fit, 83±7y fr) but fit subjects were significantly 
more mobile (p<0.001).
Urine volume was significantly greater for the fit group 
(1488+423ml fit, 833±210ml fr.;p<0.001) while groups were 
similar for weight & SA (p<0.2).
DIG dose was similar between groups but the mean [SDIG] 
tended to be greater in the frail group (0.63+0.48 fit,
1.15±0.81 fr).
Neither UDIG or %Du were significantly different between 
groups but [UDIG] was statistically greater (p<0.04) for 
frail subjects due to the reduced volume of urine passed. 
Clt was significantly greater for the fit group (112±43 fit 
80+59 fr.;p<0.04), with the difference tending towards 
significance for Clt/SA (p<0.06), but being lost for 
Clt/kg. For both Clt, Clt/SA & Clt/kg, Ql, Q3, median & 
mean were greater for the fit than frail group.
No statistical difference was seen between Clr, Clr/kg & 
Clr/SA for the fit & frail female groups, but in all cases 
the fit tended to have greater values than the frail group, 
for minimum, maximum, Ql, Q3, median and mean.
Clnr was similar between groups.
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UCr was significantly greater in the fit group (939+314 fit 
712+569 fr.?p<0.04), but [UCr] was not, SCr exhibited a 
greater variability in the frail group, while both CCr & 
CCr/SA were significantly greater for the fit group (CCr: 
73+16 ml/min fit, 54+40ml/min fr.?p<0.02).
6.4.3 Male Subjects
Of the 23 male subjects in the study, 11 were frail.
Results from fit & frail male groups are shown in appendix 
El5. Groups were matched for age (77±7y fit, 79+6y fr) but 
fit subjects were significantly more mobile (p<0.001).
Fit & frail groups passed similar urine volumes although 
the fit group tended to weigh more and have a greater SA. 
There was no statistical difference between DIG dose or 
[SDIG] for fit & frail groups - %Du, UDIG & [UDIG] were 
also similar.
Clt, Clt/kg & Clt/SA were not statistically different 
between groups of subjects, but again fit subjects had 
greater values of minimum, maximum, Ql & Q3, median & mean. 
There was no significant difference between Clr, Clr/kg & 
Clr/SA for the groups, but again Ql, Q3, median & mean 
tended to be greater in the fit group.
Median & mean Clnr & Clnr/kg were greater in the fit group 
but this was not significant.
UCr & [UCr] tended to be greater in the fit group. Although 
the range for SCr was wider in the frail group there was no 
significant difference between fit & frail groups. Both 
CCr & CCr/SA were statistically greater for the fit males 









Fig. 6.4.2 Distribution of [SDIG] Levels in Fit 6 Frail 
Elderly People Taking 125ecg DIGOXIN Daily
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Fig. 6.4.3 Distribution of [SDIG1 Levels in Fit 6 Frail 
Elderly People Taking 250acg DIGOXIN Daily
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Fig. 6.4.4 Distribution of %Du in Fit & Frail 









Fig. 6.4.5 Distribution of Clt/SA in Fit & Frail





Fig. 6.4.6 Distribution of Clr/SA in Fit & Frail 
Elderly People Taking DIGOXIN







Fig. 6.4.7 Distribution of Clnr/kg in Fit & Frail
Elderly People Taking DIGOXIN
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Fig. 6.4.8 Distribution of CCr/SA in Fit & Frail
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6.5.1 Digoxin Dose and Usage
DIG elimination was followed in a heterogeneous group of 
elderly people prescribed DIG chronically for a variety of 
cardiovascular conditions, and the influence of fitness and 
mobility on DIG excretion was investigated.
24 fit & 25 frail elderly people aged 66-96y completed the 
study. From the medical notes 33 subjects (67%) had been 
prescribed DIG for AF with or without CCF or LVF, and of 
those 30 were in AF during the study. Of the remainder, 5 
(10%) were taking DIG for CCF or LVF alone, 5 (10%) for 
other cardiac conditions and 6 (12%) for no obvious reason. 
Clinicians agree that a fast ventricular rate in the 
presence of an irregular supraventricular tachyarrhythmia 
is a definite indication for DIG therapy. However, the 
role of DIG in the treatment of CCF alone remains 
controversial, and DIG is now rarely the treatment of 
choice for this condition (42,85,88,233). If both AF & CCF 
are justifiable indications for DIG therapy 22% of patients 
studied were probably prescribed DIG unnecessarily.
Reports on drug usage have freguently shown DIG therapy to 
be questionable, particularly in the elderly, but the 
incidence of inappropriate prescribing in this study 
compares favourably with others. One study in 1977 showed 
24 patients registered with a General Practice to be taking 
DIG, 18 of whom were in sinus rhythm (84). Another study 
reviewed medical records of 150 outpatients prescribed DIG 
and found 42% taking DIG for a questionable reason (224). 
Prevalence of DIG prescribing in 5 Irish nursing homes was 
found to be 21%, with the prescription inappropriate in 48% 
of patients (225). Prevalence of DIG prescribing in English
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nursing homes was found to be 11.5% (226). Another recent 
report from Canada found that 14% of nursing home residents 
took DIG, with the prescription seeming inappropriate in 
70% of cases (227). Conversely, another study found DIG 
therapy to be questionable in only 4 out of 77 elderly 
patients (228). These subjects had recently been discharged 
from hospital after acute admission and this may explain 
the low incidence of unnecessary DIG.
Most of the above studies subsequently withdrew DIG where 
the drug seemed inappropriate, and few patients suffered a 
deterioration in health necessitating restitution of DIG 
therapy (84,98,225,227,228,229).
In this study subjects were taking DIG at a daily dose of 
0.0625mg (n=12), 0.125mg (n=24) or 0.25mg (n=13? 0.78-5.81 
ug/kg/day). No subject was taking alternate day therapy, 
or a combination of tablet strengths. Dosages are lower 
than those recommended by the manufacturer (0.25-0.5mg/day 
for normal CCr, 0.125-0.25mg daily in the elderly? 46) or 
British National Formulary (0.125mg daily in the elderly; 
45). Others recommend a dosage of 2-5ug/kg/day depending 
on renal function (44) or 1.6ug/kg daily for those with 
end-stage renal failure (103).
DIG dosage has steadily declined in recent years as reports 
have suggested an increase in mortality & morbidity 
associated with its use (230). A dose of 0.0625mg daily has 
become a popular "geriatric dose” because of these fears 
and increasing awareness that DIG clearance is reduced in 
old age (91). While toxicity is unlikely from a daily dose 
of 0.0625mg, a large proportion of patients are under- 
digitalised as a result, and this dose is only appropriate 
in those with severe renal impairment or much reduced
190
bodyweight. The use of inadequate doses are of little 
therapeutic consequence in patients with sinus rhythm, when 
the prescription is often unnecessary. However, in renal 
failure & hypokalaemia patients may be exposed to toxicity. 
In patients with AF the apparent widespread use of 
inadequate doses may be cause for concern (225).
6.5.2 Serum Digoxin Levels
[SDIG] levels obtained for each DIG dose are shown below:-
DIG dose (mg) n [SDIG] (ng/ml)
0.0625 12 0.14 - 1.38
0.125 24 0.28 - 3.00
0.250 13 0.44 - 2.50
No statistical difference was seen between sexes.
The therapeutic range for DIG is 0.80-2.OOng/ml, although 
many clinicians aim to maintain [SDIG] between 1.0-1.5ng/ml 
(44,98). While the preferred range is unaltered in old age 
(90) & renal failure (103,231), control of supraventricular 
dysrhythmias may require a [SDIG] level of up to 3ng/ml, 
when the therapeutic benefit from control of heart rate 
offsets the increased probability of side effects.
From [SDIG] alone, subjects found to be subtherapeutic, 





















From clinical observations of heart rate and appearance of 
side effects, 5 subjects appeared to be subtherapeutic
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(F01, M25,F33,F44,F52) and 1 toxic (F37) with AF. The 
prescription of DIG was also questionable in some cases, 
particularly in the absence of AF when [SDIG] was 
subtherapeutic. In such cases DIG can often be withdrawn 
(84,98,225,228,229). Signs & symptoms of toxicity are dose 
related (94), with [SDIG] above 3ng/ml, or a daily 
maintenance dose in excess of 0.7mg or 6ug/kg, invariably 
associated with side effects (89). However, studies have 
shown there to be considerable overlap in the [SDIG] at 
which toxicity occurs when [SDIG] may be as low as lng/ml 
(85,103,228).
Although [SDIG] is generally thought to be a useful 
diagnostic aid where over or under-digitalisation are 
suspected, some groups have proposed that knowledge of 
[SDIG] adds little to the clinical picture when the 
physician already has information on DIG dose, renal 
function, serum K+ & cardiac status (232,233). Evaluation 
of the use and outcome of [SDIG] assays have also shown 
that few are carried out in appropriate circumstances (86). 
[SDIG] can only be interpreted in the clinical context 
since numerous other factors need to be taken into account 
including thyroid & renal function & electrolyte balance 
(85,86,89,233,234).
These results suggest that a dose of 0.0625mg daily is 
unlikely to produce [SDIG] levels within the therapeutic 
range except in severe renal impairment; those with AF and 
subtherapeutic levels (n=22) may have benefitted from an 
increased dose and those without AF whose [SDIG] was below 
0.8ng/ml (n=9) could probably have been withdrawn from DIG. 
Other studies have also drawn similar conclusions where a 
substantial proportion of underdigitalisation has been
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found following a daily dose of 0.0625mg (225,235,236). A 
daily dose of 0.125mg is more appropriate in the elderly 
and carries only a small risk of toxicity but O.lmg tablets 
would be a useful alternative. The recommendation of 
0.25mg daily in the elderly with CCr greater than 25ml/min 
(102,237) may be too high for those with a low bodyweight.
Toxicity is more likely to occur at a lower [SDIG] in 
patients with hypothyroidism, hypokalaemia, hyperkalaemia 
or other electrolyte disturbances, where the myocardium is 
sensitized to DIG (89,92,98). Hypothyroidism renders 
patients more sensitive to DIG and side effects may occur 
within the therapeutic range (238,239). Conversely, 
hyperthyroidism is associated with DIG resistance where 
larger than usual doses are required to control supra­
ventricular dysrhythmias and an increased GFR associated 
with this condition enhances renal clearance (237). The 
maintenance dose of DIG should always be reviewed when the 
thyroid dysfunction is brought under control.
In this study subjects with thyroid disorders were 
receiving treatment to render them euthyroid, but possible 
over or under treatment of the thyroid disorder could 
affect their DIG sensitivity. 4 subjects were hypothyroid 
(F04,F17,F21,F46), 2 were previously hyperthyroid (F33,M23) 
No hypothyroid subjects exhibited any signs of toxicity, 
but F33 appeared to be clinically subtherapeutic when 
taking 0.125mg DIG daily, giving [SDIG] of 1.03ng/ml but a 
pulse rate of 102bpm.
Both low (<3.5mmol/l) and elevated (>5mmol/l) serum 
potassium levels are associated with the appearance of DIG 
toxicity when [SDIG] is within the therapeutic range (89). 
Hypokalaemia can arise from diuretic therapy which is often
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used in combination with DIG for the treatment of CCF.
Other causes of low serum K+ include poor nutrition, 
diarrhoea & vomiting and chronic wasting disease. In cases 
of suspected toxicity both serum K+ & [SDIG] should be 
measured. No subject in the community had had a recent K+ 
measurement despite 34 regularly taking a diuretic, whereas 
1 patient in hospital (F17) had had K+ measured & 2 
patients had [SDIG] levels taken during their admission. 
Despite the recommendation that [SDIG] can only be 
interpreted in the clinical context, this appears to be 
rarely the case.
For a given dose [SDIG] was found to be highly variable, 
exhibiting an eleven-fold range for those taking 0.125mg 
daily. [SDIG] is influenced by dose, and for an individual 
an increase in dose is accompanied by a proportional 
increase in [SDIG], since DIG pharmacokinetics are 
independent of dose after single doses & at steady state 
(92,240,241). However, for any DIG dose a considerable 
interindividual variation in [SDIG] is seen, even within a 
group of patients with comparable CCr (242).
In this study [SDIG] correlated with dose, Clt & Clr for 
females; Clt & Clr for males? dose, UDIG, Clt & Clr for the 
entire group. In all cases [SDIG] & CCr appeared to be 
correlated with a significance level of p<0.05. These 
correlations are in agreement with those reported by other 
groups (236,240). Some have subsequently attempted to 
devise a nomogram or equation to enable [SDIG] to be 
predicted for given dose & renal function (103,243,244,245) 
while others have constructed a scoring system to aid 
selection of an appropriate DIG dose (246). Investigations 
have shown that while dose & CCr are the most important
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determinants of [SDIG], plots of measured v predicted 
[SDIG] consistently yield a degree of unexplained variance, 
suggesting that other factors need to be taken into account 
(89,91,92,103,236,240,242). Incorporation of additional 
parameters such as age, sex, lean body mass & [albumin] 
into equations has not been shown to significantly increase 
the accuracy of prediction with the degree of scatter 
remaining clinically unacceptable (105,113,184,235,245,247, 
248); in one instance calculated [SDIG] level overestimated 
actual measured level in 33% of patients studied (242). 
Substantial interindividual variation in [SDIG] may be due 
to differences in one or more of the following aspects of 
DIG disposition: absorption, distribution, protein binding, 
drug interactions, diagnoses, metabolism, elimination or 
compliance. The way in which these factors can alter DIG 
disposition in old age & ill health are discussed in 1.4.3.
6.5.3 Total Body Clearance of Digoxin
Total body clearance was calculated from [SDIG] & fraction 
of dose absorbed (67%) and found to range from 19-224ml/min 
(95±54) for females, 34-264ml/min (128+69) for males. Many 
other studies have calculated DIG elimination half-life or 
[SDIG], but where Clt has been determined results are 
similar to those in the present study. One study (91) found 
mean Clt to be 37±6ml/min for elderly subjects (age 81±2y) 
and 106+14ml/min for younger subjects (47±5y). Another 
calculated Clt to be 109+17ml/rain for a group of elderly 
males (78+2y), assuming 95% absorption (242).
No statistical difference was seen for Clt, Clt/kg & Clt/SA 
between females & males, suggesting that DIG excretion is 
similar in both sexes. This has also been concluded in 
other studies (184,247), although the prediction of [SDIG]
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has been found to be more accurate for females (228,244).
In order to calculate Clt it was assumed that all subjects 
absorbed an equal fraction of the DIG dose administered, 
but this cannot be proven from data in this study. For a 
drug in steady state, the extent, but not the rate, of 
absorption is important in determining the concentration of 
drug in the blood at all times (44). While age per se has 
not been shown to affect the extent of drug absorption 
(including DIG) via simple diffusion, certain disease 
states have (9,12,13,91,235). Therefore, the data is 
interpreted with caution.
Clt correlated with mobility score, SCr, CCr, [SDIG], Clr & 
Clnr for females; CCr, dose, [SDIG], Clr & Clnr for males; 
age, mobility score, SCr, CCr, [SDIG], Clr & Clnr for the 
entire group. Previous studies have shown DIG Clt to be 
reduced in old age (91), as seen in the present study for 
the entire group despite the relatively narrow age range 
examined (66-96y). Age is associated with a decline in CCr 
and this was seen in the present study. While a definitive 
statement cannot be made on the relative importance of age 
& CCr in Clt determination, it would seem that CCr is the 
more important when correlation coefficients are observed. 
Females: age v CCr r=-0.375; age v Clt r=-0.426; CCr v Clt 
r=0.659. Males: age v CCr r=-0.504; age v Clt r=-0.453;
CCr v Clt r=0.573.
An increase in mobility score was significantly correlated 
with a decrease in Clt for the females & entire group, 
tending towards significance for the males. In this study 
mobility score was evenly distributed throughout the age 
range so that no correlation was seen between these two
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parameters. However, a correlation was seen between 
mobility score & CCr, known to strongly influence Clt, and 
it is again difficult to separate out the importance of 
these two factors.
The effect of chronic exercise on DIG kinetics has not been 
investigated since it would involve chronic dosing to 
healthy subjects. However, the effect of acute exercise on 
DIG distribution has been examined in two studies. One 
study measured [DIG] in thigh muscle & serum following two 
weeks of dosing with DIG, before & after one hours exercise 
(249). Increased binding of DIG to muscle was seen 
immediately following exercise accompanied by a reduction
in [SDIG]? 30 minutes later [SDIG] had increased, but not
to pre-exercise levels. The ratio [muscle DIG]/[serum DIG] 
was greater after exercise suggesting that mobilization of 
DIG from other tissue compartments was responsible for the 
increased [DIG] in muscle observed after exercise. The 
second study however, failed to show a change in [SDIG]
following a period of maximal exercise (250).
Changes in posture & physical activity have marked effects 
on cardiac output & plasma volume and cause alterations in 
the concentration of nonfilterable constituents, although 
the extent to which these changes influence drug 
disposition has been given little attention (171,251). One 
study compared [SDIG] in 8 healthy volunteers after 2h of 
normal physical exercise with that after 2h of recumbency 
(171). Rest in the supine position was associated with a 
relative increase in [SDIG] of 63% although interindividual 
variation was considerable (28-91%) while urinary excretion 
of DIG remained unchanged. The combined effect of these 
observations was a decline in Clr although CCr remained
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unchanged. Recumbency has been shown to produce 7-8% 
increase in plasma volume which cannot account for the 
increase in [SDIG]. A reduced Clr could be the result of a 
lowered tubular secretion associated with a decline in 
renal blood flow at rest. Alternatively, changes in DIG 
binding to muscle could be responsible for the increased 
[SDIG] since muscle binds about 60% of the body store of 
DIG, any change in binding can have a profound effect on 
[SDIG].
A second study investigated the effect of rest in the 
supine position on [SDIG] in outpatients taking DIG 
chronically (252). Rest was associated with a rise in 
[SDIG] which appeared to reach "steady state” after 2h. 
[SDIG] increased by a mean of 28% although again the inter­
individual variation was great (0-75%). This suggests that 
everyday physical activity may affect [SDIG], but in an 
unpredictable and variable fashion.
In the present study all subjects took DIG in the morning, 
and [SDIG] was measured llh post-dose after a full day of 
activity or inactivity. It is possible that the level of 
activity, as rated using the mobility score, and posture, 
may have influenced [SDIG]. If DIG binding to skeletal 
muscle is greatest in those who were most active (lowest 
mobility score) this would have the effect of reducing 
[SDIG] & increasing Clt, as seen in the present study. 
Stimulation of renal blood flow by physical activity could 
also enhance Clr.
It is possible that mobility alone can influence Clt, 
although to what extent cannot be determined. When subjects 
were ranked in order of decreasing CCr a trend was seen 
towards a reduction in Clt. However, one subject with a
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2CCr of 34ml/min/l.73m had a Clt of 1 -97ml/mm/kg, while
2another with a CCr of 97ml/mm/l.73m had a Clt of
1.28ml/min/kg. It is apparent that while there is a
statistically strong correlation between CCr & Clt, other 
factors besides CCr are important.
Other studies which have investigated the effect of CCr on 
Clt using patients with renal failure have also found a
degree of unexplained variance (105). Mobility may be an
additional factor in the determination of DIG Clt, but it 
seems likely that any influence is small.
The variation in Clt may alternatively be explained by an 
unequal extent of absorption occurring between subjects.
The effects of disease states & drug interactions on DIG 
absorption have been discussed in 1.4.3. At steady state 
the amount of drug absorbed is equal to that excreted.
In this study the percentage of dose excreted unchanged in 
urine was variable, ranging from 19-83% (45+19) for females 
& 25-85% (48+16) for males? 8 subjects had more than 67% 
unchanged DIG in urine. Possible reasons for this could 
include increased absorption, differences in compliance or 
lack of specificity of the assay. Extent of DIG absorption 
has been reported to vary between subjects but most studies 
were carried out before the standardization of DIG tablets, 
when variation in bioavailability was partly due to 
differences in dissolution rate. Comparative studies using 
i.v. and oral formulations would be needed to determine 
whether absorption in elderly people was constant. It 
remains possible that the extent of absorption may have 
varied among the population studied, although it is not 
possible to say by how much. A low %Du may be indicative 
of more extensive metabolism and non-renal elimination.
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6.5.4 Renal Clearance of Digoxin
Renal clearance was calculated from [SDIG] & DIG excreted
unchanged in urine in 24h and varied from 10-171ml/min (66+
47) for females, 27-194 ml/min (85+45) for males. The ratio
of renal clearance of DIG/renal clearance of creatinine,
Clr/CCr, varied from 0.3 3-2.46 (1.09+0.56) for females,
0.55-1.79 (1.03+0.34) for males. In another study, mean Clr
2 .was found to range from 83-119ml/min/l.73m m  healthy
2 . volunteers & 53-73ml/mm/l.73m in elderly patients with
heart failure? chronic renal failure was also seen to be
associated with a reduced Clr (92). A second study found
Clr to vary from 4-57ml/min, with a mean Clr/CCr of 1.04,
in a group of elderly people aged between 65-94y (237).
In many subjects renal excretion of unchanged DIG is the 
most important route of elimination. Nomograms & equations 
for [SDIG] prediction usually include information on CCr 
since most of that DIG renally excreted is via glomerular 
filtration of which CCr is an estimate (chapter 2). Using 
data from the present study, a plot of CCr v [SDIG] for 
each DIG dose gave a straight line for the majority of 
subjects, and a high CCr was associated with a low [SDIG]. 
However, a small but significant proportion of subjects 
fell outside this relationship, usually with a greater than 
expected [SDIG] given their CCr. This considerable scatter 
has been noted in other studies (253), causing difficulties 
with prediction of [SDIG] as previously discussed. When 
DIG half-life is plotted against CCr a similar variation 
has been seen (92,93).
These results suggest that clearance of DIG & creatinine 
are related and may possibly be excreted via a common 
pathway. However, the wide range in Clr/CCr seen in this
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study suggests that this relationship does not hold for all 
subjects. Clr was found to correlate with SCr, CCr, %Du, 
[SDIG] & Clt for females; CCr, UDIG & Clt for males? age, 
mobility score, SCr, CCr, %Du, UDIG, SDIG & Clt for the 
entire group.
Previous studies have also shown Clr to be reduced in old 
age (91,237) probably due to the inevitable decline in CCr 
seen with advancing years, since CCr & Clr are closely 
related in most cases. Again it is not possible to say 
whether mobility asserts an additional effect on Clr or 
whether the correlation is the result of the relationship 
between CCr & mobility. The effect of exercise on the 
renal excretion of DIG has not been fully investigated, but 
it seems likely that CCr is more important than mobility, 
which may assert a small additional influence on Clr.
6.5.5 Non-renal Excretion of Digoxin 
When renal clearance is subtracted from total body 
clearance the product represents that DIG which is cleared 
by other "non-renal” routes. This DIG may either be 
excreted unchanged by an alternative route eg. secretion 
into bile, or else metabolized to form a compound that can 
be renally eliminated or excreted by another route. It is 
now thought that nonrenal routes of excretion are 
responsible for the elimination of approximately 20-40% of 
the administered dose although metabolism appears to be 
more extensive in about 10% of those taking DIG (254,255).
In this study Clnr ranged from -30-105ml/min for females & 
-35-130ml/min for males? 8 subjects had a negative value 
for Clnr (Clr>Clt). This suggests that some subjects may 
have absorbed in excess of 67% of the dose. An increase in
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DIG available for systemic circulation would have the 
effect of increasing Clt to create a positive value for 
Clnr. Lack of specificity in the DIG assay could also 
account for this result if other compounds in serum or 
urine cross-reacted with the DIG antibody.
Clnr for most subjects was calculated to be greater than 
zero, suggesting that not all DIG was eliminated unchanged 
in urine. The range for Clnr suggests that the importance 
of the non-renal route(s) may vary between individuals, and 
it has been proposed that DIG metabolism may increase 
during chronic therapy (111). Most subjects studied had 
been taking DIG for a number of years - only one subject 
(M55) had recently been prescribed DIG and 3 weeks had 
elapsed before inclusion into the study. Compromised renal 
function is often associated with an enhancement of non- 
renal routes of elimination. However, in this study Clnr 
was independent of both CCr & Clr, suggesting that renal 
function does not determine Clnr. Similar conclusions have 
been drawn by other groups investigating DIG metabolism in 
those with renal impairment (110), and faecal excretion of 
DIG and metabolites has not been found to alter greatly 
when renal function is diminished (256). It has also been 
shown that the total body clearance of DIG, which includes 
both renal & extrarenal clearances, is in a linear 
relationship with renal clearance of creatinine (104). The 
pattern of correlations suggests that mobility is not a 
factor in the determination of Clnr, and cannot explain the 
variation in Clnr observed in this or other studies.
6.5.6 Urinary Excretion of Digoxin
Since subjects in this study were taking a variety of 
doses, DIG excreted in urine in 24h was expressed as a
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percentage of dose administered. %Du ranged from 19-83% 
for females, 25-85% for males, and there was no significant 
difference between sexes. Other studies have found %Du to 
vary from 12-69% (42±4) in a group of 20 elderly people 
(237), and to average 36+28% in 53 hospitalized elderly 
people with a mean age of 72y (236). The latter study noted 
that neither a variation in weight nor co-administration of 
diuretics affected %Du, but a decrease in CCr was 
associated with a reduction in %Du. Another study found 
mean %Du to be 59+6% (range 38-82%) in a group of elderly 
people with heart failure taking good bioavailability 
tablets (257).
In the present study %Du correlated with Clr & Clnr for 
females; Clnr for males? UDIG, Clr & Clnr for the entire 
group. Neither age, mobility score or CCr appeared to 
influence %Du, but Clr appears to be an important 
determinant. Those with a low %Du could either have 
absorbed less DIG or metabolized a relatively greater 
proportion of the dose. It has been estimated that around 
10% of those taking DIG are subject to reduced absorption 
due to the action of various enteric organisms (85). An 
additional 10% exhibit a more extensive metabolic pathway 
when between 20-55% of the dose is excreted as a DIG 
metabolite (98). The degree of metabolism is probably not 
related to renal function, which is in agreement with the 
findings from this study where no correlation was seen 
between %Du or Clnr & CCr.
Whenever a 24h urine collection is required, there are 
inherent problems in obtaining an accurate collection, 
except when patients are catheterised. Males generally 
have less problem collecting urine, but no difference was
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seen between sexes for %Du, suggesting that collections 
were comparable in accuracy between males & females. 
Inaccuracy of urine collection cannot explain the results 
from those individuals having a greater than average 
recovery.
6.6 DIGOXIN EXCRETION IN FIT & FRAIL ELDERLY PEOPLE
6.6.1 Sex Difference
Subjects were divided into fit & frail groups which were 
further separated into males & females. Males were less 
elderly than females but this was not statistically 
significant. Trends between fit & frail groups were 
similar when sexes were separated, and %Du, [SDIG], Clt, 
Clr, Clnr were not significantly different for males & 
females. Fit & frail groups are therefore of mixed sex 
except were specific differences were seen (UCr, CCr, 
weight, SA). These will be discussed under each heading 
where applicable.
6.6.2 Comparison of Age & Mobility Score
Data were collected from 24 (12F) fit & 25 (14F) frail 
subjects taking DIG long-term. Mobility score was evenly 
distributed throughout the age range, so that while no 
significant difference was seen between ages of fit & frail 
groups, mobility score was significantly greater in the 
frail group. There was no overlap between groups with 
respect to mobility score - fit subjects scored 1 (n=17) or 
2 (7), frail subjects scored 3 (13), 4 (8) or 5 (4). To 
achieve an even distribution of scores throughout the age 
range it was necessary to extend recruitment of subjects 
beyond the one General Practice and hospital used in 
previous studies. Patients were therefore recruited from
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an additional 5 General Practices & 4 Community Hospitals. 
Although the time taken for recruitment was increased, it 
enabled fit & frail groups to be comparable for age so that 
the effects of other factors such as frailty & CCr could be 
more clearly elucidated.
6.6.3 Comparison of Digoxin Dose & [SDIG]
Subjects were prescribed 0.0625, 0.125 or 0.25mg DIG daily, 
with no significant difference seen between fit & frail 
groups in terms of daily dosage or dose per kg bodyweight. 
[SDIG] tended to be greater in the frail group, who 
exhibited a wider variation for a given dose, but these 
observations failed to reach significance. As discussed in
6.5.2 the determination of [SDIG] is complex, and frail 
could differ from fit subjects at any stage of DIG 
disposition.
Reduced absorption of DIG in fit subjects could explain the 
lower [SDIG], particularly if they consumed a diet higher 
in bran fibre or fat both of which have been shown to 
impair absorption of DIG. However, %Du was similar between 
groups suggesting that both absorption & metabolism are 
comparable.
Vd of DIG has been shown to be reduced in the elderly (106) 
but similar within a group of elderly subjects (237), 
although the effect of frailty is not known. No significant 
difference in weight or SA was seen between fit & frail 
groups when separated according to sex while the trend seen 
for [SDIG] remained. Body composition can influence DIG 
distribution, and fit subjects would be more likely to have 
a greater proportion of muscle as indicated by an increased 
UCr, which could reduce [SDIG]. Frailty is likely to be 
associated with a greater degree of muscle wasting.
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Polypharmacy is most likely to occur in frail subjects who 
generally have multiple pathology requiring numerous drugs. 
19 frail & 2 fit subjects were in care during the study.
It is possible that those at home took DIG less regularly 
than those in care who are more likely to have their 
medications supervised. This could account for the reduced 
[SDIG] seen in fit subjects, and while the blood samples 
taken 5 days apart appeared to indicate that all 
participants were in steady state, this cannot be proved 
unequivocally. Polypharmacy among the least fit could give 
rise to more drug interactions which could increase [SDIG] 
in the frail elderly.
The most significant differences between the fit & frail 
groups were those of mobility score & CCr. In 6.5.3 the 
relationship between CCr & mobility was discussed and it 
was difficult to say whether mobility independently 
contributed to the [SDIG] & clearance. Hales had a 
significantly greater CCr than females although the 
difference was reduced for CCr/SA. For both sexes CCr & 
CCr/SA were significantly greater in the fit than frail 
groups. CCr appears to be the most important factor in the 
determination of [SDIG] and it seems likely that this would 
explain at least some of the difference observed in [SDIG] 
between fit & frail groups.
6.6.4 Comparison of Excretion of Digoxin In Urine 
Urine volume & UCr excreted in 24h was significantly 
greater in males than females, and so fit & frail groups 
compared were of separate sexes. Urine volume & UCr were 
significantly greater in the fit group of females. A 
similar trend was seen for UCr in males, but urine volume 
was comparable between groups. While it is possible that
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urine collections were incomplete for frail groups, UCr 
would be expected to be greatest in those who are most 
active, since the quantity of creatinine excreted is 
related to muscle mass.
Range & mean %Du were similar between fit & frail groups, 
for both sexes, suggesting that frailty, immobility or 
reduced CCr did not significantly influence the quantity of 
unchanged DIG excreted in urine. It would seem that the 
extent of both DIG absorption & metabolism did not differ 
significantly between fit & frail groups, otherwise % 
recovery of unchanged DIG in urine would be expected to be 
different between groups.
6.6.5 Comparison of Digoxin Clearance
Total body clearance could not be.calculated since DIG was 
administered orally and the exact fraction of dose absorbed 
was not known, and so apparent body clearance was instead 
determined. Renal clearance was calculated from [SDIG] at 
steady state & DIG in urine, and therefore did not require 
such assumptions to be made. Clnr was taken to be the 
difference between Clt & Clr.
The fit had a significantly greater Clt than the frail
group when the entire group and females were considered,
and this observation tended towards significance for males.
The significance of this relationship was reduced when Clt
2was expressed per kg bodyweight or 1.73m SA, but the trend 
could still clearly be seen.
Fit tended to have a greater Clr than frail for the entire 
group, males & females, but in all cases this trend failed 
to reach significance. Median & mean Clr, Clr/kg & Clr/SA 
were consistently lower in the frail groups, likewise Q1 & 
Q3. Clnr, Clnr/kg & the ratio Clr/CCr were similar for
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each group. The observed difference in Clt between fit & 
frail groups could be due to either an unequal extent of 
absorption, difference in CCr, or influence of frailty. 
Since clearance is independent of Vd, changes in body 
composition cannot explain the differences seen. In 6.6.4 
%Du was discussed in relation to fit & frail groups. While 
urine volumes differed between groups %Du did not, 
suggesting that absorption & metabolism were similar 
between groups, even though extent may vary between 
individuals. Both Clt & Clr correlated with CCr, as in 
other studies, since in most individuals the majority of 
DIG is eliminated by glomerular filtration and to a lesser 
degree tubular secretion.
CCr was significantly different between fit & frail groups 
and this is likely to explain some of the observed 
differences in Clt & Clr. Although those with the lowest 
CCr tended to have the lowest Clt & Clr values, this was 
not unequivocally so, and this degree of variability also 
seen in other studies confounds any predictive method for 
[SDIG] based on CCr. The ratio Clr/CCr was similar between 
groups, and close to unity, suggesting that creatinine &
DIG are cleared by a common pathway. Clnr was comparable 
between groups suggesting that the degree of non-renal 
elimination is unchanged in the frail state. Other studies 
have found that Clnr is similar for a range of renal 
functions and results from the present study are in 
agreement with these findings (104,256).
From these results it would appear that the association 
between frailty & CCr is the most likely cause of the trend 
towards a reduced Clt & Clr seen in the frail groups.
Since mobility score & CCr were correlated, it is difficult
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to say whether frailty & immobility has an additional 
influence on Clt & Clr above that from CCr.
In an attempt to separate out the influence of frailty from 
CCr, sub-groups of fit & frail males were formed. Subjects
were selected whose CCr/SA was within the range 45-105
2ml/min/1.73m and using this method subgroups of 11 fit & 8 
frail males were formed. Results are given in appendix E16. 
The distribution of CCr & mobility score amongst females 
did not facilitate the formation of fit & frail subgroups 
for females, and sexes were not combined since males had a 
greater CCr than females.
No significant difference was seen between fit & frail 
males with respect to age, dose, CCr & CCr/SA. With the 
equalization of CCr between fit & frail groups no 
significant difference was seen between groups for [SDIG], 
Clt, Clr or Clnr. These results would suggest that frailty 
& immobility exert little, if any, additional influence on 
the determination of DIG clearance. CCr appears to be the 
most important of those factors measured, and appears to be 
reduced in frailty. The unexplained variance observed in 
the prediction of [SDIG] is unlikely to be accounted for by 
the fitness of the subject.
6.7 CONCLUSIONS
The elderly are frequently prescribed digoxin because of an 
increased prevalence of the two primary indications for 
digoxin therapy, namely atrial fibrillation and congestive 
cardiac failure, associated with old age (242,258).
However, widespread use of the drug has resulted in rates 
of toxicity which can approach 20% of hospitalized 
geriatric patients taking digoxin (259). There is also a
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significant incidence of underdigitalisation (91,225), and 
this is becoming more common as digoxin doses fall (230) 
following fears of increased mortality and morbidity 
associated with its use.
DIG has a narrow therapeutic ratio and many studies have 
been carried out in an attempt to accurately predict serum 
[DIG], Many factors have been found to influence [SDIG] 
but the scatter between measured and predicted [SDIG] 
remains wide, and the unexplained variance has rendered the 
use of nomograms and equations clinically unacceptable. 
While dose & renal function appear to be the most important 
determinants of [SDIG], other factors which also contribute 
include extent of absorption, distribution, metabolism & 
excretion, also disease state, compliance and drug 
interactions as discussed in 6.5.
The aim of the present study was to determine whether 
immobility & frailty exert an additional influence on the 
determination of [SDIG] and efficiency of elimination.
When patterns of correlations were examined many of the 
parameters studied were interrelated, and it was hard to 
make a definitive statement on the importance of mobility. 
Results appeared to indicate that if mobility does 
influence the efficiency of DIG elimination, then that 
influence is only slight and of minor significance compared 
to that of renal function. This suggests that incorporation 
of a "mobility factor" into an equation used to predict 
[SDIG] would not significantly enhance prediction accuracy 
and account for a degree of unexplained variance.
When subjects were divided into fit & frail groups a 
similar conclusion was drawn. The fit group had a greater 
total body clearance & renal clearance than the frail group
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but this was confounded by the increased CCr seen in fit 
subjects. Males were divided further into fit & frail 
groups, each with a similar CCr range, and clearances re­
examined. It was found that the trend towards an increased 
clearance in fit subjects was lost, with Clt & Clr becoming 
comparable for both groups. This suggested that the 
differences observed between fit & frail groups could 
partially be explained by the difference in CCr.
Thus while frailty, as defined for the purposes of this 
study, cannot be proposed as an explanation for the 
variability in [SDIG], the difference in renal function 
between fit & frail subjects should be considered. Many of 
the equations devised to predict [SDIG] also predict CCr 
from SCr and do not take into account frailty. This may
explain some of the inaccuracies seen when nomograms or
equations are employed. Nevertheless, when CCr is measured 
and plotted against [SDIG] or Clt a straight line is not 
seen, suggesting that the difference in CCr is not solely 
responsible for the scatter. Further work is required to
determine which other factors besides those already
mentioned are important in the determination of [SDIG].
From this study it was observed that a significant 
proportion of subjects on DIG were underdigitalised, with 
63% having [SDIG] less than 0.8ng/ml. It has previously 
been proposed that the decline in DIG dosage in recent 
years has been the result of numerous articles published 
which have found a significant degree of DIG toxicity in 
those taking DIG (225,230). The popular "geriatric dose" of 
0.0625mg daily is inappropriate in all but the most severe 
cases of renal insufficiency or muscle wasting, and 
subtherapeutic [SDIG] levels can give cause for concern in
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those with uncontrolled AF. However, toxicity is unlikely 
with this dose and would only be seen in patients 
exhibiting an enhanced sensitivity to DIG. A maintenance 
dose of 0.125mg daily would appear to be the most 
appropriate dose for elderly subjects, alternatively a 
O.lmg tablet may increase the proportion of subjects with 
[SDIG] within the therapeutic range.
Further to this is the question of when the prescription 
for DIG is appropriate which remains a controversial issue. 
While it is agreed that DIG therapy is necessary in 
supraventricular tachyarrhythmias, its role in CCF remains 
uncertain. Results from the present study suggest that 
prescribing trends are changing so that fewer patients are 
prescribed DIG in the absence of AF. Nevertheless, a 
proportion of patients remain who have been prescribed DIG, 
often in small doses, for a number of years on the basis of 
an uncertain diagnoses. Review of patients in General 
Practice on long term DIG would seem to be appropriate, 
since all are at risk of toxicity, particularly if 
concomitant diuretic therapy results in hypokalaemia.
Despite the vast literature concerning patterns of DIG 
elimination, more work needs to be carried out to determine 
causes of extensive interindividual variability observed 
for both [SDIG] & clearances. Those patients on long term 
DIG should be regularly reviewed since therapy is not 
without hazard, and a change in clinical condition can 
force [SDIG] beyond the therapeutic range. If the 
prescription remains appropriate, then steps should be 
taken to ensure that the patient receives maximal therapy 
to adequately control the condition but minimize the 
possibility of toxic side effects.
CHAPTER SEVEN
CONCLUSIONS FROM STUDIES IN FIT & FRAIL ELDERLY PEOPLE
Demographic trends indicate that the proportion of elderly 
people in the community is likely to expand in developed 
countries in the foreseeable future. Prevalence & incidence 
of ill health and disability increases in old age and it is 
not therefore surprising that those over retirement age are 
the main consumers of prescribed medication. In this age 
group adverse drug reactions are known to be two to three 
times more common due to the increased drug consumption and 
altered drug response. Knowledge of these facts has 
stimulated research into age-related changes in drug 
handling in an attempt to reduce the incidence of adverse 
drug reactions and make drug usage in the elderly safer.
Far from forming a single homogeneous group, the elderly 
can readily be seen to differ widely in their physical 
abilities even in the absence of discernable disease. Some 
elderly people remain independent, exhibiting little loss 
of function, until well into their ninth decade, while 
others appear to require full care soon after retirement. 
Many studies have been carried out to identify and quantify 
physiological changes associated with increasing 
chronological age, and these have subsequently been 
extended to investigate age-related changes in drug 
disposition. However, most such studies have been carried 
out using healthy elderly volunteers who themselves are 
frequently ill defined, and it is not yet widely known 
whether ill health & immobility contribute an additional 
decrement to the decline in many physiological functions 
associated with ageing.
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As discussed in 1.2, the first precise definition of the 
"healthy elderly" was made in 1976 in the "Senieur 
Protocol", the result of a concerted working party to 
establish admission criteria for immunogerontological 
studies (29). However, this definition was not subsequently 
employed in drug studies, probably because it is too 
exacting for widespread use, with multiple clinical, 
biochemical & haematological investigations required before 
recruitment into a study. The number of potential 
volunteers disqualified from participation in a study by 
the strict exclusion criteria set down in the Senieur 
Protocol would appear to be too great for practicable usage 
in the majority of studies.
An alternative operational definition was proposed by a 
second group in 1988 in an attempt to dissociate biological 
& chronological age, and the terms "fit" & "frail" were 
coined for the purpose (28)? the exact definitions are 
given in 1.2. Whilst the definitions used by this group 
are much less strict than those in the Senieur Protocol, 
they nevertheless require both clinical examination & 
laboratory investigations. Frail subjects were dissociated 
from their fit counterparts by their loss of independence, 
impaired ability to carry out activities of daily living, 
reduced mobility and probable requirement for prescribed 
medication. Whilst frail subjects could suffer from 
certain musculoskeletal and cardiovascular conditions, both 
fit & frail subjects were required to be free from 
significant hepatic, renal, cardiac, respiratory or 
metabolic disorders to fulfil the admission criteria.
Using these later definitions studies have found the frail
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elderly to have reduced mental function, reduced total body 
potassium & albumin, and alterations in other electrolytes 
when compared to their fit counterparts. While the fit 
elderly exhibit the normal biological reduction in hepatic 
volume & blood flow, the frail elderly appear to possess an 
additional decrement in hepatic drug clearance, possibly 
due to a reduction in the specific activity of some hepatic 
enzymes. However, it is not yet known whether the normal 
reduction in renal function observed in the fit elderly is 
exaggerated in frail patients to further reduce renal drug 
clearance beyond that expected.
The main shortfall in the use of these later definitions is 
that the majority of elderly subjects in both the community 
and in care are not included, since most have some 
significant pathology requiring regular medication. Thus, 
those elderly people with well controlled chronic 
conditions which do not adversely influence quality of life 
are excluded from possible investigation despite their 
appearance of "fitness”. Important changes in drug 
disposition could potentially be missed in those groups of 
elderly people most commonly prescribed medication either 
in General Practice or hospital.
The primary aim of this thesis was to devise working 
definitions which could readily differentiate between the 
two groups of elderly people most commonly encountered in 
clinical practice, that is, those who are well & active 
despite the presence of a chronic condition, and those who 
are infirm & relatively immobile in the presence of similar 
diagnoses. The groups thus defined were termed "fit” & 
"frail" since these titles most appropriately describe the
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two populations, and precise definitions are given in 
appendix Al.
Together the fit & frail groups appear to form the majority 
of those elderly people for whom medication is prescribed. 
The definitions were constructed in such a way as to be 
easily applied to an individual without reliance on 
laboratory investigations, and thus they are composed of 
social & functional criteria. In the course of the 
following studies few individuals were not readily 
categorized.
The main criticism of these operational definitions is that 
without the use of laboratory investigations undiagnosed 
pathology may lead to a frail subject being categorized as 
fit, although the converse is unlikely to occur. While 
this problem was recognised, the reduction in accuracy was 
felt to be more than offset by the ease of application of 
the definitions.
Once the main populations of elderly people were defined, 
studies were carried out to determine whether fit & frail 
groups of elderly people differed in terms of renal 
function, and renal & hepatic drug clearance using model 
drugs frusemide, digoxin & paracetamol.
It is often desirable to know a patients renal function 
when drugs are prescribed whose elimination is accomplished 
via renal clearance, in order to prevent their 
accumulation. Since renal function is known to decline in 
old age, the margin for safety is reduced for renally 
excreted drugs with a narrow therapeutic window.
Creatinine clearance, taken as an estimate of glomerular 
filtration rate, was measured in a wide range of elderly
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people in order to determine whether drug dosage levels 
should take into account the "fitness” of an individual. 
Since the classical measurement of CCr is a difficult & 
lengthy procedure, equations to predict CCr have previously 
been constructed using SCr alone. Therefore, in addition to 
the usual 24h CCr measurement, CCr was predicted using 12 
different equations, and also urine collections of less 
than 24 hours. Measured & predicted CCr were compared 
between groups of fit & frail elderly people to determine 
whether frailty compromised the accuracy of CCr prediction.
In addition to the fit & frail subjects invited to 
participate in this study from General Practice & long-stay 
hospital wards, elderly people were recruited from the 
R.I.C.E. volunteer panel. All were free from discernable 
disease on clinical examination & laboratory 
investigations, fully mobile, and living independently in 
the community, and none were taking regular medication. 
These subjects were termed "very fit" and this group was 
taken to be comparable to the healthy elderly groups 
defined by previous investigators.
When the CCr of the very fit group was compared with the 
CCr of those defined as "fit" for the purposes of the 
ensuing drug studies, no significant difference was found 
between them. This suggests that the fit group as defined 
in this thesis is similar to those fit groups defined in 
other studies, at least in terms of renal function and 
probably renal drug clearance. The advantage of the present 
fit definition is that subjects included in the admission 
criteria are more frequently found in the clinical setting 
and thus more truly representative of those elderly people 
active in the community.
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A statistical difference was seen between the sexes in 
terms of UCr, SCr & CCr and so results from males & females 
were analysed separately although similar patterns were 
seen for both groups. For both sexes CCr was found to 
decline with increasing age. CCr was compared between the 
very fit, fit & frail elderly males & females, and found to 
be comparable between the very fit & fit groups. However, 
frailty appeared to contribute an additional decrement to 
an individuals CCr since frail groups had a consistently 
reduced CCr when compared to their fit counterparts of 
similar age & weight.
Using urine collections of about 8 hours, predicted CCr 
closely approximated to measured 24h CCr for most elderly 
people studied. Accuracy of prediction did not appear to 
be influenced by diuretic use, magnitude of measured CCr, 
nor frailty. However, CCr prediction using any of the 12 
equations was less reliable, particularly when equations 
were employed which relied only upon the SCr level. While 
diuretic use did not affect the outcome, CCr was 
consistently overpredicted using the equations in those 
with the lowest measured CCr, ie. the frail elderly, who 
are probably at greatest risk from adverse drug reactions.
From this study it would seem that CCr can be most 
accurately predicted in elderly subjects using a urine 
collection of less than 24 hours. Urine collections carried 
out overnight are probably the most accurate & convenient, 
although time of day has little influence on prediction 
accuracy. Furthermore, diuretic use, magnitude of measured 
CCr and frailty do not appear to compromise the accuracy of 
prediction. In the elderly, CCr seems to be less well
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predicted using any of the classical equations, although 
equations into which age & bodyweight are incorporated 
yield the most favourable results. Using this method of 
prediction CCr is likely to be overestimated in those frail 
individuals who have a low measured CCr. Differences in 
body composition between fit & frail subjects are probably 
important in the explanation of the reduction in prediction 
accuracy associated with frailty. These finding have 
important consequences when CCr is predicted in the course 
of drug dosage calculations, since those who are frail 
would seem to be more likely to receive an inappropriate 
dose. This has not previously been recognised.
From the CCr study it appears that frail subjects are 
likely to have a reduced CCr when compared to their fit 
counterparts of a similar age & sex, and it would therefore 
seem reasonable to suppose that renal drug clearance is 
also reduced in frailty. In order to test this hypothesis 
the renal excretion of frusemide, a commonly used diuretic, 
was followed in fit & frail elderly people, and the 
efficiency of elimination compared between the two groups. 
Although the frusemide study was flawed with respect to 
sampling times, the results were taken to be orientating 
and qualitative.
All subjects in this study were prescribed frusemide as 
Frumil or frusemide BP tablets, to treat a variety of 
cardiovascular conditions. Therefore, no subject was fit 
according to the definitions of other groups, although many 
were fully mobile and able to live independently in the 
community. It was these subjects who were categorized as 
fit for the purposes of the present study.
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Subjects taking Frumil appeared to eliminate FRU more 
efficiently than those taking frusemide and so two separate 
groups were formed according to the preparation taken. 
Despite the likelihood that two populations were present, 
patterns observed between fit & frail groups were similar. 
Frail subjects tended to have an increased elimination tl/2 
and reduced serum & renal clearance when compared to their 
fit counterparts, although it was not clear whether this 
trend was due to the reduced CCr also observed in the frail 
group or due to frailty per se. In an attempt to separate 
out the influences of age, CCr and frailty, fit & frail 
subjects taking Frumil were age-matched and the groups 
again compared. When no significant difference was seen 
for age or CCr between the two groups, frail subjects still 
appeared to eliminate FRU less efficiently although this 
observation was only of borderline significance. However, 
it appeared that some subjects with a low CCr excreted FRU 
rapidly, suggesting that in some cases nonrenal routes of 
elimination were important.
These results suggest that while frailty may be responsible 
for a small reduction in FRU elimination rate this is 
probably of only limited clinical significance. More 
important is the additional decrement in CCr which seems to 
be contributed by the frail state, which could be due to 
differences in activity, posture and renal blood flow 
between the two groups.
Unfortunately hepatic function cannot be measured as easily 
as renal function since the standard liver function tests 
are more a measure of hepatic damage. Therefore, since 
parallel studies could not be run for hepatic as renal
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function, it was instead necessary to monitor the 
elimination of a model drug whose clearance is accomplished 
solely by hepatic metabolism. Paracetamol, a widely used 
and well tolerated analgesic, was selected as the model 
drug since it is known to be extensively metabolised, with 
only 5% of the therapeutic dose excreted unchanged in 
urine.
Paracetamol & clearance were measured and compared
between groups of fit & frail subjects, and it was found 
that both kinetic parameters were consistently altered in 
frailty in such a way as to suggest impaired PAR 
metabolism. This observation remained when subjects were 
age-matched. Possible explanations for these results could 
include a reduction in liver perfusion or hepatic enzyme 
activity occurring in frailty, which could be the result of 
differences in diet, activity or posture. Although the 
exact mechanisms by which the reduction in hepatic 
metabolism occurred in frail subjects could not be 
elucidated from this study, it seems likely that reduced 
clearance of the model drug reflects a real difference in 
hepatic function between the fit & frail elderly.
Digoxin elimination has been widely investigated in elderly 
people since its use is associated with increased morbidity 
& mortality in this age group. While many studies have 
attempted to quantify the importance of a number of factors 
known to influence serum DIG concentration at steady state, 
a high degree of unexplained variance has rendered any 
resulting equations unworkable in clinical practice.
Digoxin clearance was therefore compared in fit & frail 
subjects in order to determine whether frailty could 
contribute to this unexplained variance.
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Fit & frail groups were comparable in age & bodyweight, but 
a significant difference was seen between them for CCr and 
DIG clearance. When the effects of renal function and 
frailty were separated by matching fit & frail subjects for 
CCr, the difference in DIG clearance between the groups was 
lost. This suggested that whilst frailty appeared to 
contribute little, if any, influence to [SDIG] for a given 
dosage, the reduction in CCr associated with frailty could 
explain a degree of the unexplained variance observed in 
other studies.
The detection of physiological differences between fit & 
frail groups defined in this thesis suggests that at least 
two populations of elderly people do in fact exist. While 
the definitions set down for the purposes of the studies 
differed from those used by previous groups, some constancy 
lay between them since the very fit subjects used in the 
CCr study had similar renal function to the fit subjects 
used in ensuing studies.
The question of why the frail elderly should handle some 
drugs less efficiently than their fit counterparts is not 
easy to answer, and little work to date has addressed this 
problem.
It is likely that differences in activity & posture between 
the two groups, with subsequent changes in blood flow 
patterns, may in part be responsible for some of the 
changes seen. However, few frail subjects appear to revert 
to the fit state even after hospital admission for 
mobilization & rehabilitation and so it was not possible to 
determine prospectively whether an increase in fitness & 
activity is associated with improved drug handling in 
particular patients used as their own controls. This would
222
be suitable material for further study although numbers 
would be limited by the low incidence of recovery observed 
during the course of these studies.
Differences in muscle mass & overall body composition are 
probably also important in the explanation of the changes 
associated with frailty.
Another important factor may be a difference in the extent 
of drug absorption which could occur between the groups, 
and again this has been poorly investigated to date. 
However, in both the frusemide & digoxin studies percent 
dose recovered in urine was similar between fit & frail 
groups which suggests that extent of absorption differs 
relatively little between them.
The importance of these findings may be seen in the light 
of drug dosage calculations which are at times necessary 
when potentially toxic drugs are prescribed whose 
therapeutic window is narrow. While numerous nomograms & 
equations exist to facilitate the selection of a correct 
therapeutic dosage which is unlikely to produce toxic side 
effects, none appear to take into account the physical 
condition of the patient beyond their renal or hepatic 
function, which is in itself often unknown. Results from 
this study suggest that CCr may be lower than expected for 
a given age & weight in frail elderly subjects, and this 
can lead to obvious discrepancies in drug dosage 
calculations. In addition, hepatic drug clearance, at least 
in drugs whose metabolism is via conjugation with sulphate 
or glucuronide moieties, may also be impaired in the frail 
elderly when compared to their fit counterparts.
The well documented excess of adverse drug reactions
223
observed in people over retirement age is undoubtedly due 
in part to the increased consumption of prescribed 
medication observed in this age group. However, it is 
possible that the incidence of such reactions could be 
reduced if the physical abilities of patients were taken 
into account when drugs were prescribed in addition to the 
normal reduction in renal and hepatic drug clearance known 
to occur in old age. If drug dosage levels were further 
reduced in those with the appearance of frailty it is 
possible that dose-related drug reactions could be reduced 
in this group of elderly people who are at greatest risk of 
their occurrence.
One another's light
It's hard to guess what brought me here,
Away from where I've hardly ever been and now 
Am never likely to go again.
Faces are lost, and places passed 
At which I could have stopped 
And stopping, been glad enough.
Some faces left a mark?
And I on them might have wrought 
Some kind of charm or spell 
To make their futures work,
But it's hard to guess 
How one thing on another 
Works an influence.
We pass-
And lit briefly by one another's light 
Think the way we go is right.
By Brian Patten
from "Vanishing Tricks"
Reproduced by kind permission of Unwin Hyman Ltd.
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FRAIL Unable to perform activities of daily living. Help 
required to live alone, or else live in Part III, 
residential or nursing home, or hospital. Unable to 
walk far unaided, and rarely able to go outside. 
Usually on regular medication, often for a number of 
conditions, which adversely affect quality of life.
FIT Able to perform activities of daily living unaided
& safely live independently without support. May be 
on regular medication, but the condition for which 
it is prescribed is well controlled, and does not 
affect quality of life.
VERY Able to perform all activities of daily living
FIT unaided & safely live independently without support.
No abnormal pathology detectable on clinical 
examination & laboratory investigation. Occasional 
over-the-counter preparations may be taken, but no 
regular prescribed medication.












Free walking both inside & outside the 
home for a good distance without effort, 
possible limitations only on longer 
distances.
Free walking within the home or ward but 
limited mobility outdoors. At times 
housebound. Able to manage stairs.
Sits for most of the day. Only able to walk 
short distances to the toilet & rooms on 
the same level. Unable to manage stairs.
Able to sit upright in chair or wheelchair. 
Requires help to transfer, unable to walk 
more than a few steps.
Restricted to bed for the majority of time 
& unable to weight bear. May leave bed for 
short periods eg. toileting, but unable to 
sit upright. Requires help with feeding & 
needs to be turned in bed.
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Appendix B1
Conl A Cminl Digoxin • J
Coat-A-Count® 
DIGOXIN
is a solid-phase ,25I radioiinm unoassay designed for the quantitative m easurem ent of digoxin in serum . It is intended 
strictly for in vitro diagnostic use as an aid in m onitoring the therapeutic  adm in istration  of this cardioglycoside. 
Catalog N um bers: TK D I1 (100 tubes) T K D I2  (200 tubes) T K D I5  (500 tubes) T K D IX  (1000 tubes).
The 100-tube kit contains not more than 3 m icrocuries (111 kilobecquerels) of radioactive IZ5!-digoxin; the 200-tubc 
^  kit contains not m ore than  6 m icrocuries (222 kilobecquerels); the 500-tube kit contains not m ore th an  15
 m icrocuries (555 kilobecquerels), and the 1000-tube kit contains not m ore than  30 m icrocuries (1110
kilobecquerels).
In t r o d u c t io n
The Coat-A-Count procedure  is a solid-phase radioim m unoassay, w herein  I25I-labeled digoxin com petes for a fixed 
tim e w ith digoxin in the patient sam ple for antibody sites. The antibody being im m obilized to the wall of a polypropylene 
tube, decanting  the supernatant suffices to term inate the com petition and to isolate the antibody-bound fraction of 
the radiolabeled digoxin. C ounting the tube in a gamm a counter then yields a num ber, w hich converts by way of 
a calibration curve to a m easure of the digoxin present in the patient sample.
P ro c e d u re  There is only one reagent to dispense, and a single one-hour incubation. All com ponents are
supplied ready to use. No centrifuge is requ ired . Sam ple and  tracer additions can be handled 
sim ultaneously, if desired, w ith the help of an autom atic pipetter-diluter. The sim plicity of the 
Coat-A-Count p rocedure recom m ends it for high-volume testing.
S e p a ra t io n  The coated-tube methodology offers significant advantages in reliability, as well as speed and
convenience, since the tube :■ can be vigorously decanted, w ithout loss of antibody-bound material. 
This results in a clean separation of bound from free, w ith  negligible nonspecific binding.
D a ta  R e d u c tio n  Conventional RIA techniques of calculation and quality  control a re  applicable. The assay has 
been optim ized for linearity  in a logit-log representation th roughout the range of its calibrators. 
Moreover, the computation can  be sim plified by om itting the correction for nonspecific binding, 
w ithout com prom ising results or quality  control.
C a lib ra t io n  The kit is equipped w ith hum an serum -based standards having digoxin values ranging from
0.5 to 8 ng/ml (0.6 -10.2 nmol/l). T he calibrators are  supplied in liquid form, ready to use.
C o u n ts  The tracer has a high specific activity, w ith total counts in th e  order of 50,000 cpm  at iodination.
M axim um  binding is approximately 50%, m inim izing the  counting  tim e requ ired  for adequate 
precision .
A ccu racy  Extensive recovery experim ents have show n that the assay is accurate over a broad spectrum
of digoxin values. Its accuracy has been fu rth er verified in patient com parison studies against 
a well-established, double-antibody digoxin radioim m unoassay.
S p ec ific ity  The an tiserum  is highly specific for digoxin, w ith  very low crossreactiv ity  to other com pounds
that might be present in patient sam ples. Neither protein, lipem ia, bilirubin nor hemolysis has 
any effect on the assay.
S e n s i t iv i ty  The procedure  can detect as little as 0.1 ng/ml. CVs are low and uniform , and no end of run
effect has been observed in assays involving as m any as 300 tubes.
J
2  • Coat-A-Count Digoxin
M a t e r ia ls  S u p p lie d — I n i t i a l  P r e p a r a t io n
■  Precautions: Before opening the kit, review the paragraphs on safety, printed on the inside front cover as they relate to the safe handling and 





Vials of Tracer 
Supplied














1 DIGOXIN ANTIBODY-COATED TUBES TDI1
100 (200,* 500,t  1 0 0 0 polypropylene tubes coated w ith antibodies to digoxin and  packaged in zip-lock bags. 
Store refrigerated and protected from  m oisture, carefully resealing the bags after opening: stable at 2 -8 ° C  for 
at least one year from  the date of m anufacture. Color: orange.
2  I125I| DIGOXIN TDI2
O ne vial (two vials,* five v ia ls.t ten v ia lst) of iodinated digoxin supplied in liquid form, ready to use. Each vial 
conta ins 105 m l. Store refrigerated: stable at 2 -8 °C  for at least 30 days after opening, or until the expiration 
date m arked on the vial.
3  DIGOXIN CALIBRATORS DIC3-8
O ne set (two se ts .t th ree  se tsf) of six vials, labeled A through F, of digoxin calibrators supplied in liquid form, 
ready to use. The zero calibrator A contains 5 ml, and each of the rem aining calibrators B through F contains 
2 m l. Store refrigerated: stable at 2 -8 °C  for at least 30 days after reconstitution.
T he calibrators contain respectively 0, 0.5, 1, 2, 4 and 8 nanogram s of digoxin per m illiliter (ng/ml) in processed 
hu m an  serum ; equivalently: 0, 0.6, 13, 2.6, 5.1 and 10.2 nanomoles per liter (nmol/1). Interm ediate calibration 
poin ts can  be obtained by m ixing the calibrators in suitable proportions. The life of the calibrators may be extend­
ed  by freezing. Aliquot if necessary  to avoid repeated freezing and thawing.
‘ Pertains to the 200-tube TKDI2 kit. 
tP e rta in s  to the  500-tube TKDI5 kit. 
tP e rta in s to the  1000-tube TKDIX kit
M a t e r ia ls  R e q u ire d  B u t  N o t  P ro v id e d
• G am m a c o u n te r-co m p a tib le  w ith  standard  12 x 75m m  tubes
•  Vortex m ixer
Radioimmunoassay:
•  Plain 12x 7 5 m m  polypropylene tu b e s - fo r  use as NSB tubes, available from  DPC
• M icropipets: 100 fi\ and  1000 fi\
For the 1.0 ml reagent addition, a reliable repeating dispenser |Nichiryo or equivalent) is also suitable With the 
help of an automatic pipetter-diluter, sample and reagent additions may be handled simultaneously.
•  Incubation  ba th  capable of m aintaining 3 7 °C -n e ith e r  an oven nor a heat block is suitable.
•  Foam  decan ting  rack -av ailab le  from  DPC
A tri-level, hum an  serum -based im m unoassay  control, containing digoxin as one of over 25 assayed constituents, is 
available from  DPC (catalog num ber: CON6).
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Coat-A-Count Digoxin • ^
S p e c im e n  C o lle c t io n
T he patient need not be fasting, and  no special preparations are necessary. C ollect blood by ven ipuncture  into plain 
tubes, an d  separate the  se ru m  from  the cells. The tim e of collection should be noted. T he procedure  calls for 100/d 
of se ru m  per tube.
The sam ples m ay be stored under refrigeration for seven days, or for up to tw o  m onths frozen at -2 0 °C . Before assay, 
allow  the sam ples to com e to room  tem perature  and mix by gentle sw irling  or inversion. Aliquot, if necessary, to 
avoid repeated  thaw ing and  freezing. Do not attem pt to thaw  frozen specim ens by heating them  in a w ater bath .
R a d io im m u n o a s s a y  P ro c e d u re
All components must be at normal room temperature before use.
1  P la in  T \ibes: Label four p lain (uncoated) 12x75m m  polypropylene tu b es  T (total counts) and NSB (nonspecific 
binding) in duplicate.
Because nonspecific binding in the Coat-A-Count procedure is characteristically low, the NSB tubes may be safely 
omitted without compromising accuracy or quality control.
C oated  T\ibes: Label twelve Digoxin Antibody-Coated Tubes A (m axim um  binding) and B through F in duplicate. 








2  Pipet 1 0 0 /i l  of the zero calibrator A into the NSB and A tubes, and! 1 0 0  /ll of each remaining calibrator,
control and patient sample into the tubes prepared. P ip et d irec tly  to  th e  b o tto m .
3  Add 1.0 ml of | U5I] Digoxin to every tube. Vortex.
Laboratories equipped with a reliable pipetter-diluter may handle steps 2 and1 3 simultaneously. No more than 
ten minutes should elapse during the dispensing of the tracer. Set the T tubes aside for counting (at step 6); 
they require no further processing.
4  Incubate for 60 m in u te s  a t  37°C.
Use a waterbath; neither an oven nor a heat block is suitable. The incubation may be shortened to as little as 
30 minutes (at 37°C), at the expense of slightly less binding.
3  Decant thoroughly.
Removing all visible moisture will greatly enhance precision. Using a foam decanting rack, decant the contents 
of all tubes (except the T tubes) and allow them to drain for 2 or 3 minutes. Then strike the tubes sharply on 
absorbent paper to shake off all residual droplets.
0  Count for 1 minute in a gamma counter.
• Coat-A-Count Digoxin
A lternate  "STAT" Procedure
W hen circum stances requ ire  fast tu rnaround , the following "stat" p rocedure  may be used . The assay does not reach 
equilibrium  under the conditions described below, and thus the tim ing must be  m eticulously controlled. The "stat" 
p rocedure  should be relied on only for rough answ ers and only for one or tw o patient sam ples (plus controls). Careful 
selection of controls w ith  digoxin concentrations above and below the region of interest will enhance the reliability 
of the  results.
1  C o a le d  T u b es: Label six Digoxin Antibody-Coated Tubes A (m axim um  binding), B and E. Label additional





2  Pipet 1 0 0 /d  of the calibrators, patient sample(s) and controls into the tu b es p repared . P ipe t d irec tly  to  th e  
b o tto m .
3  Add 1.0 ml of Buffered (1251) Digoxin to every tube. Vortex.
4, Incubate for 15 m inu tes  at 50°C
Use a waterbath: neither an oven nor a heat block is suitable.
3 D ecant thoroughly, and count for 1 m inute in a gam m a counter.
C a lc u la t io n  o f  R e s u lts
To calculate digoxin concentrations from a logit-log representation of the calibration curve, first calculate for each p a ir 
of tu b es the  average NSB-corrected counts per m inute:
Net C oun ts = Average CPM  m inus  Average NSB CPM
Then determ ine the binding of each pair of tu b es as a percent of m axim um  binding (MB), w ith the NSB-corrected 
counts of the A tubes taken as 100%:
Percent B ound =  Net C o u n ts  x jqq
N et M B  C ounts
The calculation can be simplified by omitting the correction for nonspecific binding; sam ples w ith in  range of the calibrators 
yield v irtua lly  the sam e results w hen Percent Bound is calculated d irectly  from  Average CPM.
Using the logit-log graph paper provided w ith  the kit, plot Percent Bound on the  vertical axis against C oncentration 
on the horizontal axis for each of the calibrators B through F, and d raw  a straight line approxim ating the pa th  of these  
five points. Digoxin concentrations for the  unknow ns m ay then be estim ated from  the line by interpolation. 
Although o ther approaches are acceptable, data reduction by the logit-log m ethod just described has.certain advantages 
in this co n tex t-fo r example, in allowing easier recognition of deviant calibration points -  since the Coat-A-Count Digoxin 
procedure  has been optim ized for linearity  in that representation.
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21.919 21,835 21.650 100.0% 0
B
17,475
17,455 17.465 17,280 79.8% 0.5
C
15,102
15,038 15,070 14,885 68.8% 1.0
D
10,903
10,861 10,882 10,697 49.4% 2.0
E
7,185
6,895 7,040 6,855 31.7% 4.0
F
4,354




16,076 15,843 15,658 72.3% 0.8
X2
12,286
12,202 12,244 12,059 55.7% 1.5
X3
7,557
7,793 7,675 7,490 34.6% 3.6
Q u a lity  C on tro l P aram eters: T = 48,921 cpm . %NSB = 0.4%. %MB = 44.3% .
20%  In te rcep t = 7.5 ng/m l. 50% In tercep t = 2.0 ng/m l. 80% In tercep t = 0.5 ng/m l.
Q u a l i t y  C o n tr o l
R ecord K eeping: It is good laboratory practice to record for each assay tthe lot num bers and reconstitution dates
of the com ponents used .
S a m p le  H an d lin g: The instructions for handling and storing patient sam files and com ponents should be carefully  
observed. Dilute high patient se ru m  sam ples w ith  the kit's zero calibrator p rio r to assay. All sam ples, including the 
calibrators and  controls, should be assayed in duplicate. It is good laboratory p ractice  to use a disposable-tip m icropipet, 
changing the  tip betw een sam ples, in order to avoid carry-over contam ination. Pairs of control tubes m ay be spaced 
throughout the assay to help verify the absence of significant drift. Inspect the results for agreem ent w ith in  tube  
pairs, and take care to avoid carry-over from  sam ple to sam ple.
Controls: Controls or serum  pools w ith low, intermediate and  high digoxin concentrations should routinely be assayed 
as unknow ns, and the results charted  from day to day as described in J.O. W estgard et al, "A m ulti-rule chart for 
quality control" Clinical Chemistry 2 7  (1981) 493-501. See also Scandinavian Journal o f  Clinical and Laboratory In ­
vestigation 44 (1984) Suppl 171 and 172. Repeat sam ples are a valuable additional tool for monitoring interassay precision.
D ata R ed u ction : It is good practice to construct a graph of the calibration  curve as a visual check on the appropri­
ateness of the  transform ation used , even w here the calculation of results iis handled by computer. See fu rther S.E. 
Davis et al, "R adioim m unoassay data processing w ith a sm all program m able  calculator" Journal o f  Imm unoassay I 
(1980) 15-25; and R.A. Dudley et al, "Guidelines for im m unoassay data reduction" Clinical Chemistry 31 (1985) 1264-71.
Q. C. P aram eters: We recom m end keeping track of these  perform ance m easures:
•  T = Total C ounts (as counts per minute)
• %NSB = 100 x (Average NSB C ounts + Total Counts)
• %MB = 100 x ((Average MB C ounts minus Average NSB Counts) * Toltal Counts)
And the 20, 50 and 80 percent "intercepts,” w here
• 20% = Digoxin Concentration at 20 Percent Bound, etc.
^  • Coat-A-Count Digoxin
P e r fo r m a n c e  C h a ra c te r is t ic s
In the sections below, digoxin results a re expressed as nanogram s of digoxin per milliliter (ng/ml). To convert to nanomoles 
per liter (nmol/1), m ultiply by 1.281:
ng/m l x 1.281 — nmol/1 
Sensitivity
Forty zero calibrator (m axim um  binding) tubes were processed in a single assay, along w ith a set of non-zero calibrators 
and controls. M ean and standard deviation w ere calculated for the counts-per-m inute of the forty zero tubes. Then, 
from a standard curve prepared  by the logit-log technique and using th is m ean as th e  zero point, the apparent digoxin 
concentration w as determ ined at increasing standard deviations from  the m ean.
Mean + SD of Apparent Approximate
40 MB tubes Mean minus % B/B0 Concentration Sensitivity
2SD 97.1% 0.04
18,995 ± 268 3SD 95.7% 0.06 0.1 ng/ml
______________________________ 4SD___________ 94.3%___________ 0 0 8 ________________ ■
The detection limit (or "least detectable dose") of an assay is com m only defined as the apparent concentration two 
standard deviations below the counts at m axim um  binding or else as the concentration at 95% B/B0. By the more 
conservative definition, the Coat-A-Count Digoxin assay has a detection limit of approxim ately 0.1 ng/ml.
Kinetics
To determ ine the effect of em ploying incubation tim es other than 1 hour at 37°C or 15 m inutes at 50°C, as specified 
on pages 3 and 4, respectively, assays w ere set up in parallel, using incubations of 30, 60, 90 and 120 m inutes at 
37°C and 10, 15 and 20 m inutes at 50°C. Various quality control perform ance m easu res were m onitored, including: 
nonspecific binding and m axim um  binding (percent of total counts); the correlation coefficient (rho) of the logit-log 
line; the assay CV, based on the b inding of the replicates; the  20, 50 and  80 percent intercepts (ng/ml); and the binding 
of the calibrators (% B/B0). In addition, several sam ples w ere assayed as u n k n o w n s in each of the assays.
Parameter 30 min 37° 6 0  m in  37° 90 min 37° 120 min 37° 10 min 50° 15 m in 50° 20 min 50°
Total Counts 46,734 cpm 43 ,046  cpm  44,256 cpm 42,818 cpm 44,001 cpm 43,715 cpm  42,868 cpm
% NSB 1.3% 1.2% 1.2% 0.7% 0.5% 0.5% 0.4%
% MB 27% 38% 47% 50% 22% 28% 28%
rho -0.997 -0 .9 9 7 - 0.999 - 0.998 -0 .996 -  0.998 -  0.995
Assay CV 1.7% 1.7% 1.8% 1.8% 2.9% 1.9% 1.8%
Intercep ts:
20% B/B0 8.8 ng/ml 7.3 ng/ml 6.4 ng/ml 6.1 ng/ml 11.4 ng/ml 10.4 ng/ml 10.0 ng/ml
50% B/B0 2 4 2.0 1.8 1.6 2.7 2.3 2.3
80% B/B0 0.7 0.6 0.5 0.5 0.6 0.5 0.6
C alib rators:
B —0.5 ng/ml 84% 82% 81% 78% 83% 80% 79%
C - l  0 73% 70% 66% 63% 72% 70% 72%
D —2.0 57% 51% 48% 46% 58% 54% 55%
E - 4 .0 36% 32% 29% 28% 41% 38% 37%
F -8 .0 22% 19% 17% 16% 25% 24% 23%
Sam ples:
1 0.6 ng/ml 0 .6  ng/ml 0.4 ng/ml 0.5 ng/ml 0.5 ng/ml 0.5 ng/ml 0.5 ng/ml
2 0.9 0.8 0.8 0.9 0.9 0.8 0.8
3 0.9 1.0 1.0 0.9 0.8 1.0 0.7
4 1.8 1.7 1.7 1.6 1.9 1.8 1.6
5 1.8 1.9 2.0 1.8 1.7 1.8 1.7
6 1.8 2.0 1.9 1.9 1.6 1.8 1.8
7 2 5 2.7 2.7 2.5 2.3 2.4 2.5
8 2.7 2.9 3.1 2.9 2.5 2.6 2.7
9 3.1 3.3 3.2 3.3 2.8 3.1 3.0
10 3.6 4.0 3.8 3.5 3.6 3.6 3.9
Mean: 2.0 ng/ml 2.1 ng/ml 2.1 ng/ml 2.0 ng/ml 1.9 ng/ml 1.9 ng/ml 1.9 ng/ml
Based on these and sim ilar results, one hour at 37°C was chosen as the Basic Procedure, and fifteen m inutes at 50°C  




The reliability of D iagnostic P roducts Corporation's Coat-A-Count Digoxin p rocedure  was assessed  by exam ining its 
reproducibility  on sam ples selected to represent a range of digoxin levels.
In traassay: Statistics w ere calculated for each of three 














Interassay: Statistics were calculated for each of th ree  















To determ ine w hether there  is any position effect due to delays in the addition of reagents or decanting, pairs of tubes 
were spaced throughout a long assay for each of th ree  sam ples. The results show no significant position (or "end of 




























The kit's high calibrator (8 ng/ml) was serially diluted w ith a lipemic serum  pool. T h is causes the degree of lipem ia 
to increase as the digoxin concentration (due to the calibrator) decreases. These d ilutions w ere assayed along w ith 










16 in 32 4.3 4 1 105%
8 in 32 2.0 2.2 91%
4 in 32 1.0 1.2 83%
2 in 32 0.7 0.7 100%
1 in 32 0.4 0.4 100%
Protein Effect
To sim ulate various protein concentrations, experim ents w ere perform ed in which 6.0 ml aliquots of a hum an serum  
pool w ere freeze-dried  and then reconstituted w ith various volum es of water. Each reconstitu ted  aliquot w as then 
assayed by the Coat-A-Count Digoxin procedure. Note that aliquots reconstituted w ith  half the original volum e rep re ­
sent an extrem ely high protein concentration, in the order of 14 gm /dl. T hese results indicate that even w ide variations 
in protein have v irtually  no effect on the  Coat-A-Count Digoxin assay.
Protein O E % O/E
Experiment Reconstitution Concentration Observed Expected Recovery
1 3.0 ml 2.00 x -  14.0 gm/dl 4.6 4.6 100%
6.0 l.OOx -  7.0 2.3 — (100%)
12.0 0.50 x -  3.5 1.1 1.2 92%
2 3.0 ml 2.00 x -1 4 .0  gm/dl 11.3 12.0 94%
6.0 1 00 x -  7.0 6 0 — (100%)
12.0 0.50x -  3.5 2.9 3.0 100%
3 3 0 ml 2.00 x -  14 0 gm/dl 4.0 4.0 100%
6.0 l.OOx -  7.0 2.0 — (100%)
12.0 0.50 x -  3.5 1.0 1.0 100%
4 3.0 ml 2.00 x -  14 0 gm/dl 11.0 11.2 98%
6.0 l.OOx -  7 0 5.6 -*> (100%)
12.0 0.50 x -  3.5 3.0 2.8 107%
• Coat-A-Count Digoxin
Specificity
T he digoxin a n tise ru m  is highly specific for digoxin, w ith an extremely low crossreactivity  to o ther naturally occurring 
steroids or therapeu tic  d rugs that m ay be present in patient samples.
ng/ml Apparent
Compound Added Concentration- ngdnl Crnssrenctivity
Deslanoside C 10 5.4 0.54
5 2.6 0.52
1 0.5 0.50
Lanatoside 100 33.3 0.33
10 3.6 0.36
1 0.5 0.50
Digitoxin 1,000 3.7 0.0037
500 2.1 0.0042
Dihydrodigoxin 5 0.06 0.012
1 0 —
Cortisol 100,000 0.6 0.000006
4,000 0.05 0.000013
From the table it is clear that the Coat-A-Count Digoxin procedure  is not suitable for use on patients receiving either 
D eslanoside C or Lanatoside, tw o com pounds w ith m olecular struc tu res sim ilar to that of digoxin.
Effect of B ilirubin  and  Hemolysis
T'o sim ulate severe icterus, th ree  serum  sam ples were spiked with 20 mg/dl of bilirubin. In another experim ent, to 
sim ulate m ild, m oderate and  severe hemolysis, th ree  serum  sam ples w ere spiked w ith 10, 15 and 30 /d /m l of packed 
red blood cells. All sam ples were assayed both  spiked and unspiked by the Coat-A-Count Digoxin procedure with 
the following results.
Bilirubin Packed Red Blood Cells /d/ml
Sample Unspiked 20 mg/dl Sample Unspikcd 10________ 15________ 30
1 0.9 1.2 1 0.9 0.9 0.9 1.0
2 2.5 2.5 2 2 5 2.5 2.5 2.6
3 6.1 5 8  3 6.1 5.9 5.7 5.6
T he results show  that neither severe icterus (bilirubin up to 20 mg/dl) nor gross hemolysis has any effect on the Coat-A- 
Count Digoxin p rocedure .
M atrix Effects
The Coat-A-Count Digoxin calibrators are hum an serum  based. To determ ine the effect on the assay of preparing 
the calibrators in o ther m atrix m aterials, several digoxin free m aterials were assayed by the Coat-A-Count procedure. 
Note that all resu lts a re  below the detection lim it of the assay.
Apparent
Digoxin
Matrix % B/B0 Concentration
Normal Human Serum 
Charcoal-Absorbed, #393 101.0% 0.00 ng/ml
Normal Human Serum 
Charcoal-Absorbed, #059 97.2% 0.04 ng/ml
Normal Human Plasma
Heparinized, Charcoal Absorbed 104.0% _
5% Bovine Serum Albumin 100.0% 0.00 ng/ml
10% Human .Serum Albumin 
Charcoal-Absorbed 96.5% 0.07 ng/ml
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Effect of Anticoagulants
To determ ine w hether anticoagulants interfere w ith the assay, blood was collected from  six norm al volunteers into 
plain, heparin ized  and EDTA vacutainer tubes. All sam ples were assayed by the Coat-A-Count Digoxin procedure, 
w ith the following results.
Sample Serum Heparin EDTA
1 5.9 5.4 5.4
2 4.6 4.9 5.1
3 5.7 4.1 5.7
4 5.7 5.1 5.3
5 5.6 5.0 5.8
6 5.1 5.3 5.4
Average: 5.4 5.0 5.5
O n the basis of these results it is recom m ended that sam ples be collected as se rum .
Parallelism
Six patient serum  sam ples w ere assayed both undiluted and diluted w ith the kit's zero calibrator. The observed and 
expected values are presented below in ng/ml.
ample Dilution
O E % O/E 
Observed Expected Recovery Sample Dilution
O E % O/E 
Observed Expected Recovery
1 8 in 8 (undiluted) 6.1 4 8 in 8 (undiluted) 6.9
4 in 8 2.9 3.0 97% 4 in 8 3.6 3.5 103%
2 in 8 1.6 1.5 107% 2 in 8 1.8 1.7 106%
1 in 8 0.9 0.8 113% 1 in 8 0.9 0.9 100%
2 8 in 8 (undiluted) 5 8 5 8 in 8 (undiluted) 6.7
4 in 8 2.8 2.9 97% 4 in 8 3.4 3.4 100%
2 in 8 1.4 1.5 93% 2 in 8 1.8 1.7 106%
1 in 8 0 8 0.7 114% 1 in 8 0.9 0.8 113%
3 8 in 8 (undiluted) 6.8 6 8 in 8 (undiluted) 7.2
4 in 8 3.0 3.4 88% 4 in 8 3.6 3.6 100%
2 in 8 1.5 1.7 88% 2 in 8 1.8 1.8 100%
1 in 8 0.8 0.9 89% 1 in 8 1.0 0.9 111%
Curve D isplacem ent
Four sam ples w ere each assayed by the Coat-A-Count Digoxin procedure in assays w hich included one-to-one d ilutions 














1 unspiked 0.0 3 unspiked 0.8
1 + A (0) 0.0 0.0 100% 3 4 A (0) 0.5 0.4 125%
1 + B (0.5) 0.3 0.3 100% 3 4 B (0.5) 0.7 0.7 100%
I + C (1) 0.5 0.5 100% 3 4 C (1) 1.0 0.9 111%
1 + D (2) 1.0 1.0 100% 3 4 D (2) 1.4 1.4 100%
/ + E (4) 2.0 2.0 100% 3 4 E (4) 2.5 2.4 104%
/ 4 F (8) 3.8 4.0 95% 3 4 F (8) 4.3 4.4 98%
2 unspiked 0.4 4 unspiked 2.8
2 4 A (0) 0 2 0.2 100% 4 4 A (0) 1.3 1.4 93%
2 4 B (0.5) 0.4 0.5 80% 4 4 B (0.5) 1.7 1.7 100%
2 4  C (1) 0.8 0.7 114% 4 + C (1) 2.0 1.9 105%
2 4 D (2) 1.2 1.2 100% 4 4 D (2) 2.4 2.4 100%
2 4 E (4) 2.1 2.2 95% 4 4 E (4) 3.4 3.4 100%
2 4 F (8) 4.2 4.2 100% 4 4 F (8) 5.2 5.4 96%
• Coat-A-Count Digoxin
C om parison  w ith  a Reference M ethod
W ith DPC's well-established Double Antibody Digoxin radioim m unoassay serving as the reference m ethod, 100 patient 
sam ples w ere sim ultaneously assayed by the solid-phase Coat-A-Count kit and by the Double Antibody kit. Linear 
regression analysis of the results yielded the following relationship.
(Coat-A-Count) » 0.97 (D ouble  A n tibody) -  0.05 ng/ml
r = 0.988 SEE = 0.16 n = 100
C l in ic a l  A p p lic a t io n s
Im m unoassay has proved itself a particu larly  useful aid in determ ining drug overdoses in patients treated  w ith  cardiac 
glycosides. T he technique is also useful (a) in clarifying situations w here a patien t’s sym ptom s m ight be due either 
to in trinsic heart d isease  or to digitalis intoxication; (b) w here there is doubt concerning the type of digitalis preparation 
th e  patient is ta k in g - in  th is case, digitoxin im m unoassay is also necessary ; (c) for m easuring  the digoxin ingestion 
of patients w ith  an inadequate history of previous dosage; (d) in docum enting cases of underdigitalization as well 
as digitalis (digoxin) excess; (e) in m onitoring the  toxic response in patients w ith  m yocardial d isease  associated w ith 
hypokalem ia, hypom agnesem ia, hypercalcem ia, hypoxia and alkalosis, w hich are particularly  sensitive to digitalis; 
and  (f) in preventing overdigitalization, particularly  in patients w hose renal function is deteriorating or for w hom  an 
increased  digoxin dosage is contem plated.
T he high sensitivity of digoxin im m unoassay  is especially necessary  in view of the sm all differences and occasional 
overlap that exist betw een therapeutic  and toxic levels of circulating digoxin. (Intoxication is defined in term s of a r­
rhy thm ias and d istu rbances of cardiac  conduction due to the drug's presence.) Sm ith et al, in 1969, reported  serum  
digoxin concentrations of 0.8 -  2.4 ng/ml (1.0 -  3.1 nmol/1) in nontoxic patients, and 2.1 -  8.7 ng/ml (2.7 -  11.1 nmol/1) 
in toxic patients, based  on data taken six hours post-dose in patients w ith norm al renal function.8 M ore recent clinical 
investigations have confirm ed the association of toxicity w ith serum  levels above 2 ng/ml. However, sole reliance on 
the  digoxin concentration for the determ ination of digitalis toxicity is not w arran ted  and  m ust be supplem ented w ith 
additional clinical and  e lectrocardiographic inform ation.
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T echnical A ssistance: If questions arise  concerning the Coal A-Count Digoxin reagents, or for fu rther advice on
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Appendix Cl
INFORMATION SHEET FOR KIDNEY FUNCTION STUDY
Dr. Parker is carrying out a project with St. Marks Road 
surgery and the Research Institute for Care of the Elderly, 
St. Martins Hospital, looking at the way in which kidneys 
function as the body ages. This involves collecting all 
urine passed during a 24 hour period. Thank you for 
helping us with this study.
These instructions should be followed carefully during the 
period of the study. If you are not sure what to do at any 
time, then let someone know - phone the numbers given at 
the bottom of this sheet.
1) When you wake up note the exact time at which you empty
your bladder (pass water) first thing. Throw this
specimen away, into the toilet.
2) Each and every time you pass a urine specimen after
this time, for the next 24 hours, please collect it, in
the container provided. ALL urine should be collected, 
even at night time.
3) Exactly 24 hours later, from the passing your first 
sample of water (into the toilet) please pass your 
final specimen, and save it.
4) Dr. Parker will call or telephone during the first day 
of the study, to check that you are having no problems 
with the urine collection. He will call to take a small 
blood sample first thing in the morning when the urine 
collection is completed.
5) Please record how much meat you eat during the study.
6) Dr. Parker will ask you at what time you got up, and 





TIME URINE COLLECTION STARTED
TIME URINE COLLECTION TO FINISH
MEAT EATEN
IN CASE OF QUERY PLEASE DO NOT HESITATE TO CONTACT SUE 
ELLMERS (STUDY CO-ORDINATOR) AT WORK ON BATH 835866
OR AT HOME ON BATH 834963
244
Appendix C2
MEASUREMENT OF 24h CREATININE CLEARANCE IN THE ELDERLY
Name : ........................... Study No. : . .
Address : ........................... Study Date : . .
.............................  Mobility Score :
.............................  Height/cm. . . .
Tel. No : ...........................
Weight/kg. . . .
D.O.B. : ...........................
Age : ........................... SA/m2...........
G.P. : ...........................
Diagnoses : .........................................
Continent or catheterised: 
Drugs : .................

























MEASUREMENT OF SINGLE 24h CCR IN THE ELDERLY
Name : .......................... Study No. : . . . .
Address : .......................... Study Date : . . . .
.............................  Mobility Score : . .











Time Collection started : . . . . 




Total volume urine ...............
smoker
Total collection period .......... hours
Time of blood sample ............
Meat Eaten: R.I.C.E.
St. Martins Hospital, 
Bath. (Tel : 835866)
Comments. . ' .......................
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Appendix C4 Denographic Details & Medications of Subjects in CREATININE Study
subject sex/age wt/ht fit MSc smoker EtOH
F07CC F 80 64/163 Y 1 no 9/wk
F09CC F 66 63/160 Y 1 no occ.
F15CE F 76 66/159 Y 1 no no
F18CC F 65 61/155 Y 1 no no
F19C F 79 62/170 Y 1 no no
F20CE F 84 60/156 Y 2 ex. 7/wk
F21CE F 72 55/161 Y 1 no occ.
F23CC F 71 70/159 Y 1 no occ.
F27CE F 64 74/160 Y 1 no occ.
F30CE F 60 79/159 Y 1 no occ.
F31CC F 73 64/160 Y 1 ex. occ.
F36CE F 69 51/161 Y 1 no no
F37C F 66 55/160 Y 1 no occ.
F39C F 76 47/152 Y 1 no occ.
F41CE F 60 70/166 Y 1 no no
F44CC F 67 69/167 Y 1 no occ.
F46CC F 67 61/161 Y 1 no no
F47C F 70 53/156 Y 1 16/day no
F48C F 70 57/156 Y 1 no occ.
F49C F 66 72/159 Y 1 ex. occ.
F50C F 73 65/158 Y 1 no occ.
F51CE F 73 78/155 Y 1 ex. occ.
F53CC F 67 75/159 Y 1 no occ.
F55C F 73 61/153 Y 1 no occ.
































Appendix C4 Denographic Details & Medications of Subjects in CREATININE Study (contd)
subject sex/age wt/ht fit MSc smoker EtOH diagnoses drugs
F59C F 72 66/143 Y 1 no occ. nild renal 
impairment
Burinex K, KC1 
Beconase
F60C F 63 60/164 Y 1 no occ. hypertension Tenoret, multivitau
F62C F 73 77/155 Y 1 no occ. nil nil




F65C F 75 73/175 Y 1 no occ. Ca breast tamoxifen
F66CE F 60 75/165 Y 1 no occ. nil nil
F68CC F 79 70/165 Y 1 no occ. nil aspirin
F69CC F 73 67/170 Y 1 no occ. PA B12 injections
F71CE F 64 63/160 Y 1 no 14/wk nil nil
F73CC F 65 79/164 Y 1 no occ. nil nil
F74C F 70 60/155 Y 1 no occ. OA diclofenac
F75CC F 70 65/163 Y 1 no occ. nil nil
F76CE F 67 80/167 Y 1 ex. occ. hypothyroid thyroxine
F78CE F 66 66/169 Y 1 no 7/wk nil nil
F81CE F 65 62/158 Y 1 ex. 3/wk nil piperazine oestrone
F86CC F 67 56/161 Y 1 no occ. nil bisacodyl
F91CE F 68 56/157 Y 1 10/day 3/wk nil nil
F93C F 66 76/167 Y 1 ex. 21/wk nil betahistine
F94CC F 73 70/149 Y 1 1/day occ. nil nitrazepam
F96CE F 64 53/150 Y 1 no occ. nil nil
F97CC F 71 59/164 Y 1 no occ. nil nil





H22CC H 70 90/175 Y 1 no occ. nil Rennies
H35CE H 71 77/179 Y 1 ex. occ. nil nil
M38C H 65 58/161 Y 1 no occ. depression mianserin




Appendix C4 Denographic Details & Medications of Subjects in CREATININE Study (contd)
subject sex/age wt/ht fit/MSc smoker EtOH diagnoses drugs
M54CC M 62 60/166 Y / l no occ. nil nil
M57CE M 68 71/166 Y / l 8/day 7/wk nil nil
M61CC M 73 88/183 Y / l no occ. nil nil
M64C M 75 68/168 Y / l ex. occ. glaucoma pilocarpine ED
M67CE M 64 79/183 Y / l heavy-
pipe
occ. nil nil
M72CC M 72 80/184 Y / l no occ. nil nil
H77CE M 72 67/173 Y / l ex. occ. nil nil
M79CE M 73 63/162 Y / l 2/day occ. nil nil
M80CC M 66 81/175 Y / l no 40/wk nil nil
M82CC M 66 78/172 Y / l no no nil nil
M83CC M 67 81/171 Y / l no 20/wk nil nil
M84CE M 65 70/171 Y / l no 7/wk nil nil
H85CC M 67 84/180 Y / l no occ. nil nil
H92CC H 68 78/171 Y / l yes 14/wk nil nil
H95CE M 70 66/164 Y / l no 1/wk nil nil
H98CE M 64 74/172 Y / l no occ. nil nil
M99CC M (65 66/168 Y / l no occ. nil nil
H100CE M 64 70/164 Y / l no 9/wk nil nil





78 65/160 N / 3 no
74 71/170 N / 4 no
82 65/150 N / 4 no
78 41/150 N / 4 no
diverticulitis
no CVA















Appendix C4 Demographic Details & Medications of Subjects in CREATININE Study (contd)
subject sex/age Wt/ht fit MSc smoker EtOI
F17C F 79 83/178 N 4 no no
F18C F 84 45/163 N 3 no no
F21C F 88 50/152 N 4 no no
F22C F 73 63/157 N 4 no no
F24C F 77 92/157 N 4 no no
F25C F 79 44/152 N 4 no no
F28C F 86 50/163 N 3 occ. occ
F29C F 83 45/150 N 3 no no
F30C F 83 55/160 N 3 no no
F31C F 84 N 4 no no
F34C F 79 83/178 N 3 no no
F37C F 73 63/157 N 3 no no
F39C F 88 N 4 no no
F41C F 81 50/163 N 3 no no
F42C F 88 48/152 N 4 no no
F44C F 89 43/157 N 3 no no
F46C F 71 55/152 N 3 no no
F02GPC F 78 83/152 Y 1 no no
F04GPC F 79 55/152 Y 1 no no
diagnoses drugs






CVA & R hemiplegia paracetamol,lactulose
MI 1986
CVA & R hemiplegia Trasidrex,paracetamol
hypertension, OA aspirin
spasticity of legs paracetamol,temazepam
? MS, catheterised prochlorperazine
RA, constipation mianserin,aspirin





CVA & R hemiplegia paracetamol,lactulose
hypotension ranitidine,paracetamol
t R arm, falls fludrocortisone,temazepam




CVA & L hemiplegia prednisolone
NIDDM, below knee digoxin,timolol ED
amputation Milpar
AF, falls digoxin,co-proxamol
mitral valve disease warfarin,temazepam 





Appendix 04 Demographic Details & Medications of Subjects in CREATININE Study (contd)
subject sex/age wt/ht fit MSc smoker EtOH diagnoses drugs
F05GPC F 78 51/163 Y 1 no no epilepsy carbamazepine,phenytoin 
inositol nicotinate
F07GPC F 80 62/165 Y 1 no no hypothyroid, reflux thyroxine,cinnarazine
F09GPC F 80 56/147 Y 1 no occ. cervical spondylosis co-proxamol,nabumetone 
neuritis
M02C M 80 71/180 N 4 no no CVA & hemiplegia thioridazine














M07C M 80 80/170 N 3 no no CVA, diverticulitis ranitidine
M10C M 78 55/173 N 5 no no IED, CCF, anaemia Frumil,FeS04,paracetamol
M13C M 68 72/173 N 4 no no IDDM, catheterised 
CVA & L hemiplegia
Actrapid,Monotard
ibuprofen




salbutamol & Becotide inh.
H19C M 97 50/170 N 5 no no COAD metoclopramide,ranitidine




M23C M 81 60/163 N 4 no no CVA & hemiplegia 
urinary frequency
Frumil, acebutolol
M26C M 78 63/168 N 4 no occ. CVA,hemiplegia,NIDDH oxprenolol,paracetamol
M27C M 83 65/178 N 5 N/K N/K AF, CCF, CVA digoxin,ampicillin 
protriptyline,aspirin
M32C M 76 62/178 N 4 no no ? MI
lung fibrosis
Atrovent & salbutamol nebs 
Becotide inh,ranitidine




H43C M 72 86/168 N 4 N/K no AF,CCF,hypertension digoxin,Frumil,folic acid 
Parkinsonism sodium valproate
dementia, epilepsy ascorbic acid,paracetamol 
CVA, hemiplegia
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Appendix C4 Demographic Details & Medications of Subjects in CREATININE Study (contd) 
subject sex/age wt/ht fit/MSc smoker EtOH diagnoses drugs




M03GPC M / 76 87/174 Y / l no yes ? 
excess
OA, renal stone diclofenac,quinine sulphate
M06GPC M / 79 68/168 Y / l no no nocturia Mucaine
H08GPC M / 82 74/175 Y / l no no hypertension
migraine
propranolol,paracetamol
HIOGPC M / 82 75/174 Y / l no 7/wk DO yeast tablets
M11GPC M / 88 66/170 Y / l no no cholecystectomy digoxin
wt = weight (kg)
ht = height (cm)
fit = fit Y
frail N
MSc = mobility score
EtOH = alcohol (units/week)
2 5 2












































































F53CC 1.04 24.00 24.00 989.5 83.2
















































F97CC 2.96 24.00 24.00 1190.8 65.4
F15CE 1.26 24.00 24.00 753.5 38.9


































































1190 66 1.77 65







































1820 28 1.62 30
1935 42 1.67 43
























































































F41CE 1.23 24.00 24.00 1135.8 57.8
F51CE 1.29 24.00 24.00 1116.9 60.2





























































F91CE 1.03 24.00 24.00 915.5 151.3
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periods, for Subjects in CREATININE study (contd)
24h 24h
urine CCr CCr I 24h SA CCr




















1552 47 1.52 54
1965 64 1.78 62
1855 60 1.78 58
















1967 65 1.64 68
605 62 1.54 69
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F48C 1.23 24.00 24.00 945.0 66.5 1420 53 1.57 59
F49C 1.46 24.00 24.00 1036.9 60.5 1715 49 1.73 49
F50C 1.28 24.00 24.00 994.8 46.5 2140 54 1.67 56
F55C 1.27 24.00 24.00 786.0 41.4 1900 43 1.57 47
F58C 1.20 24.00 24.00 1038.8 59.4 1750 60 1.78 58





































































































































































M92CC 1.44 24.00 24.00 1930.3 65.9 2930 93 1.91 84
H82CC 1.86 24.00 24.00 1590.9 94.7 1680 59 1.95 53
M85CC 1.52 24.00 24.00 1342.6 46.8 2870 61 2.05 52
H54CC 1.10 24.00 24.00 1223.1 93.4 1310 77 1.67 80
























































H08CC 1.95 24.00 24.00 1720.9 66.4 2590 61 2.08 51



















































































Appendix C5 SCr, OCr & CCr, calculated for 8 & 24h periods, for Subjects in CREATININE study (contd)
total 24h 24h
[SCr] urine T.int ng [OCr] urine CCr CCr I 24h SA CCr
subject lg/dl colln hours OCr mg/dl vol/il nl/nin nl/nin CCr n2 1.73n2
M35CE 1.54 1400 7.00 421.6 163.4 258 65 93
2220 8.33 611.4 178.3 343 79 113
0700 8.67 509.0 184.4 276 64 91
24.00 1542.0 175.8 877 70 1.94 62
H67CE 1.52 24.00 24.00 1208.6 64.3 1880 55 2.01 48
H57CE 1.66 24.00 24.00 1216.5 116.4 1045 51 1.78 49
H84CE 1.06 24.00 24.00 1783.0 57.5 3100 117 1.82 111
H98CE 2.25 1420 7.34 436.1 75.2 580 44 102
2010 5.83 387.5 161.5 240 49 114
0630 10.33 552.2 83.7 660 40 93
23.50 1375.8 93.0 1480 43 1.86 40
H79CE 1.81 1315 6.25 307.0 102.3 300 45 132
2230 9.25 452.9 123.1 368 45 132
0700 8.50 118.5 127.4 93 13 38
24.00 878.4 115.4 761 34 1.67 35
H38C 1.23 1410 7.17 457.4 79.4 576 86 118
2100 6.83 347.2 86.8 400 69 95
0700 10.00 485.7 138.8 350 66 90
24.00 1290.3 97.3 1326 73 1.60 79
H43C 1.36 24.00 24.00 1775.0 59.0 3010 91 2.10 75
H64C 1.19 1255 5.92 359.7 81.8 440 85 116
2300 10.08 499.9 81.3 615 69 95
0700 8.00 385.8 148.4 260 68 93
24.00 1245.4 94.7 1315 73 1.76 71
F08C 1.50 1320 7.58 302.1 39.8 760 44 142
2000 6.67 125.1 37.7 332 21 68
0545 9.75 241.3 38.2 632 27 87
24.00 668.5 38.8 1724 31 1.43 37
F09C 4.32 1425 6.42 191.7 84.1 228 12 120
2130 7.08 30.6 38.7 79 2 20
0730 10.00 378.5 48.4 782 15 150
23.50 600.8 55.2 1089 10 1.71 10
F12C 2.56 1420 8.33 389.4 120.2 324 30 125
2000 5.67 126.0 217.2 58 14 58
0600 10.00 355.9 92.7 384 23 96
24.00 871.3 113.7 766 24 1.85 22
F15C 1.24 1600 6.00 191.4 41.1 466 43 116
2040 4.67 135.5 123.2 110 39 105
1005 13.42 340.6 66.1 515 34 92
24.09 667.5 61.2 1091 37 1.67 39
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periods, for Subjects in CREATININE study (contd)
24h 24h
urine CCr CCr I 24h SA CCr
























1239 17 2.04 15


















Appendix C5 SCr, OCr & CCr, calculated for 8 & 24h periods, for Subjects in CREATININE study (contd)
total 24h 24h
[SCr] urine T.int *9 [OCr] urine CCr CCr % 24h SA CCr
subject ng/dl colln hours OCr ig/dl vol/nl il/iin il/nin CCr a2 1.7312
F34C 1.39 1300 7.00 167.3 75.4 222 29 104
2215 9.25 189.4 124.6 152 25 89
0530 7.25 201.4 51.6 390 33 118
23.50 558.1 73.0 764 28 2.03 24
F37C 1.62 1400 8.00 233.4 77.8 300 30 125
2100 7.00 252.3 95.9 263 37 154
0600 9.00 82.5 64.5 128 9 38
24.00 568.2 82.2 691 24 1.68 25
F39C 2.24 1430 8.33 268.1 75.9 353 24 104
1830 4.00 104.5 67.0 156 19 82
0600 11.50 353.0 59.3 595 23 100
23.83 725.6 65.7 1104 23
F41CD 2.10 1200 5.00 92.2 31.8 290 15 107
2300 11.00 164.9 33.3 495 12 86
0700 8.00 148.0 31.5 470 15 107
24.00 405.1 32.3 1255 14 1.52 16
F42CD 1.82 1430 7.50 270.4 39.5 685 33 110
2130 7.00 253.4 105.6 240 33 110
0645 9.25 334.4 113.4 295 33 110
23.75 858.2 70.3 1220 30 1.44 35
F44CD 1.76 1300 7.25 161.2 76.8 210 21 124
2000 7.00 122.7 85.2 144 17 100
0630 10.50 159.6 67.9 235 14 82
24.75 443.7 75.3 589 17 1.38 21
F46CD 4.01 1330 3.50 34.5 115.0 30 4 57
2100 7.50 161.1 76.7 210 9 129
0700 10.00 175.9 59.0 298 7 100
21.00 371.5 69.1 538 7 1.54 8
F02GPC 1.34 24.00 24.00 915.5 58.7 1560 47 1.91 43
F04GPC 1.11 24.00 24.00 1111.3 73.4 1515 70 1.54 78
F05GPC 1.01 24.00 24.00 896.9 47.2 1900 62 1.52 70
F07GPC 1.59 24.00 24.00 882.9 42.8 2064 39 1.70 39
F09GPC 1.29 24.00 24.00 673.0 44.6 1510 36 1.54 41
H02C 1.14 23.00 23.00 634.1 41.2 1538 40 1.88 37
H03C 1.14 1310 5.17 240.3 31.0 775 68 119
1900 5.83 284.8 49.0 581 71 125
0500 10.00 294.6 51.7 570 43 75
21.00 819.7 42.6 1926 57 1.88 53
259
Appendix C5 SCrf OCr & CCr, calculated for 8 & 24h periods, for Subjects in CREATININE study (contd)
total 24h 24h
[SCr] urine T.int ig [OCr] urine CCr CCr I 24h SA CCr
subject ng/dl colln hours OCr ng/dl vol/nl nl/nin nl/nin CCr 12 1.73n2
H04C 6.71 1300 4.00 124.0 139.3 89 8 80
2100 8.00 302.3 129.2 234 9 90
0500 8.00 372.2 33.2 1122 12 120
20.00 798.5 55.3 1445 10 1.78 10
H05C 6.71 1300 6.00 205.7 123.2 167 9 82
2100 8.00 289.6 108.9 266 9 82
0700 10.00 521.7 52.2 1000 13 118
24.00 1017.0 71.0 1433 11 1.78 10
H06C 1.94 1330 6.50 201.5 231.6 87 27 75
2030 7.00 288.5 267.1 108 35 97
0700 10.50 527.5 214.4 246 43 119
24.00 1017.5 230.7 441 36 1.88 34
M07C 0.98 1530 6.50 178.7 91.6 195 47 96
1930 4.00 127.6 83.9 152 54 110
0855 13.42 362.8 62.2 583 46 94
23.92 669.1 71.9 930 49 1.68 51
H10C 2.43 1210 2.42 138.4 108.1 128 39 186
2005 7.92 204.9 36.5 562 18 86
0645 10.67 285.5 47.4 602 18 86
21.01 628.8 48.7 1292 21 1.63 22
H13C 1.05 1400 8.00 335.8 65.6 512 67 106
2220 8.33 369.3 41.2 897 70 111
0600 7.67 246.8 65.6 376 51 81
24.00 951.9 53.3 1785 63 1.87 58
H14C 2.62 1500 5.50 98.8 33.2 298 11 44
2255 7.92 353.8 89.8 394 28 112
0945 10.83 473.9 55.4 856 28 112
24.25 926.5 59.9 1548 25 1.63 26
M19C 2.05 24.00 24.00 415.6 51.7 804 14 1.54 16
H20C 4.86 1500 9.00 263.8 77.6 340 10 83
2200 7.00 218.8 124.3 176 11 92
0600 8.00 333.4 45.7 730 14 117
24.00 816.0 65.5 1246 12 1.78 11
H23C 1.77 1430 7.50 233.3 57.5 406 29 121
2045 6.25 133.8 77.8 172 20 83
0740 10.92 251.1 163.1 154 22 92
24.67 618.2 84.5 732 24 1.66 25
H26C 1.66 1440 8.42 241.3 86.2 280 29 67
1645 2.08 244.2 290.7 84 118 274
0640 13.92 548.0 50.9 1076 40 93
24.42 1033.5 71.8 1440 43 1.72 43
2 6 0

















































































H01GPC 1.47 24.00 24.00 1385.6 99.7 1390 65 1.80 63
H03GPC 1.35 24.00 24.00 1305.4 77.5 1685 67 2.07 56
H06GPC 1.30 24.00 24.00 1559.4 131.6 1185 83 1.80 80
H08GPC 1.50 24.00 24.00 1492.7 130.9 1140 69 1.91 63
H10GPC 1.97 24.00 24.00 1257.0 84.1 1495 44 1.92 40
M11GPC 1.60 24.00 24.00 1110.0 61.0 1820 48 1.78 47





















age (years) 60 100 78.0 77.1 8.4 60 97 78.0 76.3 8.2
mobility score 1± 5 1.0 2.1 1.3 1 5 1.0 2.2 1.4 •
height (cm) 137 178 157.0 157.4 7.9 147 187 172.0 171.5 7.3 ****
weight (kg) 36 94 60.5 60.8 12.8 40 96 71.0 71.0 12.1 ****
LBM (kg) 30 57 42.1 42.2 5.7 34 60 50.0 50.0 5.6 ****
SA (m2) 1.23 2.15 1.63 1.64 0.22 1.36 2.20 1.82 1.83 0.18
urine volume (ml) 249 3217 1333 1375 584 360 3742 1440 1517 641
OCr (mg in 24h) 240 2441 834 823 313 302 2624 1223 1192 433 ****
[OCr] (mg/lOOml) 22.4 420.8 60.8 67.9 39.7 26.9 240.6 77.5 87.3 39.7
[SCr] (mg/lOOml) 0.34 4.32 1.24 1.39 0.69 0.55 6.71 1.45 1.67 1.01 **
24h CCr (ll/min) 7 141 47.0 48.7 24.1 10 193 59.0 60.5 30.0 ***
24h CCr/SA 
(ml/min/1.73m2)
8 167 50.0 51.8 26.3 10 164 53.0 56.4 26.1
CCram (ml/min) 1 160 49.0 50.5 30.4 6 195 63.5 67.6 41.1 **
CCrpm (ml/min) 2 156 49.0 51.9 31.6 9 209 61.5 63.2 36.9 *
CCm (ml/min) 6 153 43.0 46.1 26.2 3 186 51.5 53.9 30.3
* p<0.05 ** p<0.005 ***' p<0.001 ** ** p<0.0001
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Appendix C7 Summary of Results From All Females in CCr Prediction Study
n min max median mean s.d. 951 C.I. r m
age (years) 146 60 100 78.0 77.1 8.4 76 - 78
lobility score 146 1 5 1.0 2.1 1.3 1.9 - 2.3
height (ci) 146 137 178 157.0 157.4 7.9 156 - 159
veight (kg) 146 36 94 60.5 60.8 12,8 59 - 63
SA (12) 146 1.23 2.15 1.63 1.64 0.22 1.60 - 1.67
urine vol (ll) 146 249 3217 1333 1375 584 1279 - 1470
tiie interval (h) 146 21.00 25.42 24.00 23.88 0.52 23.79-23.96
OCr (mg/24h) 146 240 2441 834 823 313 772 - 874
[OCr] (ig/lOOil) 146 22 421 60.8 67.9 39.7 61.4 - 74.4
[SCr] (ig/lOOil) 146 0.34 4.32 1.24 1.39 0.69 1.27 - 1.50















































46 - 58 




























CCr (il/iin) 146 7 141 47.0 48.7 24.1 45 - 53
CCr/SA
(il/iin/1.73i2)
146 8 167 50.0 51.8 26.3 48 - 56
CCr/70kg 
(ml/min/70kg)





























































Appendix C7 Summary of Results From All Females in CCr Prediction Study (contd)
cn min max median mean S.d. 951 C.I. r m
E3 (ml/*in/1.73m2) 146 10 159 43.2 45.4 20.9 42 - 49 0.844 0.67
dE3 -28 43 7.1 6.4 14.2
E3F (ml/iin/1.73i2) 146 9 143 38.9 40.9 18.8 38 - 44 0.844 0.61
dE3F -21 51 11.5 10.9 14.5
E4 (ml/min) 146 7 149 49.8 51.2 22.8 47 - 55 0.826 0.78
dE4 -53 42 -2.4 -2.5 13.9
E4F (ml/min) 146 6 126 42.4 43.5 19.4 40 - 47 0.826 0.67
dE4F -36 45 4.3 5.2 13.6
E5 (ml/min/1.73n2) 146 20 276 74.3 80.2 37.6 74 - 86 0.779 1.11
dE5 -118 28 -23.4 -28.4 23.8
E6 (ml/min) 146 16 329 70.6 78.9 44.7 72 - 86 0.696 1.29
dE6 -202 36 -22.5 -30.2 32.9
E6F (ml/min) 146 13 253 54.9 61.2 34.4 56 - 67 0.774 1.01
dE6F -126 42 -6.9 -12.6 24.7
E7 (ml/min/1.73m2) 146 86 118 103.2 103.9 6.7 103 - 105 0.293 0.07
dE7 -101 61 -56.2 -52.1 25.2
E8 (ml/min/1.73m2) 146 69 95 83.1 83.6 5.3 83 - 85 0.293 0.06
dE8 -80 82 -35.3 -31.8 25.2
E9 (ml/min) 146 7 144 48.2 49.5 22.1 46 - 53 0.825 0.76
dE9 -49 43 -1.1 -0.8 13.8
E9F (ml/min) 146 6 115 38.5 39.6 17.7 37 - 42 0.825 0.60
dE9F -28.2 46.9 7.5 9.1 13.8
E10 (ml/min/70kg) 146 10 203 53.0 56.0 27.1 52 - 60 0.858 0.75
dE10 -40 48 -0.1 1.2 15.9
E10F (ml/min/70kg) 146 9 172 45.1 47.6 23.0 44 - 51 0.858 0.64
dElOF -27 56 8.5 9.6 16.2
Ell (ml/min) 146 13 297 60.8 68.7 39.5 62 - 75 0.726 1.19
dEll -167 41 -15.5 -20.0 27.6
E11F (ml/min) 146 12 178 42.7 46.9 23.5 43 - 51 0.716 0.70
dEllF -54 49 3.8 1.8 18.0
E12F (ml/min) 143 8 86 39.0 40.6 16.1 38 - 43 0.784 0.57





























































** p<0.01 *** p<0.001
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Appendix C9 Summary of Results From All Hales in CCr Prediction Study
n min max median
age (years) 99 60 97 78.0
mobility score 99 1 5 1.0
height (cm) 99 147 187 172.0
weight (kg) 99 40 96 71.0
SA (m2) 99 1.36 2.20 1.82
urine vol (ml) 99 360 3742 1440
time interval (h) 99 20.00 27.33 24.00
UCr (mg/24h) 99 302 2624 1223
[OCr] (mg/100ml) 99 27 241 77.5
[SCr] (mg/lOOml) 99 0.55 6.71 1.45
24h CCr (ml/min) 78 10 193 57.5
CCram (ml/min) 78 6 195 63.5
dCCram 78 -87 17 0.0
ICCram 78 30 350 100.0
CCrpm (ml/min) 78 9 209 61.5
dCCrpm 78 -75 29 -2.0
ICCrpm 78 37 274 106.5
CCrn (ml/min) 78 3 186 51.5
dCCm 78 -43 50 3.0
ICCrn 78 7 149 93.5
CCr (ml/min) 99 10 193 59.0
CCr/SA
(ml/min/1.73m2)
99 10 164 53.0
CCr/70kg 
(ml/min/70kg)

































mean s.d. 951 C.I. r m
76.3 8.2 74 - 78
2.2 1.4 1.9 - 2.5
171.5 7.3 170 - 173
71.0 12.1 69 - 73
1.83 0.18 1.79 - 1.87
1517 641 1389 - 1645
23.89 0.90 23.71 - 24.07
1192 433 1106 - 1278
87.3 39.7 79.4 - 95.2
1.67 1.01 1.47 - 1.87



























47 - 61 
2.7 - 8.8 
87 - 97
0.905 0.87
60.5 30.0 55 - 67
56.4 26.1 51 - 62















36 - 43 0.781 0.53









Appendix C9 Sumary of Results Froi All Hales in CCr Prediction Study (contd)
n lin iax ledian lean s.d. 951 C.I. r 1 C
E5 (nl/min/1.73i2) 99 12 170 63.2 67.7 28.9 62 - 73 0.726 0.80 22.4
dE5 -90 37 -6.1 -11.3 20.5
E6 (il/iin) 99 9 186 58.6 64.6 32.1 58 - 71 0.670 0.72 21.3
dE6 -103.6 1.0 -4.1 25.3
E7 (il/iin/1.73i2) 99 88 118 103.2 104.5 6.5 104 - 106 0.420 0.11 98.6
dE7 -92 52 -48.8 -48.1 24.1
E8 (il/iin/1.73i2) 99 71 95 83.1 84.1 5.2 83 - 85 0.420 0.08 79.4
dES -72 75 -28.8 -27.7 24.4
E9 (il/iin) 99 8 156 48.0 50.4 23.9 46 - 55 0.861 0.69 9.0
dE9 -33 49 8.8 10.1 15.4
E10 (il/iin/70kg) 99 7 137 45.7 48.0 22.7 43 - 53 0.804 0.68 8.0
dE10 -42.5 58 10.4 11.2 16.1
Ell (il/iin) 99 8 172 50.7 56.5 29.0 51 - 62 0.694 0.67 15.9
dEll -82 53 7.6 4.0 23.1
E12 (il/iin) 97 12 148 47.0 48.5 22.1 44 - 53 0.844 0.63 9.6
dE12 -32 52 13.0 13.1 16.0
267





H.Sc weight SA 0 vol. OCr [SCr] CCr


























[SCr] (ng/lOOnl) 0.206 0.292
**






























** p<0.01 *** p<0.001
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Appendix Cll Influence of Diuretic Dse on CCr Prediction in Females - Hann-Whitney Test





















age (years) 75.6 8.2 79.3 8.2
mobility score 1.9 1,2 2.4 1,3
weight (kg) 60.4 11.0 61.3 15.1
SA (m2) 1.62 0.17 1.66 0.27
urine volume (ml) 1423 592 1306 570
OCr (mg in 24h) 152 326 782 291
[OCr] (mg/lOOml) 70.1 47.9 64.8 23.6
[SCr] (mg/lOOml) 1.31 0.60 1.49 0.79
CCr (ml/min) 52.1 26.0 43.9 20.5
CCr/SA
(ml/min/1.73m2)

























































































* p<0.05 ** p<0.02
Appendix C12 Influence of Diuretic Use on CCr Prediction in Hales - Mann-Whitney Test



















age (years) 75.2 8.6 78.3 7.2
nobility score 1.9 1.4 2.8 1.2
weight (kg) 70.1 12.1 72.5 12.0
SA (n2) 1.82 0.18 1.85 0.17
urine vol (il) 1457 641 1622 638
UCr (ng/24h) 1213 441 1155 423
[UCr] (ng/lOOnl) 93.7 44.5 76.1 26.5
[SCr] (ng/lOOml) 1.48 0.57 1.99 1.46
CCr (nl/nin) 63.4 25.6 55.5 36.3
CCr/SA
(nl/nin/1.73n2)

























































































* p<0.05 ** p<0.002
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Appendix C13 Influence of 24h CCr on prediction of CCr in Females - Mann-Whitney Test





















age (years) 74.3 8.1 80.1 7.6
mobility score 1.5 0.9 2.8 1.3
weight (kg) 62.0 11.1 59.4 14.4
SA (m2) 1.64 0.16 1.63 0.27
urine volume (ml) 1522 551 1220 582
UCr (mg in 24h) 987 280 649 247
[SCr] (ng/lOOml) 1.09 0.35 1.70 0.81
24h CCr (ml/min) 66.4 18.6 30.0 12.2
24h CCr/SA 
(ml/min/1.73m2)

































































































* p<0.001 ** p<0.0001
Appendix C14 Influence of 24h CCr on prediction of CCr in Hales - Mann-Whitney Test






















age (years) 74.0 7.0 79.6 8.7 ***
nobility score 1.7 1.1 2.9 1.4 ****
veight (kg) 73.6 11.6 67.2 11.9 *
SA (i2) 1.87 0.17 1.77 0.18 *
urine volume (ml) 1675 715 1294 437 *
DCr (mg in 24h) 1361 411 953 346 ****
[OCr] (mg/lOOml) 92.7 41.6 79.5 35.9
[SCr] (mg/lOOml) 1.24 0.35 2.28 1.30
24h CCr (ml/min) 79.3 23.1 34.0 14.6 ****
24b CCr/SA 
(nl/nin/1.73m2)





























































































0.433 0.58 18 ****
**
* p<0.05 ** p<0.006 ***p<0.001 **** p<0.0003
2 7 2
Appendix C15 All Fit v Frail Females in CCr Prediction Study - Mann-Whitney Test
all fit females (n=91) all frail females (n=55)
all fit all fit all fit all fit all fit frail frail frail frail frail
mean s.d. r m c mean s.d. r m c
age (years) 74.0 7.5 82.4 7.0
mobility score 1.2 0.4 3.6 0.6
weight (kg) 62.8 11.2 57.5 14.6
SA (m2) 1.65 0.16 1.61 0.29
urine volume (ml) 1578 517 1039 536
UCr (mg in 24h) 934 239 639 335
[SCr] (mg/lOOml) 1.24 0.42 1.63 0.94
24h CCr (ml/min) 56.6 19.5 35.5 25.5
24h CCr/SA 
(ml/min/1.73m2)












































































































* p<0.05 ** p<0.005 *** p<0.0005 **** p<0.0001
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Appendix C16 Very Fit v Fit Females - CCr Prediction Study - Mann-Whitney Test





















age (years) 69.4 4.5 69.1 4.7
mobility score 1.0 0.0 1.1 0.2
weight (kg) 61.5 9.2 65.9 9.8
SA (m2) 1.63 0.13 1.70 0.13
urine volume (ml) 1613 500 1605 496
UCr (mg in 24h) 1000 139 981 217
[SCr] (ng/lOOml) 1.27 0.49 1.17 0.22
24h CCr (ml/min) 59.4 15.5 61.2 21.1
24h CCr/SA 
(ml/min/1.73m2)



























































































Appendix C17 Fit v Frail Females - CCr Prediction Study - Mann-Whitney Test





















age (years) 79.8 5.9 79.9 6.1
mobility score 1.3 0.5 3.6 0,6
weight (kg) 62.0 13.0 59.0 14.8
SA (m2) 1.64 0.19 1.61 0.24
urine volume (ml) 1422 488 1082 604
OCr (mg in 24h) 851 256 661 371
[SCr] (mg/lOOml) 1.28 0.50 1.63 1.01
24h CCr (ml/min) 52.0 22.3 37.7 28.5
24h CCr/SA 
(ml/min/1.73m2)

























































































* p<0.002 ** p<0.001 *** p<0.0005 **** p<0.0001
2 7 5
Appendix C18 Very Fit v Frail Feiales - CCr Prediction Study - Mann-Whitney Test





















age (years) 72.5 4.2 72.4 4.6
■obility score 1.0 0.0 3.6 0.5
weight (kg) 62.4 10.1 60.1 16.9
SA (i2) 1.64 0.13 1.62 0.32
urine voluie (il) 1721 525 1043 498
OCr (ig in 24h) 1035 113 629 210
[SCr] (ig/lOOil) 1.31 0.69 1.56 1.37
24h CCr (nl/nin) 61.8 16.2 43.6 41.0
24h CCr/SA 
(il/iin/1.73i2)

























































































* p<0.05 ** p<0.01 *** p<0.005 **** p<0.002
2 7 6
Appendix C19 All Fit v Frail Hales in CCr Prediction Study - Hann-Whitney Test
all fit nales (n=57) all frail Bales (n=42)
all fit all fit all fit all fit all fit frail frail frail frail frail
Bean s.d. r B C Bean s.d. r B C
age (years) 73.6 7.5 80.1 7.6
Bobility score 1.1 0.4 3.7 0.7
weight (kg) 74.0 10.4 66.9 13.1
SA (b2) 1.88 0.16 1.77 0.18
urine voluie (ul) 1651 610 1336 645
UCr (ng in 24h) 1371 286 950 483
[SCr] (ag/lOOnl) 1.42 0.40 2.00 1.43
24b CCr (Bl/ain) 72.5 26.2 44.3 27.3
24b CCr/SA 
(Bl/Bin/1.73n2)
































































































* * * < i
* p<0.05 ** p<0.01 ***p<0.005 **** p<0.0002
2 7 7
Appendix C20 Very Fit v Fit Hales - CCr Prediction Study - Hann-Whitney Test





















age (years) 68.5 3.2 68.7 3.3
mobility score 1.0 0.0 1.3 0.8
weight (kg) 76.4 8.5 69.8 14.2
SA (m2) 1.91 0.13 1.81 0.24
urine volume (ml) 1765 743 1437 526
OCr (mg in 24h) 1573 230 1225 381
[SCr] (mg/lOOml) 1.47 0.32 1.38 0.37
24h CCr (ml/min) 78.3 23.3 65.7 20.1
24h CCr/SA 
(ml/min/1.73m2)





























































































* p<0.03 ** p<0.02
2 7 8
Appendix C21 Fit v Frail Hales - CCr Prediction Study - Hann-Whitney Test





















age (years) 78.0 6.9 77.9 6.9
nobility score 1.2 0.5 3.6 0.6 i t  * * *
weight (kg) 72.8 10.5 66.0 11.0 *
SA (i2) 1.86 0.16 1.76 0.16 *
urine volune (nl) 1546 472 1399 706
OCr (ng in 24h) 1260 240 993 532 ****
[SCr] (ng/lOOml) 1.46 0.42 1.60 0.77
24h CCr (nl/nin) 64.9 19.5 49.2 25.3 **
24h CCr/SA 
(nl/nin/1.73i2)











































0.700 0.57 15.4 **** 























0.699 0.62 16.8 i t  i t  i t  it  











0.653 0.63 15.8 ***











0.540 0.68 25.3 ****
****
* p<0.05 ** p<0.01 *** p<0.001 **** p<0.0005
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Appendix C22 Very Fit v Frail Hales - CCr Prediction Study - Hann-Whitney Test





















age (years) 69.3 3.4 69.1 3.3
nobility score 1.0 0.0 3.4 0.5
weight (kg) 76.6 8.8 64.0 11.3
SA (n2) 1.91 0.15 1.76 0.16
urine volune (nl) 1881 647 1675 645
UCr (ng in 24h) 1519 145 1153 688
[SCr] (ng/lOOnl) 1.44 0.30 1.57 0.89
24h CCr (nl/nin) 76.0 15.5 58.4 29.3
24h CCr/SA 
(nl/nin/1.73n2)

























































































* p<0.05 ** p<0.0001
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Appendix D1
INFORMATION SHEET FOR WATER TABLET STUDY
Dr. Parker is carrying out a project with the St. Marks 
Road GP's surgery, and the Research Institute for the Care 
of the Elderly, St. Martins Hospital, looking at the way in 
which the water tablets you are taking are handled by your 
body. Thank you for helping us with this study.
These instructions should be followed carefully during the 
period of the study. If you are not sure what to do at any 
time , then let someone know. Phone numbers are given at 
the bottom of this sheet.
1) Take your water tablets (Frumil or Frusemide) at your 
usual time and write the exact time on this paper.
2) After taking your tablets please empty your bladder 
(pass water) as soon as you possibly can. Throw this 
specimen away into the toilet.
3) Each and every time you pass a urine specimen after 
this time, please collect it, in a container provided. 
Write on the container the time at which the urine was 
collected. ALL urine should be collected, even at 
night time. If you should happen to run out of 
containers in which to collect urine, a clean jam jar, 
or similar, covered in silver foil or paper, will do.
4) Exactly 24 hours later from the time of taking your 
water tablets, collect a final urine specimen & save it
5) You may take your next water tablet once you have 
collected the final urine specimen.
6) Dr. Parker will call three times during the first day 
of the study, to take blood samples, (during the day 
time), and once again the following morning.
7) Please record how many times you eat meat during the 
study and approximately how much you eat.
8) Dr. Parker will ask you at what time you got up & went 
to bed on the study day, and how far you walked.
Very many thanks.
DAY URINE COLLECTION TO START
TIME WATER TABLET TAKEN
MEAT EATEN
IN CASE OF QUERY PLEASE DO NOT HESITATE TO CONTACT
SUE ELLMERS (STUDY CO-ORDINATOR) AT WORK ON BATH 835866 OR
AT HOME ON BATH 834963
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Appendix D2
STUDY TO MEASURE FRUSEMIDE METABOLISM IN THE ELDERLY
Name : ..........................Study No..............
Address : .........................Study Date............
...........................  Mobility Score. . . .
......................... Height/cm..........







Continent or catheterised 
Drugs : .................
Intended Time for FRU to be taken :
Time FRU taken : Dose FRU given :
INTENDED ACTUAL
Blood samples : 2 h ............ -.................
4 h ............ -.................
8 h ............ -.................
2 4 h ............ -.................
Urine samples : Time Vol/ml
1)  -...................
2)  -...................
alcohol 3)  -.............
4) .......... -...................
5) .......... -...................
tobacco 6) ............ -...................
7)  ........................... - ................................................
8)  -...................
meat 9)  -.............
10)  -...................
11)  -...................
12)  - ...................
13) .......... -...................
TOTAL URINE VOL :  IN  HRS
Comments :
RICE, St. Martins Hospital, Bath. Tel : 834963
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Appendix D3 Demographic Details of Subjects Taking Part in FRUSEMIDE Study 
subject sex/age wt/ht fit/MSc sioker EtOH diagnoses drugs
F01GPF
F04GPF
70 74/158 Y / 2









F05GPF F 74 79/157 Y / l no occ. LVF, OA, nocturia Frumil,Surgam,terodilene









F11GPF F 80 74/168 Y / l no occ. AF & hypertension 
goitre - euthyroid
Frumil,enalapril
F14GPF F 78 73/161 N / 3 no no IDDM, angina, CHF 





F18GPF F 79 45/155 Y / l 3/day no HI, thyroidectomy frusemide, folic acid
F21GPF F 74 66/162 Y / l H/K N/K IHD, hypertension Frumil, atenolol
F22GPF F 67 41/148 Y / l no N/K CABG,iitral & aortic fruseiide, digoxin 
valve replaceients warfarin 
angina
F24GPF F 82 56/161 N / 3 no no CCF, thoracoplasty 
# R. NOF '88
Frumil, nitrazepam








F28GPF F 81 41/152 N / 4 no occ. AF, R. hemiplegia 
i L humerus & femur
Frumil, digoxin 
paracetamol








F47F F 81 72/154 N / 4 no no 1 NOF, osteoporosis 
anaemia
Frumil,ferrous sulphate
F49F F 81 84/168 N / 3 no occ. NIDDM, RA, angina 






Appendix D3 Demographic Details of Subjects Taking Part in FRUSEMIDE Study (contd) 



































no 7/wk osteoporosis Frumil,Milpar,co-codamol
heavy occ. muscular dystrophy frusemide,spironolactone
GU, heart failure ranitidine
no occ. pleural effusion Frumil, GTN
LVF temazepam
no no CCF, COAD, OA frusemide,captopril,digoxin
chest infection prednisolone,isosorbide DN
Becotide&salbutamol inh.
no no LVF, COAD, anxiety Frumil, digoxin
trigeminal neuralgia aminophylline
N/K N/K claudication, COAD Frumil, Beconase
hypertension salbutamol inh.
N/K N/K angina,asthma,gout Frumil,GTN,prednisolone
cataracts & myopia aminophylline,allopurinol
IHD, leg oedema
N/K N/K cardiac murmur Frumil,digoxin,Gaviscon
partial gastrectomy nitrazepam,folic acid
R. Dupytrons cytamen
N/K N/K R leg ulcer Frumil,verapamil,dothiepin
cervical laminectomy carbamazepine,temazepam
no no CHF, COAD, asthma Frumil,prednisolone
blind L eye, gout salbutamol&Atrovent nebs
pipe occ. LVF, hypertension Frumil, oxprenolol
varicose leg ulcer
no no LVF, hypertension Frumil,captopril,digoxin












yes LVF, peripheral frusemide,captopril,Milpar






bladder instability terodilene,co-proxamol 
Duovent & Bricanyl inh.
no CVA '87, hypothyroid frusemide,sinemet,thyroxine 
MI ;82, # NOF prednisolone,pivampicillin
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Appendix D4 FRUSEMIDE in Urine and Serun of Subjects in FRU Study
FRU urine ng FRU cun SFRU tine
subject dose urine T.int [UFRU] vol in ng sanple fron [SFRU]
start ig colln lins ig/dl ml urine UFRU tine 0 hour ncg/dl
F01GPF 40 0910 115 0.68 411 2.79 2.79 0915 2.00 31.33
@ 0715 1020 70 0.36 340 1.21 4.00 1112 3.95 17.67
1121 61 0.45 154 0.69 4.69 1520 8.08 4.09
1233 72 0.87 69 0.60 5.29 0718 24.05 1.11
1402 89 1.15 53 0.61 5.90
1740 218 0.19 335 0.65 6.55
2000 140 0.07 290 0.19 6.74
2205 125 0.12 144 0.17 6.91
0430 385 0.01 720 0.04 6.95
0655 145 0.01 245 0.03 6.98
H02GPF 80 0715 75 2.19 185 4.05 4.05 0755 1.92 115.93
§ 0600 0800 45 2.57 226 5.81 9.86 1000 4.00 41.07
0915 75 11.84 76 9.00 18.86 1405 8.08 14.55
1045 90 4.44 66 2.93 21.76 0605 24.08 4.28
1230 105 3.55 62 2.20 23.99
1500 150 3.09 58 1.79 25.78
1700 120 1.93 45 0.87 26.65
2000 180 1.57 72 1.13 27.78
2400 240 0.96 90 0.86 28.64
0600 360 0.50 125 0.63 29.27
M03GPF 80 0900 105 1.48 330 4.89 4.89 0915 2.00 129.68
§ 0715 1100 120 0.00 545 11.73 16.62 1120 4.08 67.08
1215 75 2.27 385 8.74 25.36 1519 8.07 18.20
1715 300 2.32 164 3.80 29.16 0715 24.00 3.87
2300 345 1.83 134 2.45 31.61
0530 390 1.16 122 1.42 33.03
0720 110 1.00 8 0.08 33.11
F04GPF 40 0845 75 1.58 60 0.95 0.95 0930 2.00 52.56
§ 0730 0955 70 1.24 266 3.29 4.24 1135 4.08 23.77
1220 145 2.38 228 5.43 9.67 1535 8.08 12.09
1625 245 3.07 83 2.55 12.22 0740 24.00 0.00
1745 80 2.18 44 0.96 13.18
2120 215 1.81 80 1.45 14.63
0645 565 2.01 167 3.35 17.98
F05GPF 40 0915 120 0.71 406 2.87 2.87 0915 2.00 29.00
§ 0715 1105 110 1.03 217 2.23 5.10 1120 4.08 34.97
1335 150 1.00 228 2.28 7.38 1520 8.08 15.41
1635 180 0.86 154 1.32 8.70 0715 24.00 6.50
2115 280 0.49 237 1.15 9.85
0440 445 0.17 450 0.77 10.62
0645 125 0.08 220 0.17 10.79
F06GPF 40 1147 107 0.61 432 2.65 2.65 1205 2.08 61.45
§ 1000 1346 119 1.07 628 6.73 9.38 1407 4.12 40.85
1433 47 0.92 142 1.30 10.68 1800 8.00 7.17
1643 130 0.57 430 2.44 13.12 0947 23.78 0.00
1955 192 0.36 611 2.22 15.34
0600 605 0.39 230 0.89 16.23
0958 258 0.42 50 0.21 16.44
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Appendix D4 FRUSEMIDE in Urine and Serum of Subjects in FRU Study (contd)
FRU urine mg FRU cum SFRU time
subject dose urine T.int [UFRU] vol in mg sample from [SFRU]
start mg colln mins mg/dl ml urine UFRU time 0 hour mcg/dl
H07GPF 40 1020 75 0.93 108 1.00 1.00 1105 2.00 24.59
§ 0905 1110 50 1.08 130 1.41 2.41 1300 3.92 17.84
1210 60 1.59 107 1.70 4.11 1720 8.25 3.42
1310 60 1.39 108 1.50 5.61 1544 30.65 0.00
1445 95 1.20 138 1.66 7.27
1615 90 0.70 150 1.05 8.32
2025 250 0.74 157 1.16 9.48
0030 245 0.25 165 0.41 9.89
0510 280 0.06 594 0.37 10.26
0900 230 0.04 318 0.13 10.39
M08GPF 40 1100 150 0.83 223 1.84 1.84 1030 2.00 34.18
§ 0830 1600 300 1.74 212 3.68 , 5.52 1230 4.00 24.70
2030 270 1.19 232 2.77 8.29 1630 8.00 14.77
2315 165 0.77 88 0.68 8.97 0833 24.05 7.05
0700 465 0.51 232 1.19 10.16
0829 89 0.48 60 0.29 10.45
F09GPF 40 0845 85 1.72 339 5.82 5.82 0925 2.08 48.60
§ 0720 1130 165 3.81 155 5.91 11.73 1120 4.00 28.11
1730 360 2.46 139 3.42 15.15 1520 8.00 13.49
2330 360 0.52 174 0.91 16.06 0722 24.03
0430 300 0.15 265 0.40 16.46
0700 150 0.23 100 0.23 16.69
H10GPF 40 2127 147 0.51 807 4.12 4.12 2110 2.17 42.06
e 1900 2223 56 0.98 245 2.41 6.53 2245 3.75 39.91
2343 80 1.19 248 2.95 9.48 0925 14.42 15.04
0430 287 1.70 172 2.93 12.41 1905 24.08 16.25
0948 318 1.62 97 1.57 13.98
1300 192 1.63 62 1.01 14.99
1448 108 0.54 156 0.84 15.83
1642 114 0.38 168 0.63 16.46
1908 146 0.89 120 1.07 17.53
F11GPF 40 1000 120 1.15 435 5.01 5.01 1105 3.08 69.90
§ 0800 1145 105 1.99 486 9.65 14.66 1303 5.05 20.83
1330 105 3.22 138 4.45 19.11 1605 8.08 1.06
1545 135 3.32 74 2.46 21.57 0818 24.30 0.00
1815 150 1.87 60 1.12 22.69
2130 195 0.86 122 1.05 23.74
0110 220 0.47 114 0.54 24.28
0530 260 0.05 110 0.06 24.34
0730 120 0.01 165 0.01 24.35
M13GPF 40 0950 175 0.47 528 2.46 2.46 0857 2.03 55.09
6 0655 1125 95 0.97 117 1.13 3.59 1058 4.05 19.66
1345 140 0.82 107 0.88 4.47 1520 8.42 0.00
1610 145 0.08 262 0.20 4.67 0705 24.17 0.00
2205 355 0.04 375 0.15 4.82
0650 525 0.00 555 0.00 4.82
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Appendix D4 FROSEHIDE in Drine and Serum of Subjects in FRO Study (contd)
FRO urine mg FRO cum SFRO time
subject dose urine T.int [UFRO] vol in mg sample from [SFRO]
start mg colln tins mg/dl ll urine OFRO time 0 hour mcg/dl
F14GPF 120 1120 140 0.45 825 3.73 3.73 1105 2.08 24.70
§ 0900 1154 34 1.13 546 6.15 9.88 1310 4.17 63.88
1445 171 1.76 540 9.52 19.40 1719 8.32 30.77
1610 85 0.98 387 3.81 23.21 0901 24.02 16.35
1745 95 1.35 202 2.72 25.93
2400 375 1.62 265 4.29 30.22
0530 330 0.69 300 2.06 32.28
0855 205 0.52 152 0.79 33.07
M16GPF 40 1100 180 0.35 552 1.91 1.91 1018 2.30 57.45
§ 0800 1200 60 0.44 174 0.76 2.67 1214 4.23 48.22
1500 180 0.43 278 1.20 3.87 1558 7.97 12.23
1830 210 0.35 267 0.94 4.81 0807 24.12 1.33
2030 120 0.04 310 0.12 4.93
2300 150 0.06 250 0.15 5.08
0230 210 0.11 125 0.14 5.22
0700 270 0.04 200 0.08 5.30
H17GPF 80 0945 45 0.24 127 0.30 0.30 1110 2.00 140.53
g 0900 1255 190 0.47 309 1.45 1.75 1308 3.97 164.64
1452 117 0.81 118 0.96 2.71 1652 7.78 67.64
1727 155 0.97 79 0.77 3.48 0909 23.98 6.77
1905 98 0.74 103 0.76 4.24
2230 205 0.41 326 1.35 5.59
0700 510 0.28 320 0.90 6.49
0839 99 0.06 174 0.11 6.60
F18GPF 40 1015 135 0.68 167 1.13 0.13 0954 1.90 22.65
§ 0800 1117 62 0.79 220 1.74 2.87 1202 4.03 27.75
1313 116 1.30 230 3.00 5.87 1605 8.08 9.71
1546 153 1.27 172 2.18 8.05 0803 24.05 4.88
2245 419 1.32 195 2.58 10.63
0620 455 0.59 152 0.90 11.53
0810 110 0.46 48 0.22 11.75
F21GPF 40 0900 105 1.03 289 2.97 2.97 0915 2.00 59.86
6 0715 1020 70 1.32 208 2.75 5.72 1150 4.58 26.11
1330 90 0.77 224 1.73 7.45 1515 8.00 6.55
1525 115 0.44 78 0.34 7.79 0725 24.17 0.00
1900 215 0.39 120 0.47 8.26
2200 180 0.21 95 0.20 8.46
0545 465 0.00 393 0.00 8.46
0710 85 0.00 42 0.00 8.46
F22GPF 40 0935 69 0.83 204 1.69 1.69 1030 2.07 78.54
§ 0826 1010 35 1.24 136 1.68 3.37 1247 4.35 104.91
1220 130 1.48 242 3.57 6.97 1623 7.95 16.32
1600 220 1.73 203 3.51 10.45 0822 24.93 7.91
1900 180 0.89 130 1.16 11.61
2220 200 0.60 114 0.68 12.29
0800 580 0.39 64 0.25 12.54
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Appendix D4 FRDSEHIDE in Drine and Serui of Subjects in FRO Study (contd)
FRO urine ng FRO cun SFRU tine
subject dose urine T.int [UFRO] vol in ng sanple fron [SFRU]
start *g colln nins mg/di nl urine OFRO tine 0 hour ncg/dl
F24GPF 40 1130 150 1.59 417 6.63 6.63 1100 2.00 38.54
@ 0900 1555 265 1.76 350 6.17 12.80 1314 4.23 23.04
2135 340 1.32 44 0.58 13.38 1650 7.83 6.86
0830 655 1.35 235 3.18 16.56 0903 24.05 3.67
M25GPF 40 1035 145 1.26 575 7.22 7.22 1022 2.20 24.98
g 0810 1230 115 0.82 179 1.46 8.68 1216 4.10 9.51
1445 135 1.61 75 1.21 9.89 1608 7.97 0.00
1845 240 1.05 129 1.35 11.24 0800 23.83 0.00
2230 225 0.55 203 1.12 12.36
0345 315 0.46 171 0.78 13.14
0745 240 0.44 126 0.55 13.69
F26GPF 40 1000 90 0.72 235 1.69 1.69 1026 1.93 49.20
§ 0830 1045 45 1.78 330 5.87 7.56 1230 4.00 21.52
1145 60 1.58 350 5.53 13.09 1630 8.00 0.00
1430 165 2.08 240 5.00 18.09 0822 23.87 0.00
0230 720 0.66 80 0.53 18.62
0545 195 1.02 128 1.31 19.93
0745 120 0.43 145 0.63 20.56
F27GPF 40 0935 65 1.57 58 0.91 0.91 1043 2.22 103.93
@ 0830 1055 80 2.56 130 3.33 4.24 1247 4.28 131.31
1230 95 2.72 250 6.79 11.03 1655 8.42 19.05
1515 165 2.49 205 5.10 16.13 0838 24.13 0.00
2330 495 0.66 140 0.92 17.05
0545 375 1.13 160 1.80 18.85
0805 140 0.05 80 0.04 18.89
F28GPF 40 1000 120 2.48 168 4.17 4.17 1000 2.00 114.00
@ 0800 1155 115 4.27 238 10.16 14.33 1153 3.88 107.86
1610 255 5.26 110 5.79 20.12 1606 8.10 44.86
2200 350 0.00 255 0.00 20.12 0755 23.92 4.88
0230 270 0.00 190 0.00 20.12
0800 330 0.00 320 0.00 20.12
F29GPF 40 1010 130 1.04 48 0.50 0.50 0948 1.80 24.42
§ 0800 1145 95 1.65 210 3.47 3.97 1202 4.03 46.24
1340 115 2.77 315 8.73 12.70 1555 7.92 30.73
2100 440 4.46 225 10.04 22.74 0732 23.53 0.00
0115 255 2.33 135 3.14 25.88
0740 385 1.01 175 1.76 27.64
F40F 40 1130 255 0.93 870 8.11 8.11 0930 2.25 51.85
§ 0715 1640 310 2.53 120 3.03 11.14 1130 4.25 34.00
2015 215 3.83 90 3.45 14.59 1530 8.25 8.83
2400 225 2.58 180 4.65 19.24 0700 23.75 0.00
0400 240 0.33 350 1.14 20.38
0715 195 0.34 270 0.91 21.29
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Appendix D4 FRUSEMIDE in Urine and Serna of Subjects in FRU Study (contd)
FRU urine ng FRU cun SFRU tine
subject dose urine T.int [UFRU] vol in ng sanple fron [SFRU]
start ng colln nins ng/dl nl urine UFRU tine 0 hour ncg/dl
M45F 80 0900 130 0.99 350 3.47 3.47 0930 2.67 32.57
g 0650 1130 150 1.38 324 4.47 7.94 1137 4.79 19.09
1445 195 1.95 116 2.26 10.20 1540 8.84 8.64
2245 480 0.92 182 1.68 11.88 0700 24.17 2.00
0247 242 0.21 590 1.23 13.11
0630 223 0.49 655 3.21 16.32
0715 45 0.34 96 0.33 16.65
F47F 80 1245 58 0.93 415 3.87 3.87 1337 1.83 45.39
G 1147 1400 75 1.98 375 7.41 11.28 1600 4.22 22.06
1700 180 2.58 220 5.67 16.95 2000 8.22 4.38
2230 330 2.78 110 3.06 20.01 1125 23.37 1.67
0620 470 1.43 215 3.07 23.08
0945 205 1.19 115 1.37 24.45
1210 145 0.98 90 0.88 25.33
M48F 40 1115 210 1.83 200 3.66 3.66 0955 2.17 127.35
g 0745 1635 320 2.69 160 4.30 7.96 1145 4.00 92.01
0815 940 1.55 548 8.49 16.45 2140 13.92 38.92
0720 23.58 26.00
F49F 40 1300 180 1.69 108 1.83 1.83 1155 1.92 70.10
G 1000 1400 60 1.80 20 0.36 2.19 1615 6.25 0.00
1520 80 1.15 80 0.92 3.11 2145 11.75 0.00
1645 85 0.48 62 0.30 3.41 0715 21.25 0.00
2000 195 0.00 50 0.00 3.41
2130 90 0.00 18 0.00 3.41
0225 295 0.00 310 0.00 3.41
0550 205 0.00 178 0.00 3.41
0950 240 0.00 14 0.00 3.41
F50F 40 0900 120 1.63 110 1.79 1.79 0945 2.75 108.00
§ 0700 1115 135 1.62 102 1.65 3.44 1140 4.67 73.80
1615 300 3.11 30 0.93 4.37 2130 14.50 0.00
0015 480 1.50 30 0.45 4.82 0700 24.00 0.00
0700 405 0.39 200 0.77 5.59
F51F 40 0855 100 2.52 410 10.33 10.33 0945 2.50 93.36
G 0715 1025 90 1.57 225 3.54 13.87 1150 4.58 56.96
1120 55 2.85 75 2.14 16.01 1620 9.08 13.80
1200 40 0.23 225 0.52 16.53 0655 23.67 8.51
1340 100 4.61 80 3.69 20.22
1720 220 2.66 110 2.93 23.15
0630 790 1.07 260 2.77 25.92
F52F 40 1120 195 2.46 188 4.62 4.62 0955 1.83 210.92
§ 0805 1900 460 2.56 75 1.92 6.54 1130 3.42 230.24
2230 210 2.80 70 1.96 8.50 2120 13.25 27.74
0230 240 2.22 130 2.88 11.38 0742 23.62 11.92
0610 220 1.69 86 1.45 12.83
0750 100 1.69 36 0.61 13.44
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Appendix D4 FROSEHIDE in Drine and Serum of Subjects in FRU Study (contd)
FRU urine ng FRU cun SFRU tine
subject dose urine T.int [UFRU] vol in ng sanple fron [SFRU]
start ng colln nins ng/dl nl urine UFRU tine 0 hour ncg/dl
M53F 40 1000 105 1.11 340 3.77 3.77 1035 2.33 138.94
§ 0815 1155 115 4.36 360 15.69 19.46 1210 3.92 56.48
1600 245 4.69 210 9.85 29.31 1635 8.33 13.79
2220 380 2.48 255 6.33 35.64 0754 23.65 0.00
0540 440 1.39 370 5.14 40.78
H54F 40 1020 140 1.88 60 1.13 1.13 1015 2.25 49.09
§ 0800 1155 95 2.69 90 2.42 3.55 1200 4.00 109.53
1615 260 3.34 144 4.81 8.36 1615 8.25 65.75
2025 250 3.49 70 2.44 10.80 0733 23.55 41.54
2300 155 1.70 90 1.53 12.33
0300 240 1.42 78 1.11 13.44
0736 276 1.08 124 1.34 14.78
F55F 80 1145 135 2.42 235 5.69 5.69 1145 2.25 213.22
§ 0930 1400 135 2.56 230 5.89 11.58 1405 4.58 117.33
2055 415 3.18 240 7.63 19.21 1705 7.58 71.05
0905 23.58 52.56
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Appendix D5 SCr, UCr, & CCr, calculated over 8 & 24 hour periods, for Subjects in FRUSEMIDE Study
total 24h 24h
[SCr] urine T.int ng [DCr] urine CCr CCr % 24h SA CCr
subject ig/dl colln hours UCr ug/dl vol/ml nl/nin nl/nin CCr n2 1.73n2
F01GPF 1.16 1402 6.78 122.4 11.92 1027 26 43
2205 8.05 486.5 63.26 769 87 145
0655 8.83 374.0 38.76 965 61 102
23.66 982.9 35.60 2761 60 1.83 57
H02GPF 1.41 1500 9.00 438.3 65.12 673 58 94
2400 9.00 505.5 244.19 207 66 106
0600 6.00 319.3 255.42 125 63 102
24.00 1263.0 125.67 1005 62 2.10 51
H03GPF 1.56 1215 5.00 227.9 18.09 1260 49 153
2300 10.75 350.4 117.60 298 35 109
0720 8.33 140.5 108.10 130 18 56
24.08 718.9 42.59 1688 32 1.79 31
F04GPF 1.00 1220 4.83 145.6 26.28 554 50 114
2120 9.00 222.5 107.51 207 41 93
0645 9.42 249.8 149.58 167 44 100
23.25 617.9 66.58 928 44 1.49 51
F05GPF 1.70 1335 6.33 265.6 31.21 851 41 75
2115 7.67 440.6 112.69 391 56 102
0645 9.50 611.4 91.26 670 63 115
23.50 1317.8 68.92 1912 55 1.88 50
F06GPF 1.03 1643 6.72 325.6 19.95 1632 78 147
1955 3.20 150.2 24.58 611 76 143
0958 14.05 304.3 108.67 280 35 66
23.97 780.1 30.92 2523 53 1.81 50
H07GPF 1.75 1615 7.17 479.6 64.73 741 64 110
0030 8.25 520.5 161.66 322 60 103
0900 8.50 465.0 50.99 912 52 90
23.92 1465.3 74.19 1975 58 2.07 49
H08GPF 2.70 1600 7.50 303.5 69.76 435 25 86
2315 7.25 360.1 112.54 320 31 107
0829 9.23 463.1 158.60 292 31 107
23.98 1126.6 107.6 1047 29 1.83 27
F09GPF 1.15 1130 4.17 142.9 28.93 494 50 106
2330 12.00 349.9 111.78 313 42 89
0700 7.50 281.5 77.12 365 54 115
23.67 774.3 66.07 1172 47 1.34 61
M10GPF 1.32 2343 4.72 307.8 23.68 1300 82 106
0948 10.08 580.7 215.88 269 73 95
9.33 585.2 115.66 506 79 103
24.13 1473.9 71.03 2075 77 1.99 67
F11GPF 1.46 1545 7.75 340.9 30.09 1133 50 94
2130 5.75 320.7 176.19 182 64 121
0730 10.00 430.9 110.76 389 49 92
23.50 1092.4 64.11 1704 53 1.88 49
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Appendix D5 SCr, DCr, & CCr, calculated over 8 & 24h periods, for Subjects in FRUSEMIDE Study (contd)
total 24h 24h
[SCr] urine T.int ng [DCr] urine CCr CCr I 24h SA CCr
subject mg/dl colln hours DCr ig/dl vol/ml nl/nin nl/nin CCr 12 1.7312
M13GPF 1.30 1345 6.83 310.7 41.31 752 58 81
2205 8.33 632.3 99.27 637 97 135
0650 8.75 407.9 73.49 555 60 83
23.91 1350.9 69.49 1944 72 1.96 64
F14GPF 1.95 1445 5.75 334.4 17.50 1911 50 109
2400 9.25 486.0 56.91 854 45 98
0855 8.92 462.8 102.38 452 44 96
23.92 1282.9 39.88 3217 46 1.83 43
M16GPF 1.59 1500 7.00 423.3 42.16 1004 63 91
2300 8.00 568.5 68.74 827 74 107
0700 8.00 532.1 163.72 325 70 101
23.00 1523.9 70.68 2156 69 2.08 58
H17GPF 4.19 1457 5.95 387.8 70.00 554 26 130
2230 7.55 357.9 70.45 508 19 95
0839 10.15 425.5 86.14 494 17 85
23.65 1171.2 75.27 1556 20 2.15 16
F18GPF 1.11 1546 7.77 242.5 30.74 789 47 104
2245 6.98 222.0 113.87 195 48 107
0810 9.42 267.7 133.86 200 43 96
24.17 732.3 61.85 1184 45 1.40 56
F21GPF 1.59 1330 6.25 305.3 42.35 721 51 102
2200 8.50 419.2 143.06 293 52 104
0710 9.17 427.2 98.20 435 49 98
23.92 1151.7 79.48 1449 50 1.74 50
F22GPF 1.41 1600 7.57 272.8 34.75 785 43 165
2220 6.33 185.7 76.10 244 35 135
0800 9.67 62.5 97.72 64 8 31
23.57 521.1 47.68 1093 26 1.41 34
F24GPF 1.28 1555 6.92 473.9 61.79 767 89 178
2135 5.67 47.3 107.53 44 11 22
0830 10.92 382.3 162.70 235 46 92
23.50 903.6 86.39 1046 50 1.60 54
M25GPF 1.60 1445 6.58 274.6 33.12 829 43 86
2230 7.75 428.0 128.91 332 58 116
0745 9.25 433.9 146.08 297 49 98
23.58 1136.4 77.94 1458 50 1.71 51
F26GPF 1.62 1430 6.00 168.3 14.57 1155 29 100
0230 12.00 135.1 168.90 80 12 41
0745 5.25 357.6 130.98 273 70 241
23.25 661.0 43.83 1508 29 1.81 28
F27GPF 3.34 1515 6.75 238.2 37.04 643 18 129
2330 8.25 214.8 153.44 140 13 93
0805 8.58 199.7 83.19 240 12 86
23.58 653.0 63.83 1023 14 1.83 13
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Appendix D5 SCr, DCr, & CCr, calculated over 8 & 24h periods, for Subjects in FRUSEMIDE Study (contd)
total 24h 24h
[SCr] urine T.int ng [DCr] urine CCr CCr % 24b SA CCr
subject ng/dl colln hours DCr ng/dl vol/il nl/nin nl/nin CCr n2 1.73n2
F28GPF 2.77 1610 8.17 83.1 16.10 516 6 50
2200 5.83 150.2 58.90 255 16 108
0800 10.00 263.4 51.65 510 16 108
24.00 496.4 38.75 1281 12 1.33 16
F2SGPF 1.44 1340 5.67 110.8 19.34 573 23 85
2100 7.33 148.3 65.93 225 23 85
0740 10.67 293.8 94.78 310 32 119
23.67 553.0 49.91 1108 27 1.63 29
F40F 1.77 1130 4.25 135.0 15.52 870 30 97
2015 8.75 214.0 101.90 210 23 74
0715 11.00 450.0 56.25 800 39 126
24.00 799.0 42.50 1880 31 2.15 25
M45F 3.20 1445 7.75 408.0 51.65 790 27 96
2245 8.00 245.0 134.62 182 16 57
0715 8.50 658.0 49.07 1341 40 142
24.25 1311.0 56.68 2313 28 1.90 25
F47F 1.43 1700 5.21 183.0 18.12 1010 41 124
2230 5.50 108.0 98.18 110 23 70
1210 13.67 396.0 94.29 420 34 103
24.38 687.0 44.61 1540 33 1.72 33
M48F 1.66 1115 3.50 49.2 24.62 200 14 61
1635 5.33 132.6 82.89 160 25 109
0815 15.67 383.8 70.03 548 25 109
24.50 566.0 62.33 908 23 1.75 23
F49F 0.72 1645 6.75 209.9 77.75 270 72 131
2130 4.75 103.8 152.66 68 51 93
0950 12.33 336.2 66.98 502 63 115
23.83 650.0 77.38 840 55 2.00 48
F50F 3.34 1615 4.25 57.4 191.35 30 7 58
0700 14.75 442.0 192.17 230 15 125
1115 4.25 74.2 72.78 102 9 75
23.25 573.0 158.29 362 12 1.28 17
F51F 1.11 1340 6.42 391.7 38.59 1015 92 263
1720 3.67 45.4 41.25 110 19 54
0630 13.16 115.0 44.24 260 13 37
23.25 552.1 39.86 1385 35 1.26 49
F52F 2.91 1120 3.25 31.5 16.73 188 6 67
2230 11.17 111.5 76.90 145 6 67
0750 9.33 222.3 88.23 252 14 156
23.75 365.0 62.39 585 9 1.41 11
M53F 1.98 1600 8.00 797.8 87.67 910 84 350
2220 7.33 223.9 87.79 255 26 108
1020 12.00 380.4 78.92 482 25 113
27.33 1420.0 86.22 1647 24 1.54 27
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Appendix D5 SCr, DCr, & CCr, calculated over 8 & 24h periods, for Subjects m  FRUSEMIDE Study (contd)
[SCr] urine T.int














ng [DCr] urine CCr
DCr ng/dl vol/il ll/nin
251.3 85.49 294 29
183.3 114.59 160 25
236.8 117.21 202 26
671.0 102.29 656
261.9 56.33 465 54
333.9 139.14 240 44
596.0 84.54 705
24h 24h
CCr % 24h SA CCr







Appendix D6 Summary of Kinetic Parameters Studied in Subjects Taking FRUMIL or FRUSEMIDE
subject FRU
urine
































F04GPF FH 40 928 44.95 4.097 120.8 2.369 108.6 158.9 618 1.00 44 51
F05GPF FM 40 1912 26.98 9.132 72.9 0.923 39.4 83.0 1318 1.70 55 51
F06GPF FM 40 2523 41.10 1.855 119.1 1.701 97.9 260.5 780 1.03 53 51
F09GPF FM 40 1172 41.73 3.278 122.6 2.990 102.3 158.9 774 1.15 47 61
F11GPF FM 40 1704 60.88 0.823 144.3 1.950 175.7 * 1092 1.46 53 49
F14GPF FS 120 3217 27.56 11.416 104.8 1.436 57.8 119.6 1283 1.95 46 43
F18GPF FS 40 1184 29.38 9.330 99.5 2.211 58.5 114.4 732 1.11 45 56
F21GPF FM 40 1449 21.15 1.724 137.2 2.079 58.0 149.4 1152 1.59 50 50
F22GPF FS 40 1093 31.35 6.953 39.0 0.951 24.4 59.6 521 1.41 26 32
F24GPF FM 40 1046 41.40 7.291 116.6 2.082 96.5 196.4 904 1.28 50 54
F26GPF FM 40 1508 51.40 1.733 191.6 2.555 196.9 520.2 661 1.62 29 28
F27GPF FM 40 1023 47.23 1.488 47.0 0.618 44.4 95.7 653 3.34 14 13
F28GPF FM 40 1281 50.30 4.607 31.1 0.759 31.3 80.6 496 2.77 12 16
F29GPF FM 40 1108 69.10 6.594 61.4 1.007 84.8 96.0 553 1.44 27 29
F40F FM 40 1880 53.23 2.051 130.3 1.401 138.6 93.5 799 1.77 31 25
F47F FM 80 1540 31.63 4.943 278.9 4.358 176.4 322.7 687 1.43 33 33
F49F FS 40 840 8.55 * * * * * 650 0.72 55 48
F50F FM 40 472 13.98 3.494 47.8 1.258 13.4 16.8 573 3.34 12 16
F51F FS 40 1385 64.80 6.637 49.3 1.369 63.4 129.0 552 1.11 35 48
F52F FM 40 585 33.60 8.504 15.5 0.310 10.3 37.8 365 2.91 9 11
F55F FS 80 * * 20.166 19.3 0.247 * 43.7 * 1.81 * *
H02GPF FM 80 1005 36.59 6.776 115.0 1.250 84.1 255.3 1263 1.41 62 51
H03GPF FM 80 1688 41.39 5.344 93.8 1.321 77.6 201.3 719 1.56 32 31
M07GPF FM 40 1975 25.98 2.114 273.2 3.105 141.9 379.2 1465 1.75 58 48
H08GPF FM 40 1047 26.13 11.897 71.2 1.032 37.2 68.9 1127 2.70 29 27
M10GPF FM 40 2075 43.83 7.557 58.8 0.726 51.5 91.7 1474 1.32 77 67
H13GPF FM 40 1944 12.05 1.361 196.1 2.514 47.3 227.3 1351 1.30 72 64
H16GPF FM 40 2156 13.25 4.105 83.8 0.921 22.2 42.4 1524 1.59 69 57
H17GPF FM 80 1556 8.25 4.497 58.0 0.624 9.6 7.2 1171 4.19 20 16
M25GPF FS 40 1458 34.23 1.361 421.9 6.592 288.8 * 1136 1.60 50 51
M45F FS 80 2313 20.81 6.267 262.5 3.750 109.3 185.9 1310 3.20 28 25
M48F FS 40 908 41.13 10.719 19.7 0.308 16.1 19.7 566 1.66 23 23
M53F FM 80 1535 50.98 2.168 129.5 2.641 132.0 399.1 1420 1.78 46 52
M54F FS 40 656 36.95 15.595 14.3 0.227 10.6 21.5 671 1.98 24 27
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Appendix D7 FRUSEMIDE v FRUMIL - Mann-Whitney test
FM FS FM FS FM FS FM FS FM FS
n n nin nin nax nax Q1 Q1 Q3 Q3
age (years) 25 10 65 67 100 89 74 69 84 87
Mobility score 25 10 1 1 4 4 1 1 4 4
UCr (ng) 25 9 365 521 1524 1310 657 559 1291 1209
SCr (ng/lOOnl) 25 10 1.00 0.72 4.19 3.20 1.31 1.11 2.24 1.96
CCr (nl/nin) 25 9 9 23 77 55 28 25 57 48
CCr/SA
(nl/nin/1.73m2)
25 9 11 23 67 56 26 26 53 49
FRU dose (ig) 25 10 40 40 80 120 40 40 40 80
IDu/dose 25 9 8.25 8.55 69.10 33.07 23.56 12.15 48.76 21.28
Urine vol (nl) 25 9 472 656 2761 3217 1046 874 1928 1886
weight (kg) 25 10 38 36 93 84 54 44 80 74
SA (*2) 25 10 1.28 1.26 2.15 2.00 1.57 1.38 1.98 1.90
tl/2 (h) 25 9 0.823 1.360 11.897 20.170 1.953 6.450 6.685 13.51
Cls (nl/nin) 25 9 15.5 14.3 278.9 421.9 60.1 19.5 140.7 183.6
Cls/kg
(nl/nin/kg)
25 9 0.310 0.227 4.358 6.592 0.922 0.278 2.534 2.981
Clr (nl/nin) 25 8 9.6 10.6 196.9 288.8 38.3 18.2 120.3 97.9
Cl 0-6h 
(nl/nin)
24 8 7.2 19.7 520.2 185.9 81.2 27.0 248.3 126.7













age (years) 80.0 78.5 79.6 77.4 8.5 8.9
Mobility score 2.0 3.0 2.4 2.8 1.2 1.3
UCr (mg) 904 671 957 825 351 324
SCr (ig/lOOil) 1.590 1.630 1.864 1.655 0.839 0.678
CCr (il/min) 46.0 35.0 41.8 36.9 19.8 12.3
CCr/SA
(il/min/1.73m2)
48.8 43.5 40.3 39.2 17.6 12.4
FRU dose (ng) 40.0 40.0 48.0 56.0 16.3 28.0
IDu/dose 41.10 31.35 36.18 32.75 16.17 15.35
Urine vol (ml) 1535 1184 1515 1450 564 819
weight (kg) 71.0 64.0 68.8 61.8 16.9 16.1
SA (12) 1.810 1.730 1.770 1.661 0.261 0.267
tl/2 (h) 4.105 9.330 4.493 9.830 2.849 5.550
Cls (il/iin) 116.6 49.3 116.3 114.5 68.5 139.1
Cls/kg
(ll/min/kg)
1.401 1.369 1.723 1.899 0.988 2.092





170.1 86.7 131.3 59.5
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Appendix D8 Female v Hale Elderly taking FROHIL - Hann-Whitney test
Female Hale Female Hale Female Hale Female Hale Female Hale
n n min min max max Q1 Q1 Q3 Q3
age (years) 16 9 65 67 100 86 74 72 84 84
Hobility score 16 9 1 1 4 4 1 1 4 3
DCr (mg) 16 9 365 719 1318 1524 584 1149 963 1470
SCr (mg/lOOml) 16 9 1.00 1.30 3.34 4.19 1.19 1.37 2.52 2.24
CCr (ml/min) 16 9 9 20 60 77 17 31 52 71
CCr/SA
(ml/min/1.73m2)
16 9 11 16 61 67 18 29 51 60
FRO dose (mg) 16 9 40 40 80 80 40 40 40 80
iDu/dose 16 9 13.98 8.25 69.10 50.97 28.14 12.65 51.12 42.61
Drine vol (ml) 16 9 472 1005 2761 2156 1029 1291 1836 2025
weight (kg) 16 9 38 49 93 93 50 70 75 92
SA (m2) 16 9 1.28 1.54 2.15 2.15 1.43 1.81 1.83 2.09
tl/2 (h) 16 9 0.823 1.360 9.132 11.900 1.763 2.140 6.181 7.170
Cls (ml/min) 16 9 15.5 58.0 278.9 273.2 51.2 65.0 142.5 162.8
Cls/kg
(ml/min/kg)
16 9 0.310 0.624 4.358 3.105 0.944 0.823 2.508 2.577
Clr (ml/min) 16 9 10.3 9.6 196.9 141.9 40.7 29.7 131.1 108.1
Clr/kg
(ml/min/kg)
16 9 0.206 0.103 2.756 2.694 0.629 0.392 2.313 1.353
Cl 0-6h 
(ml/min)
15 9 16.8 7.2 520.2 399.1 83.0 55.7 196.4 317.3
2 9 8













age (years) 80.5 78.0 80.5 77.9 9.4 7.0
Hobility score 2.5 2.0 2.5 2.2 1.3 1.1
OCr (ig) 730.5 1351.0 775.5 1279.3 257.5 251.6 **
SCr (ng/lOOnl) 1.525 1.590 1.812 1.956 0.805 0.938
CCr (al/nin) 38.5 58.0 36.2 51.7 17.6 20.7
CCr/SA
(nl/ain/1.73n2)
41.0 51.1 37.1 46.0 17.4 17.4
FRU dose (ig) 40.0 40.0 42.5 57.8 10.0 21.1
IDu/dose 41.56 26.12 40.38 28.71 15.48 15.4
Orine vol. (nl) 1365 1688 1431 1665 626 423
weight (kg) 65.0 81.0 63.1 79.1 15.8 14.4 *
SA (12) 1.730 1.990 1.671 1.946 0.245 0.195 *
ti/2 (h) 3.796 4.500 4.157 5.090 2.605 3.332
Cls (il/iin) 119.9 93.8 114.3 119.9 68.8 71.9
Cls/kg
(■1/iin/kg)
1.826 1.250 1.809 1.570 1.040 0.927
Clr (il/iin) 90.7 51.5 90.1 67.0 58.4 46.2
Clr/kg
(il/ain/kg)
1.394 0.636 1.411 0.938 0.859 0.799
Cl 0-6h 
(il/ain)
139.4 201.3 160.7 185.8 127.8 143.5
* p<0.03 ** p<0.001
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Appendix D9 Feaale v Hale Elderly taking FRDSEMIDE - Mann-■Whitney test
Feaale Male Feaale Male Feaale Male Feaale Male Feaale Male
n n nin nin nax nax Q1 Q1 Q3 Q3
age (years) 6 4 67 69 87 89 67 69 83 89
Mobility score 6 4 1 1 4 4 1 2 4 4
DCr (ag) 5 4 521 566 1283 1310 536 592 1008 1266
SCr (ng/lOOnl) 6 4 0.72 1.60 1.95 3.20 1.01 1.62 1.85 2.90
CCr (al/ain) 5 4 26 23 55 50 31 23 51 45
CCr/SA
(al/nin/1.73n2)
5 4 32 23 56 51 38 23 52 45
FRO dose (ag) 6 4 40 40 120 80 40 40 90 70
IDu/dose 5 4 8.55 20.81 64.80 41.13 18.05 24.17 48.08 40.08
Orine vol (tl) 5 4 840 656 3217 2313 967 719 2301 2099
weight (kg) 6 4 36 63 84 70 40 63 80 69
SA (*2) 6 4 1.26 1.54 2.00 1.90 1.30 1.58 1.93 1.86
tl/2 (h) 5 4 6.64 1.36 20.17 15.60 6.80 2.59 15.79 14.38
Cls (al/nin) 5 4 19.3 14.3 104.8 421.9 29.1 15.7 102.2 382.0
Cls/kg
(al/ain/kg)
5 4 0.247 0.230 2.211 6.590 0.599 0.250 1.823 5.880
Clr (al/ain) 4 4 24.4 10.6 63.8 288.8 32.8 12.0 62.5 243.9
Cl 0-6h 
(al/ain)
5 3 43.7 19.7 129.0 185.9 51.7 19.7 124.3 185.9
Clr/kg 
(al/ain/kg)
4 4 0.60 0.17 1.77 4.51 0.64 0.19 1.65 3.77
300













age (years) 78.5 78.5 76.5 78.8 8.0 11.3
Mobility score 3.0 3.5 2.7 3.0 1.4 1.4
UCr (mg) 650 904 748 921 311 359
SCr (mg/lOOml) 1.260 1.820 1.352 2.110 0.466 0.746
CCr (il/iin) 45.0 26.0 41.4 31.3 11.2 12.7
CCr/SA
(ml/min/1.73m2)
47.6 26.2 45.3 31.4 8.7 12.9
FRU dose (mg) 40.0 40.0 60.0 50.0 33.5 20.0
IDu/dose 29.37 35.59 32.33 33.28 20.32 8.78
Urine vol (ml) 1184 1183 1544 1334 956 734
weight (kg) 59.0 64.0 59.5 65.3 21.1 3.2
SA (m2) 1.615 1.730 1.618 1.725 0.331 0.148
tl/2 (h) 9.33 8.49 10.90 8.49 5.53 6.09
Cls (ml/min) 49.3 141.1 62.4 179.6 37.9 198.7
Cls/kg
(ml/min/kg)
1.37 2.03 1.24 2.72 0.72 3.06
Clr (ml/min) 58.2 62.7 51.1 106.2 18.0 129.9
Cl 0-6h 
(ml/min)
114.4 21.5 93.3 75.7 38.8 95.4
Clr/kg 
(ml/min/kg)












FRU dose (ng) 25
iDu/dose 25
















Results Fron All Subjects
nin nax 01 Q3
65 100 74 84
1 4 1 4
365 1524 657 1290
1.00 4.19 1.31 2.24
9 77 28 57
11 67 26 53
40 80 40 40
8.25 69.10 23.56 48.76
472 2761 1046 1928
38 93 54 80
1.28 2.15 1.57 1.98
1.823 11.897 1.953 6.685
1.22 21.65 2.41 6.39
15.5 278.9 60.1 140.7
1.310 4.358 0.922 2.534
9.6 196.9 38.3 120.3
>.103 2.756 0.562 1.926








































n 25 25 25 25 25 25 25 25 25 25 25
KSc 0.441
OCr 0.468 0.439










ig FRU 0.229 0.424 0.153 0.111 0.056 0.055
% Du/ 
dose
0.031 0.172 0.393 0.095 0.256 0.142 0.097
0 vol 0.685
****
0.387 0.600Hi 0.265 0.640***
0.442 0.042 0.208
weight 0.278 0.263 0.609
***
0.063 0.458 0.099 0.118 0.218 0.549
***
SA 0.323 0.308 0.687
****




tl/2 0.294 0.152 0.032 0.012 0.066 0.021 0.180 0.134 0.195 0.090 0.090
Cls 0.506 0.271 0.317 0.488 0.503 0.449 0.069 0.026 0.436 0.164 0.196
Cls/kg 0.359 0.113 0.127 0.499 0.329 0.443 0.097 0.021 0.200 0.202 0.169
Clr 0.298 0.065 0.005 0.466 0.222 0.245 0.097 0.549
***
0.161 0.011 0.009












FRU dose (ng) 10
IDu/dose 9












































































Appendix D13 Spearoans Coefficient of Rank Correlation for Subjects Taking FRUSEMIDE
urine Cls/kg
age MSc UCr SCr CCr CCr/SA FRU IDu/ vol weight SA tl/2 Cls nl/nin
years ng ng/dl nl/nin 1.73n2 ng dose nl kg n2 h nl/nin /kg
n 10 10 9 10 9 9 10 9 9 10 10 9 9 9
M.Sc 0.507
UCr 0.067 0.235
SCr 0.229 0.306 0.579
CCr 0.284 0.494 0.350 0.456
CCr/SA 0.381 0.518 0.050 0.652 0.733
ng FRU 0.011 0.131 0.701 0.631 0.146 0.263
% Du/ 0.045 0.510 0.517 0.022 0.550 0.067 0,496
dose
U vol 0.591 0.332 0.600 0.282 0.350 0.217 0.730 0.217
weight 0.450 0.119 0.531 0.232 0.476 0.195 0.564 0.718 0.094
SA 0.470 0.161 0.513 0.261 0.373 0.296 0.539 0.715 0.047 0.985
tl/2 0.726 0.543 0.111 0.301 0.429 0.332 0.297 0.095 0.492 0.377 0.333
CIS 0.596 0.656 0.639 0.075 0.819 0.450 0.216 0.557 0.900 0.100 0.067 0.767
***
Cls/kg 0.581 0.702 0.602 0.167 0.797 0.524 0.108 0.535 0.820 0.017 0.000 0.800 0.983
kkkk
Clr 0.641 0.450 0.452 0.182 0.738 0.533 0.195 0.286 0.754 0.120 0.119 0.881 0.907 0.929
kkk kkk kkk
*** p<0.01 **** p<0.001
Appendix D14 Fit v Frail Elderly taking FRUMIL - Hann-Whitney 0 test
fit frail fit
lin nin lax
age (years) 67 65 85
Hobility score 1 3 3
OCr (lag) 618 365 1524
SCr (ng/lOOnl) LOO 1.28 3.34




FRO dose (ng) 40 40 40
$Du/dose 12.1 8.3 60.9
Drine vol (nl) 928 472 2761
weight (kg) 41 38 91
SA (12) 1.34 1.28 2.08
tl/2 (h) 0.823 2.051 11.897








frail fit frail fit frail
nax Q1 Q1 Q3 Q3
100 70.8 81.0 80.5 93.0
4 1.0 3.0 2.0 4.0
1420 745.8 553.0 1379.5 1171.0
4.19 1.16 1.43 1.71 2.91
62 40.3 12.0 62.3 46.0
54 43.3 16.1 58.2 51.1
80 40.0 40.0 40.0 80.0
69.1 20.2 31.6 45.5 51.0
1880 1141 1005 2095 1556
93 68.3 49.0 79.5 92.0
2.15 1.79 1.41 1.97 2.10
8.504 1.665 3.494 5.563 6.776
278.9 72.5 47.8 191.6 129.5
4.358 0.922 0.759 2.563 2.082
176.4 43.2 13.4 116.9 132.0
2.756 0.573 0.353 2.191 1.723
n = 14 for fit subjects n = 11 for frail subjects
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Appendix D14 Fit v Frail Elderly taking FROHIL - Mann-Whitney D test (contd)
fit frail fit frail fit frail
ledian nedian lean lean s.d. s.d. P
age (years) 77.5 82.0 76.0 84.1 5.7 9.6 **
Hobility score 1.0 4.0 1.5 3.5 0.7 0.5 ***
DCr (ig)) 1109.5 719.0 1069.4 814.0 328.3 340.0
SCr (ig/lOOil) 1.525 1.770 1.622 2.171 0.652 0.974
CX^ : (ll/iin) 53.0 31.0 50.7 30.4 17.5 17.0 **
CCr/SA
(nl/nin/1.73m2)
50.6 28.7 48.1 30.3 15.2 15.8 *
FRO dose (mg) 40.0 40.0 40.0 58.2 0.0 20.9
iDu/dose 34.04 41.39 33.86 39.13 15.33 17.47
Drine vol (il) 1808 1281 1727 1245 567 449
weight (kg) 74.5 61.0 72.4 64.4 13.2 20.5
SA (12) 1.830 1.630 1.824 1.700 0.202 0.318
tl/2 (h) 2.696 4.943 4.004 5.115 3.334 2.064
Cls (il/iin) 121.7 93.8 130.7 98.0 64.3 72.2
Cls/kg
(il/iin/kg)
2.014 1.258 1.862 1.546 0.872 1.137
Clr (il/iin) 62.5 84.1 85.0 77.7 54.5 56.8
Clr/kg
(il/iin/kg)
0.891 1.093 1.252 1.226 0.842 0.907
* p<0.05 ** p<0.02 *** p<0.001
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Appendix D15 Fit v Frail Elderly taking FRUSEMIDE - Mann-Whitney test
fit frail fit frail fit frail fit frail fit frail
n n sin sin sax sax 01 01 Q3 Q3
age (years) 3 7 67 67 79 89 67 69 79 88
Mobility score 3 7 1 3 1 4 1 3 1 4
UCr (ng) 3 6 521 552 1136 1310 521 563 1136 1290
SCr (ng/lOOil) 3 7 1.11 0.72 1.60 3.20 1.11 1.22 1.60 1.98
CCr (si/sin) 3 6 26 23 50 55 26 24 50 48
CCr/SA 3 6 32 23 56 48 32 25 56 48
(ml/iin/1.73m2)
FRU dose (ng) 3 7 40 40 40 120 40 40 40 80
iDu/dose 3 6 29.37 8.55 34.22 64.80 29.37 17.75 34.22 47.04
Orine vol (si) 3 6 1093 656 1458 3217 1093 794 1458 2539
weight (kg) 3 7 41 36 64 84 41 63 64 78
SA (12) 3 7 1.31 1.26 1.71 2.00 1.31 1.54 1.71 1.91
tl/2 (h) 3 6 1.36 6.27 9.33 20.17 1.36 6.54 9.33 16.74
Cls (il/iin) 3 6 39.0 14.3 422.0 262.5 39.0 18.0 422.0 144.2
Cls/kg
(■1/sin/kg)
3 6 0.95 0.23 6.59 3.75 0.95 0.24 6.59 2.01
Clr (ffll/min) 3 5 24.4 10.6 288.8 109.3 24.4 13.4 288.8 86.6
Clr/kg
(sl/sin/kg)
3 5 0.60 0.17 4.51 1.77 0.60 0.21 4.51 1.67
Cl 0-6h 
(sl/nin)
2 6 59.6 19.7 114.4 185.9 59.6 21.0 114.4 143.2
3 0 8













age (years) 69.0 81.0 71.7 79.9 6.4 9.0
Mobility score 1.0 4.0 1.0 3.6 0.0 0.5
DCr (mg) 732 660 796 839 313 358
SCr (mg/lOOml) 1.410 1.810 1.373 1.776 0.247 0.782
CCr (il/iin) 45.0 31.5 40.3 35.2 12.7 12.9
CCr/SA
(ml/min/1.73m2)
50.6 35.2 46.0 35.7 12.5 11.9
FRO dose (mg) 40.0 40.0 40.0 62.9 0.0 31.5
IDu/dose 31.35 32.25 31.65 33.30 2.44 19.33
Orine vol (ml) 1184 1147 1245 1553 190 1010
weight (kg) 45.0 70.0 50.0 66.9 12.3 15.5
SA (12) 1.400 1.830 1.473 1.741 0.210 0.258
tl/2 (h) 6.95 11.07 5.88 11.80 4.09 5.35
Cls (ll/sin) 100.0 34.5 187.0 78.3 206.0 96.4
Cls/kg
(ml/min/kg)
2.21 0.84 3.25 1.22 2.96 1.36
Clr (ml/min) 58.5 57.8 123.9 51.5 143.8 40.2
Clr/kg
(ml/min/kg)
1.30 0.79 2.14 0.91 2.09 0.74
Cl 0-6h 
(ml/min)
87.0 81.7 87.0 86.6 38.7 68.3
* p<0.0001
3 0 9
Appendix D16 Fit v Frail Age Hatched Elderly taking FRUMIL - Hann-Whitney test
fit frail fit frail fit frail fit frail fit frail
n n ain ain aax aax Q1 Q1 Q3 Q3
age (years) 8 7 77 76 85 86 78 81 83 84
Mobility score 8 7 1 3 3 4 1 3 2 4
UCr (ag) 8 7 618 496 1524 1420 655 687 1381 1263
SCr (ag/lOOnl) 8 7 1.00 1.28 3.34 4.19 1.23 1.41 2.46 2.77
CCr (al/ain) 8 7 14 12 69 62 29 20 57 50
CCr/SA
(al/ain/1.73a2)
8 7 13 16 61 54 27 16 56 52
FRO dose (ag) 8 7 40 40 40 80 40 40 40 80
IDu/dose 8 7 13.25 8.25 60.88 50.97 26.01 31.62 50.36 50.30
0 vol (ill) 8 7 928 1005 2156 1688 1029 1046 1907 1556
weight (kg) 8 7 41 41 91 93 56 49 85 92
SA (i2) 8 7 1.34 1.33 2.08 2.15 1.57 1.54 2.02 2.10
tl/2 (h) 8 7 0.82 2.17 11.90 7.29 1.55 4.50 4.10 6.78
Cls (il/iin) 8 7 47.0 31.1 273.2 278.9 74.3 58.0 179.8 129.5
Cls/kg
(al/ain/kg)
8 7 0.618 0.624 3.105 4.358 0.949 0.759 2.881 2.641
Clr (al/ain) 8 7 22.2 9.6 196.9 176.4 39.0 31.3 167.3 132.0
Clr/kg
(al/ain/kg)
8 7 0.244 0.103 2.625 2.756 0.550 0.763 2.465 2.694
Clr 0-6h 
(al/ain)
7 7 42.4 7.2 520.2 399.1 68.9 80.6 379.2 322.7
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age (years) 79.0 82.0 80.1 81.7 2.9 3.1
mobility score 2.0 3.0 1.8 3.4 0.7 0.5
DCr (lg) 933 904 989 951 368 341
SCr (mg/lOOml) 1.605 1.560 1.826 2.060 0.796 1.064
CCr (ll/sin) 45.5 33.0 42.9 36.4 17.9 17.5
CCr/SA
(ml/min/1.73m2)
48.6 33.2 41.9 36.1 16.9 16.6
FRO dose (mg) 40.0 80.0 40.0 68.6 0.0 19.5
iDu/dose 43.34 41.39 38.94 37.22 15.77 14.53
0 vol (nl) 1340 1535 1439 1379 468 270
weight (kg) 74.5 64.0 70.6 66.6 17.1 20.2
SA (12) 1.830 1.720 1.791 1.747 0.258 0.297
tl/2 (h) 2.70 4.94 3.69 5.09 3.53 1.68
Cls (il/iin) 121.7 115.0 131.8 117.6 72.8 79.3
Cls/kg
(il/iin/kg)
2.159 1.321 1.942 1.862 0.973 1.310
Clr (il/iin) 105.4 84.1 103.7 86.8 65.4 56.7
Clr/kg
(al/ain/kg)
1.871 1.093 1.575 1.435 0.980 1.002
Clr 0-6h 
(ml/min)
158.9 201.3 203.5 208.9 178.3 134.6
* p<0.05 ** p<0.005
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Appendix El
INFORMATION SHEET FOR HEART TABLET STUDY
Dr. Parker is carrying out a project with St. Mark's Road 
Surgery looking at the way in which the heart tablets 
(Digoxm or Lanoxin) you take are handled by your body.
This will involve noting the exact time at which your heart 
tablet was taken on 2 occasions, collecting your urine for 
24 hours, and having 3 blood samples taken over 5 days.
YOUR MEDICATION WILL NOT BE ALTERED OR STOPPED DURING THE 
TRIAL.
These instructions should be followed carefully during the 
study. If you are not sure what to do at any time, then 
let someone know. Phone numbers are given at the bottom of 
the page. If you change your mind and no longer want to 
help us, also phone these numbers.
1) On the morning of the study please do not take your 
heart tablet until Dr. Parker calls. When he arrives, he 
will ask you to empty your bladder. Following this, you 
may then take your heart tablet.
2) Every time you pass urine after taking the tablet please 
collect it all, in a separate container provided. Write on 
the container your name, and time at which the urine was 
passed. ALL urine should be collected, even at night time. 
If you should happen to run out of containers in which to 
collect urine, a clean jam jar, or similar, will do.
3) Eleven hours after taking your heart tablet Dr Parker 
will call at your home, and take a small blood sample from 
you. You must continue to collect your urine.
4) Exactly 24 hours from when you started the urine 
collection, you must again pass urine, and save it. Dr 
Parker will again call on you, take a blood sample, and 
collect the urine. Once the urine collection has been 
completed, you may take your heart tablet as usual.
5) About 5 days later, a further blood sample will be taken 
Dr. Parker will arrange this with you at the time of the 
study. We will need to know the exact time you took your 
heart tablet, but no urine collections will be necessary.
6) If you are taking any other tablets, you may take these 
as normal, but let us know what you have taken.
Dr. Parker will call at................on..................
Please do not take your heart tablet until he arrives.
Dr. Parker will then call at....... on ............. evening
and again at...............on................... morning
Please do not take your next heart tablet until he arrives.
We will phone you to arrange the last visit, which will be 
about five days later.
IN CASE OF QUERY, PLEASE DO NOT HESITATE TO CONTACT 
SUE ELLMERS (STUDY CO-ORDINATOR) AT WORK ON BATH 835866
OR AT HOME ON BATH 834963
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Appendix E2
MEASUREMENT OF DIGOXIN CLEARANCE IN THE ELDERLY
Name : .......................... Study No..............
Address : ......................... Study Date............




DOB : .................................. 2





Int. Start (1)...... (2).....Date (1)........ (2).......
Act.Time n (1)...... (2).....Date (1)........ (2).......
Pulse Rate (1)...... (2)...... Rhythm..........BP.........
Dose.........  Dose unchanged 3/52......... Compliance Y / N
Digitalisation : sub-therapeutic - toxic - OK (from obs)
Time/llh Date Time/llh DateBlood Samples
Intended
Actual
Start urine col In............. Date....






















Appendix E3 Demographic Details and Medications of Subjects Taking Part in DIGOXIN Study 
subject sex/age wt/ht fit/MSc smoker EtOH diagnoses drugs
F01D F 77 35/137 Y / 2 yes occ. AF, confusion 
1 L. NOF '89
digoxin, paracetamol









calcuim heparin inj. 
temazepam




F08DGP F 81 41/152 N / 4 no 14/wk CCF, fast AF 
CVA, catheterised 
# L femur, PE 1984
digoxin,co-amilofruse 
bisacodyl
F11D F 75 50/151 N / 4 no no fast AF, LVF, CVA digoxin, trimethoprim




F14DGP F 90 52/151 Y / l no 1/wk glaucoma digoxin
F15DGP F 82 54/156 Y / 2 no no AF, diverticulitis digoxin













F19DGP F 76 75/165 Y / l no 14/wk AF, OA digoxin,nifedipine,amiloride 
spinal decompression diclofenac,frusemide












F24DGP F 96 44/148 N / 3 no occ. AF,partially sighted digoxin, co-amilofruse
F29D F 90 46/149 N / 4 no no AF, CCF, CVA 1982 digoxin, co-amilofruse
F30D F 81 53/152 N / 5 no no AF,CCF,IHD,leg ulcer digoxin,captopril,cefadroxil 
















































of Subjects Taking Part in DIGOXIN Study (contd)
diagnoses drugs
AF, LVF, COAD digoxin, co-amilofruse
thyrotoxicosis 1977 chlormethiazole,salbutamol
AF, R. THR digoxin, co-amilofruse
CVA & L hemiplegia temazepam
CVA 1972, anaemia digoxin,warfarin,FeS04
mitral valve disease tetrabenazine,co-amilofruse
cervical spondylosis digoxin,Premarin


















AF, chest pain digoxin,diclofenac,Gaviscon
cervical spondylosis captopril,bumetanide
CCF, HI 1977, SOB 
emphysema, HH
LVF, OA, THR 













AF, CCF, emphysema digoxin, co-amilozide 
R nephrectomy 1947 GTN, Hucaine, oxygen




cardiomyopathy 1989 digoxin,frusemide,captopril 
thyrotoxicosis 1989 warfarin,captopril 
fast AF, CCF, TIA's co-dydramol
AF, pseudomembranous digoxin, theophylline 
colitis 1990, COAD Duovent inh., temazepam 
erythema multiforma
3 no occ. COAD, OA digoxin, co-amilofruse 
salbutamol inh., temazepam
OA, bowel resection digoxin, temazepam 
depression paracetamol, senna
? alcoholic ispagula husk
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Appendix E3 Demographic Details and Medications of Subjects Taking Part in DIGOXIN Study (contd) 
subject sex/age wt/ht fit/MSc smoker EtOH diagnoses drugs
noM35DGP M / 89 60/169 Y / 1
H36DGP M / 70 78/184 Y / 1
H40DGP H / 75 78/179 Y / 1
M41DGP H / 85 71/178 Y / 1
H42DGP H / 82 69/171 Y / 1
M43DGP M / 78 75/172 Y / 1
M47DGP M / 88 80/162 N / 3
M48DGP H / 78 74/162 Y / l
M49D M / 81 67/182 N / 4
M50DGP M / 81 77/165 N / 3
M51DGP M / 76 95/178 Y / 1
H53DGP M / 67 65/171 N / 3
no











M55DGP M / 67 55/171 N / 3 ex.




AF, CVA x 2
digoxin, aspirin 
ascorbic acid,
no angina, HI 1976 digoxin,nifedipine,GTN
hypertension isosorbide dinitrate
TURP, claudication inosital nicotinate











no lild CCF, AF 
glaucoma
digoxin
pilocarpine & timolol ED
no AF,CCF,gangrene toe digoxin, co-amilofruse
21/wk nephrectomy '42 (TB) digoxin,bendrofluazide
urinary frequency allopurinol,aminophylline 
diclofenac
occ. AF, RA, leg ulcers digoxin,co-amilofruse








occ. AF & IHD
no AF, angina, COAD 
indigestion





= fit: Y for fit, N for frail 
= alcohol consumption- approx. units per week 











Appendix E4 Summary of Results from the DIGOXIN Study
Ho. H.Sc fit SCr (UCrl tine CCr U vol U DIG U DIG S DIG dose \ Du total Cl renal Cl
■g/dl ig/dl hours ■l/iin ■1 ■cg/24h ■cg/dl ng/ii ■eg ■l/iin ■1/ain
1 2 Y 0.62 0.50 125.0 116.32
2 2 Y 1.27 65.5 25.42 69.6 2059 51.77 2.51 0.83 62.5 82.83 35.04 43.31
4 5 N 2.69 420.8 23.83 63.5 580 23.80 4.10 0.80 125.0 19.04 72.70 20.66
5 5 N 2.19 3.00 125.0 19.39
8 4 N 2.38 95.9 23.15 29.8 1026 23.90 2.33 0.39 62.5 38.24 74.56 42.56
11 4 N 0.36 85.6 23.92 141.2 852 50.70 5.95 0.26 125.0 40.56 223.69 135.42
12 1 Y 0.58 75.8 24.00 84.9 936 43.42 4.64 0.48 125.0 34.74 121.17 62.82
14 1 Y 0.59 38.3 24.00 78.7 1746 49.39 2.83 0.20 62.5 79.02 145.40 171.49
15 2 Y 0.62 108.9 24.05 108.1 888 52.89 5.96 0.46 125.0 42.31 126.43 79.85
16 1 Y 0.72 44.5 24.07 80.1 1871 28.65 1.53 0.14 62.5 45.84 207.71 142.11
17 3 N 1.05 98.7 23.93 68.7 1050 77.96 7.42 0.32 125.0 62.37 181.75 169.18
18 1 Y 0.64 61.5 24.00 73.5 1102 43.05 3.91 0.28 62.5 68.88 103.86 106.77
19 1 Y 1.27 58.4 24.05 64.1 2010 97.74 4.86 1.08 250.0 39.10 107.70 62.85
20 3 N 0.82 66.9 23.91 44.1 776 74.53 9.60 1.74 250.0 29.81 66.85 29.75
21 4 N 1.18 100.4 24.50 28.4 490 23.74 4.84 0.68 62.5 37.98 42.76 24.24
22 3 N 1.18 45.3 23.50 31.3 1150 41.31 3.59 0.50 125.0 33.05 116.32 57.37
24 3 N 0.72 32.5 24.00 31.3 1000 52.00 5.20 2.50 250.0 20.80 46.53 14.44
29 4 N 0.69 71.9 24.25 35.1 490 78.00 15.92 1.31 125.0 62.40 44.40 41.35
30 N 2.32 38.8 24.33 9.4 820 19.40 2.37 1.38 62.5 31.04 21.07 9.76
33 3 M 0.88 45.1 24.83 27.0 786 72.70 9.25 1.03 125.0 58.16 56.47 49.02
34 5 N 0.60 57.7 24.00 61.6 922 86.90 9.43 1.00 125.0 69.52 58.16 60.35
37 2 Y 0.67 32.9 24.00 49.4 1449 63.31 4.37 0.88 250.0 25.32 132.18 49.96
44 3 N 0.34 74.3 25.34 126.6 881 165.90 18.83 1.24 250.0 66.36 93.81 92.91
46 1 Y 0.75 63.4 24.03 78.3 1336 39.80 2.98 0.53 125.0 31.84 109.74 52.15
52 2 Y 1.61 84.6 24.00 63.9 1752 85.10 4.86 1.85 250.0 34.04 62.88 31.94
54 2 Y 1.66 101.5 24.00 52.0 1224 20.90 1.71 0.36 62.5 33.44 80.78 40.32
3 4 N 2.08 115.6 27.00 77.9 2270 46.96 2.07 0.30 62.5 75.14 96.93 108.70
6 4 N 2.37 114.3 24.01 45.6 1362 67.12 4.93 1.70 125.0 53.70 34.21 27.42
9 1 Y 1.18 133.4 24.50 106.0 1378 90.00 6.53 0.52 250.0 36.00 223.69 120.19
10 3 N 1.16 91.0 25.04 44.6 854 44.70 5.23 0.59 125.0 35.76 98.58 52.61
13 Y 1.05 85.8 24.00 83.2 1466 62.00 4.23 0.49 125.0 49.60 118.69 87.87
23 1 Y 0.55 49.3 24.00 193.3 3105 117.80 3.79 0.45 250.0 47.12 258.49 181.79
25 4 N 0.73 49.3 24.00 28.8 614 22.80 3.71 0.49 62.5 36.48 59.35 32.31
26 3 N 0.98 104.0 25.25 108.4 1548 106.10 6.85 0.38 125.0 84.88 153.05 193.90
31 3 N 0.80 139.8 23.50 61.0 492 62.50 12.70 0.71 250.0 25.00 163.83 61.13
35 1 Y 0.91 87.7 23.92 84.9 1264 52.70 4.17 0.28 125.0 42.16 207.71 130.70
36 1 Y 1.45 222.4 23.28 87.2 794 72.60 9.14 0.44 250.0 29.04 264.36 114.58
38 1 Y 1.10 106.3 24.58 82.4 1258 32.70 2.60 0.26 62.5 52.32 111.85 87.34
40 1 Y 0.92 116.0 23.83 99.5 1128 88.90 7.88 0.76 125.0 71.12 76.53 81.23
41 1 Y 0.61 72.9 24.00 105.1 1266 52.90 4.18 0.64 125.0 42.32 90.87 57.40
42 1 Y 1.41 101.9 24.15 68.0 1364 61.90 4.54 1.08 125.0 49.52 53.85 39.80
43 1 Y 1.09 59.0 24.05 88.4 2356 64.10 2.72 0.50 250.0 25.64 232.64 89.03
47 3 N 1.41 60.8 24.22 46.7 1574 25.60 1.63 0.31 62.5 40.96 93.81 57.35
48 1 Y 1.28 68.4 23.83 56.1 1502 58.40 3.89 1.30 125.0 46.72 44.74 31.20
49 4 N 0.95 38.5 24.00 48.0 1707 54.00 3.16 0.72 125.0 43.20 80.78 52.08
50 3 N 0.91 30.7 24.25 86.8 3742 86.40 2.31 0.99 125.0 69.12 58.75 60.61
51 1 Y 1.16 104.6 24.00 102.3 1634 125.90 7.71 0.75 250.0 50.36 155.09 116.57
53 3 N 1.13 93.0 23.28 82.8 1406 163.90 11.66 0.98 250.0 65.56 118.69 116.14
55 3 N 0.77 38.1 24.00 96.0 2795 32.60 1.17 0.41 125.0 26.08 141.85 55.22
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Appendix E5 SCr, DCr & CCr, calculated over 8 & 24 hour periods, for Subjects in DIGOXIN Study
total 24h 24h
[SCr] urine T.int mg [OCr] urine CCr CCr % 24h SA CCr
subject ng/dl colln hours OCr ig/dl vol/Bl il/flin nl/nin CCr 12 1.73112
F02D 1.27 1515 6.75 348.7 37.7 925 68 97
1845 3.50 145.6 34.7 420 55 79
0955 15.17 853.5 119.5 714 74 106
Totals 25.42 1347.8 65.5 2059 70 1.95 62
F04D 2.69 1330 3.50 420.4 362.4 116 74 116
1550 2.33 430.3 589.5 73 114 178
0950 18.00 1589.8 406.6 391 55 86
Totals 23.83 2440.5 420.8 580 64 1.79 61
F08GPD 2.38 1730 10.65 320.6 81.7 334 18 60
0600 12.50 662.9 95.8 692 37 123
Totals 23.15 983.5 95.9 1026 30 1.33 39
F11D 0.34 1400 5.67 184.8 72.2 256 160 113
2045 6.75 185.9 68.8 270 135 96
0815 11.50 358.7 110.0 326 153 109
Totals 23.92 729.4 85.6 852 141 1.46 167
F12GPD 0.58 1545 7.50 128.2 46.8 274 49 58
0130 9.75 454.3 93.5 486 134 158
0815 6.75 126.6 71.9 176 54 64
Totals 24.00 709.1 75.8 936 85 1.48 99
F14GPD 0.59 1300 5.75 191.9 37.2 516 94 119
2315 10.25 253.7 26.0 976 70 89
0715 8.00 223.0 87.8 254 79 100
Totals 24.00 668.6 38.3 1746 79 1.49 91
F15GPD 0.62 1350 6.13 288.8 87.5 330 127 118
2150 8.00 353.6 92.1 384 119 110
0745 9.92 324.8 186.7 174 88 81
Totals 24.05 967.2 108.9 888 108 1.55 121
F16GPD 0.72 1400 6.07 186.1 82.3 226 71 89
2245 8.75 306.4 40.5 756 81 101
0800 9.25 340.0 38.2 889 85 106
Totals 24.07 832.5 44.5 1871 80 1.61 86
F17GPD 1.05 1200 3.93 182.0 82.0 222 74 107
2245 10.75 487.8 112.9 432 72 104
0800 9.25 366.7 92.6 396 63 91
Totals 23.93 1036.5 98.7 1050 69 1.63 73
F18GPD 0.64 1325 5.92 150.1 61.0 246 66 89
2305 9.67 285.2 71.0 402 77 104
0730 8.41 242.9 53.5 454 75 101
Totals 24.00 678.2 61.5 1102 74 1.49 85
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Appendix E5 SCr, OCr & CCr, calculated over 8 & 24h periods, for Subjects in DIGOXIN Study (contd)
total 24h to 4*. cr
[SCr] urine T.int ug [OCr] urine CCr CCr % 24h SA CCr
subject ug/dl colln hours OCr ug/dl vol/nl ul/nin ul/uin CCr n2 1.7312
F19GPD 1.27 1330 5.30 276.7 28.3 979 69 108
2240 9.17 427.0 83.4 512 61 95
0815 9.58 469.5 90.5 519 64 100
Totals 24.05 1173.2 58.4 2010 64 1.87 59
F20D 0.82 1330 5.58 83.8 40.0 222 32 73
1930 6.00 156.9 53.7 292 53 120
0750 12.33 273.1 104.2 262 45 102
Totals 23.91 518.8 66.9 776 44 1.61 47
F21GPD 1.18 1310 7.17 328.0 96.5 340 65 232
0630 17.33 163.9 109.2 150 13 46
Totals 24.50 491.9 100.4 490 28 1.40 35
F22D 1.18 1200 5.50 194.0 32.2 602 50 161
1930 7.50 103.0 37.9 272 19 61
0600 10.50 224.1 81.2 276 30 97
Totals 23.50 521.1 45.3 1150 31 1.59 34
F24GPD 0.72 1120 4.83 81.0 10.8 750 39 126
1630 5.17 73.2 81.3 90 33 106
0630 14.00 170.5 106.6 160 28 90
Totals 24.00 324.7 32.5 1000 31 1.36 40
F29GPD 0.69 1145 4.00 47.4 37.6 126 29 83
1930 7.75 41.5 90.2 46 13 37
0800 12.50 263.4 82.8 318 51 146
Totals 24.25 352.3 71.9 490 35 1.40 43
F30D 2.32 0700 10.00 98.5 133.1 74 7 78
1500 8.00 141.9 31.1 456 13 144
2120 6.33 77.5 26.7 290 9 100
Totals 24.33 317.9 38.8 820 9 1.51 11
F33D 0.88 1140 3.50 38.2 15.9 240 21 78
2030 8.83 111.9 32.9 340 24 89
0900 12.50 204.6 99.3 206 31 115
Totals 24.83 354.7 45.1 786 27 1.43 33
F34GPD 0.60 1400 6.00 124.9 24.9 502 58 94
1905 5.08 126.3 63.2 200 69 111
0800 12.92 281.2 127.8 220 60 97
Totals 24.00 532.4 57.7 922 62 1.68 63
F37GPD 0.67 1330 5.25 164.1 15.1 1087 78 159
2220 8.83 261.2 76.8 340 74 151
0815 9.92 51.0 232.0 22 13 27
Totals 24.00 476.3 32.9 1449 49 1.45 59
F44D 0.34 1415 6.25 184.0 167.2 110 144 113
2210 7.92 209.0 133.1 157 129 102
0920 11.17 262.0 42.7 614 115 91
Totals 25.34 655.0 74.3 881 127 1.39 158
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Appendix E5 SCr, OCr & CCr, calculated over 8 & 24h periods, for Subjects in DIGOXIN Study (contd)
total 24h 24h
[SCr] urine T.int ug [OCr] urine CCr CCr % 24h SA CCr
subject ug/dl colln hours OCr ug/dl vol/ul ul/uin nl/nin CCr u2 1.73U2
F46GPD 0.75 1600 7.50 251.2 103.8 242 74 95
2130 5.50 204.9 84.0 244 83 106
0832 11.03 390.8 46.0 850 79 101
Totals 24.03 846.9 63.4 1336 78 1.56 87
F52GPD 1.61 1415 8.75 424.9 107.8 394 50 78
2100 6.75 377.9 57.4 658 58 91
0530 8.50 680.2 97.2 700 83 130
Totals 24.00 1482.0 84.6 1752 64 1.70 65
F54GPD 1.66 1245 4.42 281.4 44.1 638 64 123
2200 9.25 397.6 126.6 314 43 83
0820 10.33 461.5 169.7 272 45 87
Totals 24.00 1140.5 101.5 1224 52 1.70 53
F01D 0.62 1.17
F05D 2.19 1.44
M03D 2.08 0830 10.50 1080.5 114.3 945 82 105
1845 10.25 1198.0 120.4 995 94 121
0100 6.25 345.6 104.7 330 44 56
Totals 27.00 2624.1 115.6 2270 78 1.93 70
H06D 2.37 1530 6.17 479.7 58.1 825 55 120
1940 4.17 102.6 131.5 78 17 37
0920 13.67 974.9 212.4 459 50 109
Totals 24.01 1557.2 114.3 1362 46 1.71 46
M09GPD 1.18 1330 6.50 654.9 153.0 428 142 134
2200 8.50 785.2 133.0 590 130 123
0730 9.50 398.2 110.6 360 59 56
Totals 24.50 1838.3 133.4 1378 106 2.20 83
H10GPD 1.16 1630 7.12 183.7 113.4 162 37 82
2330 7.00 180.8 83.7 216 37 82
0925 10.92 412.6 86.7 476 54 120
Totals 25.04 777.1 91.0 854 45 1.79 43
M13GPD 1.05 1400 5.00 407.1 46.5 876 129 155
2115 7.25 462.3 122.3 378 101 122
0900 11.75 388.2 183.1 212 52 63
Totals 24.00 1257.6 85.8 1466 83 1.91 75
M23GPD 0.55 0900 10.75 664.7 117.0 568 187 97
1530 6.50 449.6 23.8 1888 209 108
2215 6.75 415.3 64.0 649 186 96
Totals 24.00 1529.6 49.3 3105 193 2.04 164
H25D 0.73 1500 4.00 74.0 127.6 58 42 145
1915 4.25 27.9 139.6 20 15 52
1100 15.75 200.5 37.4 536 29 100
Totals 24.00 302.4 49.3 614 29 1.36 37
Appendix E5 SCr, OCr & CCr, calculated over 8 & 24h periods, for Subjects in DIGOXIN Study (contd)
total 24h 24h
[SCr] urine T.int ug [UCr] urine CCr CCr 1 24h SA CCr
subject ug/dl colln hours OCr ug/dl vol/ul ul/nin ul/uin CCr n2 1.73U2
M26D 0.98 1445 6.25 717.2 99.3 722 195 181
2130 6.75 439.8 81.4 540 111 103
0945 12.25 455.6 159.3 286 63 58
Totals 25.25 1609.6 104.0 1548 108 2.00 94
H31GPD 0.80 1135 3.92 202.5 151.1 134 108 177
1730 5.91 140.2 143.1 98 49 80
0710 13.67 345.0 132.7 260 53 87
Totals 23.50 687.7 139.8 492 61 1.80 59
H35GPD 0.91 1345 5.42 289.3 272.9 106 98 115
2230 8.75 460.0 86.5 532 96 113
0815 9.75 358.6 57.3 626 67 79
Totals 23.92 1107.9 87.7 1264 85 1.69 87
H36GPD 1.45 1550 7.83 555.8 402.7 138 82 94
2225 6.58 507.3 248.7 204 89 102
0717 8.87 703.0 155.5 452 91 104
Totals 23.28 1766.1 222.4 794 87 2.00 75
H38GPD 1.10 1250 5.08 287.2 105.6 272 86 105
2200 9.17 496.3 143.4 346 82 100
0820 10.33 553.7 86.5 640 81 99
Totals 24.58 1337.2 106.3 1258 82 1.68 85
H40GPD 0.92 1505 7.08 372.9 126.9 294 95 95
2100 5.92 358.4 122.7 292 110 110
0750 10.83 577.3 106.5 542 97 97
Totals 23.83 1308.6 116.0 1128 100 1.98 87
M41GPD 0.61 1545 7.75 271.3 222.3 122 96 91
2100 5.25 235.8 94.3 250 123 117
0800 11.00 415.8 46.5 894 103 98
Totals 24.00 922.9 72.9 1266 105 1.88 97
H42GPD 1.41 1345 4.80 432.3 184.7 234 106 156
2252 9.12 427.9 105.9 404 55 81
0906 10.23 530.4 73.1 726 61 90
Totals 24.15 1390.6 101.9 1364 68 1.82 65
M43GPD 1.09 1357 5.98 387.5 60.4 642 99 113
2242 8.75 549.0 68.3 804 96 109
0801 9.32 453.1 49.8 910 74 84
Totals 24.05 1389.6 59.0 2356 88 1.91 80
M47GPD 1.41 1515 7.25 334.8 37.0 904 55 117
2115 6.00 229.9 74.7 308 45 96
0813 10.97 391.6 108.2 362 42 89
Totals 24.22 956.3 60.8 1574 47 1.92 42
M48GPD 1.28 1510 9.33 395.5 138.3 286 55 98
2320 8.17 462.0 70.0 660 74 132
0540 6.33 169.2 30.4 556 35 63
Totals 23.83 1026.7 68.4 1502 56 1.85 53
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Appendix E5 SCr, OCr & CCr, calculated over 8 & 24h periods, for Subjects in DIGOXIN Study (contd)
total 24h 24h
[SCr] urine T.int ng [OCr] urine CCr CCr 1 24h SA CCr
subject ug/dl colln hours OCr ug/dl vol/nl nl/iin nl/nin CCr 12 1.73B2
H49D 0.95 1430 6.00 185.7 24.6 755 54 113
2205 7.58 166.4 58.6 284 39 81
0830 10.42 304.5 45.6 668 51 106
Totals 24.00 656.6 1707 48 1.84 45
M50GPD 0.91 1515 7.08 22.5 31.1 1679 135 155
2130 6.25 350.7 83.9 418 103 118
0825 10.92 775.0 47.1 1645 130 149
Totals 24.25 1148.2 30.7 3742 87 1.90 79
H51GPD 1.16 1400 6.25 372.9 181.0 206 86 84
2330 9.50 747.1 125.8 594 113 111
0745 8.25 589.6 70.7 834 103 101
Totals 24.00 1709.6 104.6 1634 102 2.18 81
M53GPD 1.13 0757 10.87 707.2 106.2 666 96 116
1456 6.98 332.4 63.4 524 70 84
2022 5.43 268.4 124.3 216 73 88
Totals 23.28 1308.0 93.0 1406 83 1.77 81
H55GPD 0.77 1525 7.67 326.9 21.1 1550 92 96
2230 7.08 423.8 56.9 745 130 135
0745 9.25 313.0 62.6 500 73 76
Totals 24.00 1063.7 38.1 2795 96 1.62 103
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Appendix E6 Suaaary of Results Froa All Feaale Subjects Taking DIGOXIH
n ain aax Q1 Q3 nedian aean s.d.
age (years) 26 73 96 77 84 81.5 81.9 5.8
nobility score 26 1 5 2 4 3.0 2.8 1.4
urine voluae (al) 24 490 2059 828 1421 1013 1133 461
OCr (ng in 24h) 24 318 2441 499 1024 693.7 816.0 474.5
[OCr] (ag/lOOal) 24 32.5 420.8 45,1 93.3 66.2 82.1 75.8
[SCr] (mg/lOOml) 26 0.34 2.69 0.62 1.36 0.785 1.092 0.662
CCr (al/ain) 24 9 141 32 79 63.7 62.5 32.0
CCr/SA
(al/ain/1.73a2)
24 11 167 41 87 61.6 69.7 37.9
dose (ug) 26 62.5 250.0 62.5 156.2 125.0 134.6 70.0
IDu 24 19.0 82.8 32.1 62.4 38.7 45.28 18.53
ODIG (ug in 24h) 24 19.4 165.9 31.4 77.1 51.24 56.95 32.7
[ODIG] (ug/lOOal) 24 1.5 18.8 2.9 7.1 4.7 5.79 4.27
[SDIG] (ng/al) 26 0.14 3.00 0.382 1.26 0.740 0.913 0.715
Clt (al/ain) 26 19 224 54 123 87.3 94.9 53.6
Clt/SA
(al/ain/1.73a2)
26 23 265 60 146 98.3 107.9 62.0
Clt/kg (al/ain/kg) 26 0.398 4.474 1.011 2.430 1.627 1.804 1.039
Clr (al/ain) 24 10 171 34 90 51.1 66.3 46.7
Clr/SA
(al/nin/1.73n2)
24 11 199 34 109 58.7 74.3 53.1
Clr/kg (al/ain/kg) 24 0.184 3.298 0.547 1.990 0.976 1.234 0.882
Clr/CCr 24 0.326 2.461 0.689 1.446 0.970 1.091 0.565
Clnr (al/ain) 24 -30 105 5 61 40.3 34.5 33.9
Clnr/kg (al/ain/kg) 24 -0.583 2.092 0.109 1.069 0.589 0.637 0.647
weight (kg) 26 35 76 46 60 52.5 53.9 10.1
SA (a2) 26 1.17 1.95 1.42 1.64 1.50 1.54 0.17
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Appendix E7 Speamans Coefficient of Rank Correlation for All Female Subjects Taking DIGOXIN
Clt/kg Clr/kg
age H.Sc weight SCr CCr dose %Du ODIG SDIG Clt ml/min Clr ml/min Clnr 
years kg ig/dl ml/min meg meg ng/ml ml/min /kg ml/min /kg ml/min
n 26 26 26 26 24 26 24 24 26 26 26 24 24 24
H.Sc 0.213
weight -0.068 -0.248
SCr 0.172 0.323 0.353
CCr -0.375 -0.527 0.162 -0.612 
H i
dose 0.066 0.017 0.003 -0.206 0.068
IDu -0.346 -0.168 -0.090 -0.426 0.395 -0.346
ODIG -0.124 -0.053 0.018 -0.413 0.219 0.723
H i i
0.365









0.055 0.086 0.026 -0.744
H i i






0.041 0.152 0.035 -0.732
H i i
















Clnr -0.070 -0.126 0.084 0.020 0.154 0.229 -0.611
H i
-0.277 -0.245
Clnr/kg 0.014 -0.086 -0.034 -0.007 0.095 0.229 -0.658 -0.310 -0.194
***
*** ****
*** p<0.01 **** p<0.001
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Appendix E8 Summary of Results From All Hale Subjects Taking DIGOXIN
n min max
age (years) 23 66 89
mobility score 23 1 4
urine volume (ml) 23 492 3742
OCr (mg in 24b) 23 302 2624
[OCr] (mg/lOOml) 23 30.7 222.4
[SCr] (mg/lOOml) 23 0.55 2.37




dose (ug) 23 62.5 250.0
IDu 23 25.0 84.9
ODIG (ug in 24h) 23 22.8 163.9
[ODIG] (ug/lOOml) 23 1.2 12.7
[SDIG] (ng/ml) 23 0.26 1.70




Clt/kg (ml/min/kg) 23 0.552 3.462




Clr/kg (ml/min/kg) 23 0.422 2.281
Clr/CCr 23 0.546 1.788
Clnr (ml/min) 23 -35 130
Clnr/kg (ml/min/kg) 23 -0.416 1.734
weight (kg) 23 41 96
SA (m2) 23 1.36 2.20
Q1 Q3 median mean s.d.
75 81 79.0 77.8 6.4
1 3 2.0 2.2 1.2
1258 1707 1406 1603 784
956 1557 1308 1273 484
59.0 114.3 91.00 90.56 42.3
0.91 1.28 1.090 1.130 0.423
56 99 83.1 81.9 33.4
52 87 79.0 75.2 27.2
125.0 250.0 125.0 152.2 70.1
36.0 53.7 46.7 47.73 16.35
47.0 88.9 62.00 69.24 34.33
2.7 6.9 4.2 5.08 3.05
0.41 0.76 0.520 0.654 0.357
77 164 111.8 127.8 69.2
76 158 107.5 117.4 59.5
1.173 2.560 1.780 1.583 0.900
53 116 81.2 85.0 45.1
51 97 71.0 77.7 38.0
0.787 1.449 1.041 1.167 0.545
0.699 1.228 1.034 1.060 0.337
7 79 30.6 39.7 44.1
0.111 0.848 0.411 0.581 0.629
64 78 74.0 71.6 12.4
1.77 1.98 1.880 1.860 0.182
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Appendix E9 Speamans Coefficient of Rank Correlation for All Hale Subjects Taking DIGOXIN
Clt/kg Clr/kg
age H.Sc weight SCr CCr dose IDu ODIG SDIG Clt ml/min Clr il/iin Clnr 
years kg ug/dl ml/min meg meg ng/ml ml/min /kg ml/min /kg ml/min
n 23 23 23 23 23 23 23 23 23 23 23 23 23 23
H.Sc 0.236
weight -0.447 -0.350
SCr -0.164 0.041 0.226
CCr -0.504 -0.570 0.584 -0.340
*** ***
dose -0.606 -0.405 0.357 -0.067 0.498
***
IDu -0.007 0.131 0.253 0.173 0.145 -0.290
ODIG -0.594 -0.292 0.605 0.047 0.588 0.759 0.366
*** *** *** ****
SDIG -0.081 0.021 0.016 0.141 -0.182 0.317 0.166 0.418
Clt -0.453 -0.377 0.300 -0.171 0.573 0.626 -0.401 0.324 -0.536
*** ***
Clt/kg -0.329 -0.326 -0.010 -0.299 0.456 0.495 -0.463 0.131 -0.609 0.939
*** kkkk
Clr -0.403 -0.378 0.526 -0.122 0.731 0.462 0.179 0.555 -0.474 0.799 0.691
kkkk kkk kkkk kkk
Clr/kg -0.377 -0.269 0.270 -0.159 0.623 0.348 0.156 0.401 -0.589 0.788 0.776 0.931
kkk kkk kkkk kkkk kkkk
Clnr -0.112 -0.286 -0.126 -0.229 0.088 0.431 -0.933 -0.193 -0.300 0.637 0.678 0.101 0.110
**** *** ***
Clnr/kg -0.046 -0.264 -0.272 -0.301 0.057 0.324 -0.923 -0.299 -0.356 0.583 0.686 0.045 0.106 0.977
kkkk kkk kkk kkkk
*** p<0.01 **** p<0.001
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age (years) 26 23 81.5
nobility score 26 23 3.0
urine voluie (nl) 24 23 1013
OCr (ng in 24b) 24 23 694
[OCr] (ng/lOOml) 24 23 66.2
[SCr] (ng/lOOil) 26 23 0.785




dose (ncg) 26 23 125.0
%Du 24 23 38.67
ODIG (ncg in 24h) 24 23 51.24
[ODIG] (ncg/lOOnl) 24 23 4.742
[SDIG] (ng/nl) 26 23 0.740




Clt/kg (nl/nin/kg) 26 23 1.627




Clr/kg (nl/nin/kg) 24 23 0.976
Clnr (nl/nin) 24 23 40.3
Clnr/kg (nl/nin/kg) 24 23 0.589
Clr/CCr 24 23 0.970
weight (kg) 26 23 52.5











79.0 81.9 77.8 5.8 6.4
2.0 COCM 2.2 1.4 1.2
1406 1133 1603 461 784
1308 816 1273 475 484
91.0 82.1 90.6 75.8 42.3
1.090 1.092 1.130 0.662 0.423
83.2 62.5 81.9 32.0 33.4
79.0 69.7 75.2 37.9 27.2
125.0 134.6 152.2 70.0 70.1
46.72 45.28 47.73 18.53 16.35
62.00 56.95 69.24 32.70 34.33
4.179 5.791 5.078 4.266 3.052
0.520 0.913 0.654 0.715 0.357
111.8 94.9 127.8 53.6 69.2
107.5 107.9 117.4 62.0 59.5
1.583 1.804 1.780 1.039 0.900
81.2 66.3 85.0 46.7 45.1
71.0 74.3 77.7 53.1 38.1
1.041 1.234 1.167 0.882 0.545
30.6 34.5 39.7 33.9 44.1
0.411 0.637 0.581 647 0.629
1.060 1.091 1.034 0.565 0.337
74.0 53.9 71.6 10.1 12.4
1.880 1.540 1.860 0.174 0.182
* p<0.03 ** p<0.02 *** p<0.001
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Appendix Ell Sunnary of Results Fron All Subjects Taking DIGOXIN
n nin nax Q1 Q3 nedian nean s.d.
age (years) 49 66 96 77 84 80.0 80.0 6.3
aobility score 49 1 5 1 4 3.0 2.5 1.3
urine volune (nl) 47 490 3742 881 1634 1264 1363 676
DCr (ng in 24h) 47 302 2624 657 1348 983.5 1039.6 527.2
[OCr] (ng/lOOnl) 47 30.7 420.8 49.3 101.9 74.30 86.21 61.21
[SCr] (ng/lOOnl) 49 0.34 2.69 0.71 1.28 0.980 1.110 0.557
CCr (nl/nin) 47 9 193 47 87 69.6 72.0 33.8
CCr/SA
(ml/min/1.73m2)
47 11 167 46 87 69.8 72.4 32.9
dose (ug) 49 62.5 250.0 93.8 250.0 125.0 142.9 69.9
IDu 47 19.04 84.88 33.44 62.37 42.31 46.48 17.35
ODIG (ug in 24h) 47 19.4 165.9 41.3 78.0 54.00 62.97 33.71
[ODIG] (ug/lOOnl) 47 1.17 18.83 2.83 6.85 4.37 5.44 3.70
[SDIG] (ng/nl) 49 0.14 3.00 0.40 1.02 0.590 0.792 0.585
Clt (nl/nin) 49 19 264 59 144 98.6 110.3 63.0
Clt/SA 49 23 265 65 154 99.6 112.4 60.4
(il/iin/1.73i2)
Clt/kg (nl/nin/kg) 49 0.398 4.474 1.036 2.468 1.583 1.793 0.966
Clr (nl/nin) 47 10 194 41 109 60.4 75.4 46.4
Clr/SA 47 11 199 41 97 59.3 76.0 45.8
(Bl/min/1.73m2)
Clr/kg (nl/nin/kg) 47 0.184 3.298 0.717 1.469 1.004 1.201 0.729
Clr/CCr 47 0.326 2.461 0.699 1.314 1.007 1.063 0.463
Clnr (nl/nin) 47 -35 130 6.87 64 31.5 37.0 38.9
Clnr/kg (nl/nin/kg) 47 -0.583 2.092 0.111 1.015 0.508 0.610 0.632
weight (kg) 49 35 96 51 75 61.0 62.2 14.2
SA (n2) 49 1.17 2.20 1.49 1.89 1.690 1.690 0.239
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Appendix E12 Spearmans Coefficient of Rank Correlation for All Subjects Taking DIGOXIN
Clt/kg Clr/kg
age H.Sc weight SCr CCr dose IDu ODIG SDIG Clt ml/min Clr ml/min Clnr 
years kg mg/dl ml/min meg meg ng/ml ml/min /kg ml/min /kg ml/min
n 49 49 49 49 47 49 47 47 49 49 49 47 47 47
H.Sc 0.282
weight -0.369 -0.372 
***
SCr 0.027 0.212 0.356
CCr -0.507 -0.507 0.424 -0.378
**** **** ***
dose -0.255 -0.203 0.234 -0.160 0.300
IDu -0.207 -0.041 0.174 -0.153 0.274 0.303
ODIG -0.388 -0.195 0.394 -0.196 0.094 0.742 0.380
*** *** **** ***
SDIG 0.231 0.286 0.066 0.202 -0.371 0.454 -0.109 0.407
*** ***
Clt -0.487 -0.492 0.264 -0.345 0.653 0.318 -0.132 0.189 -0.669
**** **** **** ****
Clt/kg -0.390 -0.408 -0.092 -0.486 0.523 0.204 -0.186 0.021 -0.694 0.920
*** *** **** **** **** ****
Clr -0.527 -0.429 0.314 -0.375 0.754 0.142 0.417 0.384 -0.633 0.826 0.729
**** *** **** *** *** **** **** ****
Clr/kg -0.466 -0.333 -0.009 -0.478 0.642 0.043 0.399 0.267 -0.673 0.775 0.796 0.926
*** *** **** *** **** **** **** ****
Clnr -0.065 -0.212 -0.038 -0.074 0.116 0.360 -0.815 -0.216 -0.233 0.552 0.591 0.049 0.054
**** **** ****
Clnr/kg 0.032 -0.134 -0.194 -0.114 0.037 0.289 -0.838 -0.305 -0.221 0.471 0.560 -0.038 0.018 0.977
*** *** **** ****
*** p<0.01 **** P<0.001
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Appendix E13 Fit v Frail Elderly Subjects Taking DIGOXIN - Mann-Whitney Test
fit frail fit frail
n n min min
age (years) 24 25 66 67
nobility score 24 25 1 3
urine volume (ml) 23 24 794 490
OCr (mg in 24h) 23 24 476 302
[OCr] (mg/lOOml) 23 24 32.9 30.7
[SCr] (mg/lOOml) 24 25 0.55 0.34
CCr (ml/min) 23 24 49 9
CCr/SA
(ml/min/1.73m2)
23 24 52 11
dose (ug) 24 25 62.5 62.5
IDu 23 24 25.3 19.0
DDIG (ug in 24h) 23 24 20.9 19.4
[ODIG] (ug/lOOml) 23 24 1.53 1.17
[SDIG] (ng/ml) 24 25 0.14 0.26
Clt (ml/min) 24 25 35 19
Clt/SA
(ml/min/1.73m2)
24 25 31 23
Clt/kg (ml/min/kg) 24 25 0.461 0.398
Clr (ml/min) 23 24 31 10
Clr/SA
(ml/min/1.73m2)
23 24 29 11
Clr/kg (ml/min/kg) 23 24 0.422 0.184
Clnr (ml/min) 23 24 -30 -35
Clnr/kg (ml/min/kg) 23 24 -0.583 -0.416
Clr/CCr 23 24 0.500 0.326
weight (kg) 24 25 35 41
SA (m2) 24 25 1.17 1.33
fit frail fit frail fit frail
max max Q1 Q1 Q3 Q3
90 96 76 78 84 85
2 5 1 3 2 4
3105 3742 1224 778 1752 1513
1838 2624 850 499 1391 1127
222.4 420.8 59.0 45.1 104.6 100.0
1.66 2.69 0.63 0.75 1.27 1.75
193 141 68 31 99 82
164 167 65 39 87 77
250.0 250.0 78.1 93.7 250.0 125.0
82.8 84.9 34.0 31.5 50.4 64.8
125.9 165.9 43.4 27.4 85.1 78.0
9.14 18.83 2.83 2.57 4.86 9.38
1.85 3.00 0.38 0.40 0.81 1.28
264 224 83 52 195 118
229 265 83 57 175 122
3.462 4.474 1.238 0.984 3.025 1.899
182 194 50 30 117 85
199 180 53 34 99 89
3.298 2.820 0.808 0.583 1.479 1.348
130 105 13 3 70 44
1.923 2.092 0.194 0.049 1.183 0.905
2.179 2.461 0.666 0.707 1.139 1.400
96 85 54 46 76 66
2.20 2.00 1.55 1.42 1.94 1.80
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age (years) 79.0 81.0 78.9 81.0 5.9 6.7
mobility score 1.0 3.0 1.3 3.6 0.5 0.8 ****
urine volume (ml) 1378 961 1517 1216 520 780 **
UCr (mg in 24h) 1173 709 1170 915 371 625 **
[OCr] (mg/lOOil) 75.8 73.1 84.5 87.9 40.0 77.2
[SCr] (mg/lOOml) 0.985 0.980 0.988 1.228 0.353 0.688
CCr (ml/min) 82.4 47.4 85.2 59.4 29.0 33.7 ***
CCr/SA
(ml/min/1.73m2)
83.3 46.8 82.6 62.6 24.1 37.4 ■kilt
dose (ug) 125.0 125.0 151.0 135.0 75.8 64.2
%Du 42.32 40.76 46.06 46.88 6.00 18.89
DDIG (ug in 24h) 58.40 53.00 63.30 62.65 26.95 39.73
[ODIG] (ug/lOOml) 4.18 5.06 4.41 6.43 1.95 4.65
[SDIG] (ng/ml) 0.500 0.720 0.628 0.949 0.393 0.695
Clt (ml/min) 117.5 74.6 132.8 88.7 66.7 51.8 **
Clt/SA
(ml/min/1.73m2)
122.4 75.9 131.7 93.9 60.6 55.2 *
Clt/kg (ml/min/kg) 2.098 1.206 2.060 1.537 0.968 0.911 *
Clr (ml/min) 81.2 53.9 86.1 65.2 43.4 47.8
Clr/SA
(ml/min/1.73m2)
79.6 55.3 84.4 67.9 43.9 47.1
Clr/kg (ml/min/kg) 1.187 0.927 1.309 1.098 0.722 0.736
Clnr (ml/min) 41.2 24.9 45.5 28.9 41.7 35.0
Clnr/kg (ml/min/kg) 0.553 0.927 0.684 1.098 0.649 0.736
Clr/CCr 0.981 1.062 1.006 1.117 0.423 0.502
weight (kg) 67.5 59.0 66.5 58.1 14.7 12.7 *
SA (m2) 1.760 1.620 1.757 1.626 0.253 0.201 *
* p<0.05 ** p<0.02 *** p<0.003 **** p<0.001
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Appendix E14 Fit v
fit frai
age (years) 12 1
nobility score 12 1
urine volune (nl) 11 1
CCr (ng in 24h) 11 1
[OCr] (ng/lOOnl) 11 1
[SCr] (ng/lOOnl) 12 1
CCr (nl/nin) 11 1
CCr/SA 11 1
(nl/nin/1.73n2)
dose (ug) 12 1
%Du 11 1
ODIG (ug in 24h) 11 1
[DDIG] (ug/lOOnl) 11 1
[SDIG] (ng/il) 12 1
Clt (nl/nin) 12 1
Clt/SA 12 1
(nl/nin/1.73n2)
Clt/kg (nl/nin/kg) 12 1
Clr (nl/nin) 11 1
Clr/SA 11 1
(nl/nin/1.73n2)
Clr/kg (nl/nin/kg) 11 1
Clnr (nl/nin) 11 1
Clnr/kg (nl/nin/kg) 11 1
Clr/CCr 11 1
weight (kg) 12 1
SA (n2) 12 1









73 74 90 96
1 3 2 5
888 490 2059 1150
476 318 1482 2441
32.9 32.5 108.9 420.8
0.58 0.34 1.66 2.69
49 9 108 141
53 11 121 167
62.5 62.5 250.0 250.0
25.3 19.0 82.8 69.5
20.9 19.4 97.7 165.9
1.53 2.33 5.96 18.83
0.14 0.26 1.85 3.00
35 19 208 224
31 23 223 265
0.461 0.398 3.462 4.474
32 10 172 169
33 11 199 180
0.515 0.184 3.298 2.820
-30 -2 98 105
-0.583 -0.039 1.923 2.092
0.500 0.326 2.179 2.461
35 41 76 66
1.17 1.33 1.95 1.79
- Hann-Whitney Test
fit frail fit frail
Q1 Q1 Q3 . ®
77 77 84 90
1 3 2 5
1102 678 1871 1013
678 354 1173 856
44.5 45.2 84.6 97.3
0.62 0.67 1.27 2.22
64 29 80 66
59 35 91 68
62.5 109.4 218.7 156.2
33.4 30.4 68.9 62.4
39.8 23.8 63.3 78.0
2.51 3.85 4.86 9.51
0.30 0.47 0.87 1.47
87 44 131 99
87 54 166 119
1.277 0.961 2.745 2.024
43 23 107 77
41 25 124 89
0.611 0.408 2.224 1.602
-3 6 68 46
-0.070 0.137 1.183 0.971
0.666 0.704 1.452 1.621
51 45 65 59
1.48 1.40 1.70 1.62
3 3 2













age (years) 80.5 82.0 80.7 83.0 4.6 6.6
mobility score 1.5 4.0 1.5 3.9 0.5 0.9 ***
urine volume (ml) 1449 852 1488 833 423 210 ***
UCr (mg in 24h) 850 521 939 712 314 569 *
[OCr] (mg/lOOml) 63.4 71.9 66.9 94.9 24.4 100.6
[SCr] (mg/lOOml) 0.695 0.965 0.917 1.243 0.414 0.803
CCr (ml/iin) 73.5 35.1 73.0 53.7 16.3 39.5 **
CCr/SA
(ml/min/1.73m2)
85.4 43.4 78.9 61.9 21.0 47.4 *
dose (ug) 125.0 125.0 130.2 138.4 77.5 65.7
IDu 39.10 38.24 47.03 43.79 20.19 17.70
DD1G (ug in 24h) 49.4 52.0 52.4 60.8 22.7 39.8
[UDIG] (ug/lOOml) 3.91 5.95 3.65 7.60 1.43 5.04 *
[SDIG] (ng/ml) 0.490 1.015 0.632 1.154 0.476 0.811
Clt (ml/iin) 113.0 62.5 112.4 79.9 43.1 58.6 *
Clt/SA
(ml/min/1.73m2)
131.4 69.3 127.0 91.6 52.6 66.6
Clt/kg (ml/min/kg) 2.253 1.099 2.102 1.548 0.919 1.100
Clr (ml/min) 62.8 42.6 76.7 57.5 45.1 48.1
Clr/SA
(ml/min/1.73m2)
59.6 55.4 84.2 66.0 53.1 53.7
Clr/kg (ml/min/kg) 0.980 0.972 1.371 1.118 0.896 0.889
Clnr (ml/min) 41.5 22.9 38.7 30.9 38.6 30.4
Clnr/kg (ml/min/kg) 0.624 0.509 0.683 0.598 0.732 0.593
Clr/CCr 0.776 0.980 1.040 1.134 0.536 0.607
weight (kg) 54.0 48.5 57.0 51.3 11.6 8.1
SA (m2) 1.555 1.450 1.585 1.501 0.205 0.137
* p<0.04 ** p<0.02 *** pCO.OOl
3 3 3
Appendix E15 Fit v Frail Elderly Hales Taking DIGOXIN - Hann-Whitney Test
fit frail fit frail
n n min min
age (years) 12 11 66 67
mobility score 12 11 1 3
urine volume (ml) 12 11 794 492
OCr (mg in 24h) 12 11 923 302
[OCr] (ng/lOOnl) 12 11 49.3 30.7
[SCr] (mg/IOOml) 12 11 0.55 0.73
CCr (ml/min) 12 11 56 29
CCr/SA
(ml/min/1.73m2)
12 11 52 37
dose (ug) 12 11 62.5 62.5
IDu 12 11 25.6 25.0
DDIG (ug in 24h) 12 11 32.7 22.8
[DDIG] (ug/lOOml) 12 11 2.60 1.17
[SDIG] (ng/ml) 12 11 0.26 0.30
Clt (ml/min) 12 11 45 34
Clt/SA
(ml/min/1.73m2)
12 11 42 35
Clt/kg (ml/min/kg) 12 11 0.605 0.552
Clr (ml/min) 12 11 31 27
Clr/SA
(ml/min/1.73m2)
12 11 29 28
Clr/kg (ml/min/kg) 12 11 0.422 0.442
Clnr (ml/min) 12 11 -4 -35
Clnr/kg (ml/min/kg) 12 11 -0.053 -0.416
Clr/CCr 12 11 0.546 0.575
weight (kg) 12 11 60 41
SA (m2) 12 11 1.68 1.36
fit frail fit frail fit frail
max max Q1 Q1 Q3 Q3
89 87 71 79 82 81
2 4 1 3 1 4
3105 3742 1260 854 1601 2270
1838 2624 1145 688 1665 1557
222.4 139.8 69.5 38.5 113.6 114.3
1.45 2.37 0.91 0.80 1.26 1.41
193 108 83 46 104 87
164 103 75 43 87 81
250.0 250.0 125.0 62.5 250.0 125.0
71.1 84.9 37.5 35.8 50.2 69.1
125.9 163.9 54.3 32.6 89.7 86.4
9.14 12.70 3.82 2.07 7.41 6.85
1.30 1.70 0.44 0.38 0.76 0.98
264 164 80 59 230 142
229 158 71 76 212 132
3.462 2.579 1.056 1.173 3.199 1.826
182 194 63 52 119 109
154 168 57 49 98 97
2.272 2.281 0.867 0.777 1.460 1.449
130 99 16 -2 81 44
1.734 1.682 0.226 -0.022 1.197 0.839
1.540 1.788 0.643 0.699 1.138 1.396
96 85 70 62 80 77
2.20 2.00 1.83 1.71 2.03 1.92
3 3 4













age (years) 78.0 79.0 77.2 78.5 6.8 6.2
lobility score 1.0 3.0 1.1 3.4 0.3 0.5 ***
urine volume (ml) 1543 1669 1371 1548 614 963
OCr (mg in 24h) 1363 1064 1382 1154 289 627
[OCr] (mg/lOOml) 94.8 91.0 100.6 79.6 45.5 37.6
[SCr] (mg/lOOml) 1.095 0.980 1.059 1.208 0.279 0.544
CCr (ml/min) 87.8 61.0 96.4 66.1 33.9 25.6 **
CCr/SA
(ml/min/1.73m2)
82.3 58.6 86.0 63.44 27.1 23.0 *
dose (ug) 125.0 125.0 171.9 130.7 71.1 65.3
IDu 46.92 43.20 45.16 50.53 11.83 20.44
ODIG (ug in 24h) 63.1 54.0 73.3 64.8 27.5 41.4
[ODIG] (ug/lOOml) 4.20 3.71 5.12 5.04 2.15 3.93
[SDIG] (ng/il) 0.510 0.590 0.623 0.689 0.310 0.414
Clt (ll/iin) 136.9 96.9 153.2 100.0 80.9 41.3
Clt/SA
(ml/min/1.73m2)
119.1 86.9 136.4 96.7 69.8 39.0
Clt/kg (ml/min/kg) 1.733 1.447 2.017 1.522 1.054 0.645
Clr (ml/min) 88.4 57.3 94.8 74.3 41.7 48.1
Clr/SA
(ml/min/1.73m2)
85.3 55.2 84.6 70.2 35.9 40.5
Clr/kg (ml/min/kg) 1.207 0.822 1.253 1.074 0.554 0.545
Clnr (ml/min) 30.7 27.0 51.8 26.5 45.0 41.2
Clnr/kg (ml/min/kg) 0.424 0.403 0.685 0.467 0.596 0.673
Clr/CCr 1.032 1.122 0.975 1.098 0.307 0.370
weight (kg) 75.0 65.0 76.0 66.8 1.1 12.3
SA (m2) 1.910 1.800 1.928 1.786 0.164 0.178
* p<0.05 ** p<0.025 *** p<0.001
3 3 5
Appendix E16 Fit v Frail Elderly Hales Matched for CCr - Mann-Whitney Test




age (years) 11 8 66 67
nobility score 11 8 1 3
urine volune (nl) 11 8 794 492
OCr (ng in 24h) 11 8 923 657
[OCr] (mg/lOOnl) 11 8 59.0 30.7
[SCr] (ng/lOOnl) 11 8 0.61 0.77
CCr (nl/nin) 11 8 56 46
CCr/SA
(nl/nin/1.73n2)
11 8 52 45
dose (ug) 11 8 62.5 62.5
%Du 11 8 25.6 25.0
UDIG (ug in 24b) 11 8 32.7 32.6
[ODIG] (ug/lOOnl) 11 8 2.60 1.17
[SDIG] (ng/nl) 11 8 0.26 0.30
Clt (nl/nin) 11 8 45 34
Clt/SA
(nl/nin/1.73n2)
11 8 42 35
Clt/kg (nl/nin/kg) 11 8 0.61 0.55
Clr (nl/nin) 11 8 31 27
Clr/SA
(nl/nin/1.73n2)
11 8 29 28
Clr/kg (nl/nin/kg) 11 8 0.42 0.44
Clnr (nl/nin) 11 8 -4 -35
Clnr/kg (nl/nin/kg) 11 8 -0.05 -0.42
Clr/CCr 11 8 0.546 0.575
weight (kg) 11 8 60 55
SA (n2) 11 8 1.68 1.62
fit frail fit frail fit frail
nax nax Q1 Q1 Q3 Q3
89 81 75 70 82 81
2 4 1 3 1 4
2356 3742 1258 1373 1502 2664
1838 2624 1108 782 1710 1596
222.4 139.8 72.9 38.2 116.0 115.3
1.45 2.37 0.92 0.83 1.28 1.84
106 108 82 51 102 94
97 103 75 49 87 91
250.0 250.0 125.0 125.0 250.0 218.7
71.1 84.9 36.0 30.4 50.4 73.6
125.9 163.9 52.9 48.7 88.9 101.2
9.14 12.70 3.89 2.13 7.71 10.46
1.30 1.70 0.44 0.39 0.76 0.99
264 164 77 64 224 150
229 158 67 59 211 147
3.46 2.58 0.98 0.87 3.10 2.38
131 194 57 53 117 114
134 168 53 51 95 110
2.18 2.28 0.81 0.78 1.43 1.70
130 99 13 -8 81 76
1.73 1.68 0.19 -0.11 1.31 1.26
1.540 1.788 0.585 0.626 1.139 1.400
96 85 69 63 78 77
2.20 2.00 1.82 1.73 2.00 1.92
336













age (years) 78.0 79.0 78.0 76.5 6.4 5.9
nobility score 1.0 3.0 1.1 3.4 0.3 0.5 *
urine volume (ml) 1364 1628 1401 1915 385 1000
OCr (mg in 24h) 1337 1228 1369 1332 299 630
[OCr] (mg/lOOml) 101.9 98.5 105.3 84.2 44.6 42.3
[SCr] (mg/100ml) 1.100 0.965 1.106 1.249 0.239 0.617
CCr (ml/min) 87.2 80.4 87.6 75.8 15.6 22.5
CCr/SA
(ml/min/1.73m2)
81.2 74.4 78.9 72.0 12.0 21.1
dose (ug) 125.0 125.0 164.8 148.4 70.0 66.3
IDu 46.72 59.63 44.98 55.33 12.39 22.31
ODIG (ug in 24h) 62.0 64.8 69.3 77.4 24.8 41.7
[ODIG] (ug/lOOml) 4.23 4.05 5.24 5.61 2.21 4.44
[SDIG] (ng/il) 0.520 0.715 0.638 0.774 0.320 0.458
Clt (ml/min) 118.7 107.8 143.6 106.0 77.4 46.5
Clt/SA
(ml/min/1.73m2)
115.2 101.4 128.8 101.0 67.9 45.4
Clt/kg (ml/min/kg) 1.633 1.547 1.907 1.572 1.031 0.757
Clr (ml/min) 87.9 60.9 86.9 84.4 33.0 53.2
Clr/SA
(nl/min/1.73m2)
80.6 58.9 78.3 78.5 29.8 45.2
Clr/kg (ml/min/kg) 1.187 0.980 1.160 1.185 0.474 0.609
Clnr (ml/min) 30.6 4.7 50.6 22.5 47.0 48.4
Clnr/kg (ml/min/kg) 0.414 0.075 0.674 0.400 0.624 0.784
Clr/CCr 1.056 1.043 0.978 1.068 0.322 0.437
weight (kg) 75.0 66.0 75.6 68.8 11.5 9.6




INFORMATION SHEET FOR PARACETAMOL STUDY
Dr. Parker is carrying out a project with the St. Marks 
Road GP's surgery, and the Research Institute for the Care 
of the Elderly, St. Martins Hospital, looking at the way in 
which paracetamol tablets are handled by your body.
These instructions should be followed carefully during the 
period of the study. If you are not sure what to do at any 
time then let someone know. Phone numbers are given at the 
bottom of this sheet. If you change your mind and do not 
wish to help, please also phone these numbers.
1) On the morning of the study Dr. Parker will call, and 
ask you to empty your bladder. You will then have a 
small blood sample taken. Following this, you will be 
required to take the two paracetamol tablets provided.
2) Each and every time you pass urine after taking the 
tablets, please collect it, in a separate container 
provided. Write on the container your name, and the 
time at which the urine was collected. ALL urine should 
be collected, even at night time. If you should happen 
to run out of containers in which to collect urine, a 
clean jam jar, or similar, will do. If you need to 
have your bowels open, empty your bladder first.
3) Exactly 24 hours later from when you took the 
paracetamol tablets, collect a final urine specimen, 
and save it.
4) Dr. Parker will need to take a further 5 blood samples 
during the day of the study (during the day time).
Each time he needs a sample he will call at your house.
5) Dr. Parker will ask you at what time you got up, and 
went to bed on the study day, and how far you walked.
6) If you usually take tablets containing paracetamol, 
please do not take any from bedtime of the day before 
the study, and do not take any further paracetamol 
during the study until the blood sampling is complete.
7) If you are taking any other tablets you may take these
as usual, but let Dr. Parker know.
Very many thanks.
IN CASE OF QUERY PLEASE DO NOT HESITATE TO CONTACT
SUE ELLMERS (STUDY CO-ORDINATOR ) AT WORK ON BATH 835866 OR
AT HOME ON BATH 834963
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Appendix F2
STUDY TO MEASURE PARACETAMOL METABOLISM IN THE ELDERLY
Name : ....................... Study No. . .
Address : .......................  Study Date. .
.........................  Mobility Score
Tel. N o . : .......................Height/cm. . .
D.O.B. : ..................... Weight/kg. . .
Age : ......................  2
G.P. : ......................  Surface area/m
Diagnoses : .....................................
Continent or catheterised: 
Drugs : ................
Intended Time for Par. to be taken :
Time Paracetamol taken : Dose Paracetamol taken :
INTENDED ACTUAL
Blood Samples : O h .............- ...............
3 h .............-...............
4 h .............-...............
6 h .............— ...............
9 h .............- ...............
1 2 h .............-...............
Time 24h urine colIn started : ..........  (discard urine)
Urine samples : Time Vol/ml Combined
1) . • •  }..............
2) . . . .—  }..............
3) . . .  }.............
alcohol 4 ) . . . . - ............}.............
5) . . . . —........... }.............
6) . . . .- }..............
tobacco 7 ) . . . . - ............}.............
8) . .   }..........
9) . . . .-........... >.............
10) . . . .- }..............
11) . . . .- >..............
12) . . .  >..............
TOTAL URINE VOL........................ IN............... hrs
Comments
3 3 9
Appendix F3 Demographic Details of Subjects Taking Part in PARACETAMOL Study
subject sex/age wt/ht fit MSc smoker EtOI
F01GPP F 78 59/153 Y 2 no no
F02GPP F 88 50/160 Y 1 no 3/wl
F03GPP F 79 42/155 Y 1 3/day no
F04GPP F 81 57/165 Y 1 no occ
H05GPP M 82 75/175 Y 2 no occ
F06GPP F 82 45/139 Y 2 no no
F07GPP F 84 60/150 Y 2 no occ
F08GPP F 74 50/148 Y 1 no occ
H09GPP M 75 76/160 Y 1 no occ
F10GPP F 80 51/152 Y 1 no occ
M11GPP M 80 76/147 Y 1 no no
F12GPP F 74 67/164 Y 1 no no
F13GPP F 74 66/161 Y 1 >20/day 7/wl
H14P M 80 84/183 N 4 no 14/wl
F15GPP F 67 87/153 Y 1 no 1/wl
H16GPP M 73 56/158 Y 1 1/4 oz occ
F17GPP F 78 75/148 Y 2 no no
H18GPP M 69 69/169 Y 1 pipe no
F19GPP F 67 62/166 Y 2 no no
M20P M 81 81/165 N 3 no no
F21P F 93 38/145 N 4 no no
diagnoses drugs
palpitations propranolol,Betnovate cream
dry skin, cramp quinine sulphate
hypertension Navidrex K, nitrazepam
resected NG colon calcium, cod liver oil
Monastry Herbs, yeast
blind, MI 88, CHD frusemide
thyroidectomy paracetamol
hypothyroid thyroxine, cinnarizine
recent UTI prednisolone, paracetamol
asthma terbutaline & budesonide inh.
RA, hiatus hernia Indocid,cimetidine,
hypertension Gaviscon, Tenoret 50
bilateral THR astemizole, paracetamol
hypertension Gaviscon, vits B & C
minor skin lesion Yeastvite
macular degen. salbutamol inh., Benylin
red eyes, deaf chloramphenicol eye ointment
gout, hiatus hernia oxytetracycline, Gaviscon
blind R eye hydrocortisone,pilocarpine &
glaucoma, OA Propine eye drops
Ca L breast tamoxifen, nitrazepam
mastectomy co-proxamol
OA, leg ulcers indomethacin
/ tib & fib
hiatus hernia Burinex K, ranitidine





COAD aminophylline SR,salbutamol &
night cramps beclomethasone inh.,
R THR, knee pain naproxen,paracetamol,senna
depression amitriptylline,
falls & i lofepramine, KCl
petit mal epilepsy naproxen, paracetamol
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Appendix F3 Demographic Details of Subjects Taking Part in PARACETAMOL Study (contd)
subject sex/age wt/ht fit/HSc smoker EtOH diagnoses drugs
F22P F 84 42/148 N 3 no no AF, glaucoma 
R THR, blind R eye
digoxin, pilocarpine ED 
Asilone, Hilpar




M24P M 73 61/173 N 3 5cigars 4/wk hiatus hernia, TURP terodiline, temazepam
M25P M 66 89/179 Y 3 10/day no ? normal pressure 
hydrocephalus, IHD
Hilpar, paracetamol
F26P F 82 72/154 N 4 no no osteoporosis 




F27P F 84 46/147 N 3 no no cataracts, OA 
gastric erosions
Haxitrol ED
F28P F 80 67/156 H 3 10/day no t L Colies 
haematuria
amitripylline, co-proxamol




F30GPP F 68 47/162 Y 2 no occ. emphysema salbutamol&beclonethasone 
inh., oxygen
M31GPP M 68 84/172 Y 1 no 1/wk OA, indigestion Betnovate, mag.trisil.mix




M33P H 76 74/169 N 4 no no CVA x 2, TORP 
COAD, THR X 2
ranitidine, Neonaclex K 
prochlorperazine, diazepam 
aspirin, glycerine supps.
H34P H 86 46/164 N 3 no no renal failure folic acid




M36P M 73 50/156 Y 3 no 7 gastric erosions 
iron deficiency 























Demographic Details of Subjects Taking Part in PARACETAMOL Study (contd) 























































































































infected leg ulcer Milpar, paracetamol
CVAs, leg ulcer paracetamol
TURP, orchidectomy 
ex-alcoholic
OA, cholecystectomy ranitidine, temazepam 
quiescent lymphoma Gaviscon, paracetamol
cholecystectomy paracetamol




F = female 
M = male 
wt = weight (kg) 
ht = height (cm)
ft = fit ( Yes or No )
MSc = mobility score
EtOH = alcohol consumption in approx. units per week
occ. indicates irregular consumption of small amounts
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Appendix F4 PARACETAMOL Kinetics in Fit and Frail Elderly People
0-7h 0-15h
total total total
subject T.int 0 vol UPAR OPAR OPAR OPAR serus T.int [SPAR] tl/2
start hours ffll mg ug ng/nin ng/iin sasple hours ng/dl kel hours AOC
F01GPP 7.00 236 10.1 368.7 0.878 0.888 1030 0.00 0.000 0.242 2.859 81.98
§1030 6.33 284 17.5 341.6 1320 2.83 1.540
10.25 880 26.4 183.8 1442 4.20 1.068
23.58 1400 14.0 894.1 1640 6.17 0.594
1930 9.00 0.293
2230 12.00 0.160
F02GPP 7.00 140 10.2 572.4 1.363 0.966 1050 1.83 1.913 0.264 2.624 82.07
§0900 8.00 384 7.9 297.3 1255 3.92 1.006
8.50 334 6.4 91.8 1500 6.00 0.457
23.50 858 24.5 961.5 1810 9.17 0.177
2100 12.00 0.121
F03GPP 8.00 182 10.4 436.6 0.910 0.734 0900 0.00 0.004 0.234 2.959 188.17
§0900 8.75 405 0.0 301.5 1200 3.00 6.578
7.25 420 0.0 63.8 1307 4.12 1.110
24.00 1007 10.4 801.9 1500 6.00 0.655
1755 8.92 0.339
2120 12.33 0.159
F04GPP 5.50 370 29.5 414.6 1.256 0.990 0955 0.00 0.000 0.318 2.180 53.47
§1000 8.00 444 0.0 387.2 1257 2.95 1.051
10.75 820 0.0 196.2 1400 4.00 0.833
24.25 1634 29.5 998.0 1613 6.22 0.428
1845 8.75 0.194
2145 11.75 0.071
F06GPP 6.00 154 7.3 153.1 0.425 0.555 0850 0.00 0.009 0.239 2.899 100.31
§0855 6.75 390 13.0 271.3 1200 3.08 1.763
11.17 350 10.1 175.7 1250 3.92 1.457
23.92 894 30.3 600.1 1500 6.08 0.804
1755 9.00 0.380
2103 12.13 0.206
F07GPP 6.66 50 2.9 107.9 0.270 0.340 0925 0.00 0.017 0.291 2.383 64.69
§0930 6.17 110 5.9 153.9 1225 2.92 1.310
11.17 263 5.0 74.7 1332 4.03 0.977
24.00 423 13.8 336.5 1522 5.87 0.511
1830 9.00 0.204
2130 12.00 0.095
F08GPP 7.75 355 15.6 215.9 0.464 0.406 0915 0.00 0.001 0.332 2.085 50.21
§0915 6.33 345 4.4 127.0 1218 3.05 1.011
9.92 740 5.4 62.0 1321 4.10 0.808
24.00 1440 25.4 404.9 1525 6.17 0.389
1819 9.07 0.158
2122 12.12 0.055
F10GPP 5.50 184 20.5 208.5 0.632 1.232 1003 0.00 0.002 0.235 2.952 72.32
§1008 7.00 525 19.2 715.5 1311 3.05 1.186
11.75 675 0.0 73.2 1418 4.17 0.975














Appendix F4 PARACETAMOL Kinetics in Fit and Frail Elderly People (contd)
0-7h 0-15h
total total total
subject T.int 0 vol UPAR UPAR UPAR UPAR serum T.int [SPAR] tl/2
start hours il ig ng mg/min mg/min sample hours ag/dl kel hours AUC
F12GPP 7.42 338 0.0 640.3 1.438 0.924 0825 0.00 0.000 0.354 1.960 43.02
@0835 6.33 230 0.0 121.9 1146 3.18 0.877
9.50 532 0.0 91.2 1239 4.07 0.700
23.25 1100 0.0 853.5 1435 6.00 0.382
1728 8.88 0.142
2033 11.97 0.043
F13GPP 6.08 260 11.3 637.0 1.746 1.048 0845 0.00 0.073 0.278 2.490 25.86
@0850 8.42 659 16.3 274.4 1200 3.17 0.450
9.50 855 13.3 77.8 1250 4.00 0.379
24.00 1774 40.9 989.1 1445 5.92 0.201
1737 8.78 0.099
2050 12.00 0.039
F15GPP 5.67 108 6.1 284.8 0.837 0.659 1040 0.00 0.000 0.205 3.380 78.59
@1050 6.58 181 7.9 199.7 1408 3.30 1.192
12.25 830 0.0 158.3 1507 4.28 0.976
24.50 1119 14.0 642.8 1709 6.32 0.624
2002 9.20 0.392
2225 11.58 0.209
F17GPP 7.50 688 1.9 483.3 1.074 0.749 0810 0.00 0.024 0.265 2.613 59.35
@0815 7.50 830 5.4 190.7 1115 3.00 1.040
8.42 890 7.4 50.0 1223 4.13 0.867
23.42 2408 14.7 724.0 1422 6.12 0.485
1714 8.98 0.223
2014 11.98 0.108
F19GPP 5.83 99 8.0 181.7 0.519 0.573 0905 0.00 0.000 0.254 2.725 133.05
@0915 7.50 279 8.2 276.3 1220 3.08 2.648
1315 4.00 2.077
13.33 378 16.2 458.0 1535 6.33 0.783
1818 9.05 0.454
2115 12.00 0.253
F21P 0923 0.00 0.187 0.243 2.849 107.51





F22P 6.58 62 8.2 183.6 0.464 0.481 1000 0.00 0.000 0.249 2.788 99.36
@1003 3.50 32 4.2 107.4 1306 3.05 1.776
14.00 414 33.9 299.8 1403 4.00 1.452
24.08 508 46.3 590.9 1540 5.62 0.896
1829 8.43 0.444
2100 10.95 0.256
F26P 6.42 612 24.9 370.8 0.962 0.791 0950 0.00 0.041 0.289 2.397 50.13
@0952 7.08 538 13.2 269.7 1255 3.05 0.936
8.00 1118 21.0 173.9 1348 3.93 0.722



















subject T.int 0 vol UPAR UPAR UPAR UPAR serum T.int [SPAR] tl/2 Cl
start hours ml mg mg ig/min mg/min sample hours mg/dl kel hours AUC 1/h
F27P 6.92 160 10.0 299.9 0.722 0.392 0840 0.00 0.000 0.233 2.977 82.83 12.07
@0845 7.17 208 10.8 31.3 1156 3.18 1.385
10.08 430 1.6 44.0 1245 4.00 1.166
24.17 798 22.5 375.1 1530 6.75 0.600
1749 9.07 0.322
2115 12.50 0.164
F28P 7.17 214 13.3 708.4 1.647 0759 0.00 0.314 0.220 3.146 61.45 16.27
@0800 1050 2.83 1.158
1201 4.02 0.722
7.17 214 13.3 708.4 1403 6.05 0.372
1714 9.23 0.166
2003 12.05 0.125
F30GPP 7.13 426 27.2 446.0 1.043 0.756 0721 0.00 0.054 0.314 2.204 48.97 20.42
@0728 6.62 638 12.5 177.8 1025 2.95 0.983
10.08 910 17.4 52.5 1131 4.05 0.743
23.83 1974 57.1 676.3 1339 6.18 0.375
1609 8.68 0.161
1821 10.80 0.091
F37P 7.42 442 21.5 469.3 1.054 1.062 0920 0.00 0.000 0.374 1.853
@0923 2.08 156 5.4 135.8 1237 3.23 0.390
14.67 777 17.8 153.9 1350 4.45 0.284
24.17 1375 44.8 758.9 1615 6.87 0.119
1822 9.98 0.036
2125 12.03 0.000
F38P 7.00 160 0.0 154.7 0.368 0.363 0840 0.00 0.164 0.114 6.089 86.67 11.54
@0847 5.25 102 0.0 112.4 1205 3.30 0.967
11.92 320 0.0 275.4 1335 4.80 0.652
24.17 582 0.0 542.5 1545 6.97 0.470
1810 9.38 0.396
2110 12.38 0.266
F39P 4.17 305 5.9 132.5 0.529 0.627 1205 3.02 0.809 0.228 3.038 47.92 20.87
@0904 9.33 654 13.3 375.5 1307 4.05 0.648
10.67 840 8.6 127.9 1600 6.93 0.318
24.17 1799 27.8 635.8 1800 8.93 0.187
2103 11.98 0.108
F40P 6.08 45 5.1 110.5 0.303 0.650 1215 3.03 1.602 0.284 2.440 81.26 12.31
@0913 2.67 216 11.4 230.6 1319 4.10 1.566
15.08 850 15.6 361.3 1607 6.90 0.939
23.83 1111 32.1 702.4 1807 8.90 0.625
2110 11.95 0.315
F41P 6.00 102 1.1 113.3 0.315 1205 3.03 1.602 0.284 2.440 81.26 12.31
@0903 1304 4.02 1.208
1515 6.20 0.594







Appendix F4 PARACETAMOL Kinetics in Fit and Frail Elderly People (contd)
0-7h 0-15h
total total total
subject T.int 0 vol UPAR UPAR UPAR UPAR serum T.int [SPAR] tl/2
start hours nl ng ng ng/nin lg/nin sample hours ng/dl kel hours AUC
F42GPP 6.47 52 2.9 121.5 0.313 0.678 1130 2.90 1.406 0.233 2.976 134.57
€0836 6.50 198 8.1 406.3 1234 3.97 2.193
9.60 110 3.9 60.4 1436 6.00 1.330
22.57 360 14.9 588.2 1743 9.12 0.635
2031 11.92 0.345
F43P 4.30 28 1.0 36.2 0.140 1024 3.08 1.353 0.290 2.393 65.12
§0719 1128 4.15 0.903
1313 5.90 0.520
4.30 28 1.0 36.2 1618 8.98 0.259
1910 11.85 0.091
F44P 5.33 91 5.1 223.9 0.700 1218 3.02 1.227 0.263 2.636 62.50
§0917 1317 4.00 0.871
1515 5.97 0.502
5.33 91 5.1 223.9 1817 9.00 0.232
2115 11.97 0.106
F46GPP 6.17 170 8.4 391.6 1.058 1.007 1222 2.98 0.880 0.315 2.198 39.12
§0923 4.75 404 6.4 267.9 1317 3.90 0.611
1535 6.20 0.266
10.92 574 14.8 659.5 1833 9.17 0.102
2114 11.85 0.050
F47GPP 6.00 235 20.3 541.0 1.503 0.994 1245 2.92 0.805 0.255 2.718 39.27
§0950 7.25 502 16.9 249.0 1354 4.07 0.525
10.75 564 9.6 70.3 1554 6.07 0.283
24.00 1301 46.8 860.3 1855 9.08 0.128
2154 12.07 0.068
F48GPP 6.25 94 10.4 153.5 0.409 0.678 1246 2.93 2.374 0.267 2.591 127.93
§0950 7.83 334 21.1 419.5 1348 3.97 1.848
8.17 220 7.9 120.6 1549 5.98 1.080
22.25 648 39.4 693.6 1856 9.10 0.450
2155 12.08 0.214
F49GPP 3.73 284 14.4 203.4 0.909 0.778 1216 2.98 0.951 0.265 2.612 48.19
§0917 8.00 158 23.7 344.3 1314 3.95 0.708
11.75 426 0.0 132.7 1519 6.05 0.373
23.48 868 38.1 680.4 1819 9.03 0.153
2116 11.98 0.086
F51P 6.67 70 9.2 184.8 0.462 1202 2.93 1.760 0.235 2.947 97.39
§0906 15.00 750 38.0 399.3 1257 3.85 1.380
1505 5.98 0.763
21.67 820 47.2 584.1 1830 9.40 0.328
2058 11.87 0.212
F52P 2.92 160 6.8 112.9 0.644 0.660 1155 2.77 1.386 0.213 3.260 76.38
§0909 8.42 186 10.2 336.3 1252 3.72 0.998
6.35 322 5.7 189.2 1458 5.82 0.588




















Subject T.int 0 vol OPAR UPAR UPAR UPAR serun T.int [SPAR]
start hours nl ng ng ng/nin ng/nin sanple hours ng/dl
F54GPP 1124 2.73 1.049




H05GPP 6.00 116 9.7 265.3 0.737 1.393 1000 0.00 0.000
@1000 7.50 297 12.0 369.8 1253 2.88 0.989
10.75 780 7.0 165.9 1400 4.00 0.817
24.25 1193 28.6 801.0 1615 6.25 0.464
1855 8.92 0.205
2140 11.67 0.062
H09GPP 7.50 545 60.9 723.1 1.607 1.270 0910 0.00 0.001
@0915 6.50 705 19.7 343.7 1215 3.00 0.883
10.00 770 1.7 125.4 1320 4.08 0.803
24.00 2020 82.3 1192.1 1522 6.12 0.595
1815 9.00 0.259
2120 12.08 0.147
M11GPP 7.50 252 9.4 373.1 0.829 0.740 0827 0.00 0.000
@0835 6.25 265 0.0 237.7 1150 3.25 0.862
10.17 499 0.0 164.6 1242 4.12 0.715
23.92 1016 9.4 775.4 1437 6.03 0.427
1730 8.92 0.188
2036 12.02 0.068
M14P 4.22 240 10.2 164.7 0.651 0.592 0950 0.00 0.099
@0952 8.77 330 6.8 296.7 1258 3.10 0.836
10.43 515 0.0 187.6 1351 3.98 0.678
23.42 1085 17.0 649.0 1600 6.13 0.410
1902 9.17 0.234
2210 12.30 0.151
M16GPP 4.00 140 8.3 112.4 0.468 1041 0.00 0.088
@1050 1406 3.27 0.963
1504 4.23 0.763
4.00 140 8.3 112.4 1704 6.23 0.440
2000 9.17 0.219
2222 11.53 0.220
M18GPP 7.92 499 13.5 600.1 1.263 0.833 0825 0.00 0.024
@0830 7.53 780 6.9 172.4 1126 2.93 0.739
8.25 563 0.0 41.3 1235 4.08 0.590
23.70 1842 20.4 813.8 1425 5.92 0.359
1726 8.93 0.172
2030 12.00 0.087
M20P 6.57 76 8.0 97.4 0.247 0.416 0853 0.00 0.002
@0855 5.66 170 13.2 207.7 1200 3.08 1.194
11.77 776 17.5 275.0 1258 4.05 0.883























Appendix F4 PARACETAMOL Kinetics in Fit and Frail Elderly People (contd)
0-7h 0-15h
total total total
Subject T.int 0 vol OPAR OPAR OPAR OPAR serun T.int [SPAR] tl/2 Cl Cl
start hours ml ng ng ng/nin ng/nin sanple hours ng/dl kel hours AOC 1/h 1/h/kg
M23P 6.67 60 2.8 149.9 0.375 1.062 0830 0.00 0.086 0.207 3.343 69.88 14.13 0.260
§0830 5.42 235 11.5 620.3 1130 3.00 1.160
12.08 422 18.8 1230 4.00 0.926
24.17 717 33.1 770.2 1430 6.00 0.500
1740 9.17 0.260
2034 12.07 0.170
M24P 7.50 418 9.5 282.6 0.628 0.646 0910 0.00 0.058 0.186 3.734 76.52 13.07 0.214
§0913 5.00 445 5.7 202.3 1232 3.33 1.077
11.75 735 17.1 443.9 1318 4.08 0.989
24.25 1598 32.3 928.8 1514 6.02 0.597
1804 8.85 0.353
2114 12.02 0.222
M25P 0900 0.00 0.000 0.352 1.971 37.86 26.41 0.297





H29P 6.25 234 5.6 84.6 0.226 0.445 1025 0.00 0.000 0.172 4.025 40.99 24.40 0.436
§1030 5.08 235 6.0 217.8 1344 3.23 0.647
1441 4.18 0.465
11.33 469 11.5 302.4 1638 6.13 0.285
1940 9.17 0.155
2158 11.47 0.136
M31GPP 7.33 626 33.7 506.2 1.151 0.765 0717 0.00 0.000 0.245 2.834 33.37 29.97 0.357
§0725 8.42 964 18.6 217.2 1023 2.97 0.604
8.25 740 0.0 164.3 1133 4.13 0.431
24.00 2330 52.3 887.7 1340 6.25 0.268
1610 8.75 0.147
1813 10.80 0.084
M32P 21.33 360 26.7 544.8 0.426 0927 0.00 0.000 0.153 4.533 112.79 8.87 0.227
§0930 1240 3.17 1.411
1337 4.12 1.214
21.33 360 26.7 544.8 1530 6.00 0.875
1830 9.00 0.519
2132 12.03 0.367
M33P 7.50 164 18.3 229.3 0.510 0.536 0907 0.00 0.000 0.257 2.699 67.08 14.91 0.201
§0908 6.00 260 19.3 204.7 1204 2.93 1.289
11.17 698 27.4 184.6 1307 3.98 0.958
24.67 1122 65.0 618.6 1510 6.03 0.518
1810 9.03 0.232
2114 12.10 0.119
M34P 6.83 152 16.5 32.4 0.079 0.144 0900 0.00 0.153 0.095 7.332 173.07 5.78 0.126
§0907 3.84 216 18.9 59.8 1208 3.02 1.447
12.08 896 66.1 197.0 1308 4.02 1.336




Appendix F4 PARACETAMOL Kinetics in Fit and Frail Elderly People (contd)
0-7h 0-15h
total total total
Subject T.int 0 vol OPAR OPAR OPAR OPAR serun T.int [SPAR] tl/2 Cl Cl
start hours ml ng ng ng/nin ng/nin sanple hours ng/dl kel hours AOC 1/h 1/h/kg
M35P 6.70 238 15.9 322.1 0.801 0.753 0848 0.00 0.000 0.261 2.655 51.58 19.39 0.359
§0850 5.55 668 23.9 231.4 1217 3.45 0.908
10.25 1205 26.3 147.0 1322 4.53 0.675
22.50 2111 66.0 700.5 1526 6.60 0.416
1828 9.63 0.179
2105 12.25 0.092
M36P 6.33 44 5.2 210.0 0.553 0.739 0900 0.00 0.062 0.308 2.247 46.22 21.64 0.433
§0905 5.92 70 8.0 333.1 1210 3.08 0.971
11.75 481 18.7 203.8 1315 4.17 0.647
24.00 595 31.9 746.9 1510 6.08 0.338
1820 9.25 0.139
2115 12.17 0.053
H45GPP 5.42 465 31.4 354.5 1.090 0.708 1032 3.03 1.475 0.246 2.812 82.61 12.11 0.224
§0730 7.10 126 4.7 177.7 1133 4.05 1.179
12.23 390 13.1 227.4 1335 6.08 0.643
24.75 981 49.2 759.6 1633 9.05 0.327
1943 12.22 0.153
H50P 6.20 190 7.5 116.4 0.313 0.469 1217 3.07 1.028 0.238 2.910 54.46 18.36 ★
§0913 5.55 324 26.6 214.0 1328 4.25 0.686
12.33 778 0.0 266.1 1519 6.10 0.386
24.08 1292 34.1 596.5 2055 11.70 0.112
M53GPP 1138 3.13 0.241 0.157 4.417 80.05 12.49 0.169




M55GPP 5.67 214 11.2 226.4 0.666 0.716 1133 3.00 0.913 0.195 3.556 57.67 17.34 0.251
§0833 8.58 642 10.1 385.7 1232 3.98 0.720
9.25 746 0.0 138.9 1429 5.93 0.457
23.50 1602 21.4 751.1 1717 8.73 0.263
2030 11.95 0.151
M56GPP 3.67 106 2.7 54.8 0.249 0.552 1151 2.98 0.932 0.204 3.395 56.13 17.82 0.297
§0853 10.67 546 2.2 420.3 1251 3.98 0.700
9.75 1082 5.8 282.1 1445 5.87 0.452
24.09 1734 10.7 757.2 1730 8.62 0.266
2049 11.93 0.136
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Appendix F5 SCr, UCr & CCr, calculated over 8 & 24h periods, for Subjects in PARACETAMOL Study
total 24h 24h
subject/ [SCr] urine T.int ig [OCr] urine CCr CCr 1 24h SA CCr
start ng/dl colln hours OCr mg/dl vol/ml nl/nin il/nin CCr m2 1.7312
F01GPP 1.46 1630 7.00 134.1 56.83 236 22 79
0930 2250 6.33 186.6 65.71 284 34 121
0905 10.25 250.2 28.43 880 28 100
Totals 23.58 570.9 40.78 1400 28 1.60 30
F02GPP 1.80 1800 7.00 223.6 159.87 140 30 91
1100 0200 8.00 350.8 91.35 384 41 124
1030 8.50 343.9 102.97 334 37 112
Totals 23.50 918.3 107.03 858 33 1.50 38
F03GPP 1.58 1700 8.00 177.7 97.66 182 23 85
0900 0145 8.75 285.5 70.49 405 34 126
0900 7.25 161.9 38.55 420 24 89
Totals 24.00 625.1 62.08 1007 27 1.35 35
F04GPP 1.17 1530 5.50 204.9 55.37 370 53 110
1000 2330 8.00 244.8 55.14 444 44 92
1015 10.75 377.0 45.98 820 50 104
Totals 24.25 826.7 50.60 1634 48 1.63 51
F06GPP 2.11 1455 6.00 84.8 55.07 154 11 65
0855 2140 6.75 191.0 48.98 390 22 129
0850 11.17 227.4 64.85 350 16 94
Total 23.92 503.2 56.29 894 17 1.34 21
F07GPP 1.27 1610 6.66 38.7 77.35 50 8 53
0930 2220 6.17 90.6 82.40 110 19 127
0930 11.17 148.9 56.63 263 17 113
Totals 24.00 278.2 65.77 423 15 1.60 16
F08GPP 0.82 1700 7.75 252.2 71.04 355 66 110
0915 2320 6.33 174.6 50.61 345 56 93
0915 9.92 284.6 38.47 740 58 97
Totals 24.00 711.4 49.40 1440 60 1.45 72
F10GPP 1.15 1530 5.50 81.36 44.22 184 21 54
1000 2230 7.00 400.6 76.31 525 83 213
1015 11.75 174.6 25.86 675 22 56
Totals 24.25 656.6 47.44 1384 39 1.48 46
F12GPP 0.91 1555 7.42 * 293.22 86.75 338 72 97
0830 2215 6.33 256.73 111.62 230 74 100
0745 9.50 390.82 73.46 532 75 101
Totals 23.25 940.8 85.52 1100 74 1.76 73
F13GPP 1.03 1450 6.08 257.3 98.96 260 68 86
0845 2315 8.42 471.6 71.56 659 91 115
0845 9.50 446.6 52.23 855 76 96
Totals 24.00 1175.5 66.26 1774 79 1.74 79
F15GPP 0.92 1630 5.67 268.9 249.02 108 86 110
1050 2305 6.58 302.3 167.04 181 83 106
1120 12.25 482.8 58.17 830 71 91
Totals 24.50 1054.0 94.19 1119 78 1.96 69
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Appendix F5 SCr, UCr & CCr, calculated over 8 & 24h periods, for Subjects in PARACETAMOL Study (contd)
total 24h 24h
subject/ [SCr] urine T.int ng [OCr] urine CCr CCr 1 24h SA CCr
start ig/dl colln hours OCr ig/di vol/il ll/nin nl/nin CCr n2 1.73n2
F17GPP 0.92 1545 7.50 308.4 44.82 688 74 93
0815 2315 7.50 373.7 45.03 830 90 113
0740 8.42 356.5 40.06 890 77 96
Totals 23.42 1038.6 43.13 2408 80 1.79 78
F19GPP 1.53 1500 5.83 122.9 124.20 99 23 55
0910 2230 7.50 256.1 91.79 279 37 88
0910 10.67 542.4 226.01 240 55 131
Totals 24.00 921.4 149.10 618 42 1.46 50
F22P 2.14 1630 6.58 105.0 169.34 62 12 92
0955 2000 3.50 52.9 165.44 32 12 92
1000 14.00 240.3 58.04 414 13 100
Totals 24.08 398.2 78.38 508 13 1.33 17
F26P 0.90 1525 6.42 171.0 27.94 612 49 111
0900 2230 7.08 167.4 31.11 538 44 100
0630 8.00 168.8 15.10 1118 39 89
Totals 21.50 507.2 22.36 2268 44 1.77 43
F27P 0.69 1535 6.92 169.4 105.87 160 59 190
0840 2245 7.17 46.7 22.46 208 16 52
0850 10.08 98.4 22.88 430 24 77
Totals 24.17 314.5 39.41 798 31 1.37 40
F30GPP 1.00 1438 7.13 180.0 43.66 426 43 91
0730 2115 6.62 217.6 34.10 638 55 117
0720 10.08 266.2 29.25 910 44 94
Totals 23.83 669.8 33.93 1974 47 1.46 56
F37P 1.00 1640 7.42 306.0 69.23 442 69 130
0915 1845 2.08 90.1 57.76 156 72 138
0925 14.67 366.4 47.16 777 42 79
Totals 24.17 762.5 55.46 1375 53 1.90 48
F38P 0.89 1550 7.00 110.2 68.86 160 29 104
0850 2105 5.25 41.6 40.74 102 15 54
0900 11.92 212.6 66.43 320 33 118
Totals 24.17 364.4 62.61 582 28 1.52 32
F39P 1.53 1300 4.17 158.0 51.81 305 41 87
0850 2220 9.33 385.8 58.99 654 45 96
0900 10.67 491.1 58.47 840 50 106
Totals 24.17 1034.9 57.53 1799 47 2.07 39
F40P 1.25 1520 6.08 63.0 139.88 45 14 47
0915 1800 2.67 159.2 73.70 216 79 263
0905 15.08 321.7 37.85 850 28 93
Totals 23.83 543.9 48.96 1111 30 1.58 33
F41P 1.39 1445 24.00 459.4 31.90 1440 23 23 1.69 23
0845
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Appendix F5 SCr, OCr & CCr, calculated over 8 & 24h periods, for Subjects in PARACETAMOL Study (contd)
total 24h 24h
subject/ [SCr] urine T.int ig [OCr] urine CCr CCr I 24h SA CCr
start mg/dl colln hours OCr mg/dl vol/il ml/min ml/min CCr m2 1.7312
F42GPP 0.59 1500 6.47 129.1 248.25 52 56 74
0832 2130 6.50 359.9 181.77 198 156 205
0706 9.60 117.1 106.47 110 34 45
Totals 22.57 606.1 168.40 360 76 1.41 93
F44P 0.88 1330 11.00 384.5 86.80 443 66 114
0230 2025 6.92 256.8 92.71 277 70 121
0330 7.08 128.4 46.20 278 34 59
Totals 25.00 769.7 77.13 998 58 1.74 58
F46GPP 1.01 1530 6.17 292.0 171.75 170 78 132
0920 2015 4.75 207.0 51.24 404 72 122
0830 12.25 335.4 145.85 230 45 76
Totals 23.17 834.4 103.78 804 59 1.75 59
F47GPP 0.69 1545 6.00 258.6 110.06 235 104 101
0945 2300 7.25 327.2 65.17 502 109 106
0945 10.75 439.2 77.87 564 99 96
Totals 24.00 1025.0 78.79 1301 103 1.55 115
F48GPP 0.78 1600 6.25 101.4 107.84 94 35 85
0945 2350 7.83 202.8 60.72 334 55 134
0800 8.17 125.6 57.07 220 33 80
Totals 22.25 429.8 66.32 648 41 1.23 58
F49GPP 0.82 1300 3.73 101.7 35.82 284 55 86
0916 2100 8.00 240.1 151.95 158 61 95
0845 11.75 396.1 92.98 426 69 108
Totals 23.48 737.9 85.01 868 64 1.99 56
F51P 1.16 1545 6.67 70.3 100.46 70 15 68
0905 0645 15.00 266.8 35.57 750 26 118
Totals 21.67 337.1 41.11 820 22 1.26 31
F52P 1.19 1200 2.92 123.0 76.87 160 59 148
0909 2025 8.42 200.6 107.87 186 33 83
0246 6.35 175.6 52.72 322 37 93
Totals 17.69 499.2 74.72 668 40 1.34 52
F54GPP 1.70 1505 6.50 305.1 44.61 684 46 112
0835 2200 6.92 278.7 46.76 596 39 95
0910 11.17 439.5 62.78 700 39 95




M05GPP 1.68 1600 6.00 230.1 198.37 116 38 80
1000 2330 7.50 387.3 130.42 297 51 104
1015 10.75 571.6 73.28 780 53 108
Totals 24.25 1189.0 99.67 1193 49 1.92 44
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Appendix F5 SCr, OCr & CCr, calculated over 8 & 24h periods, for Subjects in PARACETAMOL Study (contd)
total 24h 24h
subject/ [SCr] urine T.int ug [OCr] urine CCr CCr 1 24h SA CCr
start ng/dl colln hours OCr ng/dl vol/ul ul/iin il/uin CCr u2 1.73U2
M09GPP 1.29 1645 7.50 509.7 93.53 545 88 117
0830 2315 6.50 375.4 53.25 705 75 100
0915 10.00 506.4 65.77 770 65 87
Totals 24.00 1391.5 68.89 2020 75 1.86 70
M11GPP 1.30 1600 7.50 385.7 153.05 252 66 97
0830 2215 6.25 363.0 136.98 265 74 109
0825 10.17 526.0 105.42 499 66 97
Totals 23.92 1274.7 125.46 1016 68 1.80 66
H14P 0.69 1403 4.22 227.1 94.64 240 130 124
0950 2249 8.77 379.1 114.88 330 104 99
0915 10.43 412.7 80.15 515 96 91
Totals 23.42 1018.9 93.91 1085 105 2.06 88
H16GPP 0.81 2300 5.50 287.4 105.28 273 108 140
1730 0845 9.75 278.5 57.79 482 59 77
1750 9.08 344.1 35.99 956 78 101
Totals 24.33 910.0 53.18 1711 77 1.58 84
M18GPP 1.61 1625 7.92 526.4 105.49 499 69 117
0830 2357 7.53 392.3 50.30 780 54 92
0812 8.25 421.8 74.92 563 53 90
Totals 23.70 1340.5 72.77 1842 59 1.81 56
M20P 3.78 1524 6.57 158.8 208.93 76 11 69
0850 2104 5.66 227.7 133.93 170 18 113
0850 11.77 459.2 59.17 776 17 106
Totals 24.00 845.7 82.75 1022 16 1.94 14
H23P 2.38 1500 6.67 56.9 94.84 60 6 30
0820 2025 5.42 260.6 110.89 235 34 170
0830 12.08 362.0 85.78 422 21 105
Totals 24.17 679.5 94.77 717 20 1.60 21
H24P 2.24 1630 7.50 1188.1 284.22 418 118 155
0900 2130 5.00 574.7 129.14 445 86 113
0915 11.75 716.8 97.52 735 45 59
Totals 24.25 2479.6 155.17 1598 76 1.72 77
M29P 1.47 2025 10.08 63.6 10.51 605 7 44
1030 1025 14.00 266.2 43.00 619 22 138
Totals 24.08 329.8 26.94 1224 16 1.64 16
M31GPP 1.11 1435 7.33 470.0 75.08 626 96 107
0715 2300 8.42 525.3 964 94 104
0715 8.25 449.7 740 82 91
Totals 24.00 1445.0 2330 90 2.02 77
M32P 1.65 0640 21.33 354.4 98.44 360 17 17 1.36 21
0920
3 5 3
Appendix F5 SCr, OCr & CCr, calculated over 8 & 24h periods, for Subjects in PARACETAMOL Study (contd)
total 24h 24h
subject/ [SCr] urine T.int ng [OCr] urine CCr CCr % 24h SA CCr
start ng/dl colln hours OCr ng/dl vol/nl nl/nin nl/nin CCr n2 1.73n2
M33P 0.94 1530 7.50 304.5 185.67 164 72 90
0800 2130 6.00 282.5 108.64 260 83 104
0840 11.17 523.3 74.97 698 83 104
Totals 24.67 1111.1 99.03 1122 80 1.88 73
M34P 3.07 1550 6.83 76.1 50.06 152 6 60
0900 1940 3.84 83.9 38.83 216 12 120
0745 12.08 243.0 27.12 896 11 110
Totals 22.75 403.0 31.88 1264 10 1.45 11
M35P 0.90 1542 6.70 196.3 82.47 238 54 95
0900 2115 5.55 201.3 30.14 668 67 118
0730 10.25 300.9 24.97 1205 54 95
Totals 22.50 698.5 33.09 2111 57 1.56 64
M36P 1.10 1520 6.33 136.2 309.51 44 33 75
0900 2115 5.92 178.5 254.93 70 46 105
0900 11.75 375.6 78.09 481 48 109
Totals 24.00 690.3 116.01 595 44 1.48 51
M45GPP 0.65 1250 5.42 122.7 26.39 465 58 95
0725 1956 7.10 96.4 76.47 126 35 57
0810 12.23 367.9 94.33 390 77 126
Totals 24.75 587.0 59.84 981 61 1.61 65
H50P 2.36 1527 6.20 92.6 48.73 190 11 85 *
0915 2100 5.55 107.9 33.31 324 14 108
0920 12.33 242.7 31.19 778 14 108
Totals 24.08 443.2 34.30 1292 13
M55GPP 1.87 1410 5.67 258.2 120.67 214 41 91
0830 2245 8.58 479.8 74.73 642 50 111
0800 9.25 456.7 61.22 746 44 98
Totals 23.50 1194.7 74.58 1602 45 1.81 43
H56GPP 1.89 1140 3.67 100.8 95.11 106 24 65
0800 2220 10.67 420.2 76.96 546 35 95
0805 9.75 494.6 45.71 1082 45 122








Appendix F6 Results fron All Subjects Taking PARACETAMOL
n nin nax Q1 Q3 nedian nean s.d.
age (years) 55 64 97 74 87 81 80.3 8.3
tl/2 (h) 55 1.960 7.332 2.463 3.260 2.834 3.004 0.928
Cl (1/h) 55 5.31 38.67 12.11 19.95 16.00 16.263 6.421
Cl (1/h/kg) 54 0.121 0.586 0.214 0.316 0.248 0.2689 0.0947
[SPAR] G 3h (ng/dl) 51 0.450 6.578 0.913 1.411 1.051 1.304 0.872
[SPAR] § 4h (ng/dl) 53 0.379 2.193 0.704 1.138 0.871 0.959 0.385
urine vol. (nl) 50 360 2408 816 1653 1120.5 1236.1 76.4
free OPAR (ng) 51 0.0 101.5 14.0 40.9 27.8 30.51 21.34
OPARG+S (ng) 43 187.7 1109.8 562.3 793.4 670.4 680.8 184.8
total OPAR (ng) 43 289.2 1192.1 596.5 814.4 702.4 715.1 185.3
OCr (ng in 24h) 50 315 2480 502 1028 724.7 805.5 55.6
[OCr] (ng/lOOnl) 50 22.4 168.4 47.5 94.3 66.29 72.75 4.89
SCr (ng/lOOnl) 55 0.50 3.78 0.90 1.70 1.19 1.382 0.656
CCr (nl/nin) 50 10 105 28 70 45 48.0 25.0
CCr/SA
(nl/nin/1.73n2)
49 11 115 33 70 51 50.7 23.7
weight (kg) 54 36 40 50 72 60 60.8 15.1
SA (n2) 54 1.23 2.12 1.46 1.80 1.62 1.640 0.235























SCr CCr CCr weight 
ng/dl nl/nin 1.73m2 kg
n 55 55 55 55 54 50 51 43 43 50 55 50 49 54
M.Sc 0.282
tl/2 0.133 0.255
Cl 0.394kkk 0.309 0.402***











0.179 0.051 0.034 0.039 0.004 0.249
UPAR
G+S




















































0.047 0.284 0.277 0.720
****
0.034 0.520 0.315 
****










*** p<0.01 **** p<0.001
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Appendix F8 Results from Female Subjects Taking PARACETAMOL
n min max Q1 Q3 median mean s.d.
age (years) 33 64 94 78 89 82 81.8 8.0
tl/2 (h) 33 1.960 6.089 2.418 2.968 2.718 2.795 0.693
Cl (1/h) 33 5.31 38.67 10.17 19.94 13.83 15.41 6.86
Cl (1/h/kg) 33 0.121 0.586 0.219 0.320 0.244 0.2695 0.1040
[SPAR] G 3h (mg/dl) 31 0.450 6.578 0.967 1.760 1.192 1.490 1.066
[SPAR] G 4h (mg/dl) 32 0.379 2.193 0.724 1.337 0.976 1.053 0.435
urine vol. (ml) 30 360 2408 766 1488 1054 1166 552
free UPAR (mg) 26 0.0 59.1 14.8 42.2 28.7 29.95 16.38
UPARG+S (mg) 25 322.7 968.5 557.2 826.8 642.3 673.4 184.1
total UPAR (mg) 25 336.5 998.0 589.5 856.9 680.3 703.4 188.1
UCr (mg in 24b) 30 315 1176 489 926 647.4 695.8 252.2
[UCr] (mg/lOOml) 30 22.4 168. ^ 42.6 85.1 62.3 69.9 6.4
[SCr] (mg/lOOml) 33 0.50 2.80 0.89 1.50 1.06 1.201 0.496
CCr (ll/min) 30 13 103 28 61 42 46.2 22.6
CCr/SA
(il/min/1.73m2)
30 16 115 33 62 48 50.1 23.0
weight (kg) 33 36 94 45 67 57 57.7 15.2
SA (m2) 33 1.23 2.07 1.36 1.74 1.55 1.567 0.222
3 5 7























SCr CCr CCr weight 
mg/dl ml/min 1.73m2 kg




Cl 0.301 0.305 0.542
***




0 vol 0.544kkk 0.298 0.318 0.563*** 0.303
free
DPAR














kkk 0.183 0.460 0.169 0.461 0.433
SCr 0.066 0.061 0.154 0.298 0.277 0.050 0.070 0.101 0.137 0.002
CCr 0.272 0.390 0.274 0.600
***










weight 0.323 0.181 0.118 0.582kkkk 0.076 0.452 0.108 0.259 0.239 0.656kkkk 0.083 0.518***
0.271










*** p<0.01 **** p<0.001
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Appendix F10 Results froa Hale Subjects Taking PARACETAMOL
n ain aax Q1 Q3 aedian Bean s.d.
age (years) 22 64 97 72 84 78 77.9 8.4
tl/2 (h) 22 1.971 7.332 2.673 3.766 3.021 3.319 1.145
Cl (1/h) 22 5.78 29.97 14.00 21.39 17.44 17.55 5.61
Cl (1/h/kg) 22 0.126 0.436 0.211 0.317 0.251 0.2679 0.0805
[SPAR] § 3h (ag/dl) 20 0.640 1.475 0.867 1.186 0.967 1.017 0.249
[SPAR] § 4h (ag/dl) 21 0.431 1.336 0.668 0.949 0.763 0.814 0.234
urine vol. (al) 20 360 2330 1018 1728 1244 1341 519
free DPAR (ag) 20 8.3 101.5 17.9 51.5 32.1 37.03 25.46
OPARG+S (ag) 18 187.7 1109.8 560.2 777.6 722.4 691.2 190.5
total DPAR (ag) 18 289.2 1192.1 613.1 804.2 754.1 731.2 185.5
DCr (ag in 24h) 20 330 2480 610 1255 963 970 504
[OCr] (ag/lOOal) 20 26.9 155.2 54.5 98.9 73.7 77.1 33.9
SCr (ag/lOOal) 22 0.65 3.78 1.01 1.98 1.63 1.653 0.777
CCr (al/ain) 20 10 105 18 76 53 50.8 28.7
CCr/SA
(al/ain/1.73a2)
19 11 88 21 73 56 51.5 25.3
weight (kg) 21 39 89 55 76 69 65.8 13.9
SA (m2) 21 1.36 2.12 1.59 1.93 1.80 1.755 0.210
359























tl/2 Cl Cl 
hours 1/h 1/h/kg




0.056 0.355 0.267 
0.164 0.295 0.296 
0.242 0.445 0.405 
0.265 0.361 0.356 
0.288 0.274 0.021 
0.185 0.175 0.278 
0.188 0.123 0.004 
0.157 0.133 0.007 













0.049 0.095 0.108 
0.278 0.074 0.501 
0.304 0.078 0.463 


































age (years) 33 22 82.0
mobility score 33 22 2.0
tl/2 (hours) 33 22 2.718
Cl (1/h) 33 22 13.83
Cl (1/h/kg) 33 21 0.270
[SPAR] § 3h (mg/dl) 31 20 1.192
[SPAR] § 4h (mg/dl) 32 21 0.976
urine volume (ml) 30 20 1054
free DPAR (mg) 31 20 25.37
OPARG+S (mg) 25 18 642.3
total DPAR (mg) 25 18 680.3
OCr (mg in 24h) 30 20 647
[DCr] (mg/lOOml) 30 20 62.34
[SCr] (mg/lOOml) 33 22 1.060




weight (kg) 33 21 57.0












78.0 81.8 77.9 8.0 8.4
3.0 2.4 2.7 1.3 1.4
3.021 2.795 3.319 0.693 1.145 *
17.44 15.41 17.55 6.86 5.61
0.251 0.244 0.268 0.104 0.081
0.967 1.490 1.017 1.066 0.249 **
0.763 1.053 0.814 0.435 0.234 *
1244 1166 1341 552 519
32.08 26.30 37.03 17.37 25.46
722.4 673.4 691.2 184.1 190.5
754.1 703.4 731.2 188.1 185.5
963 696 970 252 504 *
73.67 69.87 77.06 35.22 33.94
1.630 1.201 1.653 0.496 0.777 **
53.0 46.2 50.8 22.6 28.7
56.0 50.1 51.5 23.0 25.3
69.0 57.7 65.8 15.2 13.9 *
1.800 1.567 1.755 0.222 0.210 **4
p<0.02 *** p<0.005
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age (years) 29 26 78 83 77.3 83.5 8.2 7.3 ***
nobility score 29 26 1 4 1.5 3.7 0.7 0.7 ****
tl/2 (hours) 29 26 2.624 2.977 2.668 3.379 0.457 1.162 ****
Cl (1/h) 29 26 18.70 13.07 18.210 13.980 6.990 5.070 **
Cl (1/h/kg) 29 25 0.276 0.228 0.292 0.243 0.105 0.076 *
[SPAR] 6 3h (ag/dl) 27 24 0.983 1.258 1.318 1.289 1.155 0.379
[SPAR] § 4h (ag/dl) 28 25 0.783 0.958 0.880 1.047 0.376 0.382
urine voluae (al) 28 22 1392 1010 1392 1037 551 465 **
free DPAR (ag) 27 24 28.64 27.74 30.59 30.42 19.81 23.38
OPARG+S (ag) 25 18 766.0 567.8 749.5 585.5 176.8 153.7 ****
total OPAR (ag) 25 18 775.4 607.5 781.6 622.7 183.5 147.5 ****
total OPAR (ag) 
0 - 7h
25 18 0.837 0.487 0.889 0.575 0.419 0.369
total OPAR (ag) 
0 - 15h
25 18 0.755 0.610 0.809 0.608 0.249 0.239 ***
OCr (ag in 24h) 28 22 919.8 526.0 905.6 678.0 290.3 471.0
[OCr] (ag/lOOal) 28 22 66.29 68.67 73.36 71.97 31.32 39.01
[SCr] (ag/lOOal) 29 26 1.17 1.22 1.279 1.497 0.409 0.846
CCr (nl/nin) 28 22 49 31 54.2 40.2 22.2 26.7 *
CCr/SA
(al/ain/1.73a2)
28 21 56 39 56.3 43.1 21.2 25.2
weight (kg) 29 25 60 56 62.9 58.4 14.6 15.7
SA (m2) 29 25 1.63 1.61 1.668 1.612 0.222 0.250
* p<0.05 ** p<0.02 *** p<0.01 **** p<0.003
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Appendix F14 Fit v Frail Elderly Females Taking PARACETAMOL - Mann-Whitney Test
fit frail fit
n n median
age (years) 18 15 79
nobility score 18 15 1
tl/2 (hours) 18 15 2.613
Cl (1/b) 18 15 16.16
Cl (1/h/kg) 18 15 0.251
[SPAR] § 3h (mg/dl) 17 14 1.051
[SPAR] 6 4h (mg/dl) 18 14 0.921
urine volume (ml) 18 12 1210
free DPAR (mg) 17 14 29.1
OPARG+S (mg) 19 9 750.4
total DPAR (mg) 16 9 762.9
FPAR/PARG+S 16 9 0.043
total OPAR (mg) 
0 - 7h
16 9 0.909
total DPAR (mg) 
0 - 15h
16 9 0.756
OCr (mg in 24h) 18 12 782.3
[OCr] (mg/lOOml) 18 12 64.2
[SCr] (mg/lOOml) 18 15 1.09




weight (kg) 18 15 58
SA (m2) 18 15 1.58
* p<0.05 **
frail fit frail fit frail
nedian mean mean s.d. s.d. P
84 78.3 86.1 8.5 4.9 ***
4 1.4 3.7 0.5 0.7 ****
2.947 2.594 3.035 0.354 0.913 *
12.31 16.71 13.84 7.90 5.18
0.243 0.285 0.251 0.125 0.071
1.369 1.577 1.384 1.402 0.424
1.082 0.988 1.137 0.428 0.446
1013 1268 812 535 564
22.9 29.10 22.91 16.25 18.67
573.3 727.2 577.7 198.0 110.2 **
590.9 757.1 608.0 201.4 118.8 **
0.052 0.043 0.052 0.024 0.029
0.529 0.922 0.645 0.435 0.396
0.655 0.781 0.671 0.236 0.234
503.2 789.2 555.8 231.9 221.1 **
60.1 71.7 67.2 33.3 39.3
1.06 1.203 1.199 0.406 0.601
36 50.9 39.3 24.5 18.4
40 54.7 43.3 24.1 20.3
52 59.2 55.9 14.8 16.0
1.52 1.589 0.154 0.207 0.244
p<0.03 *** p<0.01 **** p<0.001
Appendix F15 Fit v Frail Elderly Hales Taking PARACETAMOL - Mann-Whitney Test
fit frail fit frail fit frail fit frail
n n median median mean mean s.d. s.d.
age (years) 11 11 73 81 75.7 80.1 7.7 8.9
nobility score 11 11 1 4 1.6 3.8 0.9 0.8
tl/2 (hours) 11 11 2.834 3.734 2.788 3.850 0.587 1.337
Cl (1/h) 11 11 19.39 14.31 20.68 14.31 4.46 4.97
Cl (1/h/kg) 11 10 0.297 0.212 0.305 0.228 0.062 0.082
[SPAR] § 3h (ng/dl) 10 10 0.913 1.177 0.877 1.156 0.119 0.270
[SPAR] § 4h (ng/dl) 10 11 0.708 0.939 0.684 0.932 0.113 0.256
urine volume (nl) 10 10 1722 1104 1615 1066 535 338
free OPAR (mg) 10 10 25.0 33.6 33.12 40.93 25.54 26.12
OPARG+S (mg) 9 9 766.0 562.3 789.2 593.2 132.6 194.7
total OPAR (ng) 9 9 775.4 618.6 825.1 637.4 147.3 177.7
FPAR/PARG+S 9 9 0.037 0.061 0.045 0.113 0.030 0.163
total OPAR (ng) 
0 - 7h
9 9 0.769 0.375 0.832 0.458 0.405 0.304
total OPAR (ng) 
0 - 15h
9 9 0.753 0.503 0.862 0.544 0.278 0.239
OCr (mg in 24h) 10 10 1192 633 1115 825 275 643
[OCr] (ng/lOOml) 10 10 70.8 88.3 76.4 77.7 28.9 39.9
[SCr] (ng/lOOml) 11 11 1.30 1.71 1.403 1.904 0.400 0.985
CCr (nl/nin) 10 10 58 19 60.1 41.4 17.1 35.4
CCr/SA
(ml/nin/L73m2)
10 9 60 21 59.3 42.9 15.4 31.9
weight (kg) 11 10 69 59 68.9 62.3 12.6 15.0
SA (m2) 11 10 1.81 1.68 1.787 1.720 0.196 0.229
* p<0.05 ** p<0.02 *** p<0.006 **** p<0.001
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Appendix F16 Results from Age-Sex Hatched Group Taking PARACETAMOL
n min max 01 Q3 median mean s.d.
age (years) 32 64 94 77 88 82 81.8 7.4
tl/2 (h) 32 1.971 7.332 2.405 3.393 2.905 3.104 1.102
Cl (1/h) 32 5.78 26.41 12.13 18.77 15.46 15.685 5.208
Cl (1/h/kg) 31 0.126 0.436 0.214 0.294 0.251 0.2583 0.0754
[SPAR] § 3h (mg/dl) 30 0.647 2.374 0.927 1.361 1.050 1.186 0.388
[SPAR] § 4h (mg/dl) 31 0.465 2.193 0.708 1.166 0.833 0.966 0.383
urine volume (ml) 29 360 2020 801 1519 1111.0 1135.8 449.8
free OPAR (mg) 26 0.0 101.5 16.5 38.4 29.9 31.88 22.86
OPARG+S (mg) 25 187.7 1109.8 566.1 769.2 670.3 677.7 208.4
total OPAR (mg) 25 289.2 1192.1 598.3 788.2 702.4 710.8 208.7
OCr (mg in 24b) 29 315 2480 458 1021 690.3 804.0 446.8
[OCr] (mg/lOOml) 29 26.9 168.4 49.8 101.7 66.33 77.03 38.3
[SCr] (mg/lOOml) 32 0.50 3.07 0.84 1.85 1.26 1.368 0.622
CCr (ml/min) 29 10 105 26 66 41 45.6 24.6
CCr/SA
(ml/min/1.73m2)
28 11 93 32 66 45 48.4 22.9
weight (kg) 31 36 92 50 69 58 60.7 13.9
SA (m2) 31 1.23 2.12 1.48 1.80 1.63 1.647 0.219
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0.165 0.638 0.019 
****









0.523 0.183 0.986 
****
0.408 0.020 0.604 
***
0.402 0.066 0.210 
0.148 0.093 0.364 
0.094 0.181 0.288 










0.371 0.702 0.523 
**** ***
0.288 0.558 0.569 
*** ***
0.268 0.704 0.155 
****
0.314 0.718 0.188 
****







0.529 0.345 0.975 
**** ****
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Appendix F18 Fit v Frail Age-Sex Hatched Subjects Taking PARACETAMOL - Mann-Whitney Test
fit frail fit frail fit frail fit frail
n n Median Median Mean Mean s.d. s.d. p
age (years) 16 16 82 82 81.9 81.7 7.4 7.7
Mobility score 16 16 1 4 1.6 3.6 0.7 0.7 ***
tl/2 (hours) 16 16 2.602 3.062 2.688 3.520 0.519 1.368 *
Cl (1/h) 16 16 17.08 14.29 17.08 14.29 4.68 5.47
Cl (1/h/kg) 16 15 0.264 0.222 0.272 0.243 0.054 0.093
[SPAR] § 3h (Mg/dl) 15 15 0.971 1.160 1.141 1.231 0.411 0.371
[SPAR] § 4h (Mg/dl) 16 15 0.783 0.958 0.897 1.039 0.323 0.437
urine volune (m1) 15 14 1193 1098 1237 1027 522 343
free OPAR (Mg) 14 16 29.5 32.1 30.73 33.03 18.59 27.20
OPARG+S (Mg) 13 11 746.5 602.5 760.9 587.5 202.5 181.6 **
total OPAR (Mg) 13 11 757.2 633.8 791.6 623.3 213.1 171.5 *
total OPAR (ng) 
0 - 7h
13 11 0.666 0.375 0.762 0.573 0.424 0.415
total OPAR (Mg) 
0 - 15h
13 11 0.740 0.592 0.842 0.592 0.311 0.251 *
OCr (Mg in 24h) 15 14 910 565 876 727 308 562
[OCr] (Mg/lOOMl) 15 14 68.9 61.2 78.9 75.1 31.2 45.8
[SCr] (ng/lOOnl) 16 16 1.30 1.04 1.413 1.324 0.434 0.778
CCr (Ml/Min) 15 14 44 31 46.2 44.9 18.5 30.5
CCr/SA
(Ml/Min/1.73M2)
15 13 46 40 48.2 48.5 17.6 28.6
weight (kg) 16 15 60 56 63.1 58.1 15.7 11.8
SA ( m2) 16 15 1.67 1.61 1.672 1.620 0.240 0.200
* p<0.03 ** p<0.02 *** p<0.0001
